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6 Evaluation of selected sensitizing fragrance substances 
 
The List of Undesirable Substances (LOUS) was established by the Danish Environmental 
Protection Agency (EPA) as a guide for enterprises. It addresses chemical substances of concern, 
based on their hazardous properties and the volumes used in Denmark. The latest version of LOUS 
from 2009 includes 40 chemical substances or groups of substances (DK EPA 2010). 
 
During the period 2012-2015, all substances listed on LOUS have been surveyed and further need 
for risk management measures will be evaluated. In certain cases, implementation projects have 
been launched to achieve the goals laid down in the strategies for each of these 
substances/substance groups. 
 
The present project ”Evaluation of selected sensitising fragrance substances” was initiated as a 
LOUS follow-up project by the Danish EPA. The objective of this study was to evaluate selected 
fragrance substances in relation to the classification criteria for strong sensitisers (Category 1A 
sensitisers) according to the CLP Regulation on classification, labelling and packaging of substances 
and mixtures (EC no. 1272/2008)1.   
 
The project was carried out from July to November 2015 at the National Food Institute, Technical 
University of Denmark.  
 
This report has been prepared by: 
Lea Bredsdorff and Elsa Nielsen, Division for Risk Assessment and Nutrition, National Food 
Institute, Technical University of Denmark 
 
The work has been subjected to review and discussion and has been endorsed by an advisory group 
consisting of: 
Charlotte Madsen, Division for Diet, Disease Prevention and Toxicology, National Food Institute, 
Technical University of Denmark, 
Jeanne Duus Johansen and Niels Højsager Bennike, National Allergy Centre and Department of 
Dermato-Allergology, Herlev-Gentofte Hospital, Copenhagen, Denmark 
Trine Thorup Andersen, Danish Environmental Protection Agency 
                                                                    
1 REGULATION (EC) No 1272/2008 OF THE EUROPEAN PARLIAMENT AND OF THE COUNCIL of 16 December 
2008 on classification, labelling and packaging of substances and mixtures, amending and repealing Directives 
67/548/EEC and 1999/45/EC, and amending Regulation (EC) No 1907/2006, with amendments M1-M9 and 
corrigenda C1-C2, 1 June 2015. http://eur-lex.europa.eu/legal-content/EN/TXT/PDF/?uri=CELEX:02008R1272-
20150601&from=en 
Preface 
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Fragrances are widely used in many different types of consumer products. Therefore, the general 
population can be exposed to fragrances from many different sources and consequently can have a 
substantial exposure despite the fact that fragrances most often are used in a relatively low 
concentration in individual consumer products.  
 
Many fragrances have been shown to cause harmful effects to human health. Skin sensitisation 
(contact allergy) is identified as the critical effect for a wide range of fragrances. Many fragrances 
are already classified as skin sensitisers (Skin Sens Cat 1) according to the CLP Regulation (EC no. 
1272/2008). The CLP criteria for classification of skin sensitisers were revised in 2011 and now 
provide possibility for sub-categorising skin sensitisers in two sub-categories, sub-category 1A 
(strong sensitisers) or 1B (other skin sensitisers). Some of the fragrances that are already classified 
as skin sensitisers in Category 1 may possibly fulfil the CLP criteria for classification as strong 
sensitisers in sub-category 1A.   
 
A classification of a specific substance in sub-category 1A implies that classification and labelling of 
mixtures containing the substance is required at a lower concentration (factor 10) compared to skin 
sensitisers in Category 1. The more stringent labelling requirements for sub-category 1A sensitisers 
will apply for mixtures under the scope of the CLP regulation such as e.g., washing and cleaning 
products. Consequently, the labelling may increase the protection of users (workers, consumers) as 
it will allow sensitised individuals to take precautionary measures to prevent direct skin contact 
with a product containing a strong sensitiser.  
 
The purpose of this project was to retrieve and review the available data for 42 selected fragrances 
already classified as skin sensitisers in Category 1 (harmonised and/or notified classification) in 
order to assess whether these substances fulfil the criteria for classification in sub-category 1A.  
The 42 fragrances (substances / natural extracts), hereafter referred to as substances, were selected 
by the Danish EPA based on information in a LOUS survey of selected fragrances (DK EPA, 2015) 
and in an SCCS opinion on fragrance allergens in cosmetic products (SCCS, 2012), as well as on 
other criteria set up by the Danish EPA, as described below in Chapter 2. The list of substances for 
evaluation as provided by the Danish EPA is presented in Appendix 2. 
 
The project was divided in two phases: 
 
In Phase 1, relevant information was retrieved for all the selected 42 substances as described in 
Chapter 3, section 3.1. The relevant information for the purpose of the screening in this project is 
human data (primarily patch tests in unselected and/or selected dermatitis patients) and animal 
data (local lymph node assay, guinea pig maximization test and the Buehler assay). Then, a 
preliminary evaluation of the relevant data was performed in order to identify possible sub-category 
1A candidates. Therefore, a thorough evaluation of the retrieved data was not performed in Phase 1. 
 
In Phase 2, a more detailed assessment of the data for selected sub-category 1A candidates was 
performed as described in Chapter 3, section 3.2. The quality of the data was assessed according to 
the Klimisch criteria (Klimisch et al., 1997) as described in section 3.2.1.  The ‘reliable’ data 
(assigned score 1 or 2) were then assessed against the CLP classification criteria for skin 
sensitisation with special focus on whether classification in sub-category 1A is justified. Other data 
Summary and conclusion 
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(assigned score 4) were also included in the assessment. Not ‘reliable’ data (assigned score 3) were 
not included in the assessment. The CLP classification criteria for classification in sub-category 1A 
are summarised in section 3.2.2. 
 
Based on the preliminary assessment in Phase 1, each of the 42 selected substances was given a 
priority 1 or 2 as described in Chapter 4. Priority 1 was given to those substances which were 
considered as possible sub-category 1A candidates, in total 20 substances (listed in the first table in 
Chapter 4). Priority 2 was given to those substances which were not considered as possible sub-
category 1A candidates, in total 22 substances. The justification for the prioritisation of the 
substances as 1 or 2 is presented in Appendix 3.  
Among the 20 identified possible sub-category 1A candidates, a further prioritisation was 
performed for the selection of the Phase 2 substances. The highest priority was given to the 
substances identified in the SCCS opinion (SCCS, 2012) as established contact allergens in humans 
and considered to be of special concern (marked with an ‘X’ in the right column of the table in 
Chapter 4) and/or based on the clinical experience from the National Allergy Research Centre. The 
11 substances taken forward to Phase 2 are listed in the table below: 
 
Substances CAS RN Substances of 
special concern 
according to 
SCCS (2012) 
Citral 5392-40-5 X 
Cinnamaldehyde 104-55-2 X 
Cinnamyl alcohol 104-54-1 X 
Coumarin 91-64-5 X 
Eugenol 97-53-0 X 
Farnesol  4602-84-0 X 
Geraniol 106-24-1 X 
7-Hydroxycitronellal 107-75-5 X 
Methyl oct-2-ynoate 111-12-6  
Cinnamomum cassia leaf oil /  
Cinnamomum zeylanicum, ext. 
8007-80-5 /  
84649-98-9 
 
Evernia prunastri, ext. 90028-68-5 X 
 
The results of the detailed assessment performed for the 11 substances selected for Phase 2 are 
presented in Chapter 5 as a summary of the available data, a comparison with CLP Regulation 
criteria for classification in sub-category 1A, and a conclusion on classification for each substance. 
Appendices 4-14 present the full overview of the available studies/data for the substances and the 
evaluation of their skin sensitising potential. For all 11 substances, a classification as a skin 
sensitiser in sub-category 1A is justified based on the available data.  
 
For nine of the substances, sub-category 1A is justified based on human patch test data i.e. 
frequencies in unselected and/or selected dermatitis patients and/or a high number of cases. For 
methyl oct-2-ynate, sub-category 1A is justified primarily based on non-human data (very low EC3 
values in the two LLNAs and results from GPMT and Buehler tests, and supported by human 
evidence from HRIPT studies). For Cinnamomum cassia leaf oil/Cinnamomum zeylanicum, ext., 
sub-category 1A is justified based on their constituents by read across to the major compounds such 
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as cinnamaldehyde (for Cassia bark extract, Cassia oil, Cinnamon bark extract and Cinnamon bark 
oil) and eugenol (for Cinnamon leaf oil). 
 
The experiences from the assessments in this project are discussed in Chapter 6. In general, a 
decision whether a classification of a substance as a skin sensitiser in sub-category 1A is justified or 
not is based on the available human data. This classification is generally not supported by the 
available non-human data available for the 11 substances assessed in this project. However, as a 
substance can be classified in sub-category 1A on the basis of reliable and good quality evidence 
from human cases or epidemiological studies and/or observations from appropriate studies in 
experimental animals it seems clear that sub-category 1A is justified based on the available human 
data.  
As illustrated by one of the 11 Phase 2 substances, methyl oct-2-ynate, sub-category 1A can also be 
justified primarily based on non-human data, in this case based on a very low EC3 value in the two 
LLNAs, and the results from GPMT and Buehler tests (and in this case, supported by human 
evidence from HRIPT studies).  
As illustrated by another of the 11 Phase 2 substances, Cinnamomum cassia leaf oil/Cinnamomum 
zeylanicum, ext., read across to major constituents in the fragrance could justify a classification in 
sub-category 1A.  
 
For seven of the 42 selected substances, the available data were too limited for an indication as a 
possible sub-category 1A candidate. Thus, it cannot be excluded whether these substances would 
turn out to be sub-category 1A candidates should additional human studies and/or non-human data 
become available. 
 
A relatively large proportion of the available studies have only been available from secondary 
sources, mainly attributed to unpublished data by the industry. Inclusion of these studies in this 
project is justified due to the purpose of the project, i.e. a screening of the available data for a 
preliminary assessment whether the criteria for classification in sub-category 1A according to the 
CLP criteria are fulfilled.  
Secondary sources have a reliability score 4 “not assignable” according to the reliability criteria 
proposed by Klimisch et al. (1997). For a genuine assessment of studies only available from 
secondary sources, the original study report should be available for the assessment.  
 
Conclusion: 
For all 11 substances selected for detailed assessment in Phase 2, a classification as a skin sensitiser 
in sub-category 1A is justified based on the available data.  Based on the assessments in this project, 
a decision whether a classification of a substance as a skin sensitiser in sub-category 1A is justified is 
generally based on the available human patch test data.  
One of the elements in the criteria for classification in sub-category 1A based on human patch test 
data is ‘relatively low exposure’. For the 11 substances, relatively low exposure from use as fragrance 
in cosmetics and in other consumer products has been evaluated based on the IFRA standard limit 
of each substance in each of the 11 product categories for dermal sensitisation which have been 
established by IFRA based on quantitative risk assessment (QRA). The IFRA standard limits are 
still under evaluation. Revisions of the QRA approach might result in changes of the current IFRA 
standard limits and could thus have an impact on the classification as a skin sensitiser in sub-
category 1A for the 11 substances. 
A relatively large proportion of the cited studies have only been available from secondary sources, 
mainly attributed to unpublished data by the industry. For a genuine assessment of such studies, 
the original study reports should be available for the assessment. Thus, it cannot be excluded 
whether the outcome of the assessments performed in this project could turn out differently should 
the original study reports become available for the final assessment. 
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Sammenfatning og konklusion 
Duftstoffer er meget udbredt i mange forskellige typer af forbrugerprodukter. Den generelle 
befolkning kan således blive udsat for duftstoffer fra mange forskellige kilder og kan derfor have en 
væsentlig udsættelse herfor til trods for, at duftstoffer oftest anvendes i en relativt lav koncentration 
i de enkelte forbrugerprodukter. 
 
Mange duftstoffer har vist sig at kunne være skadelige for menneskers sundhed. Hudsensibilisering 
(kontaktallergi) er blevet identificeret som den kritiske effekt for en lang række duftstoffer. Mange 
duftstoffer er allerede klassificeret som hudsensibiliserende (Skin Sens Kat 1) i henhold til CLP-
forordningen (EF nr. 1272/2008). CLP-kriterierne for klassificering af hudsensibiliserende stoffer 
blev revideret i 2011 og giver nu mulighed for at klassificere hudsensibiliserende stoffer i to 
subkategorier, subkategori 1A (stærkt sensibiliserende stoffer) eller 1B (andre hudsensibiliserende 
stoffer). Nogle af de duftstoffer, der allerede er klassificeret som hudsensibiliserende i kategori 1, 
kan muligvis opfylde CLP-kriterierne for klassificering som stærkt sensibiliserende i subkategori 1A. 
 
Klassificering af et specifikt stof i subkategori 1A vil medføre, at kemiske blandinger (produkter) 
indeholdende stoffet skal klassificeres og mærkes ved en lavere koncentration (faktor 10 lavere) i 
forhold til stoffer klassificeret i kategori 1. De skærpede mærkningskrav for stærkt sensibiliserende 
stoffer (subkategori 1A) gælder for produkter, der er omfattet af CLP forordningens mærkningskrav 
som f.eks. vaske- og rengøringsmidler. Mærkningen vil således kunne øge beskyttelsen af brugerne 
(arbejdere, forbrugere), da mærkningen vil kunne gøre det muligt for sensibiliserede individer at 
tage forholdsregler for at undgå direkte hudkontakt med et produkt, der indeholder et stærkt 
sensibiliserende stof.  
 
Formålet med dette projekt var at søge og vurdere de tilgængelige data for 42 udvalgte duftstoffer, 
som allerede er klassificeret som hudsensibiliserende i kategori 1 (harmoniseret og / eller notificeret 
klassificering) med henblik på at vurdere, om disse stoffer kan opfylder kriterierne for klassificering 
i subkategori 1A baseret på de tilgængelige data. 
De 42 duftstoffer (stoffer / naturlige ekstrakter), efterfølgende benævnt stoffer, blev udvalgt af 
Miljøstyrelsen baseret på oplysninger i et LOUS kortlægningsprojekt af udvalgte duftstoffer (DK 
EPA, 2015) og i en SCCS opinion om allergene duftstoffer i kosmetiske produkter (SCCS, 2012), 
såvel som på andre kriterier sat af Miljøstyrelsen, som beskrevet nedenfor i kapitel 2. Listen over de 
udvalgte stoffer er præsenteret i Appendix 2. 
 
Projektet var opdelt i to faser: 
 
I fase 1 blev der indsamlet relevante oplysninger for alle de udvalgte 42 stoffer, som beskrevet i 
kapitel 3, afsnit 3.1. Relevante oplysninger med henblik på screeningen i dette projekt er humane 
data (primært lappetest i ikke-selekterede og / eller selekterede dermatitis patienter) og data fra 
studier i dyreforsøg (local lymph node assay, guinea pig maximization test og Buehler assay). 
Derefter blev der lavet en foreløbig vurdering af de relevante data med henblik på at identificere 
mulige subkategori 1A kandidater. Der er således i fase 1 ikke foretaget en grundig evaluering af de 
indsamlede data. 
 
I fase 2 blev der foretaget en mere detaljeret vurdering af data for de udvalgte subkategori 1A 
kandidater, som beskrevet i kapitel 3, afsnit 3.2. Kvaliteten af  data blev vurderet i henhold til 
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Klimisch kriterierne (Klimisch et al., 1997), som beskrevet i afsnit 3.2.1. ’Reliable’ data (tildelt score 
1 eller 2) blev derefter vurderet i forhold til CLP kriterierne for hudsensibilisering med særligt fokus 
på, hvorvidt klassificering i subkategori 1A er berettiget. ’Other data’ (tildelt score 4) blev også 
inkluderet i vurderingen. Not ‘reliable’ data (tildelt score 3), blev ikke medtaget i vurderingen. CLP 
kriterierne for klassificering i subkategori 1A er sammenfattet i afsnit 3.2.2. 
 
På baggrund af den foreløbige vurdering i fase 1 fik hvert enkelt af de 42 udvalgte stoffer en prioritet 
1 eller 2, som beskrevet i kapitel 4. De stoffer, der blev vurderet som mulige subkategori 1A 
kandidater, fik en prioritet 1, i alt 20 stoffer (præsenteret i den første tabel i kapitel 4). De stoffer, 
der ikke blev vurderet som mulige subkategori 1A kandidater, fik en prioritet 2, i alt 22 stoffer. 
Begrundelsen for prioriteringen af  stofferne er præsenteret i Appendix 3. 
 
Blandt de 20 stoffer, der blev vurderet som mulige subkategori 1A kandidater, blev der foretaget en 
yderligere prioritering med hensyn til udvælgelsen af fase 2 stoffer. Den højeste prioritet blev givet 
til de stoffer, som i SCCS opinion (SCCS, 2012) er blevet udpeget som erkendte kontaktallergener 
hos mennesker og dermed betragtes som værende særligt bekymrende (markeret med et 'X' i højre 
kolonne i tabellen i kapitel 4), og/eller baseret på klinisk erfaringer fra Videncenter for Allergi. De 
11 stoffer udvalgt til fase 2 er præsenteret i den efterfølgende tabel: 
 
Stof CAS RN Stoffer som er 
særligt  
bekymrende 
(SCCS, 2012) 
Citral 5392-40-5 X 
Cinnamaldehyd 104-55-2 X 
Cinnamyl alkohol 104-54-1 X 
Coumarin 91-64-5 X 
Eugenol 97-53-0 X 
Farnesol  4602-84-0 X 
Geraniol 106-24-1 X 
7-Hydroxycitronellal 107-75-5 X 
Methyl oct-2-ynoat 111-12-6  
Cinnamomum cassia leaf oil /  
Cinnamomum zeylanicum, ext. 
8007-80-5 /  
84649-98-9 
 
Evernia prunastri, ext. 90028-68-5 X 
 
Resultaterne af den detaljerede vurdering udført for de 11 stoffer udvalgt til fase 2 er præsenteret i 
kapitel 5 i form af et sammendrag af de tilgængelige data, en sammenligning med CLP kriterierne 
for klassificering i subkategori 1A, og en konklusion for klassificering af hvert enkelt stof. I 
Appendix 4-14 er samlet de fulde vurderinger for de enkelte stoffer. For alle 11 stoffer er en 
klassificering som hudsensibiliserende i subkategori 1A begrundet på grundlag af de tilgængelige 
data.  
 
For ni af stofferne er subkategori 1A begrundet baseret på data fra humane lappetest data dvs. 
frekvenser i ikke-selekterede og/eller selekterede dermatitis patienter og/eller et højt antal tilfælde. 
For methyl oct-2-ynat er subkategori 1A primært begrundet baseret på data fra dyreforsøg (meget 
lave EC3 værdier i de to LLNA tests samt resultater fra GPMT og Buehler tests, og støttet af 
resultater HRIPT studier). For Cinnamomum cassia leaf oil/Cinnamomum zeylanicum, ext., er 
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subkategori 1A begrundet baseret på read across til hovedindholdsstofferne såsom cinnamaldehyd 
(for Cassia bark ekstrakt, Cassia olie, kanel bark ekstrakt og kanel bark olie) og eugenol (for 
Cinnamon blade). 
 
Erfaringerne fra vurderingerne i dette projekt er diskuteret i kapitel 6. Generelt er vurderingen om, 
hvorvidt en klassificering af et stof som hudsensibiliserende i subkategori 1A er begrundet eller ej, 
baseret på de tilgængelige humane data. Denne klassificering er generelt ikke understøttet af de 
tilgængelige data fra dyreforsøg for de 11 stoffer, der er vurderet i dette projekt. Da et stof kan 
klassificeres i subkategori 1A på grundlag af pålidelige humane data af god kvalitet og/eller data fra 
dyreforsøg, så er subkategori 1A berettiget på grundlag af de tilgængelige humane data. 
Som illustreret med et af de 11 fase 2 stoffer, methyl oct-2-ynat, så kan klassificering i subkategori 
1A også begrundes primært baseret på data fra dyreforsøg, i dette tilfælde baseret på en meget lav 
EC3 værdi i de to LLNA tests samt resultaterne fra GPMT og Buehler tests (og i dette tilfælde, 
støttet af dokumentation fra fra HRIPT studier).  
Som illustreret med et andet af de 11 fase 2 stoffer, Cinnamomum cassia leaf oil/Cinnamomum 
zeylanicum, ext., så kan klassificering i subkategori 1A begrundes baseret på read across til 
hovedindholdsstofferne i duftstoffet.  
 
For syv af de 42 udvalgte stoffer blev de tilgængelige data vurderet til at være for begrænsede til en 
vurdering af stoffet som en mulig subkategori 1A kandidat. Det kan således ikke udelukkes, hvorvidt 
disse stoffer ville kunne vise sig at være subkategori 1A kandidater, hvis yderligere humane data 
og/eller data fra dyreforsøg bliver tilgængelige. 
 
En forholdsvis stor del af de tilgængelige studier har kun været tilgængelige fra sekundære kilder, 
primært i form af upublicerede data fra industrien. Inddragelse af disse studier i dette projekt er 
berettiget som følge af formålet med projektet, dvs. en screening af de tilgængelige data med 
henblik på en indledende vurdering af, hvorvidt CLP kriterierne for klassificering i subkategori 1A 
er opfyldt. 
Sekundære kilder har en ’reliability’ score 4 “not assignable” i henhold til Klimisch kriterierne 
(Klimisch et al., 1997 ). For at kunne foretage en uvildig vurdering af studierne citeret fra 
sekundære kilder, så bør man have adgang til den originale studierapport. 
 
Konklusion: 
For alle 11 stoffer udvalgt til den detaljerede vurdering i fase 2 er en klassificering som 
hudsensibiliserende i subkategori 1A berettiget på grundlag af de tilgængelige data. 
Baseret på vurderingerne i dette projekt så er vurderingen om, hvorvidt en klassificering af et stof 
som hudsensibiliserende i subkategori 1A er begrundet eller ej, generelt baseret på de tilgængelige 
humane patch test data.   
Et af elementerne i kriterierne for klassificering i subkategori 1A baseret på humane patch test data 
er ’relativ lav eksponering’. For de 11 stoffer er relativ lav eksponering ved anvendelse som duftstof i 
kosmetik og andre forbrugerprodukter evalueret baseret på IFRA standard grænser for hvert enkelt 
stof i hver enkelt af de 11 produktkategorier for dermal sensibilisering som IFRA har opstillet på 
baggrund af kvantitativ risikovurdering (QRA). IFRA standard grænserne baseret på kvantitativ 
risikovurdering (QRA) er stadig under evaluering. Revidering af QRA tilgangen kunne således 
medføre ændringer i de nuværende IFRA standard grænser og kunne dermed influere på 
klassificeringen som hudsensibiliserende i subkategori 1A for de 11 stoffer. 
En forholdsvis stor del af de citerede studier har kun været tilgængelige fra sekundære kilder, 
primært i form af upublicerede data fra industrien. For at kunne foretage en uvildig vurdering af 
studierne citeret fra sekundære kilder, så bør man have adgang til den originale studierapport. Det 
kan således ikke udelukkes, at vurderingerne i dette projekt kunne falde anderledes ud, hvis de 
originale studierapporter bliver tilgængelige for den endelige vurdering. 
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Fragrances are widely used in many different types of consumer products. Therefore, the general 
population can be exposed to fragrances from many different sources and the exposure may be 
substantial despite the fact that fragrances most often are used in relatively low concentrations in 
individual consumer products.  
 
Many fragrances have been shown to cause harmful effects to human health as well as to the 
environment. In relation to human health, skin sensitisation (contact allergy) is identified as the 
critical effect for a wide range of fragrances. Many fragrances are already classified as skin 
sensitisers (Skin Sens Cat 1) according to the CLP Regulation on classification, labelling and 
packaging of substances and mixtures (EC no. 1272/2008).  
 
The CLP criteria for classification of skin sensitisers were revised in 2011 and now provide 
possibility for sub-categorising sensitisers in Category 1 in two sub-categories: Sub-category 1A or 
1B. Sub-category 1A comprises sensitisers for which exposure to a low amount of the substance may 
cause a high frequency of occurrence of skin sensitisation in humans and/or a high potency in 
animals (strong sensitisers), while sub-category 1B comprises other skin sensitisers. Sub-
categorisation of skin sensitisers in either category 1A or 1B should thus be done if justified by the 
available data. If the data do not allow for sub-categorisation, the substance should be classified in 
Category 1 according to the criteria specified. 
 
Some of the fragrances that are already classified as skin sensitisers in Category 1 and other 
fragrances which are known to cause skin sensitisation may possibly fulfil the CLP criteria for 
classification in sub-category 1A. A classification of a specific substance in sub-category 1A implies 
that classification and labelling of mixtures containing the substance is required at a lower 
concentration compared to skin sensitisers in Category 1. The hazard statement H317 (May cause an 
allergic skin reaction) will thus be required at concentrations ≥ 0.1% and labelling with the 
supplemental hazard statement EUH208 (“Contains <name of sensitising substance>. May produce 
an allergic reaction”) will be required at concentrations ≥ 0.01% for strong sensitisers (sub-category 
1A) according to the CLP Regulation. These concentration limits are a factor 10 lower than the 
concentration limits for classification and labelling of mixtures containing sensitisers in Category 1.  
 
The more stringent labelling requirements for strong sensitisers (sub-category 1A) will apply for 
mixtures under the scope of the CLP regulation such as e.g., washing and cleaning products. 
Consequently, the labelling may increase the protection of users (workers, consumers) as it will 
allow sensitised individuals to take precautionary measures to prevent direct skin contact with a 
product containing a strong sensitiser.  
 
In an SCCS (EU Scientific Committee on Consumer Safety) opinion on fragrance allergens in 
cosmetic products it is mentioned that based on data from the fragrance industry, 80 % of the total 
fragrance chemical volume is used in cosmetics and 20 % in household products (SCCS, 2012). It 
should be noted that cosmetic products are not subject to classification and labelling under the 
scope of the CLP regulation (EC no. 1223/2009). However, according to the Cosmetic Regulation 
“Perfume and aromatic compositions and their raw materials shall be referred to by the terms 
‘parfum’ or ‘aroma’. Moreover, the presence of substances, the mention of which is required under 
the column ‘Other’ in Annex III, shall be indicated in the list of ingredients in addition to the terms 
1. Introduction 
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parfum or aroma.” Annex III (entries 67-92) includes 26 fragrances which have been identified as 
human allergens and must be indicated in the list of ingredients when the concentration of the 
fragrance exceeds 0.001 % in leave-on products and 0.01 % in rinse-off products.  
 
As part of the Danish Environmental Protection Agency’s (Danish EPA) survey of the ‘List of 
Undesirable Substances’ (LOUS) a survey of selected fragrances has been carried out (DK EPA, 
2015). In that survey, 15 substances with a classification (harmonised/notified) for their skin 
sensitising potential in Category 1 according to the CLP criteria were identified.  
 
Furthermore, 82 substances / natural extracts were identified in the SCCS opinion on fragrance 
allergens in cosmetic products (SCCS, 2012) as established contact allergens in humans.  
 
Based on the LOUS review and the SCCS (2012) opinion the Danish EPA has selected 42 substances 
/ natural extracts (hereafter referred to as substances) for a screening of the available data 
regarding skin sensitisation, see Chapter 2. 
 
The purpose of this project was to retrieve and review the available data for 42 selected substances 
in order to assess whether the selected substances fulfil the criteria for classification in sub-category 
1A according to the CLP criteria. 
 
The project was divided in two phases: 
 
 Phase 1: Screening of the available data for the 42 selected substances, for a preliminary 
evaluation whether the data justify a classification as a skin sensitiser in sub-category 1A 
(strong sensitisers). 
 Phase 2: A more detailed assessment of the data for those substances identified in Phase 1 as 
possible sub-category 1A candidates. 
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2. Selection of substances 
The Danish EPA has selected 42 substances for a screening of the available data regarding skin 
sensitisation. The substances were selected based on information in the LOUS report (DK EPA, 
2015) and in the SCCS opinion (SCCS, 2012) as described below, as well as on other criteria set up 
by the Danish EPA.  
 
 
2.1 Selection of substances from the LOUS survey report 
As part of the Danish EPA’s survey of the ‘List of Undesirable Substances’ ( LOUS) a survey of 
selected fragrances has been carried out (DK EPA, 2015). In that survey “… it was decided to focus 
on harmonised classified substances registered under REACH AND included in the list of 
fragrance substances developed by IFRA”, the International Fragrance Association.  
 
In total, 44 substances with a harmonised classification (health and/or environment) were included 
in the IFRA list and these 44 substances (appear on a blue background in Appendix 1 of the LOUS 
report) were included for further assessment in the LOUS survey report. The group of the 44 
substances both includes substances which are associated with a scent and substances which are 
used in fragrance mixtures to keep the fragrance liquid (solvent), preserve the fragrance (and 
therefore also the scent), adjuvants (i.e. substances that modifies the effect of other substances), 
and pigments which are applied in order to achieve a certain wanted colour etc. 
 
Among the 44 fragrance substances in the LOUS survey report 15 of the substances were classified 
as skin sensitisers in Category 1 (either by a harmonised classification or a self-classification).  
 
 
2.2 Selection of substances from the SCCS (2012) opinion 
The EU Scientific Committee on Consumer Safety (SCCS) has published an opinion on fragrance 
allergens in cosmetic products (SCCS, 2012). In this opinion, 82 substances were identified as 
established contact allergens in humans, listed in Table 7-1 (54 individual fragrance chemicals) and 
7-5 (28 natural extracts) in the opinion.  
 
Seven of the 82 substances are among the 15 substances identified in the LOUS report with a 
notified classification for their skin sensitising potential.  
 
 
2.3 The substances selected for this project 
Among the 15 substances identified in the LOUS report with a classification (harmonised and/or 
notified) for their skin sensitising potential and the 82 substances identified in the SCCS (2012) 
opinion as established contact allergens in humans (a total of 90 substances), the Danish EPA has 
selected 42 substances (56 CAS numbers) for the screening in this project. All of the 42 substances 
either have a harmonised classification for skin sensitisation or have been self-classified for skin 
sensitisation by companies placing the substance on the market in the EU. 
 
The 42 substances were selected based on the following criteria: 
 
 High tonnage (> 100 tonnes/year) and large extent of agreement of sensitising properties: 
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The substance is registered under REACH and is classified as a skin sensitiser (either a 
harmonised classification or a self-classification). In case of self-classification >75% of the 
notifying companies have self-classified as a skin sensitiser (Skin Sens Cat 1) or 
 Low tonnage but full agreement on sensitising properties: 
The substance is not registered under REACH but has a harmonised classification as a skin 
sensitiser (Skin Sens Cat 1) or 
 Low tonnage but indication of the substance being a strong sensitiser: 
The substance is not registered under REACH but one or more companies have self-
classified the substance as a strong sensitiser (Skin Sens Cat 1A) or 
 None of the above criteria are fulfilled but the substance is identified as a ‘high risk 
substance’ in relation to sensitisation by SCCS (2012): The substance has been identified to 
be of special concern by SCCS (2012) due to a high number of reported positive human 
cases of sensitisation 
 
The remaining 48 substances that were not selected for further evaluation in Phase 1 included 
substances that were: 
 
 Low tonnage (substances not registered under REACH) and which did not fulfil any of the 
above criteria 
 High tonnage but no or very low indication of sensitising properties (substances registered 
under REACH and for which none or only a few companies have notified a self-
classification for skin sensitisation). 
 
The 42 selected substances are listed in the following table: 
Substances CAS RN Substances of 
special concern 
according to 
SCCS (2012)2 
Butyl methacrylate 97-88-1  
Benzaldehyde 100-52-7  
Citral 5392-40-5 X 
(R)-p-Mentha-1,8-diene (d-limonene) 5989-27-5  
(S)-p-Mentha-1,8-diene (l-limonene) 5989-54-8  
2-Methyl-4-phenylpentanol 92585-24-5  
A mixture of: trans-4-acetoxy-4-methyl-2-propyl-
tetrahydro-2H-pyran; cis-4-acetoxy-4-methyl-2-
propyl-tetrahydro-2H-pyran 
131766-73-9  
Turpentine oil  8006-64-2 X 
[3R-(3α,3aβ,7β,8aα)]-1-(2,3,4,7,8,8a-Hexahydro-
3,6,8,8-tetramethyl-1H-3a,7-methanoazulen-5-
yl)ethan-1-one (Acetylcedrene) 
32388-55-9  
(E)-Anethole (trans-anethole) 4180-23-8  
4-Methoxybenzyl alcohol (Anise alcohol) 105-13-5  
Benzyl salicylate 118-58-1  
2-(4-tert-Butylbenzyl)propionaldehyde 80-54-6   
                                                                    
2 Special concern in the SCCS opinion (SCCS, 2012) is defined as due to the high number of reported cases, (>100 
cases). 
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Substances CAS RN Substances of 
special concern 
according to 
SCCS (2012)2 
(Butylphenyl methylproprional) 
d-p-Mentha-1(6),8-dien-2-one (Carvone) /  
l-p-Mentha-1(6),8-dien-2-one (Carvone) /  
(S)-2-Methyl-5-(1-methylvinyl)cyclohex-2-en-1-
one (Carvone) 
99-49-0 /  
6485-40-1 / 
 2244-16-8 
 
Cinnamaldehyde 104-55-2 X 
Cinnamyl alcohol 104-54-1 X 
Citronellol /  
(R)-3,7-dimethyloct-6-en-1-ol /   
(-)-3,7-dimethyloct-6-en-1-ol 
106-22-9 /  
1117-61-9 /  
7540-51-4 
 
Coumarin 91-64-5 X 
1-(2,6,6-Trimethyl-3-cyclohexen-1-yl)-2-buten-1-
one (delta-DAMASCONE) 
57378-68-4  
Eugenol 97-53-0 X 
Farnesol  4602-84-0 X 
Geraniol 106-24-1 X 
4-(4-Hydroxy-4-methylpentyl)cyclohex-3-
enecarbaldehyde (Hydroxyisohexyl 3-
cyclohexene carboxaldehyde, HICC) 
31906-04-4 / 
51414-25-6 
X 
7-Hydroxycitronellal 107-75-5 X 
Isoeugenol 97-54-1 X 
Limonene 138-86-3 X 
Methyl oct-2-ynoate 111-12-6  
Pin-2(3)-ene /  
Pin-2(10)-ene 
80-56-8 /  
127-91-3 
 
p-Mentha-1,4(8)-diene (Terpinolene) 586-62-9  
Ylang ylang ext. /  
Ylang ylang oil 
83863-30-3 / 
8006-81-3 
X 
Cinnamomum cassia leaf oil /  
Cinnamomum zeylanicum, ext. 
8007-80-5 /  
84649-98-9 
 
Neroli Oil /  
Orange, sour, ext. 
8016-38-4 /  
72968-50-4 
 
Lemon, ext. 84929-31-7  
Orange, sweet, Valencia, ext. /  
Orange, sweet, ext. 
97766-30-8 /  
8028-48-6 
 
Clove leaf oil 8000-34-8 X 
Evernia furfuracea, ext. 90028-67-4 X 
Evernia prunastri, ext. 90028-68-5 X 
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Substances CAS RN Substances of 
special concern 
according to 
SCCS (2012)2 
Jasmine, Jasminum grandiflorum, ext. /  
Jasmine, Jasminum officinale, ext. /  
Extract Jasmine (oil), Jasmine, Jasminum 
grandiflorum, ext. 
84776-64-7 / 
90045-94-6 /  
8022-96-6 
X 
Oils, peppermint (Mentha piperita) /  
Peppermint, ext. 
8006-90-4 / 
84082-70-2 
 
Spearmint, ext. (Mentha spicita) 84696-51-5  
Balsams, Peru (Myroxylon pereirae) 8007-00-9 X 
Sandalwood, ext. /  
Sandalwood oil 
84787-70-2  / 
8006-87-9 
X 
 
 
The 42 substances selected for this project include 19 of the 20 substances considered by the SCCS 
to be of special concern (SCCS, 2012) and marked with an ‘X’ in the right column in the table above. 
The remaining of the 20 substances considered by the SCCS (2012) to be of special concern, 
linalool, was not selected for this project as a harmonised classification as Skin Sens Cat 1B recently 
has been endorsed by the EU Risk Assessment Committee (RAC). 
 
The full list of substances for evaluation in Phase 1 as provided by the Danish EPA is presented in 
Appendix 2. The list includes information of CAS Registry Number (CAS RN), substance name, 
harmonised classification for skin sensitisation in Category 1, notified classification for skin 
sensitisation in Category 1 (including sub-category 1A or 1B), approximate percentage of notified 
classifications including a classification for skin sensitisation in Category 1, REACH registration 
status, and priority according to the criteria set up by the Danish EPA. 
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3. Data collection and 
evaluation 
The project was divided in two phases: 
 
 Phase 1: Screening of the available data for the 42 selected substances with the purpose of 
performing a preliminary assessment whether the data justify a classification as a skin 
sensitiser in sub-category 1A (strong sensitisers) according to the CLP criteria, i.e. an 
identification of possible sub-category 1A candidates. 
 Phase 2: A more detailed assessment of the data for those substances identified in Phase 1 as 
possible sub-category 1A candidates. 
 
 
Data were collected for all the selected 42 substances as described in section 3.1 and the retrieved 
data were evaluated as described in section 3.2. 
 
 
3.1 Data collection 
Data from the SCCS (2012) opinion have been collected for 39 of the 42 selected substances. The 
three remaining substances (butyl methacrylate, 2-methyl-4-phenylpentanol, and the mixture of: 
trans-4-acetoxy-4-methyl-2-propyl-tetrahydro-2H-pyran; cis-4-acetoxy-4-methyl-2-propyl-
tetrahydro-2H-pyran) were not included in the SCCS (2012) opinion. 
The SCCS (2012) opinion was considered as the primary source of data for these 39 substances up 
to year 2011 for the purpose of the screening in this project as a very comprehensive literature 
search was performed as part of this opinion. 
 
A supplementary literature search in the open literature has been performed covering the period 
from January 2009 and until October 2015 for the 39 substances addressed in the SCCS (2012) 
opinion in order to ensure that potentially relevant studies published after the adoption of the SCCS 
(2012) opinion also are taken into account. For the remaining 3 substances not addressed in the 
SCCS (2012) opinion, a complete literature search has been performed. 
Then relevant information regarding skin sensitisation has been retrieved by searching literature 
databases such as SciFinder, PubMed and Scopus, as well as by searching IPCS INCHEM and 
Google for relevant international / national assessments and reports.  
 
For the substances registered under REACH (27 substances, 28 CAS RN), the REACH registrations 
in the publicly accessible part of the REACH Registration Dossier Database, hosted on the ECHA 
website, were checked in order to identify eventual additional relevant information regarding skin 
sensitisation.  
 
Additional information from the National Allergy Research Centre has been included if not already 
located from the above-mentioned sources.  
 
The LOUS survey report (DK EPA, 2015) was also checked for relevant information; however, no 
relevant information for the purpose of the screening in this project was located. 
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The relevant information for the purpose of the screening in this project, i.e. for classification for  
skin sensitisation, including a possible classification in sub-category 1A, is human data and animal 
data (local lymph node assay, guinea pig maximization test and the Buehler assay). In vitro data 
and non-test data are also included in Phase 2 if retrieved. 
 
3.1.1 Human data 
Human evidence for classification of a substance for its skin sensitising potential can be based on 
positive data from patch testing, epidemiological studies showing allergic contact dermatitis caused 
by the substance, positive data from experimental studies in man and/or well documented episodes 
of allergic contact dermatitis, using a weight of evidence approach. 
 
3.1.1.1 Epidemiological studies 
The subjects examined are eczema patients, selected occupational groups, other selected groups, or 
general population, and the endpoint studied is elicitation. Large general population studies are 
scarce. Focused studies in selected populations are more common and provide insights on 
frequency of sensitisation compared to exposure.  
 
3.1.1.2 Studies based on diagnostic patch testing  
Diagnostic patch testing is conducted in order to diagnose allergic contact dermatitis (ACD) to a 
substance and is performed according to international standards by dermatologists. The subjects 
examined are eczema patients attending dermatology clinics and the endpoint studied is elicitation 
(as an indicator of previous sensitisation). Studies of diagnostic patch testing is usually reported as 
positive patch test frequencies, e.g. number of patients having a positive patch test result in relation 
to the total number of patients tested, as well as the percentage of positives. It is important to note 
how patients or individuals have been selected for patch testing; if all patients at a clinic with 
suspected ACD are patch tested they are often called consecutive or unselected patients at the clinic. 
Sometimes more aimed patch testing is performed among selected patients from a certain work 
environment or where exposure to certain groups of allergens, such as preservatives, fragrances or 
pigments, is suspected. Patch testing in selected patients usually results in higher frequencies of 
positive patch tests compared to tests performed in consecutive or unselected patients. This is to be 
considered under the evaluation of the results. 
 
3.1.1.3 Case reports 
The subjects examined are eczema patients diagnosed with contact allergy to a particular substance 
and the endpoint studied is elicitation. Individual cases are reported and are often the first reports 
made. Usually there are more details than in larger data-sets. They are useful in early detection of 
skin sensitisers and classification. 
 
3.1.1.4 Experimental dose-response elicitation studies 
This type of studies includes serial dilution patch tests or repeated open application tests (ROAT). 
The subjects examined are sensitised individuals (usually from diagnostic patch tests) and the 
endpoint studied is elicitation. Several protocols exist. This type of study provides an indication of 
the degree of sensitivity and of safe limits of exposure for induction as well as elicitation. 
 
3.1.1.5 Experimental induction tests 
This type of studies includes the Human Repeated Insult Patch Test (HRIPT) and the Human 
Maximization Test (HMT). The subjects examined are healthy volunteers and the endpoint studied 
is induction of sensitisation. For ethical reasons, such studies are no longer to be performed for EU 
regulations, including the CLP Regulation, but historical data may exist. 
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3.1.2 Animal data 
There are three common animal test methods used to evaluate the potential of a substance to cause 
skin sensitisation:  
 
 The mouse local lymph node assay (LLNA) 
 The guinea pig maximisation test (GPMT)  
 The Buehler assay 
 
3.1.2.1 Mouse Local Lymph Node Assay  
The mouse local lymph node assay (LLNA) (OECD TG 429) is used both for determination of skin 
sensitising potential (hazard identification) and for determination of relative skin sensitisation 
potency (hazard characterisation). In both instances the metric is cellular proliferation induced in 
the draining lymph nodes following topical exposure to a chemical, lymph node cell proliferation 
being causally and quantitatively correlated with the acquisition of skin sensitisation. 
 
The test is considered positive when one of the doses results in a stimulation index (SI) ≥ 3. Potency 
is measured as a function of derived EC3-values. The EC3-value is the amount of test chemical (% 
concentration, molar value or dose per unit area) calculated from the dose-response data to elicit a 
stimulation index of 3. An inverse relationship exists between EC3-value and potency meaning that 
extremely potent sensitisers have extremely low EC3-values.  
 
It is known that the choice of vehicle may provide a variable EC3 value, which may significantly 
influence the skin sensitising potency and make it difficult to categorise/subcategorise the 
substance. 
 
Different variants of the LLNA exist, namely the reduced LLNA (rLLNA) which has been added as 
an option in the amended OECD TG 429 in 2010, the LLNA: DA (OECD TG 442A), and the LLNA: 
BrdU-ELISA (OECD TG 442B).  
The rLLNA uses only a negative control group and the equivalent of the high-dose group from the 
full LLNA. The rLLNA does not allow the determination of the potency of a sensitising chemical as 
only one dose is tested. The rLLNA also uses fewer animals than the full LLNA and should only be 
used in those circumstances where dose-response information are not required (e.g. to confirm a 
negative prediction of skin sensitising potential) and thus should not be used for sub-categorisation 
of skin sensitisers. 
The test is considered positive in the LLNA: DA when the stimulation index is ≥ 1.8 and in the 
LLNA: BrdU-ELISA when the stimulation index is ≥ 1.6.  There is no guidance on how the LLNA: 
DA or the LLNA: BrdU-ELISA can be used for sub-categorisation. 
 
3.1.2.2 Guinea Pig Maximisation Test  
The guinea pig maximisation test (GPMT) (OECD TG 406) has been used for over 40 years to detect 
the skin sensitising potential of chemicals through a test system maximizing the sensitivity by both 
intradermal and epidermal induction and use of an adjuvant (Freund’s Complete Adjuvant). The 
intradermal induction is made by injection. Consequently the test is not suited for substances which 
cannot be made up into a liquid formulation. 
 
The GPMT was originally designed to maximise the ability to identify a sensitisation hazard, rather 
than to determine skin sensitisation potency. Yet, potency categorisation is possible on the basis of 
the concentration of test material used for intradermal induction and the percentage of guinea pigs 
sensitised. However, it should be recognised that there is often a degree of uncertainty associated 
with the derivation of allergenic potencies from the GPMT. 
 
 
 
22 Evaluation of selected sensitizing fragrance substances 
 
3.1.2.3 Buehler assay 
The Buehler assay (OECD TG 406) has been in use for the last 40 years to detect the skin sensitising 
potential of chemicals using epidermal occluded exposure. The skin barrier of the test species 
(guinea pig) is kept intact in this assay.  
 
The Buehler test was originally designed to identify a sensitisation hazard, rather than to determine 
skin sensitisation potency.  Yet, potency can be categorised using the results of the Buehler assay on 
the basis of the number of animals sensitised and the concentration of the test material used for the 
epidermal induction. However, it should be recognised that there is often a degree of uncertainty 
associated with the derivation of allergenic potencies from the Buehler assay. 
 
3.1.2.4 Non-compliant skin sensitisation tests 
For the 42 selected substances, several older animal studies have been retrieved from the various 
literature sources.  Many of these studies have not been performed according to the present 
internationally accepted test guidelines. 
 
In vivo test methods which do not comply with recognised test guidelines are strongly discouraged 
in the CLP Guidance for the identification of skin sensitisers or assessment of skin sensitising 
potency. The results of such tests have to be well-validated with scientific justification and evaluated 
carefully, but may provide supportive evidence. If doubts exist about the validity and the 
interpretation of the results, the evaluation needs to be taken by using a weight of evidence 
approach. 
 
The results of such older animal studies have been included in both the Phase 1 and Phase 2 
evaluations for transparency reasons, but only as supplementary evidence. 
 
3.1.3 In vitro data 
Two in vitro skin sensitisation methods have recently (February 2015) been adopted as OECD test 
guidelines. 
 
One test is the “in chemico” skin sensitisation ‘Direct Peptide Reactivity Assay’ (DPRA) (OECD TG 
442C). This method measures the ability of chemicals to react with proteins (haptenation), a 
determinant step in the induction of skin sensitisation. It is based on the chemical reactivity of the 
compound under investigation, with lysine and cysteine residues. The test method, however, is not 
proposed as a stand-alone full replacement test for the in vivo animal studies since the DPRA test is 
covering only one single biological step in the skin sensitisation pathway and does not consider 
metabolic capacity. DPRA information may also have the potential to contribute to potency 
assessment.  
 
Another test is the in vitro skin sensitisation ‘ARE-Nrf2 luciferase test’ (OECD TG 442D). This 
method measures activation of keratinocytes and determines the direct reactivity of sensitising 
material to key cysteine residues of Keap1, a regulator of Nrf2. The Nrf2-Keap1-ARE regulatory 
pathway is considered one of the most relevant pathways for the identification of potential skin 
sensitisers. The test method, however, is not proposed as a stand-alone full replacement test for the 
in vivo animal studies since it addresses only one single biological step in the overall mechanism of 
skin sensitisation. Considering the known limitations of this test such as the limited consideration 
of metabolic aspects and the ability to detect only cysteine-reactive chemicals, it has been 
recommended that the method should only be used in combination with other information sources.  
 
In vitro data are currently not part of the classification criteria for skin sensitisers according to the 
CLP Regulation and Guidance. 
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3.1.4 Non-testing data 
At present no formally validated non-testing systems exist to predict skin sensitising potential. 
However, data such as structural alert data or data to show that the chemical structure of a molecule 
is similar to that of known sensitisers (e.g. QSARs or expert systems) may form part of the weight of 
evidence for classification. 
 
 
3.2 Evaluation of data  
Phase 1 consisted of a screening of the available data for the selected 42 substances with the 
purpose of performing a preliminary assessment if the data could be sufficient for a classification in 
sub-category 1A according to the CLP criteria, i.e. an identification of possible sub-category 1A 
candidates. Therefore, a thorough evaluation of the retrieved data was not performed in Phase 1. 
 
In Phase 2, the quality of the data for the selected substances was assessed as described in section 
3.2.1 and the data considered valid for the purpose of the screening in this project were then 
assessed against the CLP classification criteria for skin sensitisation with special focus on whether 
classification in sub-category 1A is justified. The CLP classification criteria are summarised in 
section 3.2.2. 
 
3.2.1 Quality of data 
For each substance taken forward to Phase 2 the quality of the relevant data was assessed according 
to the Klimisch criteria (Klimisch et al., 1997).  
 
Each reference was given a score 1-4: 
 
 1 = reliable without restrictions: “studies or data generated according to generally valid and/or 
internationally accepted testing guidelines (preferably performed according to GLP) or in 
which the test parameters documented are based on a specific (national) testing guideline or in 
which all parameters described are closely related/comparable to a guideline method.” 
 2 = reliable with restrictions: “studies or data (mostly not performed according to GLP), in 
which the test parameters documented do not totally comply with the specific testing 
guideline, but are sufficient to accept the data or in which investigations are described which 
cannot be subsumed under a testing guideline, but which are nevertheless well documented 
and scientifically acceptable.” 
 3 = not reliable: “studies or data in which there were interferences between the measuring 
system and the test substance or in which organisms/test systems were used which are not 
relevant in relation to the exposure (e.g. un-physiological pathways of application) or which 
were carried out or generated according to a method which is not acceptable, the 
documentation of which is not sufficient for assessment and which is not convincing for an 
expert judgment.” 
 4 = not assignable: “studies or data which do not give sufficient experimental details and which 
are only listed in short abstracts or secondary literature (books, reviews, etc.).” 
 
 
Then, ‘reliable’ data (assigned score 1 or 2) were then assessed against the CLP classification criteria 
for skin sensitisation with special focus on whether classification in sub-category 1A is justified.  
Other data (assigned score 4) were also included in the assessment.  
Not ‘reliable’ data (assigned score 3) were not included in the assessment. 
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3.3 Comparison with classification criteria according to the CLP 
Regulation 
The available data for the substances evaluated in Phase 1 and Phase 2 were compared with the 
criteria for classification as skin sensitisers in sub-category 1A according to the CLP Regulation (EC 
no. 1272/2008). The classification criteria are presented below. The criteria are complex and 
further guidance for the use of the criteria and on how to evaluate the data are found in the CLP 
Guidance document “Guidance on the application of the CLP criteria” which is available from the 
European Chemicals Agency website (ECHA, 2015). 
 
3.3.1 Classification criteria for sub-category 1A 
According to Annex I, section 3.4.2.2.1.3 in the CLP regulation (EC no. 1272/2008): “Effects seen in 
either humans or animals will normally justify classification in a weight of evidence approach for 
skin sensitisers as described in section 3.4.2.2.2. Substances may be allocated to one of the two 
sub-categories 1A or 1B using a weight of evidence approach in accordance with the criteria given 
in Table 3.4.2 and on the basis of reliable and good quality evidence from human cases or 
epidemiological studies and/or observations from appropriate studies in experimental animals 
according to the guidance values provided in sections 3.4.2.2.2.1 and 3.4.2.2.3.2 for sub-category 
1A and in sections 3.4.2.2.2.2 and 3.4.2.2.3.3 for sub-category 1B.”.  
 
3.3.1.1 Criteria given in Table 3.4.2 for sub-category 1A 
Substances showing a high frequency of occurrence in humans and/or a high potency in animals 
can be presumed to have the potential to produce significant sensitisation in humans. Severity of 
reaction may also be considered. 
 
When considering human evidence, it is necessary to take into account the size of the population 
exposed and the extent of exposure and frequency, and thus the consideration is on a case by case 
basis. Human data should be incorporated with animal data to decide the sub-categorisation. 
 
3.3.1.2 Criteria for sub-category 1A listed in CLP Annex I, 3.4.2.2.2.1 – human 
data: 
Human evidence for sub-category 1A can include: 
 
 Positive responses at ≤ 500 μg/cm2 (HRIPT, HMT – induction threshold); 
 Diagnostic patch test data where there is a relatively high and substantial incidence of 
reactions in a defined population in relation to relatively low exposure; 
 Other epidemiological evidence where there is a relatively high and substantial incidence of 
allergic contact dermatitis in relation to relatively low exposure. 
 
 
  
  
 
Evaluation of selected sensitizing fragrance substances  25 
High and substantial incidence of reactions: 
For human diagnostic patch test data, only one or two types of the following information regarding 
a relative high and substantial incidence of reactions in a defined population may be sufficient for 
sub-categorisation: 
 
Human diagnostic patch test 
data 
High frequency Low / moderate 
frequency 
General population studies ≥ 0.2 % < 0.2 % 
Dermatitis patients (unselected, 
consecutive) 
≥ 1.0 % < 1.0 % 
Selected dermatitis patients 
(aimed testing, usually special 
test series) 
≥ 2.0 % < 2.0 % 
Work place studies: 
1: all or randomly selected 
workers 
2: selected workers with known 
exposure or dermatitis 
 
≥ 0.4 % 
≥ 1.0 % 
 
< 0.4 % 
< 1.0 % 
Number of published cases ≥ 100 cases < 100 cases 
 
Relatively low exposure: 
Relatively high or low exposure relates to the concentrations people are exposed to in their daily 
lives, in the workplace, or other conditions and resulting in sensitisation. The exposure index is the 
sum of the scores obtained from the information in each row of the table below, i.e. a response in 
each row is necessary. A relatively low exposure is indicated if the exposure index is between 1 and 
4. 
 
Exposure data Relatively low exposure Relatively high exposure 
Concentration / dose < 1.0 % 
< 500 µg/cm2 
(score 0) 
≥ 1.0 % 
≥ 500 µg/cm2 
(score 2) 
Repeated exposure < once/daily (score 1) ≥ once/daily (score 2) 
Number of exposures 
(irrespective of 
concentration of 
sensitiser) 
< 100 exposures (score 0) ≥ 100 exposures (score 2) 
 
3.3.1.3 Criteria for sub-category 1A listed in CLP Annex I, 3.4.2.2.3.2 – non-human 
data: 
Animal test results for sub-category 1A: 
 
 Local lymph node assay: EC3 value ≤ 2 % 
 Guinea pig maximisation test: ≥ 30 % responding at ≤ 0,1 % intradermal induction dose or ≥ 
60 % responding at > 0,1 % to ≤ 1 % intradermal induction dose 
 Buehler assay: ≥ 15 % responding at ≤ 0,2 % topical induction dose or ≥ 60 % responding at > 
0,2 % to ≤ 20 % topical induction dose 
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3.3.1.4 Weight of evidence 
For classification of a substance, evidence shall include any or all of the following using a weight of 
evidence approach: 
 
 Positive data from patch testing, normally obtained in more than one dermatology clinic 
 Epidemiological studies showing allergic contact dermatitis caused by the substance 
 Positive data from appropriate animal studies 
 Positive data from experimental studies in man 
 Well documented episodes of allergic contact dermatitis, normally obtained in more than one 
dermatology clinic 
 Severity of reaction may also be considered 
 
Positive effects seen in either humans or animals for skin sensitisation will normally justify 
classification. In cases where evidence is available from both sources, and there is conflict between 
the results, the quality and reliability of the evidence from both sources must be assessed in order to 
decide on the classification on a case-by-case basis. 
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Phase 1 consisted of a screening of the available data for the selected 42 substances with the 
purpose of performing a preliminary assessment if the available data could be sufficient for a 
classification in sub-category 1A according to the CLP criteria, i.e. an identification of possible sub-
category 1A candidates. 
 
Based on this preliminary assessment, each of the 42 selected substances was given a priority 1 or 2: 
 
 Priority 1 was given to those substances which were considered as possible sub-category 1A 
candidates, in total 20 substances.  
 Priority 2 was given to those substances which were not considered as possible sub-category 1A 
candidates, in total 22 substances.  
 
The justification for the prioritisation of the substances as 1 or 2 is presented in Appendix 3.  
 
The 20 substances given a priority 1 are listed in the table below: 
 
Substances CAS RN Substances of 
special concern 
according to 
SCCS (2012)3   
Butyl methacrylate 97-88-1  
Citral 5392-40-5 X 
Turpentine oil  8006-64-2 X 
Cinnamaldehyde 104-55-2 X 
Cinnamyl alcohol 104-54-1 X 
Coumarin 91-64-5 X 
Eugenol 97-53-0 X 
Farnesol  4602-84-0 X 
Geraniol 106-24-1 X 
7-Hydroxycitronellal 107-75-5 X 
Limonene 138-86-3 X 
Methyl oct-2-ynoate 111-12-6  
Ylang ylang ext. /  
Ylang ylang oil 
83863-30-3 / 
8006-81-3 
X 
Cinnamomum cassia leaf oil /  
Cinnamomum zeylanicum, ext. 
8007-80-5 /  
84649-98-9 
 
                                                                    
3 Special concern in the SCCS opinion (SCCS, 2012) is defined as due to the high number of reported cases, (>100 
cases). 
4. Results, Phase 1 
28 Evaluation of selected sensitizing fragrance substances 
 
Substances CAS RN Substances of 
special concern 
according to 
SCCS (2012)3   
Clove leaf oil 8000-34-8 X 
Evernia furfuracea, ext. 90028-67-4 X 
Evernia prunastri, ext. 90028-68-5 X 
Jasmine, Jasminum grandiflorum, ext. /  
Jasmine, Jasminum officinale, ext. /  
Extract Jasmine (oil), Jasmine, Jasminum 
grandiflorum, ext. 
84776-64-7 / 
90045-94-6 /  
8022-96-6 
X 
Balsams, Peru (Myroxylon pereirae) 8007-00-9 X 
Sandalwood, ext. /  
Sandalwood oil 
84787-70-2  / 
8006-87-9 
X 
 
Among these 20 substances, five were identified in the LOUS report as having a harmonised 
classification for skin sensitisation in Category 1 (H317) according to the CLP criteria. These 
substances are: Butyl methacrylate, citral, d-limonene, l-limonene, and turpentine oil.  
 
Among these 20 substances, 17 substances were identified in the SCCS (2012) opinion as 
established contact allergens in humans and considered to be of special concern as they have given 
rise to at least 100 reported cases (the substances marked having assigned an ‘X’ in the right column 
in the table above).  
  
The remaining three substances considered to be of special concern in the SCCS (2012) opinion 
(hydroxyisohexyl 3-cyclohexene carboxaldehyde (HICC), iseugenol and linalool) were not 
prioritised further in this project. HICC and iseugenol were among the 42 substances originally 
selected for the Phase 1 preliminary assessment. These two substances were, however, not given a 
priority 1 in the Phase 1 assessment as a harmonised classification in sub-category 1A already has 
been proposed, i.e. the purpose of the project has already been fulfilled. Linalool was not selected 
for this project as a harmonised classification in sub-category 1B recently has been endorsed by the 
EU Risk Assessment Committee (RAC). 
 
Among the 20 identified possible sub-category 1A candidates, a further prioritisation was 
performed for the selection of the Phase 2 substances, i.e. the substances to go through the more 
detailed assessment of the relevant data.  
 
The highest priority was given to the substances identified in the SCCS (2012) opinion as 
established contact allergens in humans and considered to be of special concern (marked with an ‘X’ 
in the right column of the table) and/or based on the clinical experience from the National Allergy 
Research Centre. 
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The 11 substances taken forward to Phase 2 are listed in the table below: 
 
Substances CAS RN Substances of 
special concern 
according to 
SCCS (2012) 
Citral 5392-40-5 X 
Cinnamaldehyde 104-55-2 X 
Cinnamyl alcohol 104-54-1 X 
Coumarin 91-64-5 X 
Eugenol 97-53-0 X 
Farnesol  4602-84-0 X 
Geraniol 106-24-1 X 
7-Hydroxycitronellal 107-75-5 X 
Methyl oct-2-ynoate 111-12-6  
Cinnamomum cassia leaf oil /  
Cinnamomum zeylanicum, ext. 
8007-80-5 /  
84649-98-9 
 
Evernia prunastri, ext. 90028-68-5 X 
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This chapter presents the results of the detailed assessment performed for the 11 substances 
selected for Phase 2. The results are presented as a summary of the available data, comparison with 
CLP Regulation criteria for classification in sub-category 1A, and conclusion on classification for 
each substance. Appendices 4-14 present the full overview of the available studies/data for the 
substances and the evaluation of their skin sensitising potential. 
 
Most of the studies included in the 11 substance evaluations have been cited from secondary 
literature, i.e. SCCS/SCCNFP opinions, REACH-RD and reviews and therefore assigned reliability 
score 4 “Not assignable” according to the Klimisch criteria (Klimisch et al., 1997) as described above 
in Section 3.2.1. The remaining part of the studies included in the 11 substance evaluations have 
been available in form of publications from the open literature and therefore assigned reliability 
score 2 “Reliable with restrictions” according to the Klimisch criteria. A substantial part of those 
studies cited from secondary literature are unpublished data from the Industry. 
 
The studies have been assessed against the CLP classification criteria for skin sensitisation with 
special focus on whether classification in sub-category 1A is justified.  
 
One of the elements in the criteria for classification in sub-category 1A based on human patch test 
data is ‘relatively low exposure’. Relatively high or low exposure relates to the concentrations of the 
substances in cosmetics and other consumer products which individuals are exposed to in their 
daily lives, in the workplace, or other conditions and resulting in sensitisation. A cut-off 
concentration of 1 % has been set in order to discriminate between relatively high exposure (≥ 1.0 
%) and relatively low exposure (< 1.0 %). 
In the SCCS opinion on fragrance allergens in cosmetic products (SCCS, 2012) it is mentioned that 
based on data from the fragrance industry (International Fragrance Association, IFRA), 80 % of the 
total fragrance chemical volume is used in cosmetics and 20 % in household products such as e.g., 
detergents. However, no quantitative information on the concentrations of fragrances in cosmetics 
and other consumer products is available in the SCCS opinion. Whether the exposure for the 11 
Phase 2 substances is relatively high or relatively low from use as fragrance in cosmetics and in 
other consumer products has therefore been evaluated based on the IFRA standard limit of each 
substance in each of 11 finished product categories (IFRA, 2015), i.e., if the IFRA standard limit is  
< 1.0 % the exposure is thus considered as being relatively low. The IFRA standard limits have 
generally been set based on quantitative risk assessment (QRA).  
For the application of QRA, consumer product types were grouped according to key parameters 
identified within the QRA approach, i.e., sensitisation assessment factors (SAFs) and consumer 
product exposure. By using these parameters, 11 different IFRA QRA categories for dermal 
sensitisation were specified by the QRA Expert Group. For many categories there is generally a wide 
diversity of product types including cosmetics as well as other consumer products. This is because 
the categories are based on SAFs and consumer product exposure, not on the functional similarity 
of each product type. 
The overall ‘category consumer exposure level’ is driven by the product type in that category with 
the combined highest consumer exposure level and highest SAF. These data are used with the WoE 
NESIL (Weight of Evidence No Expected Sensitization Induction Level) to calculate the ‘acceptable 
exposure level’ (AEL) for individual fragrance ingredients (AEL is the NESIL divided by the SAF 
and multiplied by the consumer exposure level).  
5. Results, Phase 2  
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A default maximum level of the fragrance ingredients identified as dermal sensitisers has been set 
for practical considerations. This ‘maximum pragmatic level’ is defined as the level not exceeding 
the usual concentration of the fragrance in the finished product. If the AEL derived from QRA is less 
than the ‘maximum pragmatic level’, the AEL is applied as the IFRA standard limit. Otherwise, the 
‘maximum pragmatic level’ is applied as the IFRA standard limit.  
The tables in the individual substance evaluations (Appendices 4-14) present the IFRA standard 
limit for each of the 11 IFRA QRA categories, as well as the product type that drives the ‘category 
consumer exposure level’. 
 
 
5.1 Citral 
 
5.1.1 Summary of the available data 
 
5.1.1.1 Human data 
A total of 30 results from patch test population studies, 7 HRIPTs, 14 HMTs and 2 case studies were 
identified for citral. The positive patch test frequencies from all of the reported patch test 
population studies vary between 0.3 and 16.7% in dermatitis patients. In studies with 
unselected/consecutive dermatitis patients positive reactions range between 0.3 and 4.8% (8 
studies) and in studies with selected dermatitis patients positive reactions range between 0.3 and 
16.7% (22 studies). The total number of published cases is > 300. Sensitisation was reported in 3/7 
HRIPT studies after exposure to 3876 µg/cm2 (5%) and in 13/14 HMT studies after exposure to 
1379 µg/cm2. 
 
5.1.1.2 Non-human information 
A total of 12 LLNAs, 6 GPMTs and 1 Buehler test were identified testing skin sensitising effects of 
citral. The reported EC3 values for citral ranged between 1.2% and 15% in different vehicles. In the 
GPMTs sensitisation was observed but not quantified (i.e. number of animals affected) in 3/6 
studies with intradermal induction doses of 0.4, 5 and 10% citral. In the other GPMTs sensitisation 
was observed in 60% of the animals after an intradermal induction dose of 0.1% and in 60-100% of 
the animals after an intradermal induction dose of 25% citral. Sensitisation was also observed but 
not quantified (i.e. number of animals affected) in the Buehler test with an induction concentration 
of 20% citral. 
 
No relevant in vitro studies on citral (i.e. OECD TG 442C and OECD TG 442D) were identified in 
the literature. 
 
5.1.1.3 Exposure 
According to data from IFRA (2013a) the exposure of citral when used as fragrance in cosmetics 
and in other consumer products appears to be low.   
 
5.1.2 Comparison with criteria 
For unselected/consecutive dermatitis patients positive reactions range between 0.3 and 4.8% with 
3/8 studies reporting frequencies higher than 1%. For selected dermatitis patients positive reactions 
range between 0.3 and 16.7% with 14 out of 22 studies reporting frequencies higher than 2%. In 
addition to this there are more than 300 published cases of positive patch test reactions to citral. 
According to the CLP criteria a frequency ≥ 1% for unselected/consecutive dermatitis patients 
and/or ≥ 2% for selected dermatitis patients and/or a total number of published cases ≥ 100, equals 
a high frequency of occurrence of skin sensitisation (Table 3.4.2-b) (ECHA, 2015). The collected 
data described above from patch test studies show that citral causes a high frequency of occurrence 
of skin sensitisation based on patch test data from a minority of unselected dermatitis patient 
studies and a majority of selected dermatitis patient studies and the number of published cases.  
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In regard to the HRIPT/HMT data the positive response reported at > 500 µg/cm2 for HRIPT/HMT 
induction threshold indicate evidence for sub-category 1B according to Annex I: 3.4.2.2.2.2. 
 
In the 14 LLNAs EC3 values between 1.2 and 15% were reported for citral. Two out of the 14 LLNAs 
reported an EC3 value <2%. According to the CLP Regulation an EC3 value ≤ 2% indicates 
classification of a substance in sub-category 1A whereas an EC3 value > 2% indicates classification 
of a substance in sub-category 1B (Annex I: 3.4.2.2.3.2.). Thus, these two studies indicate 
classification of citral in sub-category 1A. However, in the other 12 LLNAs, the EC3 value was >2% 
with only one of these 12 LLNAs reporting an EC3 value (2.1%) borderline to the cut-off criteria for 
classification in sub-category 1A or 1B indicating classification of citral in sub-category 1B. Based on 
a weight of evidence for the LLNAs, classification of citral in sub-category 1B seems justified. 
 
In 1/6 of the GPMTs sensitisation was observed in 60% of the animals after an intradermal 
induction dose of 0.1%. According to the CLP criteria a positive response ≥ 30% of the animals 
responding at ≤ 0.1% intradermal induction dose indicates classification of a substance in sub-
category 1A (Annex I: 3.4.2.2.3.2.) and thus, this study indicates classification of citral into sub-
category 1A. In 2/6 GPMTs sensitisation was observed in 60-100% of the animals after an 
intradermal induction dose of 25% citral. According to the CLP criteria a positive response ≥ 30% 
responding at > 1% intradermal induction dose indicates classification of a substance in sub-
category 1B (Annex I: 3.4.2.2.3.2.); thus, these two studies indicate classification of citral in sub-
category 1B. In 3/6 the GPMTs sensitisation was reported to be observed but not quantified (i.e. 
number of animals affected) with intradermal induction doses of 0.4, 5 and 10% citral; therefore, 
these GPMTs cannot be compared with the classification criteria.  
 
Sensitisation was also reported to be observed but not quantified (i.e. number of animals affected) 
in the Buehler test with an induction concentration of 20% citral; therefore, this study cannot be 
compared with the classification criteria.  
 
Overall, there is clear evidence for classification in sub-category 1A based on the human patch test 
studies showing a high frequency of occurrence of skin sensitisation and the total number of cases 
combined with the estimated low exposure. The results from the animal studies are equivocal, 
mainly indicating classification in sub-category 1B.  A classification as a skin sensitiser in sub-
category 1A is thus warranted for citral. 
 
5.1.3 Conclusions on classification and labelling 
Based on the high frequency of sensitisation observed in human patch test studies and the high 
number of published cases combined with the estimated low exposure, a classification of citral as a 
skin sensitiser in sub-category 1A is justified.  
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5.2 Cinnamaldehyde 
 
5.2.1 Summary of the available data 
 
5.2.1.1 Human data 
A total of 52 results from patch test population studies, 7 HRIPTs, 14 HMTs and 2 case studies were 
identified with cinnamaldehyde. The positive patch test frequencies from all of the reported patch 
test population studies vary between 0.93 and 90% in dermatitis patients. In studies with 
unselected/consecutive dermatitis patients positive reactions range between 0.93 and 32.5% (8 
studies) and in studies with selected dermatitis patients positive reactions range between 1.2 and 
90% (44 studies). A single study in workers reported positive patch test reactions in 1%. The total 
number of published cases is > 2300. A LOEL-HRIPT/HMT (induction) of 775 µg/cm2 was 
established for cinnamaldehyde by the RIFM Expert Panel based on unpublished reports. 
 
5.2.1.2 Non-human information 
A total of 22 LLNAs and 2 LLNA BrdU-ELISA tests were identified testing skin sensitising effects of 
cinnamaldehyde. The reported EC3 values for cinnamaldehyde ranged between 0.2% and 3.1% in 
different vehicles.  
 
No relevant in vitro studies on cinnamaldehyde (i.e. OECD TG 442C and OECD TG 442D) were 
identified in the literature. 
 
5.2.1.3 Exposure 
According to data from IFRA (2013b) the exposure of cinnamaldehyde when used as fragrance in 
cosmetics and in other consumer products appears to be low.  
 
5.2.2 Comparison with criteria 
For unselected/consecutive dermatitis patients positive reactions range between 0.93 and 32.5% 
with 7/8 studies reporting frequencies higher than 1%. For selected dermatitis patients positive 
reactions range between 1.2 and 90% with 37 out of 44 studies reporting frequencies higher than 
2%. A single study in workers reported positive patch test reactions in 1%. In addition to this there 
are more than 2300 published cases of positive patch test reactions to cinnamaldehyde. According 
to the CLP criteria a frequency ≥ 1% for unselected/consecutive dermatitis patients and/or ≥ 2% for 
selected dermatitis patients and/or ≥ 1% for selected workers with known exposure or dermatitis 
and/or a total number of published cases ≥ 100, equals a high frequency of occurrence of skin 
sensitisation (Table 3.4.2-b) (ECHA, 2015). The collected data described above from patch test 
studies show that cinnamaldehyde causes a high frequency of occurrence of skin sensitisation based 
on these four types of information.  
In regard to the HRIPT/HMT data the positive response reported at > 500 µg/cm2 for HRIPT/HMT 
induction threshold indicate evidence for sub-category 1B according to Annex I: 3.4.2.2.2.2. 
 
In the 22 LLNAs EC3 values between 0.2 and 3.1% were reported for cinnamaldehyde with 21/22 
EC3 values <2%. According to the CLP Regulation an EC3 value  2% indicates classification of a 
substance in sub-category 1A (Annex I: 3.4.2.2.3.2.). Hence, data from LLNAs indicate classification 
of cinnamaldehyde in sub-category 1A.  
 
Overall, there is clear evidence for classification in sub-category 1A based on the human patch test 
studies showing a high frequency of occurrence of skin sensitisation and the total number of cases 
combined with the estimated low exposure. Data from HRIPT/HMT indicate evidence for sub-
category 1B. Data from the LLNAs support a sub-category 1A classification. A classification as a skin 
sensitiser in sub-category 1A is thus warranted for cinnamaldehyde. 
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5.2.3 Conclusions on classification and labelling 
Based on the high frequency of sensitisation observed in human patch test studies and the high 
number of published cases combined with the estimated low exposure and supported by data from 
LLNAs, a classification of cinnamaldehyde as a skin sensitiser in sub-category 1A is justified. 
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5.3 Cinnamyl alcohol 
 
5.3.1 Summary of the available data 
 
5.3.1.1 Human data 
A total of 34 patch test population studies, 3 HRIPTs, 25 HMTs and 4 case studies, were identified 
with cinnamyl alcohol.   The positive patch test frequencies from all of the reported patch test 
studies vary between 0.56 and 100% in dermatitis patients. In studies with unselected/consecutive 
dermatitis patients positive reactions range between 0.56 and 1.8% (4 studies) and in studies with 
selected dermatitis patients positive reactions range between 1.5 and 100% (30 studies). The total 
number of published cases is > 600. A LOEL (induction) of 4724 µg/cm2 was derived from the 
HRIPT/HMT studies. 
 
5.3.1.2 Non-human information 
A total of 5 LLNAs (two of which were reported to be conducted in accordance with OECD TG 429), 
2 GPMT, 1 Freund’s complete adjuvant test (FCAT) and 1 Buehler test were identified testing the 
skin sensitisation of cinnamyl alcohol. EC3 values between 17.9 and 30% were reported for 
cinnamyl alcohol in the LLNAs and positive reactions were observed in a GPMT (30% positive) and 
FCAT (15% positive) at intradermal induction doses of 25 and 100%, respectively. No positive 
reactions were observed in the Buehler test. 
 
No relevant in vitro studies on cinnamyl alcohol (i.e. OECD TG 442C and OECD 442D) were 
identified in the literature. 
 
5.3.1.3 Exposure 
According to data from IFRA (2008a) the exposure of cinnamyl alcohol when used as fragrance in 
cosmetics and in other consumer products appears to be low.  
 
5.3.2 Comparison with criteria 
For unselected/consecutive dermatitis patients positive reactions range between 0.56 and 1.8% with 
1/4 studies reporting frequencies higher than 1%. For selected dermatitis patients positive reactions 
range between 1.5 and 100% with 28 out of 30 studies reporting frequencies higher than 2%. In 
addition to this there are more than 600 published cases of positive patch test reactions to cinnamyl 
alcohol. According to the CLP criteria a frequency ≥ 1% for unselected/consecutive dermatitis 
patients and/or ≥ 2% for selected dermatitis patients and/or a total number of published cases ≥ 
100, equals a high frequency of occurrence of skin sensitisation (Table 3.4.2-b) (ECHA, 2015). The 
collected data described above from patch test studies show that cinnamyl alcohol causes a high 
frequency of occurrence of skin sensitisation based on frequencies in selected dermatitis patients 
and total number of cases.  
In regard to the HRIPT/HMT data the positive response reported at > 500 µg/cm2 for HRIPT/HMT 
induction threshold indicate evidence for sub-category 1B according to Annex I: 3.4.2.2.2.2.  
 
In the LLNAs EC3 values between 17.9 and 30% were reported for cinnamyl alcohol. According to 
the CLP Regulation an EC3 value larger than 2% indicates placement of cinnamyl alcohol into sub-
category 1B (Annex I: 3.4.2.2.3.2.).  
 
In the GPMT sensitisation was observed in 30% of the animals after an intradermal induction dose 
of 25% cinnamyl alcohol. According to the CLP criteria a positive response ≥ 30% of the animals 
responding at >1% intradermal induction dose indicates classification of a substance in sub-
category 1B (Annex I: 3.4.2.2.3.2.). 
 
No sensitisation was observed in the Buehler test after an induction dose of 30% cinnamyl alcohol.  
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Overall, there is clear evidence for classification in sub-category 1A based on the frequency of 
sensitisation in human patch test studies with selected dermatitis patients and the total number of 
cases combined with the estimated low exposure. Data from HRIPT/HMT indicate evidence for 
sub-category 1B. All animal studies indicate a classification in sub-category 1B. A classification as a 
skin sensitiser in sub-category 1A is warranted for cinnamyl alcohol. 
 
5.3.3 Conclusions on classification and labelling 
Based on the high frequency of sensitisation observed in human patch test studies and the high 
number of published cases combined with the estimated low exposure a classification of cinnamyl 
alcohol as a skin sensitiser in sub-category 1A is justified. 
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5.4 Coumarin 
 
5.4.1 Summary of the available data 
 
5.4.1.1 Human data 
A total of 25 patch test population studies and 2 case studies, one of which included a ROAT, were 
identified with coumarin. The positive patch test frequencies from all of the reported patch test 
studies vary between 0 and 10% in dermatitis patients. In studies with unselected/consecutive 
dermatitis patients positive reactions range between 0 and 0.8% (7 studies) and in studies with 
selected dermatitis patients positive reactions range between 0 and 10% (19 studies). The total 
number of published cases is > 200. A LOEL (induction) of 8858 µg/cm2 was derived from the 
HRIPT/HMT studies. 
 
5.4.1.2 Non-human information 
A total of 20 LLNAs and 1 GPMT were identified testing skin sensitising effects of coumarin. The 
collected evidence from the LLNAs indicates an EC3 for coumarin of ca. 50%. Sensitisation was not 
observed in the GPMT after an intradermal induction dose of 0.5% coumarin. 
 
Contaminants in coumarin may act as weak or moderate sensitizers (SCCS, 2012).  
 
No relevant in vitro studies on coumarin (i.e. OECD TG 442C and OECD 442D) were identified in 
the literature.   
 
5.4.1.3 Exposure 
According to data from IFRA (2008b) the exposure of coumarin when used as fragrance in 
cosmetics and in other consumer products appears to be low. 
 
5.4.2 Comparison with criteria 
For unselected/consecutive dermatitis patients positive reactions range between 0 and 0.8% i.e. all 
7 studies reporting frequencies lower than 1%. For selected dermatitis patients positive reactions 
range between 0 and 10% with 9 out of 19 studies reporting frequencies higher than 2%. In addition 
to this there are more than 200 published cases of positive patch test reactions to coumarin. 
According to the CLP criteria a frequency ≥ 1% for unselected/consecutive dermatitis patients 
and/or ≥ 2% for selected dermatitis patients and/or a total number of published cases ≥ 100, equals 
a high frequency of occurrence of skin sensitisation (Table 3.4.2-b) (ECHA, 2015). The collected 
data described above from patch test studies show that coumarin causes a low/moderate frequency 
of occurrence of skin sensitisation based on unselected/consecutive dermatitis patients and 10/19 
studies with selected dermatitis patients. The remaining studies with selected dermatitis patients 
(9/19) and number of published cases shows that coumarin causes a high frequency of occurrence 
of skin sensitisation in humans.  
In regard to the HRIPT/HMT data the positive response reported at > 500 µg/cm2 for HRIPT/HMT 
induction threshold indicate classification of coumarin in sub-category 1B according to Annex I: 
3.4.2.2.2.2. 
 
The collected evidence from the LLNAs indicates an EC3 for coumarin of ca. 50%. According to the 
CLP Regulation an EC3 value ≤ 2% indicates classification of a substance in sub-category 1A 
whereas an EC3 value > 2% indicates classification of a substance in sub-category 1B (Annex I: 
3.4.2.2.3.2.). Thus, all studies indicate classification of coumarin in sub-category 1B. 
 
The single GPMT with an intradermal induction dose of 0.5% gave no positive reactions which does 
not justify sub-categorisation (Table 3.4.3). 
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Overall, there is evidence for classification in sub-category 1A based on the number of cases 
combined with the estimated low exposure and supported by patch test data from selected 
dermatitis patients. Data from HRIPT/HMT indicate evidence for sub-category 1B. Data from 
LLNAs indicate a classification in sub-category 1B. A classification as a skin sensitiser in sub-
category 1A is warranted for coumarin. 
 
5.4.3 Conclusions on classification and labelling 
Based on the number of cases combined with the estimated low exposure and supported by patch 
test data from selected dermatitis patients, a classification of coumarin as a skin sensitiser in sub-
category 1A is justified.  
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5.5 Eugenol 
 
5.5.1 Summary of the available data 
 
5.5.1.1 Human data 
A total of 36 patch test population studies, 1 ROAT and 1 case study were identified with eugenol.   
The positive patch test frequencies from all of the reported patch test studies vary between 0.3 and 
55.4% in dermatitis patients. In studies with unselected/consecutive dermatitis patients positive 
reactions range between 0.3 and 1.9% (5 studies) and in studies with selected dermatitis patients 
positive reactions range between 0.62 and 55.4% (31 studies). The total number of published cases 
is > 700. A NESIL from HRIPT studies of 5900 µg/cm2 was derived based on weight of evidence by 
the RIFM Expert Panel. 
 
 
5.5.1.2 Non-human information 
A total of 15 LLNAs and one GPMT were identified testing the skin sensitisation of eugenol. EC3 
values were reported in 13 studies and ranged between 4.2 and 25.1%. Positive reactions (20%) were 
observed in the GPMT at an intradermal induction dose of 5%.  
 
No relevant in vitro studies on eugenol (i.e. OECD TG 442C and OECD 442D) were identified in the 
literature. 
 
5.5.1.3 Exposure 
According to data from IFRA (2008c) the exposure of eugenol when used as fragrance in cosmetics 
and in other consumer products appears to be low.    
 
5.5.2 Comparison with criteria 
For unselected/consecutive dermatitis patients positive reactions range between 0.3 and 1.9% with 
2 out of 5 studies reporting frequencies higher than 1%.  For selected dermatitis patients positive 
reactions range between 0.62 and 55.4% with 25 out of 31 studies reporting frequencies higher than 
2%. In addition to this there are more than 700 published cases of positive patch test reactions to 
eugenol. According to the CLP criteria a frequency ≥ 1% for unselected/consecutive dermatitis 
patients and/or ≥ 2% for selected dermatitis patients and/or a total number of published cases ≥ 
100, equals a high frequency of occurrence of skin sensitisation (Table 3.4.2-b) (ECHA, 2015). The 
collected data described above from patch test studies show that eugenol causes a high frequency of 
occurrence of skin sensitisation based on the frequency of positive reactions mainly in selected 
dermatitis patients (>2% in 21/27 studies) and the total number of cases.  
In regard to the HRIPT/HMT data the positive response reported at > 500 µg/cm2 for HRIPT/HMT 
induction threshold indicate evidence for sub-category 1B according to Annex I: 3.4.2.2.2.2. 
 
In the LLNA tests, EC3 values between 4.2 and 25.1% (13 studies) were reported for eugenol. 
According to the CLP Regulation an EC3 value larger than 2 indicates placement of eugenol into 
sub-category 1B (Annex I: 3.4.2.2.3.2.).  
 
In the GPMT sensitisation was observed in 20% of the animals after an intradermal induction dose 
of 5% which does not justify sub-categorisation into either sub-category 1A or 1B (Annex I: 
3.4.2.2.3.2.). 
 
Overall, there is clear evidence for classification in sub-category 1A based on the frequency of 
sensitisation in human patch test studies mainly with selected dermatitis patients and the total 
number of cases combined with the estimated low exposure. Data from HRIPT/HMT indicate 
evidence for sub-category 1B. Data from LLNAs indicate a classification in sub-category 1B. A 
classification as a skin sensitiser in sub-category 1A is warranted for eugenol. 
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5.5.3 Conclusions on classification and labelling 
Based on the high frequency of sensitisation observed in human patch test studies and the high 
number of published cases, combined with the estimated low exposure, a classification of eugenol 
as a skin sensitiser in sub-category 1A is justified. 
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5.6 Farnesol 
 
5.6.1 Summary of the available data 
 
5.6.1.1 Human data 
A total of 20 patch test population studies, 3 HRIPTs, 11 HMTs and 2 case studies were identified 
with farnesol.   The positive patch test frequencies from all of the reported patch test population 
studies vary between 0.02 and 13.2% in dermatitis patients. In studies with unselected/consecutive 
dermatitis patients positive reactions range between 0.35 and 0.9% (4 studies) and in studies with 
selected dermatitis patients positive reactions range between 0.02 and 13.2% (16 studies). The total 
number of published cases is > 250. Positive responses after farnesol were seen at concentrations ≥ 
6900 µg/cm2 in 5/11 HMTs.  
 
5.6.1.2 Non-human information 
A total of two LLNAs and four GPMTs were identified testing skin sensitising effects of farnesol. 
EC3 values were 5.5 and 4.1%. In the GPMTs no positive reactions were observed after intradermal 
induction doses of 0.16, 5 and 10% farnesol.  
 
No relevant in vitro studies on farnesol (i.e. OECD TG 442C and OECD 442D) were identified in the 
literature. 
 
5.6.1.3 Exposure 
According to data from IFRA (2006) the exposure of farnesol when used as fragrance in cosmetics 
and in other consumer products appears to be low. 
 
5.6.2 Comparison with criteria 
For unselected/consecutive dermatitis patients positive reactions range between 0.35 and 0.9% i.e. 
all 4 studies reporting frequencies lower than 1%. For selected dermatitis patients positive reactions 
range between 0.02 and 13.2% with 7 out of 16 studies reporting frequencies higher than 2%. In 
addition to this there are more than 250 published cases of positive patch test reactions to farnesol. 
According to the CLP criteria a frequency ≥ 1% for unselected/consecutive dermatitis patients 
and/or ≥ 2% for selected dermatitis patients and/or a total number of published cases ≥ 100, equals 
a high frequency of occurrence of skin sensitisation (Table 3.4.2-b) (ECHA, 2015). The collected 
data described above from patch test studies show that farnesol causes a low/moderate frequency of 
occurrence of skin sensitisation based on unselected/consecutive dermatitis patients and 9/16 
studies with selected dermatitis patients. The remaining studies with selected dermatitis patients 
(7/16) and number of published cases shows that farnesol causes a high frequency of occurrence of 
skin sensitisation in humans.  
In regard to the HRIPT/HMT data the positive response reported at > 500 µg/cm2 for HRIPT/HMT 
induction threshold indicate classification of farnesol in sub-category 1B according to Annex I: 
3.4.2.2.2.2. 
 
In the two LLNAs the lowest EC3 value for farnesol was 4.1%. According to the CLP Regulation an 
EC3 value ≤ 2% indicates classification of a substance in sub-category 1A whereas an EC3 value > 
2% indicates classification of a substance in sub-category 1B (Annex I: 3.4.2.2.3.2.). Thus, both 
studies indicate classification of farnesol in sub-category 1B. 
 
Sensitisation was not observed in the four GPMTs with intradermal induction doses of 0.16, 5 and 
10% farnesol which do not justify sub-categorisation (Table 3.4.3).  
 
Overall, there is evidence for classification in sub-category 1A based on the number of cases 
combined with the estimated low exposure. Data from HRIPT/HMT indicate evidence for sub-
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category 1B. Data from LLNAs indicate a classification in sub-category 1B. A classification as a skin 
sensitiser in sub-category 1A is warranted for farnesol. 
 
5.6.3 Conclusions on classification and labelling 
Based on the number of cases combined with the estimated low exposure, a classification of farnesol 
as a skin sensitiser in sub-category 1A is justified.  
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5.7 Geraniol 
 
5.7.1 Summary of the available data 
 
5.7.1.1 Human data 
A total of 84 results from patch test population studies, 7 HRIPTs, 4 HMTs and 2 case studies were 
identified with geraniol. The positive patch test frequencies from all of the reported patch test 
population studies vary between 0 and 40% in dermatitis patients. In studies with 
unselected/consecutive dermatitis patients positive reactions range between 0 and 1.2% (10 studies) 
and in studies with selected dermatitis patients positive reactions range between 0 and 40% (74 
studies). The total number of published cases is > 900. Sensitisation was reported in 2/4 HRIPT 
studies after exposure to 10% geraniol (11 810 µg/cm2) and in 1/4 HMT studies after exposure to 
4140 µg/cm2.  
 
5.7.1.2 Non-human information 
A total of 9 LLNAs, 5 GPMTs and 1 Buehler test were identified testing skin sensitising effects of 
geraniol. The reported EC3 values for geraniol ranged between 5.6% and 25.8% in different 
vehicles.  In the GPMTs sensitisation was observed but not quantified (i.e. number of animals 
affected) in 4/5 studies with intradermal induction doses of 0.1, 5 and 10% geraniol. No 
sensitisation was observed in 1/5 GMPTs with an induction concentration of 50% geraniol and in 
the Buehler test with an induction concentration of 15% geraniol. 
 
No relevant in vitro studies on geraniol (i.e. OECD TG 442C and OECD TG 442D) were identified in 
the literature. 
 
5.7.1.3 Exposure 
According to data from IFRA (2007) the exposure of geraniol when used as fragrance in cosmetics 
and in other consumer products appears to be relatively low. A recent study has indicated that up to 
0.86% of the population might be exposed to geraniol from personal care products and household 
cleaning agents at levels exceeding the estimated Acceptable Exposure Level of 55 µg/cm2 (Nijkamp 
et al., 2015). 
 
5.7.2 Comparison with criteria 
For unselected/consecutive dermatitis patients positive reactions range between 0 and 1.2% with 
2/10 studies reporting frequencies higher than 1%. For selected dermatitis patients positive 
reactions range between 0 and 40% with 44 out of 74 studies reporting frequencies higher than 2%. 
In addition to this there are more than 900 published cases of positive patch test reactions to 
geraniol. According to the CLP criteria a frequency ≥ 1% for unselected/consecutive dermatitis 
patients and/or ≥ 2% for selected dermatitis patients and/or a total number of published cases ≥ 
100, equals a high frequency of occurrence of skin sensitisation (Table 3.4.2-b) (ECHA, 2015). The 
collected data described above from patch test studies show that geraniol causes a high frequency of 
occurrence of skin sensitisation based on patch test data mainly from selected dermatitis patients 
and the number of published cases.  
In regard to the HRIPT/HMT data the positive response reported at > 500 µg/cm2 for HRIPT/HMT 
induction threshold indicate classification of geraniol in sub-category 1B according to Annex I: 
3.4.2.2.2.2. 
 
In the LLNAs EC3 values between 5.6 (vehicle: ethanol) and 25.8% (vehicle: ethanol:diethyl 
phthalate 1:3) were reported for geraniol. According to the CLP Regulation an EC3 value larger than 
2% indicates classification of geraniol in sub-category 1B.  
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In the GPMTs sensitisation was reported to be observed but not quantified (i.e. number of animals 
affected) in 4/5 studies with intradermal induction doses of 0.1, 5 and 10% geraniol, therefore, these 
GPMTs cannot be compared with the classification criteria.  
 
No sensitisation was observed in the Buehler test with an induction concentration of 15% geraniol. 
Overall, there is clear evidence for classification in sub-category 1A based on the frequency of 
sensitisation in human patch test studies mainly with selected dermatitis patients and the total 
number of cases combined with the estimated relatively low exposure. Data from HRIPT/HMT 
indicate evidence for sub-category 1B. LLNAs indicate a classification in sub-category 1B. A 
classification as a skin sensitiser in sub-category 1A is warranted for geraniol. 
 
5.7.3 Conclusions on classification and labelling 
Based on the high frequency of sensitisation observed in human patch test studies and the high 
number of published cases, combined with the estimated relatively low exposure, a classification of 
geraniol as a skin sensitiser in sub-category 1A is justified.  
 
 
  
  
 
Evaluation of selected sensitizing fragrance substances  45 
5.8 7-Hydroxycitronellal 
 
5.8.1 Summary of the available data 
 
5.8.1.1 Human data 
A total of 39 results from patch test population studies, 4 modified HRIPTs, 15 HMTs and 3 case 
studies were identified with 7-hydroxycitronellal. The positive patch test frequencies from all of the 
reported patch test population studies vary between 0 and 55% in dermatitis patients. In studies 
with unselected/consecutive dermatitis patients positive reactions range between 0.9 and 2.6% (4 
studies) and in studies with selected dermatitis patients positive reactions range between 0 and 55% 
(35 studies). The total number of published cases is > 800. A LOEL-HRIPT/HMT (induction) of 
5906 µg/cm2 was established for 7-hydroxycitronellal by the RIFM Expert Panel.  
 
5.8.1.2 Non-human information 
A total of 7 LLNAs including 1 LLNA ex vivo BrdU, 1 GPMT and 1 Buehler test were identified 
testing skin sensitising effects of 7-hydroxycitronellal. The reported EC3 values for 7-
hydroxycitronellal range between 9.8 and 33%. In the GPMTs sensitisation was observed but not 
quantified (i.e. number of animals affected) in 3/6 studies with intradermal induction doses of 0.4, 
5 and 10% citral. In the GPMT sensitisation in 60% of the animals (number of animals not 
reported) after an intradermal induction dose of 0.5% 7-hydroxycitronellal. Sensitisation was also 
observed in 38% of the animals in the Buehler test with an induction concentration of 30% 7-
hydroxycitronellal. 
 
No relevant in vitro studies on 7-hydroxycitronellal (i.e. OECD TG 442C and OECD TG 442D) were 
identified in the literature. 
 
5.8.1.3 Exposure 
 
According to data from IFRA (2013c) the exposure of 7-hydroxycitronellal when used as fragrance 
in cosmetics and in other consumer products appears to be low.    
 
5.8.2 Comparison with criteria 
For unselected/consecutive dermatitis patients positive reactions range between 0.9 and 2.6% with 
1/4 studies reporting frequencies higher than 1%. For selected dermatitis patients positive reactions 
range between 0 and 55% with 29 out of 33 studies reporting frequencies equal to or higher than 
2%. In addition to this there are more than 800 published cases of positive patch test reactions to 7-
hydroxycitronellal. According to the CLP criteria a frequency ≥ 1% for unselected/consecutive 
dermatitis patients and/or ≥ 2% for selected dermatitis patients and/or a total number of published 
cases ≥ 100, equals a high frequency of occurrence of skin sensitisation (Table 3.4.2-b). The 
collected data described above from patch test studies show that 7-hydroxycitronellal causes a high 
frequency of occurrence of skin sensitisation based on these three types of information.  
In regard to the HRIPT/HMT data the positive response reported at > 500 µg/cm2 for HRIPT/HMT 
induction threshold indicate evidence for sub-category 1B according to Annex I: 3.4.2.2.2.2.  
 
In the seven LLNAs EC3 values between 9.8 and 33% were reported for 7-hydroxycitronellal. 
According to the CLP Regulation an EC3 value  2% indicates classification of a substance in sub-
category 1A whereas an EC3 value > 2% indicates classification of a substance in sub-category 1B 
(Annex I: 3.4.2.2.3.2.). Thus, all seven studies indicate classification of 7-hydroxycitronellal in sub-
category 1B.  
 
In the GPMT sensitisation was observed in 60% of the animals after an intradermal induction dose 
of 0.5% 7-hydroxycitronellal. According to the CLP criteria a positive response ≥ 60% of the animals 
responding at >0.1% to ≤ 1% intradermal induction dose indicates classification of a substance in 
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sub-category 1A (Annex I: 3.4.2.2.3.2.) and thus, this study indicates classification of 7-
hydroxycitronellal into sub-category 1A.  
 
Sensitisation was also observed in 38% of the animals in a Buehler test with an induction 
concentration of 30% 7-hydroxycitronellal. According to the CLP criteria a positive response ≥ 15% 
of the animals responding at >20% topical induction dose indicates classification of a substance in 
sub-category 1B (Annex I: 3.4.2.2.3.3.) and thus, this study indicates classification of 7-
hydroxycitronellal into sub-category 1B. 
 
Overall, there is clear evidence for classification in sub-category 1A based on the human patch test 
studies showing a high frequency of occurrence of skin sensitisation and the total number of cases 
combined with the estimated low exposure. Except from the GMTP study, which supports a sub-
category 1A classification, the remaining animal studies (LLNA and Buehler) indicate a 
classification in sub-category 1B. A classification as a skin sensitiser in sub-category 1A is thus 
warranted for 7-hydroxycitronellal. 
 
5.8.3 Conclusions on classification and labelling 
Based on the high frequency of sensitisation observed in human patch test studies and the high 
number of published cases combined with the estimated low exposure a classification of 7-
hydroxycitronellal as a skin sensitiser in sub-category 1A is justified.  
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5.9 Methyl oct-2-ynoate 
 
5.9.1 Summary of the available data 
 
5.9.1.1 Human data 
A total of 11 results from patch test population studies and 5 case studies were identified with 
methyl oct-2-ynate. The positive patch test frequencies from all of the reported patch test 
population studies vary between 0 and 2.9% in dermatitis patients. In studies with 
unselected/consecutive dermatitis patients positive reactions range between 0 and 1.67% (3 studies) 
and in studies with selected dermatitis patients positive reactions range between 0.1 and 2.9% (8 
studies). The total number of published cases is > 25. A LOEL-HRIPT/HMT (induction) of 
194 µg/cm2 was established for methyl oct-2-ynate by the RIFM Expert Panel based on unpublished 
reports.  
 
5.9.1.2 Non-human information 
A total of 2 LLNAs (OECD TG 429), 1 GPMT and 1 Buehler test were identified testing skin 
sensitising effects of methyl oct-2-ynate. In both LLNA studies an EC3 value of <0.5% was reported. 
In the GPMT sensitisation was observed in 90 % of the animals after an intradermal induction dose 
of 0.625% methyl oct-2-ynate. Sensitisation was also observed in the Buehler test with positive 
reactions in 45-70% of the animals after an induction dose of 2.5%. 
 
No relevant in vitro studies on methyl oct-2-ynate (i.e. OECD TG 442C and OECD 442D) were 
identified in the literature.  
 
5.9.1.3 Exposure 
According to data from IFRA (2008d) the exposure of methyl oct-2-ynate when used as fragrance in 
cosmetics and in other consumer products appears to be low.    
    
5.9.2 Comparison with criteria 
For unselected/consecutive dermatitis patients positive reactions range between 0 and 1.67% with 
1/3 studies reporting frequencies higher than 1%. For selected dermatitis patients positive reactions 
range between 0.1 and 2.9% with 1 out of 8 studies reporting frequencies higher than 2%. In 
addition to this there are more than 25 published cases of positive patch test reactions to methyl 
oct-2-ynate. According to the CLP criteria a frequency ≥ 1% for unselected/consecutive dermatitis 
patients and/or ≥ 2% for selected dermatitis patients and/or a total number of published cases ≥ 
100, equals a high frequency of occurrence of skin sensitisation (Table 3.4.2-b) (ECHA, 2015). The 
collected data described above from patch test studies show that methyl oct-2-ynate causes a 
low/moderate frequency of occurrence of skin sensitisation based on these three types of 
information. In regard to HRIPT studies positive responses were observed at exposure to 194 
µg/cm2 methyl 2-ocytnoate. A positive response at ≤ 500 µg/cm2 in a HRIPT or HMT suggests 
categorisation into sub-category 1A according to Annex I: 3.4.2.2.2.1 and 3.4.2.2.2.2.  
 
In the 2 LLNAs EC3 values were <0.5%. According to the CLP Regulation an EC3 value  2% 
indicates classification of a substance in sub-category 1A (Annex I: 3.4.2.2.3.2.).  
 
In the GPMT sensitisation was observed in 90% of the animals after an intradermal induction dose 
of 0.625%. According to the CLP criteria a positive response ≥ 60% of the animals responding at > 
0.1% to ≤ 1% intradermal induction dose indicates classification of a substance in sub-category 1A 
(Annex I: 3.4.2.2.3.2.). 
 
In the Buehler test sensitisation was observed in 45-70% of the animals after an induction does of 
2.5%. According to the CLP criteria a positive response ≥ 60% of the animals responding at > 0.2% 
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to ≤ 20% topical induction dose indicates classification of a substance in sub-category 1A (Annex I: 
3.4.2.2.3.2.).  
 
Overall, there is clear evidence for classification in sub-category 1A based on the very low EC3 
values from the LLNAs. The results from GPMT and the Buehler test also supports sub-category 1A. 
Data from human patch test studies and the number of published cases justify classification of 
methyl oct-2-ynate in sub-category 1B while data from HRIPT studies justify classification of methyl 
oct-2-ynate in sub-category 1A. A classification as a skin sensitiser in sub-category 1A is thus 
warranted for methyl oct-2-ynate. 
 
5.9.3 Conclusions on classification and labelling 
Based on HRIPT data, the very low EC3 value from LLNAs and results from GPMT and Buehler 
tests a classification of methyl oct-2-ynate as a skin sensitser in sub-category 1A is justified. 
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5.10 Cinnamomum cassia leaf oil / Cinnamomum zeylanicum, ext. 
 
5.10.1 Summary of the available data 
 
5.10.1.1 Human data 
A total of 27 positive cases and frequencies between 1 and 27.8% in selected dermatitis patients 
tested with “cassia” essential oil or “cinnamon oil” were observed.  
 
5.10.1.2 Non-human information 
No animal studies with Cinnamomum cassia leaf oil / Cinnamomum zeylanicum, ext. have been 
identified. 
 
5.10.1.3 Exposure 
It has not been possible to identify any data on exposure to Cinnamomum cassia leaf oil or 
Cinnamomum zeylanicum, ext. 
 
 
5.10.2 Comparison with criteria 
One out of two studies with “cassia” essential oil gave a frequency of positive patch tests in selected 
patients of 27.8% i.e. ≥ 2%, which indicate categorisation into sub-category 1A.  
No animal studies with Cinnamomum cassia leaf oil / Cinnamomum zeylanicum, ext. have been 
identified. 
 
5.10.3 Conclusions on classification and labelling 
Data on Cinnamomum cassia leaf oil / Cinnamomum zeylanicum, ext. alone is insufficient for sub-
categorisation of Cinnamomum cassia leaf oil / Cinnamomum zeylanicum, ext. according to CLP 
criteria. It may be possible to sub-categorise Cinnamomum cassia leaf oil / Cinnamomum 
zeylanicum, ext. based on their constituents by read across to the major compounds such as 
cinnamaldehyde (for Cassia bark extract, Cassia oil, Cinnamon bark extract and Cinnamon bark oil) 
and eugenol (for Cinnamon leaf oil). 
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5.11 Evernia prunastri extract 
 
5.11.1 Summary of the available data 
 
5.11.1.1 Human data 
A total of 35 results from patch test population studies, 5 HRIPTs and 2 case studies were identified 
with Evernia prunastri ext. The positive patch test frequencies from all of the reported patch test 
population studies vary between 0 and 64% in dermatitis patients. In studies with 
unselected/consecutive dermatitis patients positive reactions range between 1.8 and 6.8% (7 
studies) and in studies with selected dermatitis patients positive reactions range between 0 and 
64% (28 studies). The total number of published cases is > 1900. A LOEL-HRIPT/HMT (induction) 
of 1417 µg/cm2 was established for Evernia prunastri ext. by the RIFM Expert Panel based on 
unpublished reports.  
 
5.11.1.2 Non-human information 
A total of 1 LLNA, 1 LLNA ex vivo BrdU and 1 GPMT were identified testing skin sensitising effects 
of Evernia prunastri ext. The reported EC3 value for Evernia prunastri ext. was 3.9% in the LLNA 
and 3.4% in the LLNA ex vivo BrdU. In the GPMT sensitisation was observed in 63% of the animals 
after an intradermal induction dose of 20% Evernia prunastri ext. 
 
No relevant in vitro studies on Evernia prunastri ext. (i.e. OECD TG 442C and OECD TG 442D) 
were identified in the literature. 
 
5.11.1.3 Exposure 
According to data from IFRA (2008e) the exposure of Evernia prunastri ext. when used as 
fragrance in cosmetics and in other consumer products appears to be low. 
 
5.11.2 Comparison with criteria 
For unselected/consecutive dermatitis patients positive reactions range between 1.81 and 6.8% i.e. 
all studies are reporting frequencies higher than 1%. For selected dermatitis patients positive 
reactions range between 0 and 64% with 23 out of 28 studies reporting frequencies higher than 2%. 
In addition to this there are more than 1900 published cases of positive patch test reactions to 
Evernia prunastri ext. According to the CLP criteria a frequency ≥ 1% for unselected/consecutive 
dermatitis patients and/or ≥ 2% for selected dermatitis patients and/or a total number of published 
cases ≥ 100, equals a high frequency of occurrence of skin sensitisation (Table 3.4.2-b) (ECHA, 
2015). The collected data described above from patch test studies show that Evernia prunastri ext. 
causes a high frequency of occurrence of skin sensitisation based on these three types of 
information.  
In regard to the HRIPT/HMT data the positive response reported at > 500 µg/cm2 for HRIPT/HMT 
induction threshold indicate evidence for sub-category 1B according to Annex I: 3.4.2.2.2.2. 
 
In the 2 LLNAs EC3 values were 3.4 and 3.9%. According to the CLP Regulation an EC3 value  2% 
indicates classification of a substance in sub-category 1A whereas an EC3 value > 2% indicates 
classification of a substance in sub-category 1B (Annex I: 3.4.2.2.3.2.). Thus, both studies indicate 
classification of Evernia prunastri ext. in sub-category 1B.  
In the GPMT sensitisation was observed in 63% of the animals after an intradermal induction dose 
of 20%. According to the CLP criteria a positive response ≥ 30% of the animals responding at > 1% 
intradermal induction dose indicates classification of a substance in sub-category 1B (Annex I: 
3.4.2.2.3.2.) and thus, this study indicates classification of Evernia prunastri ext. into sub-category 
1B. 
 
Overall, there is clear evidence for classification in sub-category 1A based on the human patch test 
studies showing a high frequency of occurrence of skin sensitisation and the total number of cases 
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combined with the estimated low exposure. The results from the animal studies indicate 
classification in sub-category 1B.  A classification as a skin sensitiser in sub-category 1A is thus 
warranted for Evernia prunastri ext.  
 
5.11.3 Conclusions on classification and labelling 
Based on the high frequency of sensitisation observed in human patch test studies and the high 
number of published cases combined with the estimated low exposure, a classification of Evernia 
prunastri ext. as a skin sensitiser in sub-category 1A is justified. 
 
 
5.12 Conclusion 
For all 11 substances selected for detailed assessment in Phase 2, a classification as a skin sensitiser 
in sub-category 1A is justified based on the available data.  
 
For nine of the substances, sub-category 1A is justified based on human patch test data i.e. 
frequencies in unselected and/or selected dermatitis patients and/or a high number of cases.  
For methyl oct-2-ynate, sub-category 1A is justified primarily based on non-human data (very low 
EC3 values in the two LLNAs and results from GPMT and Buehler tests, and supported by human 
evidence from HRIPT studies). 
For Cinnamomum cassia leaf oil/Cinnamomum zeylanicum, ext.), sub-category 1A is justified 
based on their constituents by read across to the major compounds such as cinnamaldehyde (for 
Cassia bark extract, Cassia oil, Cinnamon bark extract and Cinnamon bark oil) and eugenol (for 
Cinnamon leaf oil). 
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6.1 Sub-category 1A candidates (the 11 substances in Phase 2) 
For all 11 substances selected for detailed assessment in Phase 2, a classification as a skin sensitiser 
in sub-category 1A is justified based on the available data.  
 
Generally, sub-category 1A is justified based on the available human data: 
For nine of the 11 substances selected for detailed assessment in Phase 2 (i.e. not including methyl 
oct-2-ynate and Cinnamomum cassia leaf oil/Cinnamomum zeylanicum, ext.), sub-category 1A is 
justified based on human patch test data i.e. frequencies in unselected and/or selected dermatitis 
patients and/or a high number of cases. For two of the substances, farnesol and coumarin, sub-
category 1A is justified solely by the high number of cases from human diagnostic patch test studies.  
For human diagnostic patch test data, only one or two types of information in terms of frequency in 
defined populations / number of cases may be sufficient for sub-categorisation. Combined with the 
estimated low exposure for all these substances it seems clear that sub-category 1A is justified for 
these nine substances based on the available data.  
 
Generally, when sub-category 1A is justified based on the available human data this is not supported 
by non-human data: 
For only two of the nine substances where sub-category 1A is justified based on the available human 
data, sub-category 1A is also supported by non-human data. For cinnamaldehyde, 21/22 LLNAs 
showed an EC3 value <2% and thus, justifying sub-category 1A. For 7-hydroxycitronellal, one 
GPMT supported sub-category 1A, whereas 7 LLNAs and one Buehler test indicated a classification 
in sub-category 1B. 
For the remaining substances, non-human data, if available, do not support sub-category 1A. As a 
substance may be allocated to sub-category 1A on the basis of reliable and good quality evidence 
from human cases or epidemiological studies and/or observations from appropriate studies in 
experimental animals it seems clear that sub-category 1A is justified for these nine substances based 
on the available data, i.e. despite that the available non-human data do not support classification in 
sub-category 1A.  
The fact that data from human and non-human studies only support each other for a few substances 
may be explained by the difference in exposure. As described by Anderson et al. (2011) the 
elicitation thresholds may be lower than those required for induction and the dose required for 
induction may depend on duration frequency and site of exposure. Humans could be exposed to 
these substances repeatedly, thus causing a relatively weak sensitiser, as measured by the EC3-
value, to be of greater risk for allergic contact dermatitis in humans due to frequent exposure.   
 
Only in some cases, sub-category 1A is justified based on the available non-human data: 
Only for one of the 11 substances selected for detailed assessment in Phase 2, methyl oct-2-ynate, 
sub-category 1A is justified primarily based on non-human data, especially a very low EC3 value in 
the two LLNAs, but also the results from GPMT and Buehler tests. Furthermore, sub-category 1A is 
supported by human evidence in form of results in the HRIPT studies.  
The reason for the low/moderate frequency of occurrence of skin sensitisation in human diagnostic 
patch test data with methyl oct-2-ynate is probably the observation that patch test reactions after 
methyl oct-2-ynate occurs relatively late (after 2-4 weeks) indicating active sensitisation (i.e. the 
subjects were sensitised by the patch test) (Heisterberg et al. 2010).  
 
6. Discussion 
  
 
Evaluation of selected sensitizing fragrance substances  53 
Sub-category 1A is justified based on read across: 
For one of the 11 substances selected for detailed assessment in Phase 2, Cinnamomum cassia leaf 
oil/Cinnamomum zeylanicum, ext. it is not possible to suggest a classification in sub-category 1A 
based on the limited available data. In contrast to the other 10 substances selected for detailed 
assessment in Phase 2, this fragrance is a mixture of substances and the available data did not 
include specific information on composition and purity of the constituents in the fragrance. It may, 
however, be possible to sub-categorise Cinnamomum cassia leaf oil/Cinnamomum zeylanicum, 
ext. based on their constituents by read across to the major constituents, i.e. cinnamaldehyde (for 
Cassia bark extract (44%), Cassia oil (87%), Cinnamon bark extract (38%) and Cinnamon bark oil 
(75%)) and eugenol (for Cinnamon leaf oil (70%)). Both cinnamaldehyde and eugenol are among 
the 11 substances selected for detailed assessment in Phase 2 for which sub-category 1A is justified. 
Based on a read across it seems clear that sub-category 1A is justified for Cinnamomum cassia leaf 
oil/Cinnamomum zeylanicum, ext. based on the available data.  
 
 
6.2 Other possible sub-category 1A candidates (9 substances given 
priority 1 in Phase 1) 
In addition to the 11 substances selected for detailed assessment in Phase 2, nine other substances 
(butyl methacrylate, limonene, turpentine oil, Ylang ylang ext./oil, clove leaf oil, Evernia furfuracea 
ext., jasmine, Peru balsam, Sandalwood ext./oil) were given a priority 1 in Phase 1, i.e. considered as 
possible sub-category 1A candidates.  
 
Seven of these substances (i.e. not including butyl methacrylate and limonene) were considered as 
possible sub-category 1A candidates based on human patch test data, i.e. frequencies in unselected 
and/or selected dermatitis patients and/or a high number of cases.  
Limonene was considered as a possible sub-category 1A candidate as it is among the substances 
considered by SCCS (2012) as a substance of special concern, defined as due to the high number of 
reported cases (>100 cases).  
Butyl methacrylate was considered as a possible sub-category 1A candidate based on high frequency 
of occupational allergic contact dermatitis due to (meth)acrylates in general. 
 
Overall, all these nine substances were considered as possible sub-category 1A candidates based on 
the available human data. A detailed assessment of these substances was, however, not part of the 
current project. 
 
 
6.3 Remaining substances (22 substances given priority 2 in Phase 1) 
The remaining 22 substances selected for the preliminary assessment in Phase 1 were given a 
priority 2, i.e. not considered as possible sub-category 1A candidates.  
 
For 5 substances (d-limonene, (l-limonene), carvone, HICC, isoeugenol), a proposal for a 
harmonised classification as skin sensitiser in Category 1 H317, or sub-category 1A or 1B has already 
been submitted.  
 
For 10 substances (benzaldehyde, 2-methyl-4-phenylpentanol, acetylcedrene, trans-anethole, anise 
alcohol, benzyl salicylate, 2-(4-tert-butylbenzyl)propionaldehyde, citronellol, peppermint ext./oil, 
spearmint ext.), sub-category 1A is not justified based on human patch test data, i.e. due to a low 
frequency and low number of cases in the human studies, as well as no/equivocal sensitisation was 
noted in the non-human studies. 
 
For the remaining 7 substances (mixture (of trans-4-acetoxy-4-methyl-2-propyl-tetrahydro-2H-
pyran; cis-4-acetoxy-4-methyl-2-propyl-tetrahydro-2H-pyran), Damascone, pin-2(3)-ene/pin-
2(10)-ene, p-mentha-1,4(8)-diene, Neroli oil / Orange sour ext., lemon ext., orange sweet ext.), the 
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available data were too limited for an indication as a possible sub-category 1A candidate. Thus, it 
cannot be excluded whether these substances would turn out to be sub-category 1A candidates 
should additional human studies and/or non-human data become available. 
 
 
6.4 Exposure assessment 
One of the elements in the criteria for classification in sub-category 1A based on human patch test 
data is ‘relatively low exposure’. Relatively high or relatively low exposure relates to the 
concentrations of the substances in cosmetics and other consumer products which individuals are 
exposed to in their daily lives, in the workplace, or other conditions and resulting in sensitisation. A 
cut-off concentration of 1 % has been set in order to discriminate between relatively high exposure 
(≥ 1.0 %) and relatively low exposure (< 1.0 %). 
 
For the 11 substances selected for Phase 2, relatively high or relatively low exposure from use as 
fragrance in cosmetics and in other consumer products has been evaluated based on the IFRA 
standard limit of each substance in each of the 11 IFRA QRA product categories (IFRA, 2015), i.e., if 
the IFRA standard limit is < 1.0 % the exposure is thus considered as being relatively low. This is 
generally the case for the 11 Phase 2 substances for most of the IFRA QRA product categories where 
the IFRA standard limits have been set based on QRA.  
The SCCS has recently published a ‘Memorandum on use of Human Data in risk assessment of skin 
sensitisation’ (SCCS, 2015). It is mentioned that the data used in the QRA approach is animal data 
and/or results from predictive tests in humans, i.e., experimental induction tests such as the 
Human Repeated Insult Patch Test (HRIPT) and the Human Maximization Test (HMT). However, 
it is also mentioned that it would be more appropriate to consider the epidemiological and 
diagnostic patch test data as these represent the relevant end-point. Furthermore, it is noted that 
the QRA approach is still under evaluation.  
If the QRA approach would be revised in order to include also the epidemiological and diagnostic 
patch test data the current IFRA standard limits based on the QRA approach might change. If the 
current IFRA standard limits below 1 % would change to values above this cut-off concentration for 
relatively high/low exposure this could have an impact on the classification as a skin sensitiser in 
sub-category 1A for the 11 Phase 2 substances. 
 
 
6.5 Data quality 
A relatively large proportion of the cited studies have only been available from secondary sources, 
mainly attributed to unpublished data by the industry. Inclusion of these studies in the preliminary 
assessment of the 42 selected substances in Phase 1, as well as for the detailed assessment of the 11 
substances in Phase 2 is justified due to the purpose of the current project, i.e. a screening of the 
available data for a preliminary assessment whether the criteria for classification in sub-category 1A 
according to the CLP criteria are fulfilled.   
Secondary sources have a reliability score 4 “not assignable” according to the reliability criteria 
proposed by Klimisch et al. (1997). For a genuine assessment of studies only available from 
secondary sources, the original study report should be available for the assessment.  
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6.6 Conclusion 
For all 11 substances selected for detailed assessment in Phase 2, a classification as a skin sensitiser 
in sub-category 1A is justified based on the available data.  
 
Based on the assessments in this project, a decision whether a classification of a substance as a skin 
sensitiser in sub-category 1A is justified is generally based on the available human data.  
 
For the 11 substances selected for Phase 2, relatively low exposure from use as fragrance in 
cosmetics and in other consumer products has been evaluated based on the IFRA standard limit of 
each substance in each of the 11 IFRA QRA product categories, i.e., if the IFRA standard limit is 
< 1.0 % the exposure is thus considered as being relatively low. This is generally the case for the 11 
substances for most of the IFRA QRA product categories where the IFRA standard limits have been 
set based on QRA.  Data for the QRA are generally animal data and/or results from predictive tests 
in humans (HRIPT and HMT). As it would be more appropriate to consider the epidemiological and 
diagnostic patch test data the current IFRA standard limits might change if the QRA approach 
would be revised in order to include also the epidemiological and diagnostic patch test data. This 
could have an impact on the classification as a skin sensitiser in sub-category 1A for the 11 
substances if the current IFRA standard limits below 1 % would change to values above this cut-off 
concentration for relatively high/low exposure. 
 
A relatively large proportion of the cited studies have only been available from secondary sources, 
mainly attributed to unpublished data by the industry. For a genuine assessment of such studies, 
the original study reports should be available for the assessment. Thus, it cannot be excluded 
whether the outcome of the assessments performed in this project could turn out differently should 
the original study reports become available for the final assessment. 
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Appendix 1 List of abbreviations and acronyms 
AEL Acceptable Exposure Level 
AOO Acetone:Olive oil 
BHT Butylated hydroxytoluene 
BrdU-ELISA 5-Bromo-2-deoxyuridine-enzyme-linked immunosorbent assay 
CAS RN Chemical Abstract Service Registration Number 
DEP Diethyl Phthalate 
DMF Dimethylformamide 
DMSO Dimethyl Sulfoxide  
FM Fragrance mix  
EC3 value Effective Concentration inducting a stimulation index of 3 in the LLNA test. 
EtOH Ethanol 
FM Fragrance Mix 
GPMT Guinea Pig Maximisation Test 
IFRA International Fragrance Association 
LLNA Local Lymph Node Assay 
MEK Methyl ethyl ketone 
NESIL No Expected Sensitization Induction Level 
OECD TG Organisation for Economic Co-operation and Development Test Guideline 
PEG  Polyethylene glycol 
Pet. Petrolatum 
QRA Quantitative Risk Assessment 
REACH RD Registration, Evaluation, Authorisation and Restriction of Chemicals Registration 
Dossier 
RIFM Research Institute for Fragrance Materials, Inc. 
SAF Sensitisation Assessment Factors 
SCCNFP Scientific Committee on Cosmetic products and Non-Food Products intended for 
consumers 
SCCS Scientific Committee on Consumer Safety 
SSO  Sorbitan sesquioleate 
WoE Weight of Evidence 
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Appendix 2 List of substances for evaluation in Phase 1 
CAS Stofnavn Skin sens 1 
Harm. 
Klass. 
Skin sens 1  
Selvklass. 
(også 1A 
eller 1B) 
Andel virks. 
med Skin 
sens. selvkl. 
(ca.) 
REACH 
registr. 
Prioritet 
97-88-1 Butyl methacrylate x x   Ja 1a 
100-52-7 Benzaldehyde   x >90% Ja 1a 
5392-40-5 Citral x x   Ja 1a 
5989-27-5 (R)-p-mentha-1,8-diene (d-
limonene) 
x x   Ja 1a 
5989-54-8 (S)-p-mentha-1,8-diene (l-
limonene) 
x x   Ja 1a 
92585-24-5 2-methyl-4-phenylpentanol x x   Ja 1a 
131766-73-9 A mixture of: trans-4-acetoxy-4-
methyl-2-propyl-tetrahydro-2H-
pyran; cis-4-acetoxy-4-methyl-
2-propyl-tetrahydro-2H-pyran 
x x   Ja 1a 
8006-64-2 Turpentine oil  x x   Ja 1a 
32388-55-9 [3R-(3α,3aβ,7β,8aα)]-1-
(2,3,4,7,8,8a-hexahydro-
3,6,8,8-tetramethyl-1H-3a,7-
methanoazulen-5-yl)ethan-1-
one (Acetylcedrene) 
  x >90% Ja 1a 
4180-23-8 (E)-anethole (trans-anethole)   x >90% Ja 1a 
105-13-5 4-methoxybenzyl alcohol (Anise 
alcohol) 
  x >90% Ja 1a 
118-58-1 Benzyl salicylate   x >90% Ja 1a 
80-54-6  2-(4-tert-
butylbenzyl)propionaldehyde 
(Butylphenyl methylproprional) 
  x >90% Ja 1a 
99-49-0/ d-p-mentha-1(6),8-dien-2-one 
(Carvone) / 
  x >90% Nej 2 
60 Evaluation of selected sensitizing fragrance substances 
 
CAS Stofnavn Skin sens 1 
Harm. 
Klass. 
Skin sens 1  
Selvklass. 
(også 1A 
eller 1B) 
Andel virks. 
med Skin 
sens. selvkl. 
(ca.) 
REACH 
registr. 
Prioritet 
6485-40-1/ l-p-mentha-1(6),8-dien-2-one 
(Carvone) / 
  x >90% Ja 1a 
2244-16-8 (S)-2-methyl-5-(1-
methylvinyl)cyclohex-2-en-1-
one (Carvone) 
  x ca 50% Nej 2 
104-55-2 cinnamaldehyde   x >90% Ja 1a 
104-54-1 cinnamyl alcohol   x >90% Ja 1a 
106-22-9/ citronellol   x >90% Ja 1a 
1117-61-9/ (R)-3,7-dimethyloct-6-en-1-ol   x >90% Nej 2 
7540-51-4 (-)-3,7-dimethyloct-6-en-1-ol   x >85% Nej 2 
91-64-5 coumarin   x >90% Ja 1a 
57378-68-4 1-(2,6,6-trimethyl-3-
cyclohexen-1-yl)-2-buten-1-one 
(delta-DAMASCONE) 
  x 100% Nej 1b 
97-53-0 eugenol   x >90% Ja 1a 
4602-84-0 farnesol   x >85% Ja 1a 
106-24-1 geraniol   x >90% Ja 1a 
31906-04-4/ 4-(4-hydroxy-4-
methylpentyl)cyclohex-3-
enecarbaldehyde 
(Hydroxyisohexyl 3-
cyclohexene carboxaldehyde, 
HICC) 
  x >90% Nej 1d 
51414-25-6    x 100% Nej 1d 
107-75-5 7-hydroxycitronellal   x 100% Ja  1a 
97-54-1 isoeugenol   x 100% Nej 1b 
138-86-3 limonene x x   Nej 1c 
111-12-6 methyl oct-2-ynoate   x >90% Nej 1b 
80-56-8/ pin-2(3)-ene /   x >75% Ja 1a 
127-91-3 pin-2(10)-ene   x >90% Ja 1a 
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CAS Stofnavn Skin sens 1 
Harm. 
Klass. 
Skin sens 1  
Selvklass. 
(også 1A 
eller 1B) 
Andel virks. 
med Skin 
sens. selvkl. 
(ca.) 
REACH 
registr. 
Prioritet 
586-62-9 p-mentha-1,4(8)-diene 
(terpinolene) 
  x > 75% Ja  1a 
83863-30-3/ Ylang ylang ext. /   x >90% Nej 1d 
8006-81-3 Ylang ylang oil   x >90% Nej 1d 
8007-80-5/ Cinnamomum cassia leaf oil /   x ca. 80% Nej 2 
84649-98-9 Cinnamomum zeylanicum, ext.   x >90% Ja 1a 
8016-38-4/ Neroli Oil /   x >95% Nej 2 
72968-50-4 Orange, sour, ext.   x >95% Ja  1a 
84929-31-7 Lemon, ext.   x >95% Ja 1a 
97766-30-8/ Orange, sweet, Valencia, ext. /   x >95% Nej 2 
8028-48-6 Orange, sweet, ext.   x >95% Ja 1a 
8000-34-8 Clove leaf oil   x >80% Nej 1d 
90028-67-4 Evernia furfuracea, ext.   x >95% Nej 1d 
90028-68-5 Evernia prunastri, ext.   x >95% Nej 1d 
84776-64-7/ Jasmine, Jasminum 
grandiflorum, ext. / 
  x >95% Nej 1d 
90045-94-6/ Jasmine, Jasminum officinale, 
ext. / 
  x >95% Nej 1d 
8022-96-6 Extract Jasmine (oil), Jasmine, 
Jasminum grandiflorum, ext. 
  x ca. 30% Nej 1d 
8006-90-4/ Oils, peppermint (Mentha 
piperita) / 
  x ca. 65% Nej 2 
84082-70-2 Peppermint, ext.   x ca. 25% Ja 1?? 
84696-51-5 Spearmint, ext. (Mentha 
spicita) 
  x >95% Nej 2 
8007-00-9 Balsams, Peru (Myroxylon 
pereirae) 
  x >95% Nej 1d 
84787-70-2/ Sandalwood, ext. /   x 10 af >900 Nej 1d 
8006-87-9 Sandalwood oil   x 1 Nej 1d 
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Appendix 3 Justification for the prioritisation of the substances 
The justification for prioritisation of the substances into group 1 or 2 is based on studies identified in the literature search, REACH RD and in the SCCS (2012) opinion. 
 
CAS RN Name Harm 
class 
LLNAa) 
 
GPMT/Buehlerb) Human diagnostic patch 
test datac) 
Prioritisation 
97-88-1 Butyl methacrylate x OECD TG 429: 
EC3 > 2% (1 study). 
 
 
GPMT OECD TG 406:  80% 
responding after intradermal 
induction dose of 5% (1 
study). 
Sensitization in 1/8 non TG.  
Unselected dermatitis 
patients frequency ≥ 1% (0/1 
study). 
Selected dermatitis patients 
frequency ≥ 2% (3/8 
studies). 
Workplace selected workers 
frequency ≥ 1% (1/1 study).  
N(cases) < 100. 
1  
Based on the high frequency 
of occupational allergic 
contact dermatitis among 
dentists, nail technicians, 
fibreglass workers etc. due to 
(meth)acrylates.  
100-52-7 Benzaldehyde  OECD TG 429: 
Not sensitising (1 
study). 
 
Not sensitising in 3/3 GPMTs 
similar to TG. 
 
Selected dermatitis patients 
frequency ≥ 2% (1/4 studies). 
N(cases) < 100. 
 
Human maximisation test 
(HMT): No conclusion (1 
study). 
2 
Based on the low frequency 
and number of cases in 
human studies and no 
sensitisation in non-human 
studies.  
5392-40-5 Citral x OECD TG 429: 
EC3 ≤ 2% (2 studies). 
EC3 > 2% (8 studies).  
 
GPMT similar to OECD TG 
406:  
60 and 100% responding 
after intradermal induction 
dose of ?% (2 studies). 
Unselected dermatitis 
patients frequency ≥ 1% (5/11 
studies). 
Selected dermatitis patients 
frequency ≥ 2% (6/8 
1 
Based on the high frequency 
and number of cases in 
human studies and 
sensitisation in non-human 
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CAS RN Name Harm 
class 
LLNAa) 
 
GPMT/Buehlerb) Human diagnostic patch 
test datac) 
Prioritisation 
studies). 
N(cases) > 100. 
 
Human Repeat Insult Patch 
Test (HRIPT): Mixed results 
(2 studies). 
studies. 
SCCS substance of special 
concernd). 
5989-27-5 (R)-p-Mentha-1,8-
diene (d-limonene) 
x 
 
OECD TG 429: 
EC3 > 2% (6 studies). 
_ Unselected dermatitis 
patients frequency ≥ 1% (5/5 
studies – two with mixed 
results). 
Selected dermatitis patients 
frequency ≥ 2% (6/8 
studies). 
Workplace selected workers 
frequency ≥ 1% (1/1 studies).  
Workplace all or randomly 
selected workers frequency ≥ 
0.4% (2/2 studies). 
N(cases) < 100. 
2 
Harmonised classification 
sub-category 1B proposal. 
 
5989-54-8 (S)-p-Mentha-1,8-
diene (l-limonene) 
x _ _ Unselected dermatitis 
patients frequency ≥ 1% 
(1/1). 
N(cases) < 100. 
2 
Read-across to d-limonene. 
92585-24-5 2-methyl-4-
phenylpentanol 
x OECD TG 429: 
Not sensitising (1 
study). 
Buehler test non TG: 
ambiguous. 
Selected dermatitis patients 
frequency ≥ 2% (0/2 
studies). 
2 
Based on the low frequency 
and number of cases in 
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CAS RN Name Harm 
class 
LLNAa) 
 
GPMT/Buehlerb) Human diagnostic patch 
test datac) 
Prioritisation 
N(cases) < 100. 
 
human studies and no 
sensitisation in non-human 
studies. 
131766-73-9 A mixture of: trans-
4-acetoxy-4-methyl-
2-propyl-tetrahydro-
2H-pyran; cis-4-
acetoxy-4-methyl-2-
propyl-tetrahydro-
2H-pyran 
x OECD TG 429: 
Not sensitising (1 
study). 
GPMT non TG:  
70% responding after 
intradermal induction dose of 
?% (1 study).   
_ 2 
Based on limited data. 
 
8006-64-2 Turpentine oil x _ GPMT non TG: Sensitising. 
 
General population studies 
frequency ≥ 0.2% (1/1 study). 
Unselected dermatitis 
patients frequency ≥ 1% 
(8/10 studies). 
Selected dermatitis patients 
frequency ≥ 2% (1/1 study 
(prisoners)). 
Workplace selected workers 
frequency ≥ 1% (1/1 studies).  
N(cases) > 100. 
 
1 
Based on the high frequency 
and number of cases in 
human studies. 
SCCS substance of special 
concernd). 
32388-55-9 [3R-
(3α,3aβ,7β,8aα)]-1-
(2,3,4,7,8,8a-
Hexahydro-3,6,8,8-
 OECD TG 429: 
EC3 > 2% (1 study). 
 
_ Unselected dermatitis 
patients frequency ≥ 1% (0/3 
studies). 
N(cases) < 100. 
2 
Based on the low frequency 
and number of cases in 
human studies and no 
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CAS RN Name Harm 
class 
LLNAa) 
 
GPMT/Buehlerb) Human diagnostic patch 
test datac) 
Prioritisation 
tetramethyl-1H-3a,7-
methanoazulen-5-
yl)ethan-1-one 
(Acetylcedrene) 
 sensitisation in non-human 
studies. 
4180-23-8 (E)-Anethole (trans-
anethole) 
 _  GPMT OECD TG 406(?): 
100% responding after 
intradermal induction dose of 
2% (1 study). 
Two case stories. 
N(cases) < 100. 
 
2 
Based on the low frequency 
and number of cases in 
human studies and one non-
human study not warranting 
sub-category 1A. 
105-13-5 4-Methoxybenzyl 
alcohol (Anise 
alcohol) 
 OECD TG 429: 
EC3 > 2% (1 study). 
 
_ 
 
Unselected dermatitis 
patients frequency ≥ 1% (0/5 
studies). 
N(cases) < 100. 
 
Human maximisation test 
(HMT): Not sensitising (1 
study). 
2 
Based on the low frequency 
and number of cases in 
human studies and no 
sensitisation in non-human 
studies. 
118-58-1 Benzyl salicylate  OECD TG 429: 
EC3 > 2% (1 study). 
 
_ Unselected dermatitis 
patients frequency ≥ 1% (1/9 
studies). 
Selected dermatitis patients 
frequency ≥ 2% (2/2 studies). 
N(cases) < 100. 
2 
Based on the low frequency 
and number of cases in 
human studies and no 
sensitisation in non-human 
studies. 
80-54-6 2-(4-tert-  OECD TG 429: GPMT OECD TG 406: Not Unselected dermatitis 2 
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CAS RN Name Harm 
class 
LLNAa) 
 
GPMT/Buehlerb) Human diagnostic patch 
test datac) 
Prioritisation 
Butylbenzyl)propiona
ldehyde (Butylphenyl 
methylproprional) 
EC3 > 2% (6 studies). 
 
 
sensitising (2 studies). 
GPMT non TG:  
Strong sensitiser (1 study). 
patients frequency ≥ 1% 
(0/12 studies). 
Selected dermatitis patients 
frequency ≥ 2% (1/1 studies). 
N(cases) < 100. 
 
Human maximisation test 
(HMT): Mixed results (1 
study). 
Based on the low frequency 
and number of cases in 
human studies and equivocal 
results from non-human 
studies. 
99-49-0 / 
6485-40-1 / 
2244-26-8 
d-p-Mentha-1(6),8-
dien-2-one (Carvone) 
/  
l-p-Mentha-1(6),8-
dien-2-one (Carvone) 
/  
(S)-2-Methyl-5-(1-
methylvinyl)cyclohex
-2-en-1-one 
(Carvone) 
 OECD TG 429: 
EC3 > 2% (3 studies).  
 
_ Selected dermatitis patients 
frequency ≥ 2% (1/1 studies). 
N(cases) < 100. 
2 
Harmonised classification 
category 1 proposal. 
104-55-2 Cinnamaldehyde  OECD TG 429: 
EC3 ≤ 2% (19 studies) 
EC3 > 2% (1 study).  
 
GPMT non TG: Sensitising (4 
studies).  
Unselected dermatitis 
patients frequency ≥ 1% 
(12/12 studies). 
Selected dermatitis patients 
frequency ≥ 2% (6/7 studies). 
Workplace all or randomly 
selected workers frequency ≥ 
1 
Based on the high frequency 
and number of cases in 
human studies and 
sensitisation in non-human 
studies. 
SCCS substance of special 
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CAS RN Name Harm 
class 
LLNAa) 
 
GPMT/Buehlerb) Human diagnostic patch 
test datac) 
Prioritisation 
0.4% (1/1 studies). 
N(cases) > 100. 
concernd). 
104-54-1 Cinnamyl alcohol  OECD TG 429: 
EC3 > 2% (5 studies).  
 
 
GPMT OECD TG 406: 30% 
responding after intradermal 
induction dose of ?% (1 
study). 
GPMT non TG:  
Not sensitising (1 study). 
Buehler OECD TG 406: Not 
sensitising after topical 
induction dose of ?% (1 
study). 
Unselected dermatitis 
patients frequency ≥ 1% (6/9 
studies). 
Selected dermatitis patients 
frequency ≥ 2% (6/7 studies). 
N(cases) > 100. 
 
Human maximisation test 
(HMT): Not sensitising (1 
study). 
Human Repeat Insult Patch 
Test (HRIPT): Sensitising (1 
study). 
1 
Based on the high frequency 
and number of cases in 
human studies. 
SCCS substance of special 
concernd). 
106-22-9 / 
1117-61-9 / 
7540-51-4 
Citronellol /  
(R)-3,7-dimethyloct-
6-en-1-ol /   
(-)-3,7-dimethyloct-
6-en-1-ol 
 OECD TG 429: 
EC3 > 2% (1 study). 
GPMT non TG:  
Not sensitising after topical 
induction dose of 6% (1 
study). 
Buehler OECD TG 406: Not 
sensitising (1 study). 
Unselected dermatitis 
patients frequency ≥ 1% (2/8 
studies). 
Selected dermatitis patients 
frequency ≥ 2% (3/4 studies). 
N(cases) < 100. 
 
Human maximisation test 
(HMT):  
Not sensitising (1 study). 
Human Repeat Insult Patch 
2 
Based on the low frequency 
and number of cases in 
human studies and no 
sensitisation in non-human 
studies. 
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CAS RN Name Harm 
class 
LLNAa) 
 
GPMT/Buehlerb) Human diagnostic patch 
test datac) 
Prioritisation 
Test (HRIPT): Not 
sensitising (1 study). 
91-64-5 Coumarin   OECD TG 429: 
EC3 > 2% (1 study). 
GPMT non TG:  
Not sensitising (1 study). 
 
Unselected dermatitis 
patients frequency ≥ 1% (1/8 
studies). 
Selected dermatitis patients 
frequency ≥ 2% (3/7 studies). 
N(cases) < 100. 
1 
SCCS substance of special 
concernd). 
 
57378-68-4 1-(2,6,6-Trimethyl-3-
cyclohexen-1-yl)-2-
buten-1-one (delta-
DAMASCONE) 
 OECD TG 429(?): 
EC3 > 2% (2 studies). 
_ Human Repeat Insult Patch 
Test (HRIPT): Several 
positive and one negative 
study according to SCCS 
(2012). 
N(cases) < 100. 
2 
Based on limited data. 
97-53-0 Eugenol   OECD TG 429: 
EC3 > 2% (10 studies). 
GPMT similar to OECD TG 
406: 
20% responding after 
intradermal induction dose of 
5% (1 study). 
Unselected dermatitis 
patients frequency ≥ 1% (7/11 
studies). 
Selected dermatitis patients 
frequency ≥ 2% (6/6 
studies). 
N(cases) > 100. 
 
1 
Based on the high frequency 
and number of cases in 
human studies. 
SCCS substance of special 
concernd). 
4602-84-0 Farnesol  OECD TG 429: 
EC3 > 2% (2 studies). 
_ Unselected dermatitis 
patients frequency ≥ 1% (1/7 
studies – with a frequency of 
1 
Based on very high 
frequencies in a limited 
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CAS RN Name Harm 
class 
LLNAa) 
 
GPMT/Buehlerb) Human diagnostic patch 
test datac) 
Prioritisation 
13%). 
Selected dermatitis patients 
frequency ≥ 2% (2/4 studies 
– with frequencies of 10 and 
12%). 
N(cases) > 100. 
number of studies and the 
number of cases in human 
studies. 
SCCS substance of special 
concernd). 
106-24-1 Geraniol  OECD TG 429: 
EC3 > 2% (5 studies). 
GPMT non TG: 
Not sensitising in four 
studies.  
Sensitising in three studies.  
Unselected dermatitis 
patients frequency ≥ 1% 
(6/16 studies). 
Selected dermatitis patients 
frequency ≥ 2% (3/7 studies). 
N(cases) > 100. 
 
Human maximisation test 
(HMT):  
Not sensitising (2 studies). 
1 
Based on the high frequency 
and number of cases in 
human studies. 
SCCS substance of special 
concernd). 
31906-04-4 / 
51414-25-6 
4-(4-Hydroxy-4-
methylpentyl)cyclohe
x-3-enecarbaldehyde 
(Hydroxyisohexyl 3-
cyclohexene 
carboxaldehyde, 
HICC) 
RAC 1A OECD TG 429: 
EC3 > 2% (1 study). 
_ Unselected dermatitis 
patients frequency ≥ 1% 
(17/19 studies). 
Selected dermatitis patients 
frequency ≥ 2% (3/3 studies). 
Workplace selected workers 
frequency ≥ 1% (0/1 study).  
N(cases) > 100. 
Harmonised classification 
sub-category 1A proposal. 
 
107-75-5 7-hydroxycitronellal  OECD TG 429: 
EC3 > 2% (7 studies). 
GPMT non TG: 
60% responding after 
Unselected dermatitis 
patients frequency ≥ 1% (7/8 
1 
Based on the high frequency 
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CAS RN Name Harm 
class 
LLNAa) 
 
GPMT/Buehlerb) Human diagnostic patch 
test datac) 
Prioritisation 
intradermal induction dose of 
0.5% (1 study). 
Buehler non TG: ambiguous. 
studies). 
Selected dermatitis patients 
frequency ≥ 2% (4/6 
studies). 
N(cases) > 100. 
and number of cases in 
human studies. 
SCCS substance of special 
concernd). 
97-54-1 Isoeugenol RAC 1A  OECD TG 429: 
EC3 ≤ 2% (17 studies) 
EC3 > 2% (6 studies).  
 
_ Unselected dermatitis 
patients frequency ≥ 1% (9/9 
studies). 
Selected dermatitis patients 
frequency ≥ 2% (8/8 
studies). 
Workplace selected workers 
frequency ≥ 1% (0/1 study).  
N(cases) > 100. 
Harmonised classification 
sub-category 1A proposal. 
 
138-86-3 Limonene x _ _ Unselected dermatitis 
patients frequency ≥ 1% 
(3/10 studies). 
N(cases) > 100 (mainly due to 
hydroperoxides of limonene). 
1 
SCCS substance of special 
concernd). 
111-12-6 Methyl oct-2-ynoate  OECD TG 429: 
EC3 ≤ 2% (2 studies). 
 
_ Unselected dermatitis 
patients frequency ≥ 1% (2/6 
studies). 
Selected dermatitis patients 
frequency ≥ 2% (0/1 studies). 
N(cases) < 100. 
1 
Based on the very low EC3 
value in LLNAs. 
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CAS RN Name Harm 
class 
LLNAa) 
 
GPMT/Buehlerb) Human diagnostic patch 
test datac) 
Prioritisation 
80-56-8 / 
127-91-3 
Pin-2(3)-ene /  
Pin-2(10)-ene 
 OECD TG 429: 
EC3 > 2% (1 study). 
Test substance beta-
pinene (CAS 127-91-2). 
_ Selected dermatitis patients 
frequency ≥ 2% (2/2 studies). 
Workplace selected workers 
frequency ≥ 1% (1/1 studies).  
N(cases) < 100. 
 
2 
Based on limited data. 
586-62-9 p-Mentha-1,4(8)-
diene (Terpinolene) 
 OECD TG 429: 
EC3 > 2% (1 study). 
_ Selected dermatitis patients 
frequency ≥ 2% (1/1 study). 
N(cases) < 100. 
2 
Based on limited data. 
83863-30-3 
/ 8006-81-3 
Ylang ylang ext. /  
Ylang ylang oil 
 OECD TG 429: 
EC3 > 2% (1 study). 
_ Unselected dermatitis 
patients frequency ≥ 1% 
(9/10 studies). 
Selected dermatitis patients 
frequency ≥ 2% (6/7 studies). 
N(cases) > 100. 
1 
Based on the high frequency 
and number of cases in 
human studies. 
SCCS substance of special 
concernd). 
8007-80-5 / 
84649-98-9 
Cinnamomum cassia 
leaf oil /  
Cinnamomum 
zeylanicum, ext. 
 _ _ Unselected dermatitis 
patients frequency ≥ 1% (1/1 
study). 
Selected dermatitis patients 
frequency ≥ 2% (1/1 study). 
N(cases) < 100. 
1 
Based on the high content of 
cinnamaldehyde, cinnamyl 
alcohol and/or eugenol (all 
SCCS substances of special 
concernd)). 
8016-38-4 / 
72968-50-4 
Neroli Oil /  
Orange, sour, ext. 
 _ _ Unselected dermatitis 
patients frequency ≥ 1% (1/2 
studies). 
Selected dermatitis patients 
2 
Based on limited data. 
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CAS RN Name Harm 
class 
LLNAa) 
 
GPMT/Buehlerb) Human diagnostic patch 
test datac) 
Prioritisation 
frequency ≥ 2% (2/2 studies). 
N(cases) < 100. 
 
Human maximisation test 
(HMT):  
Not sensitising (1 study). 
84929-31-7 Lemon, ext.  _ _ Unselected dermatitis 
patients frequency ≥ 1% (0/1 
studies). 
Selected dermatitis patients 
frequency ≥ 2% (3/5 studies). 
N(cases) < 100. 
2 
Based on limited data. 
97766-30-8 / 
8028-48-6 
Orange, sweet, 
Valencia, ext. /  
Orange, sweet, ext. 
 _ _ Unselected dermatitis 
patients frequency ≥ 1% (0/3 
studies). 
Selected dermatitis patients 
frequency ≥ 2% (3/4 studies). 
N(cases) < 100. 
2 
Based on limited data. 
8000-34-8 Clove leaf oil  _ _ Unselected dermatitis 
patients frequency ≥ 1% (2/2 
studies). 
Selected dermatitis patients 
frequency ≥ 2% (3/5 studies). 
N(cases) > 100. 
1 
Based on the high frequency 
and number of cases in 
human studies. 
SCCS substance of special 
concernd). 
90028-67-4 Evernia furfuracea,  OECD TG 429: _ Unselected dermatitis 1 
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CAS RN Name Harm 
class 
LLNAa) 
 
GPMT/Buehlerb) Human diagnostic patch 
test datac) 
Prioritisation 
ext. EC3 > 2% (2 studies). patients frequency ≥ 1% (5/5 
studies). 
Selected dermatitis patients 
frequency ≥ 2% (2/2 studies). 
N(cases) > 100. 
Based on the high frequency 
and number of cases in 
human studies. 
SCCS substance of special 
concernd). 
90028-68-5 Evernia prunastri, 
ext. 
 
 OECD TG 429: 
EC3 > 2% (1 study).  
_ Unselected dermatitis 
patients frequency ≥ 1% 
(10/10 studies). 
Selected dermatitis patients 
frequency ≥ 2% (6/6 
studies). 
Workplace selected workers 
frequency ≥ 1% (0/1 studies).  
N(cases) > 100. 
1 
Based on the high frequency 
and number of cases in 
human studies. 
SCCS substance of special 
concernd). 
84776-64-7 / 
90045-94-6 
/ 8022-96-6 
Jasmine, Jasminum 
grandiflorum, ext. /  
Jasmine, Jasminum 
officinale, ext. /  
Extract Jasmine (oil), 
Jasmine, Jasminum 
grandiflorum, ext. 
 OECD TG 429: 
EC3 > 2% (1 study). 
_ Unselected dermatitis 
patients frequency ≥ 1% (5/7 
studies). 
Selected dermatitis patients 
frequency ≥ 2% (7/11 
studies). 
N(cases) > 100. 
1 
Based on the high frequency 
and number of cases in 
human studies. 
SCCS substance of special 
concernd). 
8006-90-4 / 
84082-70-2 
Oils, peppermint 
(Mentha piperita) /  
Peppermint, ext. 
 _ GPMT non TG: 10-40% 
responding after intradermal 
induction dose of 0.25 -0.5% 
(4 studies). 
Unselected dermatitis 
patients frequency ≥ 1% (0/3 
studies). 
Selected dermatitis patients 
frequency ≥ 2% (3/5 studies). 
2 
Based on the low frequency 
and number of cases in 
human studies, and mixed 
results in the non-TG-non-
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CAS RN Name Harm 
class 
LLNAa) 
 
GPMT/Buehlerb) Human diagnostic patch 
test datac) 
Prioritisation 
N(cases) < 100. 
 
human studies. 
84696-51-5 Spearmint, ext. 
(Mentha spicita) 
 _ _ Unselected dermatitis 
patients frequency ≥ 1% (0/1 
study). 
Selected dermatitis patients 
frequency ≥ 2% (1/1 study). 
N(cases) < 100. 
2 
Based on the low frequency 
and number of cases in 
human studies and limited 
data. 
8007-00-9 Balsams, Peru 
(Myroxylon 
pereirae) 
 OECD TG 429: 
EC3 > 2% (1 study). 
_ General population studies 
frequency ≥ 0.2% (1/1 study 
– dependent on gender and 
year). 
Unselected dermatitis 
patients frequency ≥ 1% 
(17/17 studies). 
Selected dermatitis patients 
frequency ≥ 2% (2/3 studies). 
Workplace selected workers 
frequency ≥ 1% (0/1 studies).  
N(cases) > 100. 
1 
Based on the high frequency 
and number of cases in 
human studies and 
borderline result from the 
LLNA. 
SCCS substance of special 
concernd). 
84787-70-2 / 
8006-87-9 
Sandalwood, ext. /  
Sandalwood oil 
 _ _ Unselected dermatitis 
patients frequency ≥ 1% (4/7 
studies). 
Selected dermatitis patients 
frequency ≥ 2% (5/7 studies). 
N(cases) < 100. 
1 
Based on the high frequency 
of cases in human studies. 
SCCS substance of special 
concernd). 
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LLNA: Local Lymph Node Assay; GPMT OECD TG: Guinea Pig Maximisation Test OECD Test Guideline. SCCS (2012): Scientific Committee on Consumer Safety, Opinion 
on Fragrance allergens in cosmetic products (2012). 
a) Criteria for LLNA sub-categorisation 1A: EC3 value ≤ 2%. 
 Criteria for LLNA sub-categorisation 1B: EC3 value > 2%. 
b) Criteria for GPMT sub-categorisation 1A: ≥ 30% responding at ≤ 0.1% intradermal induction dose or ≥ 60% responding at > 0.1% to ≤ 1% intradermal 
induction dose.  
Criteria for GPMT sub-categorisation 1B: ≥ 30% to < 60% responding at > 0.1% to ≤ 1% intradermal induction dose or ≥ 30% responding at > 1% intradermal 
induction dose. 
Criteria for Buehler assay sub-categorisation 1A: ≥ 15% responding at ≤ 0.2% topical induction dose or ≥ 60% responding at > 0.2% to ≤ 20% topical induction 
dose. 
Criteria for Buehler assay sub-categorisation 1B: ≥ 15% to < 60% responding at > 0.2% to ≤ 20% topical induction dose or ≥ 15% responding at > 20% topical 
induction dose. 
c) Human diagnostic patch test data: General population studies: ≥ 0.2% = high frequency; < 0.2% = low/moderate frequency. 
Human diagnostic patch test data: Dermatitis patients (unselected, consecutive): ≥ 1% = high frequency; < 1% = low/moderate frequency.  
 Human diagnostic patch test data: Selected dermatitis patients: ≥ 2% = high frequency; < 2% = low/moderate frequency. 
Human diagnostic patch test data: Work place studies: selected workers with known exposure or dermatitis: ≥ 1% = high frequency; < 1% = low/moderate 
frequency. 
Human diagnostic patch test data: Work place studies: all or randomly selected workers: ≥ 0.4% = high frequency; < 0.4% = low/moderate frequency. 
Human diagnostic patch test data: Number of published cases (N(cases)) ≥ 100 cases = high frequency; < 100 cases = low/moderate frequency. 
d) Substances of special concern according to SCCS (2012) defined as more than 100 cases from human studies. 
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Appendix 4 Citral CAS RN 5392-40-5 
Citral is the mixture of two isomers: cis-citral (neral) and trans-citral (geranial, i.e. the aldehyde of 
geraniol, which is a hapten by itself with a moderate sensitisation potency). Geranial and neral have 
been identified as metabolites of geraniol and have been both been identified as secondary 
oxidation products when geraniol autoxidises (SCCS, 2012). 
 
Non-human information 
Table 1 summarises relevant animal studies with citral i.e. Local Lymph Node Assays (LLNAs), 
Guinea Pig Maximization tests (GPMTs) and Buehler tests.  
 
Table 1. Animal studies with citral. 
Method Results Remarks/Comments Reference 
LLNA (OECD TG 429): 5, 
10 and 25% citral. 
Vehicle: Acetone:Olive oil 
(AOO).  
Citral was shown to 
have an EC3 value of 
12.6%. 
 Basketter (2012). 
LLNA: 
LLNA:BrdU-FCM. 5, 10 and 
25% citral.  
Vehicle: AOO.  
Citral was shown to 
have an EC3 value of 
9.2%. 
Citral was classified as a 
moderate skin sensitizer 
by Jung (2012). 
Jung (2012). 
LLNA: 0.4, 2, 4, 8 and 
20% citral. 
Vehicle: 1:3 
ethanol:diethyl phthalate 
(EtOH:DEP). 
Citral was shown to 
have an EC3 value of 
1.2% (0.079 M). 
According to SCCS 
(2012) there were no 
reported deviations from 
OECD TG 429. 
Unpublished summary 
report by RIFM 2009 
(RIFM 2004b) cited 
from SCCS (2012). 
LLNA: 0.3, 1, 3, 10 and 
30% citral. 
Vehicle: 0.1% α-
tocopherol in 3:1 
EtOH:DEP. 
Citral was shown to 
have an EC3 value of 
1.5% (0.099 M). 
According to SCCS 
(2012) there were no 
reported deviations from 
OECD TG 429. 
Unpublished summary 
report by RIFM 2009 
(RIFM 2003k) cited 
from SCCS (2012). 
LLNA: 0.3, 1, 3, 10 and 
30% citral. 
Vehicle: 0.3% antioxidant 
mix (equal parts butylated 
hydroxytoluene (BHT), 
tocopherol and eugenol) in 
3:1 EtOH:DEP. 
Citral was shown to 
have an EC3 value of 
2.1% (0.14 M). 
According to SCCS 
(2012) there were no 
reported deviations from 
OECD TG 429. 
Unpublished summary 
report by RIFM 2009 
(RIFM 2003l) cited from 
SCCS (2012). 
LLNA: 0.3, 1, 3, 10 and 
30% citral. 
Vehicle: 0.1% Trolox C in 
3:1 EtOH:DEP. 
Citral was shown to 
have an EC3 value of 
3.7% (0.24 M). 
According to SCCS 
(2012) there were no 
reported deviations from 
OECD TG 429. 
Unpublished summary 
report by RIFM 2009 
(RIFM 2003m) cited 
from SCCS (2012). 
LLNA: 0.3, 1, 3, 10 and 
30% citral. 
Vehicle: 3:1 EtOH:DEP. 
Citral was shown to 
have an EC3 value of 
4.6% (0.3 M). 
According to SCCS 
(2012) there were no 
reported deviations from 
OECD TG 429. 
Unpublished summary 
report by RIFM 2009 
(RIFM 2003n) cited 
from SCCS (2012). 
LLNA: 0.3, 1, 3, 10 and 
30% citral. 
Citral was shown to 
have an EC3 value of 
According to SCCS 
(2012) there were no 
Unpublished summary 
report by RIFM 2009 
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Vehicle: 0.3% antioxidant 
mix (equal parts BHT, 
tocopherol and eugenol) in 
3:1 EtOH:DEP. 
4.6% (0.3 M). reported deviations from 
OECD TG 429. 
(RIFM 2003o) cited 
from SCCS (2012). 
LLNA: 0.3, 1, 3, 10 and 
30% citral. 
Vehicle: 3:1 EtOH:DEP. 
Citral was shown to 
have an EC3 value of 
5.3% (0.35 M). 
According to SCCS 
(2012) there were no 
reported deviations from 
OECD TG 429. 
Unpublished summary 
report by RIFM 2009 
(RIFM 2003p) cited 
from SCCS (2012). 
LLNA: 0.3, 1, 3, 10 and 
30% citral. 
Vehicle: 0.1% Trolox C in 
3:1 EtOH:DEP. 
Citral was shown to 
have an EC3 value of 
5.8% (0.38 M). 
According to SCCS 
(2012) there were no 
reported deviations from 
OECD TG 429. 
Unpublished summary 
report by RIFM 2009 
(RIFM 2003q) cited 
from SCCS (2012). 
LLNA: 2.5, 5, 10, 25 and 
50% citral. 
Vehicle: 1:3 EtOH:DEP. 
Citral was shown to 
have an EC3 value of 
6.3% (0.41 M). 
According to SCCS 
(2012) there were no 
reported deviations from 
OECD TG 429. 
Unpublished summary 
report by RIFM 2009 
(RIFM 2003r) cited from 
SCCS (2012). 
LLNA: 0.3, 1, 3, 10 and 
30% citral. 
Vehicle: 0.1% α-
tocopherol in 3:1 
EtOH:DEP. 
Citral was shown to 
have an EC3 value of 
6.8% (0.44 M). 
According to SCCS 
(2012) there were no 
reported deviations from 
OECD TG 429. 
Unpublished summary 
report by RIFM 2009 
(RIFM 2003s) cited from 
SCCS (2012). 
LLNA: (concentration not 
reported) citral. 
Vehicle: AOO. 
Citral was shown to 
have an EC3 value of 
13%. 
 Basketter et al., 2002a 
cited from Lalko and Api 
(2008). 
LLNA: 5, 10 and 25% 
citral. 
Vehicle: 4:1 AOO. 
Citral was shown to 
have an EC3 value 
between 7 and 15%. 
According to REACH- RD 
(2015c) the study was 
reliable with restrictions 
(reliability 2) and 
performed equivalent or 
similar to OECD TG 429. 
Basketter and Scholes 
1992 cited from REACH-
RD (2015c). 
GPMT: 
Intradermal induction 
0.1% citral;  
Topical induction 5% 
citral;  
Challenge dose 0.5%. 
Vehicle not reported. 
6/10 (60%) animals 
were positive. 
According to REACH- RD 
(2015d) the study is 
reliable with restrictions 
(reliability 2) and 
performed equivalent or 
similar to OECD TG 406. 
Basketter and Allenby 
1991; Basketter et al., 
1991 and Basketter & 
Scholes, 1992 cited 
from REACH-RD 
(2015d). 
GPMT: 
Intradermal induction 10% 
citral;  
Topical induction 10% 
citral;  
Challenge dose 10%. 
Vehicle not reported. 
Sensitization observed. No further information is 
available from Lalko and 
Api (2008). 
Ishihara et al., 1986a 
cited from Lalko and Api 
(2008). 
GPMT: 
Intradermal induction 
0.4% citral;  
Sensitization observed. No further information is 
available from Lalko and 
Api (2008). 
Goodwin and Johnson 
1985 cited from Lalko 
and Api (2008). 
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Topical induction 1% 
citral;  
Challenge dose 0.25%. 
Vehicle not reported.  
GPMT: 
Intradermal induction 25% 
citral in paraffin oil DAB7 
or Freund’s adjuvant/aqua 
dest. (1:1);  
Topical induction 25% 
citral in paraffin oil DAB7;  
Challenge doses 10, 5 and 
5% citral in paraffin oil 
DAB7. 
100% positive 
reactions. 
According to REACH-RD 
(2015e) the study is 
reliable with restrictions 
(reliability 2) and 
performed equivalent or 
similar to OECD TG 406. 
Study report 1978-11-
15 cited from REACH-
RD (2015e). 
GPMT: 
Intradermal induction 25% 
citral in paraffin oil DAB7 
or Freund’s adjuvant/aqua 
dest. (1:1);  
Topical induction 25% 
citral in paraffin oil DAB7;  
Challenge doses 10, 5 and 
5% citral in paraffin oil 
DAB7. 
100% positive reactions 
except for after 144 
hours after a 5% 
rechallenge where it 
was 60%. 
According to REACH-RD 
(2015f) the study is 
reliable with restrictions 
(reliability 2) and 
performed equivalent or 
similar to OECD TG 406. 
Study report 1978-11-
12 cited from REACH-
RD (2015f). 
GPMT: 
Intradermal induction 5% 
citral;  
Topical induction 25% 
citral in pet.;  
Challenge dose: 
subirritant.  
Vehicle not reported. 
Sensitization observed. No further information is 
available from Lalko and 
Api (2008). 
Klecak et al., 1977 cited 
from Lalko and Api 
(2008). 
Buehler: 
Induction concentration 
20% citral in petrolatum 
(pet.);  
Challenge dose 20% in 
pet. 
Sensitization observed. No further information is 
available from Lalko and 
Api (2008). 
Unpublished report by 
RIFM 1973 cited from 
Lalko and Api (2008). 
 
A total of 14 LLNAs, 6 GPMTs and 1 Buehler test are summarised in table 1. The reported EC3 
values for citral range between 1.2% (vehicle: 1:3 ethanol:diethyl phthalate) and 15% (vehicle: 
Acetone:Olive oil 4:1).  In the GPMTs sensitisation was observed but not quantified (i.e. number of 
animals affected) in 3/6 studies with intradermal induction doses of 0.4, 5 and 10% citral. In the 
other GPMTs 60% of the animals responded after an intradermal induction dose of 0.1% while 60-
100% of the animals responded after an intradermal induction dose of 25% citral. Sensitisation was 
also observed but not quanitfied (i.e. number of animals affected) in the Buehler test with an 
induction concentration of 20% citral. 
 
No relevant in vitro studies on citral (i.e. OECD TG 442C and OECD TG 442D) were identified in 
the literature.  
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Population studies 
Table 2 summarises patch test studies on citral involving several thousand dermatitis patients from 
various countries in Europe and Asia. Most of the studies are diagnostic patch test studies.  
 
Table 2. Population studies with citral. 
Method Results Remarks/Comments Reference 
Patch test: 
Retrospective study 
of 324 selected 
patients patch 
tested with citral 
2% in petrolatum 
(pet.). 
42/324 (13%) 
patients were 
positive.  
A retrospective study 
on patch test data 
from multicentre 
project IVDK 
(Information Network 
of Departments of 
Dermatology) (2007-
2009). 
Schnuch et al. 
(2015). 
Patch test: 
Prospective study 
of 655 consecutive 
patients patch 
tested with citral 
3.5% in pet.  
6/655 (0.92%) 
patients were 
positive. 
A prospective study of 
patch test data at the 
Department of 
Dermatology, 
Sahlgrenska University 
Hospital, Gothenburg, 
Sweden (2010-2011). 
Hagvall and 
Brared 
Christensson 
(2014). 
Patch test: 
Retrospective study 
of 1951 selected 
eczema patients 
patch tested with 
citral 2% in pet.  
20/1951 (1%, 95% 
CI: 0.6-1.4%) 
patients were 
positive. 
A retrospective study 
on patch test data at 
St John’s Institute of 
Dermatology at St 
Thomas’ Hospital, UK 
(2011-2012). 
Mann et al. 
(2014). 
Patch test:  
Prospective study 
of 1055 consecutive 
patients patch 
tested with citral 
1.5% in pet. 
7/1055 (0.66%) 
patients were 
positive. 
A prospective study on 
patch test data from 
Department of 
Dermatology, 
Sahlgrenska University 
Hospital, Gothenburg, 
Sweden (2006-2010). 
Hagvall et al. 
(2012). 
Patch test: 
Prospective study 
of 565 selected 
patients patch 
tested with citral 
2% in vaseline. 
19/565 (3.4%) 
patients were 
positive. 
A prospective study on 
patch test data from 
multicentre study, 
Hungary (2009-2010). 
Ponyai et al. 
(2012). 
Patch test: 
Retrospective study 
of 205 selected 
patients tested with 
citral 2% in pet. 
23/205 (11.2%) 
patients were 
positive. 
A retrospective study 
on patch test data 
from Department of 
Dermatology, 
University Hospital St 
Rafaël, Belgium (1990-
2011). 
Nardelli et al. 
(2013). 
Patch test: 
Prospective study 
9/100 (9%, 95% 
CI: 4.2-16.4%) 
Single-centre, double-
blind prospective 
Nagtegaal et 
al. (2012). 
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of 100 selected 
patients with 
contact allergy 
patch tested with 
citral 2% in pet. 
patients were 
positive. 
experimental 
longitudinal volunteer 
study at the 
department of 
Dermatology of the VU 
University Medical 
Centre, The 
Netherlands (2005-
2010). 
Patch test: 
Retrospective study 
of 1502 consecutive 
eczema patients 
patch tested with 
citral 2% in pet. 
5/1502 (0.3 %) 
patients were 
positive. 
A retrospective study 
of patch test data at 
Department of 
Dermato-Allergology, 
Copenhagen University 
Hospital Gentofte, 
Denmark (2008-2010).   
Heisterberg et 
al. (2011, 
2012). 
Patch test: 
Prospective study 
of 30 selected 
patients (with 
positive reactions to 
ascaridole 1 and 5 
%) patch tested 
with citral 2% in 
pet. 
2/30 (7%) patients 
were positive. 
A prospective study of 
patch test data at the 
Department of 
Dermatology, 
University Medical 
Centre Groningen, The 
Netherlands (2008-
2011).   
Bakker et al. 
(2011). 
Patch test: 
Retrospective study 
of 86 selected 
patients patch 
tested with citral 
2% in pet.  
2/86 (2.3%) 
patients were 
positive.  
A retrospective and 
descriptive analysis of 
a patch test study at 
the Cutaneous Allergy 
Unit of a tertiary 
referral hospital, Spain 
(2004-2008). 
Cuesta et al. 
(2010). 
Patch test: 
Retrospective study 
of 367 selected 
fragrance mix (FM) 
II positive patients 
patch tested with 
citral 2% in pet.  
59/367 (16.1%) 
patients were 
positive.  
A retrospective study 
on patch test data 
from multicentre 
project IVDK (2005-
2008). 
Krautheim et 
al. (2010). 
Patch test: 
Prospective study 
of 320 selected 
eczema patients 
patch tested with 
citral 2% in pet. 
2/320 (0.6%) 
patients were 
positive. 
A prospective analysis 
of selected eczema 
patients at the 
University Medical 
Center in Groningen, 
the Netherlands (2005-
2007). 
van Oosten et 
al. (2009). 
Patch test: 
Retrospective study 
of 2021 consecutive 
12/2021 (0.6%, 
95% CI: 0.3-1.1%) 
patients were 
A retrospective study 
on patch test data 
from multicentre 
Schnuch et al. 
(2007). 
  
 
Evaluation of selected sensitizing fragrance substances  81 
Method Results Remarks/Comments Reference 
patients patch 
tested with citral 
2% in pet. 
positive. project IVDK (2003-
2004). 
Patch test: 
Prospective study 
of 422 selected 
patients with 
suspected contact 
allergy patch tested 
with citral 2% in 
pet. 
5/422 (1.2%) 
patients were 
positive. 
A prospective analysis 
of patients from nine 
dermatology 
departments of 
university hospitals in 
Korea (2002-2003). 
An et al. 
(2005). 
Patch test: 
Prospective study 
of 1701 consecutive 
patients patch 
tested with citral 
2% in pet. 
12/1701 (0.7%) 
patients were 
positive. 
A prospective analysis 
of patients from six 
dermatology 
departments 
(Dortmund, 
Copenhagen, Malmö, 
Odense, London and 
Leuven) (1997-1998). 
Frosch et al., 
2005 cited 
from SCCS 
(2012). 
Patch test: Study of 
1701 patients patch 
tested with citral 
1%. Vehicle not 
reported. 
6/1701 (0.35%) 
patients were 
positive. 
 Frosch et al., 
2004 and 2005 
cited from 
Lalko and Api 
(2008). 
Patch test: Study of 
586 consecutive 
patients patch 
tested with citral 
2% in pet. 
28/586 (4.8%) 
patients were 
positive. 
According to SCCS 
2012 irritant reactions 
were observed in 
82/586 (14%). 
Heydorn et al., 
2003 cited 
from SCCS 
(2012). 
Patch test: 
Prospective study 
of 1855 consecutive 
patients patch 
tested with citral 
2% in pet. 
21/1855 (1.1%) 
patients were 
positive. 
A prospective analysis 
of patients from six 
dermatology 
departments 
(Dortmund, 
Copenhagen, Malmö, 
Odense, London and 
Leuven) (1997-1998). 
Frosch et al. 
(2002a). 
Patch test: 
Prospective study 
of 1825 consecutive 
patients patch 
tested with citral 
2% in pet. 
19/1825 (1%) 
patients were 
positive. 
Multicenter study of 
patch test data in The 
Netherlands (1998-
1999). 
de Groot et al. 
(2000). 
Patch test: Study of 
192 patients patch 
tested with citral 
1% in pet. 
8/192 (4.2%) 
patients were 
positive. 
 Frosch et al., 
1995 cited 
from Lalko and 
Api (2008). 
Patch test: Study of 1/192 (0.5%) According to Lalko and Frosch et al., 
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192 patients patch 
tested with citral 
0.1%. Vehicle not 
reported. 
patients were 
positive. 
Api (2008) the reaction 
was questionable. 
1995 cited 
from Lalko and 
Api (2008). 
Patch test: Study of 
78 selected patients 
sensitive to FM 
patch tested with 
citral 2% in pet. 
13/78 (16.7%) 
patients were 
positive. 
Multicentre study 
involving 6 countries. 
Year not stated. 
Wilkinson et 
al., 1989 cited 
from SCCNFP 
(1999). 
Patch test: Study of 
310 cosmetic 
dermatitis patients; 
408 non-cosmetic 
patients and 122 
control subjects 
patch tested with 
citral in 5%. Vehicle 
not reported. 
8/310 (2.6%) 
cosmetic dermatitis 
patients; 9/408 
(2.2%) non-
cosmetic patients 
and 1/122 (0.8%) 
control subjects 
were positive. 
 Itoh et al., 
1986 and 1988 
and Nishimura 
et al., 1984 
cited from 
Lalko and Api 
(2008). 
Patch test: Study of 
240 cosmetic 
dermatitis patients; 
584 non-cosmetic 
patients and 105 
control subjects 
patch tested with 
citral 2%. Vehicle 
not reported. 
1/240 (0.4%) 
cosmetic dermatitis 
patients; 2/584 
(0.3%) non-
cosmetic patients 
and 0/105 (0%) 
control subjects 
were positive. 
 Itoh et al., 
1986 and 1988 
and Nishimura 
et al., 1984 
cited from 
Lalko and Api 
(2008). 
Patch test: 
Prospective study 
of 182 selected 
patients suspected 
of contact allergy to 
cosmetics patch 
tested with citral 
2% in pet. 
5/182 (2.6%) 
patients were 
positive. 
 Malten et al., 
1984 cited 
from SCCNFP 
(1999). 
Patch test: Study of 
228 patients patch 
tested with citral 
1% in pet. 
4/228 (1.7%) 
patients were 
positive. 
North American 
Contact Dermatitis 
Research Group (1973-
1974). 
Michell et al., 
1982 cited 
from SCCNFP 
(1999). 
Patch test: Study of 
155 cosmetic 
dermatitis patients 
and 159 
eczema/dermatitis 
patients patch 
tested with citral 
5% in pet. 
4/155 (2.6%) 
cosmetic dermatitis 
patients and 5/159 
(3.1%) 
eczema/dermatitis 
patients were 
positive. 
According to Lalko and 
Api (2008) a total of 
48 control subjects 
were also tested with 
citral (5% pet) with no 
positive reactions. 
Ishihara et al., 
1981 cited 
from Lalko and 
Api (2008). 
Patch test: 1/4 (25%) patients  Malten 1979 
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Occupational study 
of 4 bakers with 
hand eczema patch 
tested with citral 
0.5% in pet. 
were positive. cited from 
SCCNFP 
(1999). 
 
Table 3 summarises Human Repeat Insult Patch Tests (HRIPTs) and Human Maximisation Tests 
(HMTs) with citral.  
 
Table 3. HRIPT and HMT studies with citral adapted from Lalko and Api (2008). 
Method Results Remarks/Comments Reference 
HRIPT: 
Citral 
concentration: 
1.2%.  
Vehicle: 3:1 
ethanol:diethyl 
phthalate 
(EtOH:DEP) with 
0.2% tocopherol.  
 
2/101 (2%) 
tests were 
positive. 
According to REACH-RD 
(2015g) the study is 
reliable with restrictions 
(reliability 2) and 
performed according to 
HRL Protocol #100RIFM 
and HRL Standard 
Operating Procedures. 
Study report 
2004-09-11 cited 
from REACH-RD 
(2015g). 
HRIPT: 
Citral 
concentration: 
1.2% (1400 
µg/cm2). 
Vehicle: 1:3 
EtOH:DEP.  
 
0/101 (0%) 
tests were 
positive. 
No further information 
available from Lalko 
and Api (2008). 
Unpublished 
report from RIFM 
2004b cited from 
Lalko and Api 
(2008). 
HRIPT: 
Citral 
concentration: 4-
8%.  
Vehicle: not 
reported.  
 
19/40 (48%) 
tests were 
positive. 
 Opdyke 1979 
cited from 
SCCFNP (1999). 
HRIPT: 
Citral 
concentration: 4% 
(1240 µg/cm2). 
Vehicle: petrolatum 
(pet.).  
 
0/50 (0%) tests 
were positive. 
No further information 
available from Lalko 
and Api (2008). 
Unpublished 
report from RIFM 
1971a cited from 
Lalko and Api 
(2008). 
HRIPT: 
Citral 
concentration: 1% 
(775 µg/cm2). 
Vehicle: alcohol 
SDA39C.  
0/40 (0%) tests 
were positive. 
No further information 
available from Lalko 
and Api (2008). 
Unpublished 
report from RIFM 
1965 cited from 
Lalko and Api 
(2008). 
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HRIPT: 
Citral 
concentration: 5% 
(3876 µg/cm2). 
Vehicle: alcohol 
SDA39C.  
 
5/8 (62.5%) 
tests were 
positive. 
No further information 
available from Lalko 
and Api (2008). 
Unpublished 
report from RIFM 
1964a cited from 
Lalko and Api 
(2008). 
HRIPT: 
Citral 
concentration: 
0.5% (388 
µg/cm2). 
Vehicle: alcohol 
SDA39C.  
 
0/41 (0%) tests 
were positive. 
No further information 
available from Lalko 
and Api (2008). 
Unpublished 
report from RIFM 
1964b cited from 
Lalko and Api 
(2008). 
HMT: 
Citral 
concentration: 5% 
(3448 µg/cm2). 
Vehicle: pet.  
 
16/25 (64%) 
tests were 
positive. 
No further information 
available from Lalko 
and Api (2008). 
Unpublished 
report from RIFM 
1974a cited from 
Lalko and Api 
(2008). 
HMT: 
Citral 
concentration: 5% 
(3448 µg/cm2). 
Vehicle: pet.  
 
14/25 (56%) 
tests were 
positive. 
No further information 
available from Lalko 
and Api (2008). 
Unpublished 
report from RIFM 
1974c cited from 
Lalko and Api 
(2008). 
HMT: 
Citral 
concentration: 5% 
(3448 µg/cm2). 
Vehicle: pet.  
 
12/25 (48%) 
tests were 
positive. 
No further information 
available from Lalko 
and Api (2008). 
Unpublished 
report from RIFM 
1974c cited from 
Lalko and Api 
(2008). 
HMT: 
Citral 
concentration: 5% 
(3448 µg/cm2). 
Vehicle: pet.  
 
8/25 (32%) 
tests were 
positive. 
No further information 
available from Lalko 
and Api (2008). 
Unpublished 
report from RIFM 
1974c cited from 
Lalko and Api 
(2008). 
HMT: 
Citral 
concentration: 5% 
(3448 µg/cm2). 
Vehicle: pet.  
 
11/24 (45.8%) 
tests were 
positive. 
No further information 
available from Lalko 
and Api (2008). 
Unpublished 
report from RIFM 
1974d cited from 
Lalko and Api 
(2008). 
HMT: 
Citral 
0/25 (0%) tests 
were positive. 
No further information 
available from Lalko 
Unpublished 
report from RIFM 
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concentration: 5% 
(3448 µg/cm2). 
Vehicle: butylene 
glycol.  
 
and Api (2008). 1974e cited from 
Lalko and Api 
(2008). 
HMT: 
Citral 
concentration: 4% 
(2759 µg/cm2) 
Vehicle: pet.  
 
3/25 (12%) 
tests were 
positive. 
No further information 
available from Lalko 
and Api (2008). 
Unpublished 
report from RIFM 
1972b cited from 
Lalko and Api 
(2008). 
HMT: 
Citral 
concentration: 4% 
(2759 µg/cm2). 
Vehicle: pet.  
 
3/25 (12%) 
tests were 
positive. 
No further information 
available from Lalko 
and Api (2008). 
Unpublished 
report from RIFM 
1972c cited from 
Lalko and Api 
(2008). 
HMT: 
Citral 
concentration: 4% 
(2759 µg/cm2). 
Vehicle: pet.  
 
5/25 (20%) 
tests were 
positive. 
No further information 
available from Lalko 
and Api (2008). 
Unpublished 
report from RIFM 
1972c cited from 
Lalko and Api 
(2008). 
HMT: 
Citral 
concentration: 2% 
(1379 µg/cm2). 
Vehicle: pet.  
 
2/24 (8.3%) 
tests were 
positive. 
No further information 
available from Lalko 
and Api (2008). 
Unpublished 
report from RIFM 
1972d cited from 
Lalko and Api 
(2008). 
HMT: 
Citral 
concentration: 8% 
(5517 µg/cm2) 
Vehicle: pet.  
 
8/24 (33.3%) 
tests were 
positive. 
No further information 
available from Lalko 
and Api (2008). 
Unpublished 
report from RIFM 
1971b cited from 
Lalko and Api 
(2008). 
HMT: 
Citral 
concentration: 4% 
(2759 µg/cm2). 
Vehicle: pet.  
 
9/25 (36%) 
tests were 
positive. 
No further information 
available from Lalko 
and Api (2008). 
Unpublished 
report from RIFM 
1971c cited from 
Lalko and Api 
(2008). 
HMT: 
Citral 
concentration: 4% 
(2759 µg/cm2). 
Vehicle: pet.  
 
4/25 (16%) 
tests were 
positive. 
No further information 
available from Lalko 
and Api (2008). 
Unpublished 
report from RIFM 
1971c cited from 
Lalko and Api 
(2008). 
HMT: 5/25 (20%) No further information Unpublished 
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Citral 
concentration: 4% 
(2759 µg/cm2). 
Vehicle: pet.  
 
tests were 
positive. 
available from Lalko 
and Api (2008). 
report from RIFM 
1971c cited from 
Lalko and Api 
(2008). 
HRIPT: Human Repeat Insult Patch Test, HMT: Human Maximisation Test. 
 
Case studies 
Table 4 summarises case reports with ACD where citral has been found to be among the causative 
agents.  
 
Table 4. Case studies with citral. 
Method Results Remarks/Comments Reference 
Patch test: A 30-
year old female 
patient with 
recurrent allergic 
contact cheilitis 
was patch tested 
with fragrance 
mix (FM) II and 
citral.  
Strong positive 
reaction to FM II 
and citral. The 
cheilitis was 
attributed to a lip 
salve containing 
citral. 
Case study  
(year not reported). 
Hindle et al., 
2007 cited from 
SCCS (2012). 
Patch test: Over a 
period of 2 years 
a total of 9 
beauticians with 
bilateral hand 
dermatitis were 
patch tested with 
the British 
baseline series, 
FM I and II, 
cosmetics and 
own products.  
Positive reactions 
in 5 of the 9 
beauticians were 
observed. 
Multible case study  
(UK). 
De Mozzi and 
Johnston (2014). 
 
A total of 30 results from patch test population studies, 7 HRIPTs, 14 HMTs and 2 case studies with 
citral are summarised above (Table 2, 3 and 4). As shown in Table 2 the positive patch test 
frequencies from all of the reported patch test population studies vary between 0.3 and 16.7% in 
dermatitis patients. For unselected/consecutive dermatitis patients, positive reactions range 
between 0.3 and 4.8% (8 studies) and for selected dermatitis patients positive reactions range 
between 0.3 and 16.7% (22 studies). The total number of published cases is > 300. Sensitisation was 
reported in 3/7 HRIPT studies at a citral concentration of 3876 µg/cm2 (5%). In the HMT studies 
13/14 studies with citral showed a positive result after 1379 µg/cm2. Based on these data the 
Research Institute for Fragrance Materials, Inc. (RIFM) deducted a NOEL-HRIPT4 (induction) of 
1400 µg/cm2 and a LOEL-HRIPT/HMT5 (induction) of 3876 µg/cm2. In addition, based on weight 
of evidence, a No Expected Sensitization Induction Level (NESIL) of 1400 µg/cm2 was established 
for citral by the RIFM Expert Panel (IFRA, 2013a). 
                                                                    
4 NOEL-HRIPT: No Observed Effect Level-Human Repeat Insult Patch Test 
5 LOEL-HRIPT/HMT: Lowest Observed Effect Level- Human Repeat Insult Patch Test/Human Maximisation test 
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Citral is a ”top 100” substance and has a harmonised classification for skin sensitisation (SCCS, 
2012; DK-EPA, 2015). 
 
According to SCCS (2012) citral is used in volumes greater than 175 ton per year in perfume 
formulations. It has been reported that in consumer products containing fragrance allergens that 
are required to be labelled 11.6% of a total of 516 consumer products; 25% of a total of 300 
consumer products; ca. 12% of 3000 products and 8.2% of children’s cosmetics were labelled to 
contain citral (Wijnhoven et al., 2008; Buckley, 2007; Schnuch et al., 2009 and Poulsen & Schmidt, 
2007 cited from SCCS (2012)). In addition, in 2007, 26.1% of 88 tested deodorants were labelled to 
contain citral and the fragrance was detected in 44% (range: 39-554 mg/kg) of 23 deodorants 
selected for analysis (Rastogi et al., 2007 cited from SCCS (2012)).   
 
The IFRA standard limits for citral in different IFRA QRA product categories reported by IFRA 
(2013a and 2015) are shown in table 5. 
 
Table 5. The IFRA standard limits for citral in IFRA QRA product categories. 
IFRA QRA product 
category 
Product type that drives the 
category consumer exposure 
level 
IFRA standard limits  
Category 1 Lip products 0.04% 
Category 2 Deodorants/antiperspirants 0.05% 
Category 3 Hydroalcoholics for shaved skin 0.2% 
Category 4 Hydroalcoholics for unshaved skin 0.6% 
Category 5 Hand cream 0.3% 
Category 6 Mouthwash 1.0% 
Category 7 Intimate wipes 0.1% 
Category 8 Hair styling aids 1.4% 
Category 9 Rinse-off hair conditioners 5.0%* 
Category 10 Hard surface cleaners 2.5%* 
Category 11 Candles Not restricted 
IFRA: International Fragrance Association, QRA: Quantitative Risk Assessment. 
*Maximum pragmatic level. 
 
Citral is registered under the REACH regulation with an annual tonnage band of 1000 - 10 000 
tonnes per annum. 
 
Summary and discussion of skin sensitization 
Human data 
A total of 30 results from patch test population studies, 7 HRIPTs, 14 HMTs and 2 case studies were 
identified for citral. The positive patch test frequencies from all of the reported patch test 
population studies vary between 0.3 and 16.7% in dermatitis patients. In studies with 
unselected/consecutive dermatitis patients positive reactions range between 0.3 and 4.8% (8 
studies) and in studies with selected dermatitis patients positive reactions range between 0.3 and 
16.7% (22 studies). The total number of published cases is > 300. Sensitisation was reported in 3/7 
HRIPT studies after exposure to 3876 µg/cm2 (5%) and in 13/14 HMT studies after exposure to 
1379 µg/cm2.  
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Non-human data  
A total of 12 LLNAs, 6 GPMTs and 1 Buehler test were identified testing skin sensitising effects of 
citral. The reported EC3 values for citral ranged between 1.2% and 15% in different vehicles. In the 
GPMTs sensitisation was observed but not quantified (i.e. number of animals affected) in 3/6 
studies with intradermal induction doses of 0.4, 5 and 10% citral. In the other GPMTs sensitisation 
was observed in 60% of the animals after an intradermal induction dose of 0.1% and in 60-100% of 
the animals after an intradermal induction dose of 25% citral. Sensitisation was also observed but 
not quantified (i.e. number of animals affected) in the Buehler test with an induction concentration 
of 20% citral. 
 
No relevant in vitro studies on citral (i.e. OECD TG 442C and OECD TG 442D) were identified in 
the literature. 
 
Exposure 
According to data from IFRA (2013a) the exposure of citral when used as fragrance in cosmetics 
and in other consumer products appears to be low.  
 
Comparison with criteria 
For unselected/consecutive dermatitis patients positive reactions range between 0.3 and 4.8% with 
3/8 studies reporting frequencies higher than 1%. For selected dermatitis patients positive reactions 
range between 0.3 and 16.7% with 14 out of 22 studies reporting frequencies higher than 2%. In 
addition to this there are more than 300 published cases of positive patch test reactions to citral. 
According to the CLP criteria a frequency ≥ 1% for unselected/consecutive dermatitis patients 
and/or ≥ 2% for selected dermatitis patients and/or a total number of published cases ≥ 100, equals 
a high frequency of occurrence of skin sensitisation (Table 3.4.2-b) (ECHA, 2015). The collected 
data described above from patch test studies show that citral causes a high frequency of occurrence 
of skin sensitisation based on patch test data from a minority of unselected dermatitis patient 
studies and a majority of selected dermatitis patient studies and the number of published cases.  
In regard to the HRIPT/HMT data the positive response reported at > 500 µg/cm2 for HRIPT/HMT 
induction threshold indicate evidence for sub-category 1B according to Annex I: 3.4.2.2.2.2. 
 
In the 14 LLNAs EC3 values between 1.2 and 15% were reported for citral. Two out of the 14 LLNAs 
reported an EC3 value <2%. According to the CLP Regulation an EC3 value  2% indicates 
classification of a substance in sub-category 1A whereas an EC3 value > 2% indicates classification 
of a substance in sub-category 1B (Annex I: 3.4.2.2.3.2.). Thus, these two studies indicate 
classification of citral in sub-category 1A. However, in the other 12 LLNAs, the EC3 value was >2% 
with only one of these 12 LLNAs reporting an EC3 value (2.1%) borderline to the cut-off criteria for 
classification in sub-category 1A or 1B indicating classification of citral in sub-category 1B. Based on 
a weight of evidence for the LLNAs, classification of citral in sub-category 1B seems justified. 
 
In 1/6 of the GPMTs sensitisation was observed in 60% of the animals after an intradermal 
induction dose of 0.1%. According to the CLP criteria a positive response ≥ 30% of the animals 
responding at ≤ 0.1% intradermal induction dose indicates classification of a substance in sub-
category 1A (Annex I: 3.4.2.2.3.2.) and thus, this study indicates classification of citral into sub-
category 1A. In 2/6 GPMTs sensitisation was observed in 60-100% of the animals after an 
intradermal induction dose of 25% citral. According to the CLP criteria a positive response ≥ 30% 
responding at > 1% intradermal induction dose indicates classification of a substance in sub-
category 1B (Annex I: 3.4.2.2.3.2.); thus, these two studies indicate classification of citral in sub-
category 1B. In 3/6 the GPMTs sensitisation was reported to be observed but not quantified (i.e. 
number of animals affected) with intradermal induction doses of 0.4, 5 and 10% citral; therefore, 
these GPMTs cannot be compared with the classification criteria.  
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Sensitisation was also reported to be observed but not quantified (i.e. number of animals affected) 
in the Buehler test with an induction concentration of 20% citral; therefore, this study cannot be 
compared with the classification criteria.  
 
Overall, there is clear evidence for classification in sub-category 1A based on the human patch test 
studies showing a high frequency of occurrence of skin sensitisation and the total number of cases 
combined with the estimated low exposure. The results from the animal studies are equivocal, 
mainly indicating classification in sub-category 1B.  A classification as a skin sensitiser in sub-
category 1A is thus warranted for citral. 
 
Conclusions on classification and labelling 
Based on the high frequency of sensitisation observed in human patch test studies and the high 
number of published cases combined with the estimated low exposure, a classification of citral as a 
skin sensitiser in sub-category 1A is justified.  
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Appendix 5 Cinnamaldehyde CAS RN 104-55-2 
Non-human information 
Table 1 summarises relevant animal studies with cinnamaldehyde i.e. Local Lymph Node Assays 
(LLNAs), Guinea Pig Maximization tests (GPMTs) and Buehler tests.  
 
Table 1. Animal studies with cinnamaldehyde. 
Method Results Remarks/Comments Reference 
LLNA: 
BrdU-ELISA in vivo 
and ex vivo BrdU. 1, 
5 and 10% 
cinnamaldehyde. 
Cinnamaldehyde 
was shown to 
have an EC2 
value of 6.1% in 
the BrdU-ELISA in 
vivo and an EC2 
value of 6.9 in the 
ex vivo BrdU. 
Cinnamaldehyde was 
classified as positive 
for skin sensitisation 
by Williams et al. 
(2015). 
Williams et al. 
(2015). 
LLNA: 
0.1, 0.99, 3.3, 9.9 
and 19.8% 
cinnamaldehyde. 
Cinnamaldehyde 
was shown to 
have an EC3 
value of 0.75% 
(57 mM). 
Cinnamaldehyde was 
classified as a strong 
skin sensitizer by 
Niklasson et al. (2013). 
Niklasson et 
al. (2013). 
LLNA: 
Ex vivo BrdU. 0.5, 1, 
5 and 10% 
cinnamaldehyde. 
Vehicle: Acetone: 
Olive oil (AOO). 
Cinnamaldehyde 
was shown to 
have an EC3 
value of 1.91%. 
Cinnamaldehyde was 
classified as a 
moderate skin 
sensitizer by Ulker et 
al. (2013). 
Ulker et al. 
(2013). 
LLNA: 
LLNA:BrdU-ELISA. 1, 
3 and 10%. 
Vehicle: AOO. 
Cinnamaldehyde 
was shown to 
have an EC2 
value of 2.2%. 
Cinnamaldehyde was 
classified as positive 
for skin sensitisation 
by Kojima (2011). 
Kojima 
(2011). 
LLNA: 0.1, 0.3, 1, 3 
and 10% 
cinnamaldehyde. 
Vehicle: 3:1 
ethanol:diethyl 
phthalate 
(EtOH:DEP). 
Cinnamaldehyde 
was shown to 
have an EC3 
value of 0.2% 
(0.015 M). 
According to SCCS 
(2012) there were no 
reported deviations 
from OECD TG 429. 
Unpublished 
summary 
report by RIFM 
2009 (RIFM 
2003a) cited 
from SCCS 
(2012). 
LLNA: 0.1, 0.3, 1, 3 
and 10% 
cinnamaldehyde. 
Vehicle: 0.1% α-
tocopherol in 3:1 
EtOH:DEP. 
Cinnamaldehyde 
was shown to 
have an EC3 
value of 0.2% 
(0.015 M). 
According to SCCS 
(2012) there were no 
reported deviations 
from OECD TG 429. 
Unpublished 
summary 
report by RIFM 
2009 (RIFM 
2003b) cited 
from SCCS 
(2012). 
LLNA: 0.1, 0.3, 1, 3 
and 10% 
cinnamaldehyde. 
Vehicle: 2% α-
Cinnamaldehyde 
was shown to 
have an EC3 
value of 0.6% 
According to SCCS 
(2012) there were no 
reported deviations 
from OECD TG 429. 
Unpublished 
summary 
report by RIFM 
2009 (RIFM 
92 Evaluation of selected sensitizing fragrance substances 
 
Method Results Remarks/Comments Reference 
tocopherol in 3:1 
EtOH:DEP. 
(0.045 M). 2003c) cited 
from SCCS 
(2012). 
LLNA: 0.1, 0.3, 1, 3 
and 10% 
cinnamaldehyde. 
Vehicle: 0.3% 
antioxidant mix 
(equal parts 
Butylated 
hydroxytoluene 
(BHT), tocopherol 
and eugenol) in 3:1 
EtOH:DEP. 
Cinnamaldehyde 
was shown to 
have an EC3 
value of 0.7% 
(0.053 M). 
According to SCCS 
(2012) there were no 
reported deviations 
from OECD TG 429. 
Unpublished 
summary 
report by RIFM 
2009 (RIFM 
2003d) cited 
from SCCS 
(2012). 
LLNA: 0.1, 0.3, 1, 3 
and 10% 
cinnamaldehyde. 
Vehicle: 0.1% Trolox 
C in 3:1 EtOH:DEP. 
Cinnamaldehyde 
was shown to 
have an EC3 
value of 0.7% 
(0.053 M). 
According to SCCS 
(2012) there were no 
reported deviations 
from OECD TG 429. 
Unpublished 
summary 
report by RIFM 
2009 (RIFM 
2003e) cited 
from SCCS 
(2012). 
LLNA: 0.1, 0.3, 1, 3 
and 10% 
cinnamaldehyde. 
Vehicle: 2% α-
tocopherol in 3:1 
EtOH:DEP. 
Cinnamaldehyde 
was shown to 
have an EC3 
value of 0.8% 
(0.06 M). 
According to SCCS 
(2012) there were no 
reported deviations 
from OECD TG 429. 
Unpublished 
summary 
report by RIFM 
2009 (RIFM 
2003f) cited 
from SCCS 
(2012). 
LLNA: 0.1, 0.3, 1, 3 
and 10% 
cinnamaldehyde. 
Vehicle: 3:1 
EtOH:DEP. 
Cinnamaldehyde 
was shown to 
have an EC3 
value of 0.9% 
(0.068 M). 
According to SCCS 
(2012) there were no 
reported deviations 
from OECD TG 429. 
Unpublished 
summary 
report by RIFM 
2009 (RIFM 
2003g) cited 
from SCCS 
(2012). 
LLNA: 0.1, 0.3, 1, 3 
and 10% 
cinnamaldehyde. 
Vehicle: 0.1% α-
tocopherol in 3:1 
EtOH:DEP. 
Cinnamaldehyde 
was shown to 
have an EC3 
value of 1.1% 
(0.083 M). 
According to SCCS 
(2012) there were no 
reported deviations 
from OECD TG 429. 
Unpublished 
summary 
report by RIFM 
2009 (RIFM 
2003h) cited 
from SCCS 
(2012). 
LLNA: 0.1, 0.3, 1, 3 
and 10% 
cinnamaldehyde. 
Vehicle: 0.3% 
antioxidant mix 
(equal parts BHT, 
tocopherol and 
Cinnamaldehyde 
was shown to 
have an EC3 
value of 1.3% 
(0.098 M). 
According to SCCS 
(2012) there were no 
reported deviations 
from OECD TG 429. 
Unpublished 
summary 
report by RIFM 
2009 (RIFM 
2003i) cited 
from SCCS 
(2012). 
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eugenol) in 3:1 
EtOH:DEP. 
LLNA: 0.1, 0.3, 1, 3 
and 10% 
cinnamaldehyde. 
Vehicle: 0.1% Trolox 
C in 3:1 EtOH:DEP. 
Cinnamaldehyde 
was shown to 
have an EC3 
value of 1.4% 
(0.11 M). 
According to SCCS 
(2012) there were no 
reported deviations 
from OECD TG 429. 
Unpublished 
summary 
report by RIFM 
2009 (RIFM 
2003j) cited 
from SCCS 
(2012). 
LLNA: concentration 
in vehicle not 
reported.  
Vehicle: 4:1 AOO. 
Cinnamaldehyde 
was shown to 
have an EC3 
value of 1.3% 
(0.10 M). 
According to SCCS 
(2012) there were no 
reported deviations 
from OECD TG 429. 
Elahi et al 
2004 cited 
from SCCS 
(2012). 
LLNA: 0.5, 1, 2.5, 5 
and 10% 
cinnamaldehyde. 
Vehicle: 4:1 AOO. 
Cinnamaldehyde 
was shown to 
have an EC3 
value of 3.1% 
(0.23 M). 
According to SCCS 
(2012) there were no 
reported deviations 
from OECD TG 429. 
Basketter et 
al., 2001 cited 
from SCCS 
(2012). 
LLNA: 1 and 2.5% 
cinnamaldehyde. 
Vehicle: 4:1 AOO. 
Cinnamaldehyde 
was shown to 
have an EC3 
value of 1.4% 
(0.11 M). 
Too few concentrations 
tested and few details 
in reference according 
to SCCS (2012). 
Smith and 
Hotchkiss 
2001 cited 
from SCCS 
(2012). 
LLNA: 1, 2.5, 5, 10 
and 25% 
cinnamaldehyde. 
Vehicle: 50:50 
EtOH:water. 
Cinnamaldehyde 
was shown to 
have an EC3 
value of 1.2% 
(0.091 M). 
According to SCCS 
(2012) there were no 
reported deviations 
from OECD TG 429. 
Wright et al., 
2001 cited 
from SCCS 
(2012). 
LLNA: 1, 2.5, 5, 10 
and 25% 
cinnamaldehyde. 
Vehicle: 90:10 
EtOH:water. 
Cinnamaldehyde 
was shown to 
have an EC3 
value of 1.6% 
(0.12 M). 
According to SCCS 
(2012) there were no 
reported deviations 
from OECD TG 429. 
Wright et al., 
2000 cited 
from SCCS 
(2012). 
LLNA: 0.1, 0.25, 0.5, 
1, 2.5, 5, 10 and 
25% 
cinnamaldehyde. 
Vehicle: Dimethyl 
sulfoxide (DMSO). 
Cinnamaldehyde 
was shown to 
have an EC3 
value of 0.9% 
(0.068 M). 
According to SCCS 
(2012) there were no 
reported deviations 
from OECD TG 429. 
Wright et al., 
1999 cited 
from SCCS 
(2012). 
LLNA: 1, 2.5, 5, 10 
and 25% 
cinnamaldehyde. 
Vehicle: propylene 
glycol. 
Cinnamaldehyde 
was shown to 
have an EC3 
value of 1.4% 
(0.11 M). 
According to SCCS 
(2012) there were no 
reported deviations 
from OECD TG 429. 
Wright et al., 
1998 cited 
from SCCS 
(2012). 
LLNA: 0.1, 0.25, 0.5, 
1, 2.5, 5, 10 and 
Cinnamaldehyde 
was shown to 
According to SCCS 
(2012) there were no 
Wright et al., 
1997 cited 
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25% 
cinnamaldehyde. 
Vehicle: 
Dimethylformamide 
(DMF). 
have an EC3 
value of 0.5% 
(0.038 M). 
reported deviations 
from OECD TG 429. 
from SCCS 
(2012). 
LLNA: 1, 2.5, 5, 10 
and 25% 
cinnamaldehyde. 
Vehicle: Methyl ethyl 
ketone (MEK). 
Cinnamaldehyde 
was shown to 
have an EC3 
value of 1.1% 
(0.083 M). 
According to SCCS 
(2012) there were no 
reported deviations 
from OECD TG 429. 
Wright et al 
1996 cited 
from SCCS 
(2012). 
LLNA: 1, 2.5, 5, 10 
and 25% 
cinnamaldehyde. 
Vehicle: 4:1 AOO. 
Cinnamaldehyde 
was shown to 
have an EC3 
value of 1.7% 
(0.13 M). 
According to SCCS 
(2012) there were no 
reported deviations 
from OECD TG 429. 
Wright et al., 
1995 cited 
from SCCS 
(2012). 
GPMT: 
Concentration: 
0.75% 
cinnamaldehyde (2 
samples). 
Vehicle: not reported. 
9/10 (90%) and 
10/10 (100%) 
animals were 
positive. 
 Basketter 
1992 cited 
from Bickers 
et al. (2005). 
GPMT: 
Concentration: 
0.75% 
cinnamaldehyde. 
Vehicle: 70:30 
acetone/polyethylene 
glycol (PEG) 400. 
100% of the 
animals were 
sensitised. 
 Basketter and 
Scholes 1992 
cited from 
Bickers et al. 
(2005). 
GPMT: 
Concentration: 3% 
cinnamaldehyde. 
Vehicle: not reported. 
Strong 
sensitisation 
effects reported 
(no further 
details). 
 Ishihara et al., 
1986 cited 
from Bickers 
et al. (2005). 
 
A total of 22 LLNAs, 2 LLNA BrdU-ELISA tests and 3 GPMTs are summarised in table 1. The 
reported EC3 values for cinnamaldehyde range between 0.2% (vehicle: 3:1 ethanol:diethyl phthalate 
with or without α-tocopherol) and 3.1% (vehicle: Acetone:Olive oil 4:1). In the LLNA BrdU-ELISA 
tests EC2 values were reported to be between 2.2 and 6.9%. Positive reactions were observed in all 
GPMTs with cinnamaldehyde concentrations down to 0.75%. It is, however, not clear from the 
review by Bickers et al. (2005) whether the concentration was the intradermal induction dose.  
 
No relevant in vitro studies on cinnamaldehyde (i.e. OECD TG 442C and OECD 442D) were 
identified in the literature.   
 
Human information 
Population studies 
Table 2 summarises patch test studies on cinnamaldehyde involving several thousand dermatitis 
patients from various countries in Europe and the US. Most of the studies are diagnostic patch test 
studies.  
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Table 2. Population studies with cinnamaldehyde 
Method Results Remarks/Comments Reference 
Patch test: 
Retrospective study 
of 806 selected 
patients patch 
tested with 
cinnamaldehyde 1% 
in petrolatum (pet.). 
76/806 (9.4%) 
patients were 
positive.  
A retrospective study 
on patch test data from 
multicentre project 
IVDK (Information 
Network of 
Departments of 
Dermatology) (2007-
2009). 
Schnuch et al. 
(2015). 
Patch test: 
Retrospective study 
of 1951 selected 
eczema patients 
patch tested with 
cinnamaldehyde 1% 
in pet. 
27/1951 (1.4%, 
95% CI: 0.9-
1.9%) patients 
were positive. 
A retrospective study 
on patch test data at St 
John’s Institute of 
Dermatology at St 
Thomas’ Hospital, UK 
(2011-2012). 
Mann et al. 
(2014). 
Patch test: 
Retrospective study 
of 41 selected 
children age 0-5 
years; 838 selected 
children age 6-18 
years and selected 
adults > 18 years 
patch tested with 
cinnamaldehyde 1% 
in pet.  
2/41 (4.9%) 
children age 0-5 
years; 10/838 
(1.2%) children 
age 6-18 years 
and 516/17213 
(3%) adults >18 
years were 
positive. 
A retrospective study of 
pooled patch test data 
from patients collected 
by the North American 
Contact Dermatitis 
Group (NACDG) (2005-
2012). 
Zug et al. 
(2014). 
Patch test: 
Retrospective study 
of selected allergic 
contact dermatitis 
(ACD) patients patch 
tested with 
cinnamaldehyde 1% 
in pet.  
122/5079 (2.4%) 
patients were 
positive. 
A retrospective study of 
pooled patch test data 
from patients collected 
by the North American 
Contact Dermatitis 
Group (NACDG) (2007-
2008). 
Fransway et al. 
(2013). 
Patch test: 
Retrospective study 
of 940 selected 
patients tested with 
cinnamaldehyde 1% 
in pet. 
66/940 (7%) 
patients were 
positive. 
A retrospective study 
on patch test data from 
Department of 
Dermatology, 
University Hospital St 
Rafaël, Belgium (1990-
2011). 
Nardelli et al. 
(2013). 
Patch test: 
Retrospective study 
of 164 hairdressers 
and hairdressing 
apprentices with 
eczema were tested 
3/164 (1%) 
patients were 
positive.  
   
A retrospective study of 
patch test data at 
Department of 
Occupational 
Dermatology Research 
and Education Centre, 
Lyons et al. 
(2013). 
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Method Results Remarks/Comments Reference 
with 
cinnamaldehyde 1% 
in pet. 
Australia (1993-2010). 
Patch test: 
Prospective study of 
23 selected patients 
with chronic 
idiopathic urticarial 
patch tested with 
cinnamaldehyde 1% 
in pet.  
3/23 (13%) 
patients were 
positive. 
A prospective 
longitudinal study at 
Tufts Medical Center, 
USA. Year not stated. 
Hession and 
Scheinman 
(2012). 
Patch test: 
Prospective study of 
100 selected 
patients with contact 
allergy patch tested 
with 
cinnamaldehyde 1% 
in pet. 
10/100 (10%, 
95% CI: 4.9-
17.62%) patients 
were positive. 
Single-centre, double-
blind prospective 
experimental 
longitudinal volunteer 
study at the 
department of 
Dermatology of the VU 
University Medical 
Centre, The 
Netherlands (2005-
2010). 
Nagtegaal et 
al. (2012). 
Patch test: 
Retrospective study 
of 1503 consecutive 
eczema patients 
patch tested with 
cinnamaldehyde 1% 
in pet. 
20/1503 (1.3%, 
95% CI: 0.8-2%) 
patients were 
positive. 
A retrospective study of 
patch test data at 
Department of 
Dermato-Allergology, 
Copenhagen University 
Hospital Gentofte, 
Denmark (2008-2010).   
Heisterberg et 
al. (2011). 
Patch test: 
Retrospective study 
of 157 selected 
patients (chosen out 
of 509 patients 
positive to fragrance 
allergens) patch 
tested with 
cinnamaldehyde 1% 
pet. 
Ca. 24/157 (ca. 
15%) patients 
were positive. 
A retrospective study of 
patch test data at the 
Allergy Clinic of the 
Department of 
Dermatology and 
Venereology, Zagreb 
University Hospital 
Center and School of 
Medicine, Zagreb, 
Croatia (2001-2005).   
Turcic et al. 
(2011). 
Patch test: 
Retrospective study 
of 1214 consecutive 
patients and 4527 
selected patients 
patch tested with 
cinnamaldehyde in 
1% pet. 
17/1214 (1.43%, 
95% CI: 0.67-
2.18%) and 
120/4527 
(2.64%, 95% CI: 
2.16-3.13%) 
patients were 
positive. 
A retrospective study 
on patch test data from 
multicentre project 
IVDK (Information 
Network of 
Departments of 
Dermatology) (2005-
2008). 
Uter et al. 
(2010). 
Patch test: 
Retrospective study 
7/86 (8.1%) 
patients were 
A retrospective and 
descriptive analysis of 
Cuesta et al. 
(2010). 
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Method Results Remarks/Comments Reference 
of 86 selected 
patients patch 
tested with 
cinnamaldehyde 2% 
in pet.  
positive.  a patch test study at 
the Cutaneous Allergy 
Unit of a tertiary 
referral hospital, Spain 
(2004-2008). 
Patch test: 
Retrospective study 
of 774 consecutive 
eczema patients 
patch tested with 
cinnamaldehyde 1% 
in pet. 
66/774 (8.5%) 
patients were 
positive. 
Retrospective study of 
patch test data from 
Odense University 
Hospital, Denmark 
(1995-2007). 
Andersen et al. 
(2009). 
Patch test: 
Prospective study of 
18 selected 
cinnamon-sensitive 
patients patch 
tested with 
cinnamaldehyde 2% 
in pet. 
4/18 (22%) 
patients were 
positive. 
Prospective study of 
cinnamon-sensitive 
patients at the 
Department of 
Dermatology of the VU 
University Medical 
Centre, The 
Netherlands (year not 
stated). 
Pentinga et al. 
(2009). 
Patch test: 
Prospective study of 
320 selected eczema 
patients patch 
tested with 
cinnamaldehyde 1% 
in pet. 
5/320 (1.6%) 
patients were 
positive. 
A prospective analysis 
of selected eczema 
patients at the 
University Medical 
Center in Groningen, 
the Netherlands (2005-
2007). 
van Oosten et 
al. (2009). 
Patch test: 
Retrospective study 
of 364 selected 
patients with a) 
current allergic 
dermatitis or b) past 
allergic dermatitis 
patch tested with 
cinnamaldehyde 1% 
in pet. 
a) 38/364 
(10.4%) and b) 
67/364 (19.2%) 
patients were 
positive. 
A retrospective study of 
patch test data from 
patients attending the 
Department of 
Cutaneous Allergy at St 
John’s Institute of 
Dermatology, UK 
(1982-2007). 
White (2009).  
Patch test: 
Retrospective study 
of selected ACD 
patients patch 
tested with 
cinnamaldehyde 1% 
in pet. between year 
2003-2004: 5138 
patients and year 
2005-2006: 4435 
patients. 
Year 2003-2004: 
123/5138 (2.4%) 
and year 2005-
2006: 138/4435 
(3.1%) patients 
were positive. 
A retrospective study of 
pooled patch test data 
from patients collected 
by the North American 
Contact Dermatitis 
Group (NACDG) (2005-
2006). 
Zug et al. 
(2009). 
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Method Results Remarks/Comments Reference 
Patch test: 
Prospective study of 
15 selected patients 
with eczematous 
reactions from 
ketoprofen-
containing gels 
patch tested with 
cinnamaldehyde 1% 
in pet.  
1/15 (6.7%) 
patients were 
positive. 
A prospective study on 
patch test data from 
patients from Italy 
(2006-2007). 
Foti et al. 
(2008). 
Patch test: 
Retrospective study 
of selected ACD 
patients patch 
tested with 
cinnamaldehyde 1% 
in pet. over two 
decades. Year 1984-
1985: 1199 
patients; year 1985-
1989: 3964 
patients; year 1992-
1994: 3528 
patients; year 1994-
1996: 3112 
patients; year 1996-
1998: 3443 patients 
and year 1998-
2000: 4735 
patients.  
Year 1984-1985: 
71/1199 (5.9%); 
year 1985-1989: 
123/3964 (3.1%); 
year 1992-1994: 
95/3528 (2.7%); 
year 1994-1996: 
75/3112 (2.4%); 
year 1996-1998: 
96/3443 (2.8%) 
and year 1998-
2000: 170/4735 
(3.7%) patients 
were positive. 
A retrospective study of 
pooled patch test data 
from patients collected 
by the North American 
Contact Dermatitis 
Group (NACDG) (1970-
2002). 
Nguyen et al. 
(2008). 
Patch test: 
Retrospective study 
of 2063 unselected 
patients patch 
tested with 
cinnamaldehyde 1% 
in pet. 
21/2063 (1%, 
95% CI: 0.5-
1.5%) patients 
were positive. 
A retrospective study 
on patch test data from 
multicentre project 
IVDK (2003-2004). 
Schnuch et al. 
(2007). 
Patch test: 
Prospective study of 
1603 selected 
patients with 
eczematous 
dermatitis patch 
tested with 
cinnamaldehyde 1% 
in pet. 
27/1603 (1.7%) 
patients were 
positive. 
A prospective analysis 
of multicentre data on 
patients from five US 
sites and one Canadian 
site (year not reported) 
Belsito et al. 
(2006). 
Patch test: Study of 
30 selected patients 
with a positive patch 
test to their own 
6/30 (20%) 
patients were 
positive. 
 Vocanson et al. 
(2006). 
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perfumed product 
patch tested with 
cinnamaldehyde. 
Concentration and 
vehicle not reported. 
Patch test: 
Prospective study of 
422 selected 
patients with 
suspected contact 
allergy patch tested 
with 
cinnamaldehyde 1% 
in pet. 
7/422 (1.7%) 
patients were 
positive. 
A prospective analysis 
of patients from nine 
dermatology 
departments of 
university hospitals in 
Korea (2002-2003). 
An et al. 
(2005). 
Patch test: 
Retrospective study 
of 4900 unselected 
patients patch 
tested with 
cinnamaldehyde 1% 
in pet. 
93/4900 (1.9%) 
patients were 
positive. 
A retrospective study 
on patch test data from 
multicentre project 
IVDK (1996-1999). 
Schnuch et al. 
(2002). 
Patch test: 
Prospective study of 
747 selected 
patients with 
suspected fragrance 
allergy patch tested 
with 
cinnamaldehyde 1% 
in pet. 
14/747 (1.9%) 
patients were 
positive. 
A prospective analysis 
of patients from FAZ-
Floridsdorf Allergy 
Centre, Austria (1997-
2000). 
Wohrl et al. 
(2001). 
Patch test: Study of 
226 selected 
patients sensitive to 
FM patch tested with 
cinnamaldehyde 1% 
in pet. 
30/226 (13%) 
patients were 
positive. 
Department of 
Dermatology, 
University Hospital, 
Coimbra, Portugal 
(1989-1999) 
Brites et al. 
(2000). 
Patch test: 
Retrospective study 
of 50 patients 
sensitive to FM 
patch tested with 
cinnamaldehyde 2% 
in 1% sorbitan 
sesquioleate. 
10/50 (20%) 
patients were 
positive. 
Retrospective study of 
patch test data. 
University Hospital 
Utrecht, The 
Netherlands (1994-
1998). 
Hendriks and 
van Ginkel 
(1999). 
Patch test: 
Retrospective study 
of 40 patients 
sensitive to FM 
patch tested with 
5/40 (12.5%) 
patients were 
positive. 
 Katsarma and 
Gawkrodger 
(1999). 
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Method Results Remarks/Comments Reference 
cinnamyl alcohol in 
pet. Concentration 
not reported. 
Patch test: Study of 
167 selected 
patients suspected 
of fragrance 
sensitivity patch 
tested with 
cinnamaldehyde 1% 
in pet. 
24/167 (14.4%) 
patients were 
positive. 
 Larsen et al., 
1996 cited 
from SCCNFP 
(1999). 
Patch test: 
Prospective study of 
1072 consecutive 
patients patch 
tested with 
cinnamaldehyde 1% 
in pet. 
10/1072 (0.93%) 
patients were 
positive. 
Prospective study of 
patients in a 
multicentre study 
involving 9 European 
centres. Year not 
stated. 
Frosch et al., 
1995 cited 
from SCCNFP 
(1999). 
Patch test: 
Retrospective study 
of 2447 consecutive 
patients from three 
age groups patch 
tested between 
1979-1983 with 2% 
pet. and 3440 
consecutive patients 
from three age 
groups patch tested 
between 1988-1992 
with 
cinnamaldehyde 1% 
in pet.   
Between 1979 
and 1983 754-
795/2447 (30.8-
32.5%) and 
between 1988 
and 1992 313-
440/3440 (9.1-
12.8%) patients 
were positive. 
Retrospective study of 
patch test data from 
Department of 
Dermatology, Gentofte 
Hospital, Denmark 
(1979-1983 and 1988-
1992). 
Johansen and 
Menne (1995). 
Patch test: 
Prospective study of 
61 selected patients 
sensitive to FM 
patch tested with 
cinnamaldehyde 2% 
in pet. 
21/61 (34%) 
patients were 
positive. 
Control tests in 
100 patients not 
allergic to 
fragrances 
showed no 
positive reactions 
when tested with 
cinnamaldehyde 
2% pet. 
Prospective study of 
patch test data from 
University of 
Amsterdam and 
University of Leiden, 
The Netherlands 
(1987). 
 
de Groot et al. 
(1993). 
 
Patch test: 
Prospective study of 
162 selected 
patients positive to a 
34/162 (21%) 
patients were 
positive. 
Retrospective study of 
patch test data from 
Dermatologische Klinik 
und Poliklinik, Germany 
Enders et al., 
1989 cited 
from SCCNFP 
(1999). 
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fragrance mix patch 
tested with 
cinnamaldehyde 1%. 
Vehicle not reported. 
(1987). 
Patch test: Study of 
78 selected patients 
positive to a 
fragrance mix patch 
tested with 
cinnamaldehyde 1%. 
Vehicle not reported. 
10/78 (12.8%) 
patients were 
positive. 
Multicentre study 
involving 6 countries. 
Year not stated. 
Wilkinson et 
al., 1989 cited 
from SCCNFP 
(1999). 
Patch test: 
Retrospective study 
of 1200 selected 
patients with 
dermatitis patch 
tested between 
1983 and 1984 with 
cinnamaldehyde 2% 
in pet. and 1500 
selected patients 
with dermatitis 
patch tested 
between 1984 and 
1985 with 
cinnamaldehyde 1% 
in pet. 
Between 1983 
and 1984 9/63 
(14.3%) and 
between 1984 
and 1985 3/54 
(5.6%) patients 
were positive. 
Retrospective study of 
patch test data from 
Istituto Dermatologico 
Santa Maria e San 
Gallicano, Italy (1983-
1985). 
Santucci et al. 
(1987). 
Patch test: 
Retrospective study 
of 403 selected 
patients with 
cutaneous reactions 
to cosmetic products 
patch tested with 
cinnamaldehyde. 
Concentration and 
vehicle not reported. 
6/403 (1.5%) 
patients were 
positive. 
It is unclear from the 
reference exactly how 
many patients were 
tested with cinnamyl 
alcohol. 
Adams and 
Maibach 
(1985). 
Patch test: 
Prospective study of 
182 selected 
patients suspected 
of contact allergy to 
cosmetics patch 
tested with 
cinnamaldehyde 
0.5% in pet. 
7/182 (3.7%) 
patients were 
positive. 
 Malten et al., 
1984 cited 
from SCCNFP 
(1999). 
Patch test: Study of 
20 selected perfume 
allergic patients 
6/20 (30%) 
patients were 
positive. 
 Larsen et al., 
1977 cited 
from SCCNFP 
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Method Results Remarks/Comments Reference 
patch tested with 
cinnamaldehyde 1%. 
Vehicle not reported. 
(1999). 
Patch test and 
ROAT1:  17 
cinnamaldehyde-
allergic patients (20 
controls) were 
tested with a 
dilution series of 
cinnamaldehyde in a 
patch test and a 
ROAT. 
No threshold 
could be 
established as all 
tested doses gave 
positive reactions 
in the ROAT. 
Minimum tested 
dose was 0.26 
µg/cm2.  
Copenhagen, Denmark 
and Malmö, Sweden. 
Year not stated. 
Bruze et al. 
(2003). 
Patch test and 
ROAT1: 22 
cinnamaldehyde-
allergic patients (20 
controls) were 
tested with a 
dilution series of 
cinnamaldehyde in a 
patch test and a 
ROAT. 
   
The ROAT 
threshold in 
percentage was 
higher than the 
patch test 
threshold.  
Clinical study at 
Gentofte Hospital and 
Odense University 
Hospital, Denmark. 
Year not stated. 
Johansen et al. 
(1996). 
1ROAT: Repeat Open Application Test. 
 
Table 3 summarises Human Repeat Insult Patch Tests (HRIPTs) and Human Maximisation Tests 
(HMTs) with cinnamaldehyde.  
 
Table 3. HRIPT and HMT studies with cinnamaldehyde adapted from Bickers et al. (2005). 
Method Results Remarks/Comments Reference 
HRIPT: 
Cinnamaldehyde 
concentration: 
0.5%  
Vehicle: 3:1 diethyl 
phthalate:ethanol 
(DEP:EtOH).  
 
0/94 (0%) tests 
were positive. 
 Unpublished 
report  (RIFM 
2004) cited 
from Bickers et 
al. (2005). 
HRIPT: 
Cinnamaldehyde 
concentration: 3%  
Vehicle: 3:1 
DEP:EtOH with 
0.5% α-tocopherol.  
 
4/28 (14%) tests 
were positive. 
 Unpublished 
report (RIFM 
2003b) cited 
from Bickers et 
al. (2005). 
HRIPT: 
Cinnamaldehyde 
concentration: 3%  
Study aborted 
during induction 
phase due to the 
 Unpublished 
report (RIFM 
2003b) cited 
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Vehicle: 3:1 
DEP:EtOH with 
0.5% α-tocopherol.  
number or irritant 
reactions. 
from Bickers et 
al. (2005). 
HRIPT: 
Cinnamaldehyde 
concentration: 
0.5%  
Vehicle: 3:1 
DEP:EtOH with 
0.5% α-tocopherol.  
 
0/22 (0%) tests 
were positive. 
 Unpublished 
report (RIFM 
2002a) cited 
from Bickers et 
al. (2005). 
HRIPT: 
Cinnamaldehyde 
concentration: 
0.5%  
Vehicle: 3:1 
DEP:EtOH with 
0.5% α-tocopherol.  
 
0/19 (0%) tests 
were positive. 
 Unpublished 
report (RIFM 
2002b) cited 
from Bickers et 
al. (2005). 
HRIPT: 
Cinnamaldehyde 
concentration: 0.1, 
0.5, 1 or 1.25%  
Vehicle: EtOH.  
 
0/41 (0%), 0/38 
(0%), 5/41 (12%) 
and 5/10 (50%) 
were positive after 
0.1, 0.5, 1 or 
1.25% 
cinnamaldehyde, 
respectively. 
 Danneman et 
al., 1983 cited 
from Cocchiara 
et al. (2005). 
HRIPT: 
Cinnamaldehyde 
concentration: 1%  
Vehicle: EtOH or 
petrolatum (pet.).  
 
1/55 (2%) tests 
were positive with 
ethanol as vehicle, 
no reactions with 
petrolatum as 
vehicle. 
 Marzulli and 
Maibach 1976 
and 1980 cited 
from Bickers et 
al. (2005). 
HRIPT: 
Cinnamaldehyde 
concentration: 1%  
Vehicle: alcohol 
SDA 39C.  
 
5/41 (12%) tests 
were positive. 
 Unpublished 
report (RIFM 
1973d) cited 
from Bickers et 
al. (2005). 
HRIPT: 
Cinnamaldehyde 
concentration: 
0.5%  
Vehicle: EtOH.  
 
0/38 (0%) tests 
were positive. 
 Unpublished 
report (RIFM 
1965) cited 
from Bickers et 
al. (2005). 
HRIPT: 
Cinnamaldehyde 
concentration: 
0/41 (0%) tests 
were positive. 
 Unpublished 
report (RIFM 
1964a) cited 
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0.125%  
Vehicle: EtOH.  
 
from Bickers et 
al. (2005). 
HRIPT: 
Cinnamaldehyde 
concentration: 
1.25%  
Vehicle: EtOH. 
5/10 (50%) tests 
were positive. 
 Unpublished 
report (RIFM 
1964b) cited 
from Bickers et 
al. (2005). 
HMT: 
Cinnamaldehyde 
concentration: 3% 
Vehicle: butylene 
glycol.  
 
3/25 (12%) tests 
were positive. 
 Unpublished 
report (RIFM 
1974a) cited 
from Bickers et 
al. (2005). 
HMT: 
Cinnamaldehyde 
concentration: 2%  
Vehicle: pet.  
 
11/25 (44%) tests 
were positive. 
 Unpublished 
report (RIFM 
1973c) cited 
from Bickers et 
al. (2005). 
HRIPT: Human Repeat Insult Patch Test, HMT: Human Maximisation Tests.  
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Case studies 
Table 4 summarises case reports with allergic contact dermatitis in different clinics in Europe and 
the US where cinnamaldehyde has been found as a causative agent.  
 
Table 4. Case studies with cinnamaldehyde 
Method Results Remarks/Comments Reference 
Patch test: A 33-
year old man with 
itching eczematous 
lesions was patch 
tested with 
cinnamaldehyde. 
Concentration and 
vehicle not 
reported.  
Positive reaction 
on day 2 and day 
4 was observed. 
Case study, Italy (year 
not stated). 
Guarneri 
(2010). 
Patch test: A 47-
year old man with 
dermatitis was 
patch tested with 
cinnamaldehyde. 
Concentration and 
vehicle not 
reported. 
Positive reaction 
on day 2 was 
observed. 
Case study, USA (year 
not stated). 
Decapite and 
Anderson 
(2004). 
Patch test: A 42-
year old woman 
with rash on her 
arms was patch 
tested with 
cinnamaldehyde. 
Concentration and 
vehicle not 
reported. 
Positive reaction 
after 20 min 
(anaphylaxis) was 
observed. 
Case study, UK (year 
not stated). 
Diba and 
Statham (2003). 
 
A total of 52 results from patch test population studies, 2 repeat open application tests (ROATs), 10 
HRIPTs, 2 HMTs and 3 case studies with cinnamaldehyde are summarised above (Table 2, 3 and 4). 
As shown in Table 2 the positive patch test frequencies from all of the reported patch test 
population studies vary between 0.93 and 38% in dermatitis patients. For unselected/consecutive 
dermatitis patients, positive reactions range between 0.93 and 32.5% (8 studies) and for selected 
dermatitis patients positive reactions range between 1.2 and 90% (44 studies). A single study in 
workers reported positive patch test reactions in 1%. The total number of published cases is > 2300. 
Sensitisation was reported in 6/12 HRIPT studies at cinnamaldehyde concentrations between 1 and 
3%. Both HMT studies reported positive reactions after 2-3% cinnamaldehyde. The Research 
Institute for Fragrance Materials, Inc. (RIFM) deducted a NOEL-HRIPT6 (induction) of 591 µg/cm2 
and a LOEL-HRIPT/HMT7 (induction) of 775 µg/cm2. In addition, based on weight of evidence, a 
No Expected Sensitization Induction Level (NESIL) of 590 µg/cm2 was established for 
cinnamaldehyde by the RIFM Expert Panel (IFRA, 2013b). 
 
                                                                    
6 NOEL-HRIPT: No Observed Effect Level-Human Repeat Insult Patch Test 
7 LOEL-HRIPT/HMT: Lowest Observed Effect Level- Human Repeat Insult Patch Test/Human Maximisation test 
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Two ROATs with cinnamaldehyde are summarised in table 2 (Johansen et al., 1996; Bruze et al., 
2003). Results from these studies may be used for establishing a specific concentration limit for 
cinnamaldehyde in consumer products. 
 
According to SCCS (2012) cinnamaldehyde is used in volumes less than 175 ton per year in perfume 
formulations. It has been reported that 2.5% of a total of 516 consumer products; 6% of a total of 
300 fragrance products; ca. 2% of 3000 products and 1% of children cosmetics were labelled to 
contain cinnamaldehyde (Wijnhoven et al., 2008; Buckley, 2007; Schnuch et al., 2009 and Poulsen 
& Schmidt, 2007 cited from SCCS (2012)). In addition, in 2007, 1.1% of 88 tested deodorants were 
labelled to contain cinnamaldehyde and the fragrance was detected in 4% (range: 5 mg/kg) of 23 
deodorants selected for analysis (Rastogi et al., 2007 cited from SCCS (2012)). Besides exposure 
from use of cosmetic products, cinnamaldehyde exposure also occurs from clothing, candles and 
food (SCCS, 2012).  
 
The IFRA standard limits for cinnamaldehyde in different IFRA QRA product categories reported 
by IFRA (2013b and 2015) are shown in table 5. 
 
Table 5. The IFRA standard limits for cinnamaldehyde in IFRA QRA product categories. 
IFRA QRA product 
category 
Product type that drives the 
category consumer exposure level 
IFRA standard limits 
Category 1 Lip products 0.02% 
Category 2 Deodorants/antiperspirants 0.02% 
Category 3 Hydroalcoholics for shaved skin 0.05% 
Category 4 Hydroalcoholics for unshaved skin 0.05% 
Category 5 Hand cream 0.05% 
Category 6 Mouthwash 0.4% 
Category 7 Intimate wipes 0.04% 
Category 8 Hair styling aids 0.05% 
Category 9 Rinse-off hair conditioners 0.05% 
Category 10 Hard surface cleaners 0.05% 
Category 11 Candles Not restricted 
IFRA: International Fragrance Association, QRA: Quantitative Risk Assessment. 
 
Cinnamaldehyde is registered under the REACH regulation with an annual tonnage band of 1000 - 
10 000 tonnes per annum. 
 
Summary and discussion of skin sensitization 
Human data 
A total of 52 results from patch test population studies, 7 HRIPTs, 14 HMTs and 2 case studies were 
identified with cinnamaldehyde. The positive patch test frequencies from all of the reported patch 
test population studies vary between 0.93 and 90% in dermatitis patients. In studies with 
unselected/consecutive dermatitis patients positive reactions range between 0.93 and 32.5% (8 
studies) and in studies with selected dermatitis patients positive reactions range between 1.2 and 
90% (44 studies). A single study in workers reported positive patch test reactions in 1%. The total 
number of published cases is > 2300. A LOEL-HRIPT/HMT (induction) of 775 µg/cm2 was 
established for cinnamaldehyde by the RIFM Expert Panel based on unpublished reports.  
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Non-human data 
A total of 22 LLNAs and 2 LLNA BrdU-ELISA tests were identified testing skin sensitising effects of 
cinnamaldehyde. The reported EC3 values for cinnamaldehyde ranged between 0.2% and 3.1% in 
different vehicles.  
 
No relevant in vitro studies on cinnamaldehyde (i.e. OECD TG 442C and OECD TG 442D) were 
identified in the literature. 
 
Exposure 
According to IFRA (2013b) the exposure of cinnamaldehyde when used as fragrance in cosmetics 
and in other consumer products appears to be low.    
 
Comparison with criteria 
For unselected/consecutive dermatitis patients positive reactions range between 0.93 and 32.5% 
with 7/8 studies reporting frequencies higher than 1%. For selected dermatitis patients positive 
reactions range between 1.2 and 90% with 37 out of 44 studies reporting frequencies higher than 
2%. A single study in workers reported positive patch test reactions in 1%. In addition to this there 
are more than 2300 published cases of positive patch test reactions to cinnamaldehyde. According 
to the CLP criteria a frequency ≥ 1% for unselected/consecutive dermatitis patients and/or ≥ 2% for 
selected dermatitis patients and/or ≥ 1% for selected workers with known exposure or dermatitis 
and/or a total number of published cases ≥ 100, equals a high frequency of occurrence of skin 
sensitisation (Table 3.4.2-b) (ECHA, 2015).The collected data described above from patch test 
studies show that cinnamaldehyde causes a high frequency of occurrence of skin sensitisation based 
on these four types of information.  
In regard to the HRIPT/HMT data the positive response reported at > 500 µg/cm2 for HRIPT/HMT 
induction threshold indicate evidence for sub-category 1B according to Annex I: 3.4.2.2.2.2. 
 
In the 22 LLNAs EC3 values between 0.2 and 3.1% were reported for cinnamaldehyde with 21/22 
EC3 values <2%. According to the CLP Regulation an EC3 value  2% indicates classification of a 
substance in sub-category 1A (Annex I: 3.4.2.2.3.2.). Hence, data from LLNAs indicate classification 
of cinnamaldehyde in sub-category 1A.  
 
Overall, there is clear evidence for classification in sub-category 1A based on the human patch test 
studies showing a high frequency of occurrence of skin sensitisation and the total number of cases 
combined with the estimated low exposure. Data from HRIPT/HMT indicate evidence for sub-
category 1B. Data from the LLNAs support a sub-category 1A classification. A classification as a skin 
sensitiser in sub-category 1A is thus warranted for cinnamaldehyde. 
 
Conclusions on classification and labelling 
Based on the high frequency of sensitisation observed in human patch test studies and the high 
number of published cases combined with the estimated low exposure and supported by data from 
LLNAs, a classification of cinnamaldehyde as a skin sensitiser in sub-category 1A is justified. 
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Appendix 6 Cinnamyl alcohol CAS RN 104-54-1 
According to SCCS (2012) cinnamyl alcohol is a fragrance compound known to be a prohapten and 
to form sensitising compounds by metabolic transformation, which increases the likelihood for 
cross-reactivity between cinnamyl alcohol and cinnamaldehyde.  
 
Non-human information 
Table 1 summarises relevant animal studies with cinnamyl alcohol i.e. Local Lymph Node Assays 
(LLNAs), Guinea Pig Maximization tests (GPMTs) and Buehler tests.  
 
Table 1. Animal studies with cinnamyl alcohol. 
Method Results Remarks/Comments Reference 
LLNA: 
Ex vivo LLNA-BrdU 
ELISA. 0, 0.5, 1, 5 
and 10% cinnamyl 
alcohol.  
Vehicle: Acetone: 
olive oil (AOO). 
Cinnamyl alcohol 
was shown to 
have an EC3 
value of 17.9%. 
Cinnamyl alcohol was 
classified as a weak 
skin sensitizer by Ulker 
et al. (2014). 
Ulker et al. 
(2014). 
LLNA (OECD TG 
429): 
10, 25 and 50% 
cinnamyl alcohol.  
Vehicle: AOO 
Cinnamyl alcohol 
was shown to 
have an EC3 
value of 25.2%. 
 Basketter 
(2012). 
LLNA: 
LLNA:BrdU-FCM. 
10, 25 and 50% 
cinnamyl alcohol.  
Vehicle: 4:1 AOO. 
Cinnamyl alcohol 
was shown to 
have an EC3 
value of 21%. 
Cinnamyl alcohol was 
classified as positive for 
skin sensitisation by 
Jung (2012). 
Jung (2012). 
LLNA (OECD TG 
429): 
Cinnamyl alcohol 
(concentration not 
reported). 
Vehicle: 4:1 AOO. 
Cinnamyl alcohol 
was shown to 
have an EC3 
value of 20.1% 
(1.5 M). 
 Elahi et al. 
(2004). 
LLNA: 
10, 25, 50 and 
90% cinnamyl 
alcohol. Vehicle: 
4:1 AOO. 
Cinnamyl alcohol 
was shown to 
have an EC3 
value of 21%. 
Cinnamyl alcohol was 
classified as a weak 
skin sensitizer by 
Gerberick et al. (2005). 
Estrada et al., 
2003 cited from 
Gerberick et al. 
(2005). 
GPMT: 
Intradermal 
induction 25%; 
topical induction 
25%; challenge 
dose 3% cinnamyl 
alcohol. 
Vehicle: not 
reported. 
Positive reactions 
in 3/10 (30%) of 
the tested 
animals. 
 Modjtahedi 
(2011). 
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Method Results Remarks/Comments Reference 
GPMT: 
Concentration: 
10% cinnamyl 
alcohol. 
Vehicle: not 
reported. 
Strong 
sensitisation 
effects reported 
(no further 
details). 
 Ishihara et al., 
1986 cited from 
Bickers et al. 
(2005). 
Freund’s complete 
adjuvant test: 
Intradermal 
induction dose 5% 
with challenge 
doses of 3, 10, 30 
and 100% 
cinnamyl alcohol. 
Vehicle: not 
reported. 
Positive reactions 
in 0/20, 0/20, 
0/20 and 3/20 
(15%) animals, 
respectively. 
 Study report 
1986-01-06 cited 
from REACH-RD 
(2015k). 
Buehler test: 
Induction dose 3, 
10 and 30% with a 
challenge dose of 
3% cinnamyl 
alcohol. 
Vehicle: not 
reported. 
Positive reactions 
in 0/11, 0/13 and 
0/15 animals, 
respectively. 
 Modjtahedi 
(2011). 
 
A total of five LLNAs (two of which were reported to be conducted in accordance with OECD TG 
429), two GPMTs, one Freund’s complete adjuvant test (FCAT) and one Buehler test were identified 
testing the skin sensitisation of cinnamyl alcohol. EC3 values between 17.9 and 30% were reported 
for cinnamyl alcohol in the LLNAs. Sensitisation was observed in 30% of the animals in a GPMT 
after an intradermal induction dose of 25%. Another GPMT reported strong sensitisation effects but 
without specifying the number of affected animals. In the Freund’s complete adjuvant test 15% of 
the animals had positive reactions after an intradermal induction dose of 100% cinnamyl alcohol. 
No positive reactions were observed in the Buehler test after induction doses of 3, 10 and 30% 
cinnamyl alcohol. 
 
No relevant in vitro studies on cinnamyl alcohol (i.e. OECD TG 442C and OECD 442D) were 
identified in the literature.   
 
Human information 
Population studies 
Table 2 summarises patch test studies on cinnamyl alcohol involving several thousand dermatitis 
patients from various countries in Europe and Asia. Most of the studies are diagnostic patch test 
studies.  
 
Table 2. Population studies with cinnamyl alcohol. 
Method Results Remarks/Comments Reference 
Patch test: 
Retrospective 
study of 806 
selected patients 
66/806 (8.2%) 
patients were 
positive.  
A retrospective study 
on patch test data from 
multicentre project 
IVDK (Information 
Schnuch et al. 
(2015). 
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Method Results Remarks/Comments Reference 
patch tested with 
cinnamyl alcohol 
1% in petrolatum 
(pet.). 
Network of 
Departments of 
Dermatology) (2007-
2009). 
Patch test: 
Retrospective 
study of 1951 
selected eczema 
patients patch 
tested with 
cinnamyl alcohol 
2% in pet.  
48/1951 (2.5%, 
95% CI: 1.8-
3.1%) patients 
were positive. 
A retrospective study 
on patch test data at St 
John’s Institute of 
Dermatology at St 
Thomas’ Hospital, UK 
(2011-2012). 
Mann et al. 
(2014). 
Patch test: 
Retrospective 
study of 940 
selected patients 
tested with 
cinnamyl alcohol 
1% in pet. 
129/940 (13.7%) 
patients were 
positive. 
A retrospective study 
on patch test data from 
Department of 
Dermatology, 
University Hospital St 
Rafaël, Belgium (1990-
2011). 
Nardelli et al. 
(2013). 
Patch test: 
Prospective study 
of 100 selected 
patients with 
contact allergy 
patch tested with 
cinnamyl alcohol 
1% in pet. 
13/100 (13%, 
95% CI: 7.11-
21.20%) patients 
were positive. 
Single-centre, double-
blind prospective 
experimental 
longitudinal volunteer 
study at the 
department of 
Dermatology of the VU 
University Medical 
Centre, The 
Netherlands (2005-
2010). 
Nagtegaal et al. 
(2012). 
Patch test: 
Retrospective 
study of 1501 
consecutive 
eczema patients 
patch tested with 
cinnamyl alcohol 
1% in pet. 
10/1501 (0.7%, 
95% CI: 0.3-
1.9%) patients 
were positive. 
A retrospective study of 
patch test data at 
Department of 
Dermato-Allergology, 
Copenhagen University 
Hospital Gentofte, 
Denmark (2008-2010).   
Heisterberg et al. 
(2011). 
Patch test: 
Retrospective 
study of 157 
selected patients 
(chosen out of 509 
patients positive to 
fragrance 
allergens) patch 
tested with 
cinnamyl alcohol 
5% in pet. 
54/157 (34.4%) 
patients were 
positive. 
A retrospective study of 
patch test data at the 
Allergy Clinic of the 
Department of 
Dermatology and 
Venereology, Zagreb 
University Hospital 
Center and School of 
Medicine, Zagreb, 
Croatia (2001-2005).   
Turcic et al. 
(2011). 
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Method Results Remarks/Comments Reference 
Patch test: 
Retrospective 
study of 86 
selected patients 
patch tested with 
cinnamyl alcohol 
2% in pet.  
12/86 (13.9%) 
patients were 
positive.  
A retrospective and 
descriptive analysis of a 
patch test study at the 
Cutaneous Allergy Unit 
of a tertiary referral 
hospital, Spain (2004-
2008). 
Cuesta et al. 
(2010). 
Patch test: 
Prospective study 
of 18 selected 
cinnamon-
sensitive patients 
patch tested with 
cinnamyl alcohol 
2% in pet. 
5/18 (28%) 
patients were 
positive. 
Prospective study of 
cinnamon-sensitive 
patients at the 
Department of 
Dermatology of the VU 
University Medical 
Centre, The 
Netherlands (year not 
stated). 
Pentinga et al. 
(2009). 
Patch test: 
Prospective study 
of 320 selected 
eczema patients 
patch tested with 
cinnamyl alcohol in 
2% pet. 
8/320 (2.5%) 
patients were 
positive. 
A prospective analysis 
of selected eczema 
patients at the 
University Medical 
Center in Groningen, 
the Netherlands (2005-
2007). 
van Oosten et al. 
(2009). 
Patch test: 
Retrospective 
study of 266 
selected patients 
with a) current 
allergic dermatitis 
or b) past allergic 
dermatitis patch 
tested with 
cinnamyl alcohol 
1% in pet. 
a) 24/266 
(9.02%) and b) 
44/266 (16.54%) 
patients were 
positive. 
A retrospective study of 
patch test data from 
patients attending the 
Department of 
Cutaneous Allergy at St 
John’s Institute of 
Dermatology, UK 
(1982-2007). 
White (2009). 
Patch test: 
Prospective study 
of 15 selected 
patients with 
eczematous 
reactions from 
ketoprofen-
containing gels 
patch tested with 
cinnamyl alcohol 
2% in pet.  
15/15 (100%) 
patients were 
positive. 
A prospective study on 
patch test data from 
patients from Italy 
(2006-2007). 
Foti et al. 
(2008). 
Patch test: 
Retrospective 
study of 2063 
unselected 
13/2063 (0.6%, 
95% CI: 0.2-
1.0%) patients 
were positive. 
A retrospective study 
on patch test data from 
multicentre project 
IVDK (2003-2004). 
Schnuch et al. 
(2007). 
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Method Results Remarks/Comments Reference 
patients patch 
tested with 
cinnamyl alcohol 
1% in pet. 
Patch test: 
Retrospective 
study of a) 29 
patients positive to 
their own 
deodorant and b) 
133 negative to 
their own 
deodorant patch 
tested with 
cinnamyl alcohol 
1% in pet. 
a) 3/29 (10%) 
and b) 2/133 
(1.5%) patients 
were positive. 
A retrospective study 
on patch test data from 
multicentre project 
IVDK (1998-2002). 
Uter et al. 
(2007). 
Patch test: Study 
of 30 selected 
patients with a 
positive patch test 
to their own 
perfumed product 
patch tested with 
cinnamyl alcohol. 
Concentration and 
vehicle not 
specified. 
6/30 (20%) 
patients were 
positive. 
 Vocanson et al. 
(2006). 
Patch test: 
Prospective study 
of 422 selected 
patients with 
suspected contact 
allergy patch 
tested with 
cinnamyl alcohol 
2% in pet. 
13/422 (3.1%) 
patients were 
positive. 
A prospective analysis 
of patients from nine 
dermatology 
departments of 
university hospitals in 
Korea (2002-2003). 
An et al. (2005). 
Patch test: 
Retrospective 
study of 4900 
unselected 
patients patch 
tested with 
cinnamyl alcohol 
1% in pet. 
88/4900 (1.8%) 
patients were 
positive. 
A retrospective study 
on patch test data from 
multicentre project 
IVDK (1996-1999). 
Schnuch et al. 
(2002). 
Patch test: 
Prospective study 
of 747 selected 
patients with 
suspected 
11/747 (1.5%) 
patients were 
positive. 
A prospective analysis 
of patients from FAZ-
Floridsdorf Allergy 
Centre, Austria (1997-
2000). 
Wohrl et al. 
(2001). 
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Method Results Remarks/Comments Reference 
fragrance allergy 
patch tested with 
cinnamyl alcohol 
1% in pet. 
Patch test: Study 
of 226 selected 
patients sensitive 
to FM patch tested 
with cinnamyl 
alcohol 1% in pet. 
18/226 (8%) 
patients were 
positive. 
Department of 
Dermatology, 
University Hospital, 
Coimbra, Portugal 
(1989-1999) 
Brites et al. 
(2000). 
Patch test: 
Retrospective 
study of 50 
patients sensitive 
to FM patch tested 
with cinnamyl 
alcohol 2% in 1% 
sorbitan 
sesquioleate. 
8/50 (16%) 
patients were 
positive. 
Retrospective study of 
patch test data. 
University Hospital 
Utrecht, The 
Netherlands (1994-
1998). 
Hendriks and van 
Ginkel (1999). 
Patch test: 
Retrospective 
study of 40 
patients sensitive 
to FM patch tested 
with cinnamyl 
alcohol in pet. 
Concentration not 
reported. 
4/40 (10%) 
patients were 
positive. 
 Katsarma and 
Gawkrodger 
(1999). 
Patch test: Study 
of 167 selected 
patients suspected 
of fragrance 
sensitivity patch 
tested with 
cinnamyl alcohol 
5% in lanolin. 
11/167 (6.6%) 
patients were 
positive. 
 Larsen et al., 
1996 cited from 
SCCNFP (1999). 
Patch test: 
Prospective study 
of 1072 
consecutive 
patients patch 
tested with 
cinnamyl alcohol 
1% in pet. 
6/1072 (0.56%) 
patients were 
positive. 
Prospective study of 
patients in a 
multicentre study 
involving 9 European 
centres. Year not 
stated. 
Frosch et al., 
1995 cited from 
SCCNFP (1999). 
Patch test: 
Retrospective 
study of 367 
selected patients 
patch tested with 
40/367 (10.9%) 
patients were 
positive. 
Retrospective study of 
patch test data from 
Department of 
Dermatology, Gentofte 
Hospital, Denmark 
Johansen and 
Menne (1995). 
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Method Results Remarks/Comments Reference 
cinnamyl alcohol 
1-2% in pet.   
(1979-1983 and 1988-
1992). 
Patch test: 
Prospective study 
of 50 selected 
patients positive to 
a fragrance mix 
(FM) patch tested 
with cinnamyl 
alcohol. 
Concentration not 
reported. 
17/50 (34%) 
patients were 
positive. 
Retrospective study of 
patch test data from 
Department of 
Dermatology and 
Venereology, Hungary. 
Year not stated. 
Becker et al. 
(1994). 
Patch test: 
Prospective study 
of 61 selected 
patients sensitive 
to a FM patch 
tested with 
cinnamyl alcohol 
5% in pet. 
19/61 (31%) 
patients were 
positive. 
Control tests in 
100 patients not 
allergic to 
fragrances 
showed that 
cinnamyl alcohol 
was marginally 
irritant at the 
concentration 
chosen. 
Prospective study of 
patch test data from 
University of 
Amsterdam and 
University of Leiden, 
The Netherlands 
(1987). 
 
de Groot et al. 
(1993). 
 
Patch test: Study 
of selected 
patients positive to 
a FM patch tested 
with cinnamyl 
alcohol. 
Concentration and 
vehicle not 
reported. 
14% patients 
were positive. 
Study of patch test 
data from France. No 
further information 
available from SCCNFP 
1999. 
Artigou et al., 
1989 cited from 
SCCNFP (1999). 
Patch test: 
Prospective study 
of 162 selected 
patients positive to 
a FM patch tested 
with cinnamyl 
alcohol 1%. 
Vehicle not 
reported. 
9/162 (5.6%) 
patients were 
positive. 
Retrospective study of 
patch test data from 
Dermatologische Klinik 
und Poliklinik, Germany 
(1987). 
Enders et al. 
(1989). 
Patch test: Study 
of 78 selected 
patients positive to 
a FM patch tested 
with cinnamyl 
alcohol 1%.  
5/78 (6.4%) 
patients were 
positive. 
Multicentre study 
involving 6 countries. 
Year not stated. 
Wilkinson et al., 
1989 cited from 
SCCNFP (1999). 
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Method Results Remarks/Comments Reference 
Vehicle not 
reported. 
Patch test: Study 
of 119 selected 
patients with 
contact allergy to 
cosmetic products 
patch tested with 
cinnamyl alcohol 
5% in pet. 
2/119 (1.7%) 
patients were 
positive. 
 De Groot et al., 
1988 cited from 
SCCNFP (1999). 
Patch test: Study 
of 156 selected 
patients with pure 
contact allergy to 
cosmetic products 
patch tested with 
cinnamyl alcohol 
Concentration and 
vehicle not 
reported. 
6/156 (3.8%) 
patients were 
positive. 
 Broneck et al., 
1987 cited from 
SCCNFP (1999). 
Patch test: 
Retrospective 
study of 63 
selected patients 
with dermatitis 
tested positive to 
perfume mixture 
patch tested 
between 1983 and 
1984 with 
cinnamyl alcohol 
3% in pet. and 54 
selected patients 
with dermatitis 
tested positive to 
perfume mixture 
patch tested 
between 1984 and 
1985 with 
cinnamyl alcohol 
1% in pet. 
Between 1983 
and 1984 9/63 
(14.3%) and 
between 1984 
and 1985 5/54 
(9.3%) patients 
were positive. 
Retrospective study of 
patch test data from 
Istituto Dermatologico 
Santa Maria e San 
Gallicano, Italy (1983-
1985). 
Santucci et al. 
(1987). 
Patch test: 
Retrospective 
study of 403 
selected patients 
with cutaneous 
reactions to 
cosmetic products 
patch tested with 
cinnamyl alcohol. 
17/403 (4.2%) 
patients were 
positive. 
It is unclear from the 
reference exactly how 
many patients were 
tested with cinnamyl 
alcohol. 
Adams and 
Maibach (1985). 
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Concentration and 
vehicle not 
reported. 
Patch test: study 
of 20 selected 
perfume allergic 
patients patch 
tested with 
cinnamyl alcohol 
5%.  
Vehicle not 
reported. 
15/20 (75%) 
patients were 
positive. 
 Larsen et al., 
1977 cited from 
SCCNFP (1999). 
 
Table 3 summarises Human Repeat Insult Patch Tests (HRIPTs) and Human Maximisation Tests 
(HMTs) with cinnamyl alcohol. 
 
Table 3. HRIPT and HMT studies with cinnamyl alcohol adapted from Letizia et al. (2005).  
Method Results Remarks/Comments Reference 
HRIPT: 
Sample: NA1 4%. 
Vehicle: 1:3 
ethanol:diethyl 
phthalate 
(EtOH:DEP).  
2/54 (4%) at re-
challenge, 
subjects reacted 
under occluded 
conditions but 
not under semi-
occlusive 
conditions or in a 
5-day repeated 
open application 
test. 
No further information 
available from Letizia et 
al. (2005). 
Unpublished 
report from RIFM 
(2001a, 2002a) 
cited from Letizia 
et al. (2005). 
HRIPT: 
Sample: NA 4%. 
Vehicle: 3:1 
EtOH:DEP. 
1/55, however as 
subject also 
reacted to vehicle 
control and to 
neat ethanol, it 
was concluded 
that the reaction 
was caused by 
the ethanol 
component and 
not cinnamyl 
alcohol 
No further information 
available from Letizia et 
al. (2005). 
Unpublished 
report from RIFM 
(2001b, 2002b) 
cited from Letizia 
et al. (2005). 
HRIPT (modified 
Draize): 
Sample: NA 4%. 
Vehicle: EtOH and 
petrolatum (pet.).  
4/150 (2.7%) 
reactions with 
ethanol as 
vehicle; no 
reactions with 
petrolatum as 
vehicle. 
 Jordan and King 
1977 cited from 
Letizia et al. 
(2005). 
HMT: 4/28 (14%) were No further information Unpublished 
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Method Results Remarks/Comments Reference 
Sample: 82-10-17 
(prepared via a 
borohydride 
reduction process) 
10%. Vehicle: 
DEP.  
positive (virgin 
panel)  
available from Letizia et 
al. (2005). 
report from RIFM 
(1982a) cited 
from Letizia et al. 
(2005). 
HMT: 
Sample: 82-10-
654 10%. 
Vehicle: DEP.  
4/27 
questionable 
para-allergic 
reactions; 3 of 
these subjects 
were retested 
and 2/3 reacted  
No further information 
available from Letizia et 
al. (2005). 
Unpublished 
report from RIFM 
(1982b) cited 
from Letizia et al. 
(2005). 
HMT: 
Sample: 81-10-HR 
recrystallized 
sample 10%.  
Vehicle: DEP.  
2/22 (9%) were 
positive. 
No further information 
available from Letizia et 
al. (2005). 
Unpublished 
report from RIFM 
(1981a) cited 
from Letizia et al. 
(2005). 
HMT: 
Sample: 81-10-HR 
(retest) 10%. 
Vehicle: DEP.  
2/23 (8.7%) 
were positive 
(virgin panel)  
No further information 
available from Letizia et 
al. (2005). 
Unpublished 
report from RIFM 
(1981b) cited 
from Letizia et al. 
(2005). 
HMT: 
Sample: 79-10-
ED-UN 10%. 
Vehicle: DEP.  
6/28 (21%) were 
positive. 
No further information 
available from Letizia et 
al. (2005). 
Unpublished 
report from RIFM 
(1980a) cited 
from Letizia et al. 
(2005). 
HMT: 
Sample: 79-10-
ED-W (washed 
with alkali) 10%. 
Vehicle: DEP.  
0/24 (0%) were 
positive. 
No further information 
available from Letizia et 
al. (2005). 
Unpublished 
report from RIFM 
(1980b) cited 
from Letizia et al. 
(2005). 
HMT: 
Sample: 79-10-0 
10%.   
Vehicle: DEP.  
2/22 (9%) were 
positive plus 1 
questionable 
reaction.  
No further information 
available from Letizia et 
al. (2005). 
Unpublished 
report from RIFM 
(1980d) cited 
from Letizia et al. 
(2005). 
HMT: 
Sample: 79-10-N 
(pure form of 79-
10-0) 10%.  
Vehicle: DEP.  
0/35 sensitisation 
reactions (0%); 7 
irritations 
reactions and 1 
hyper-irritation 
reaction.  
No further information 
available from Letizia et 
al. (2005) and Bickers 
et al 2005. 
Unpublished 
report from RIFM 
(1980e) cited 
from Letizia et al. 
(2005) and 
Bickers et al. 
(2005). 
HMT: 
Sample: 79-10-
ED-W and F 
1/28 (4%) was 
positive. 
No further information 
available from Letizia et 
al. (2005). 
Unpublished 
report from RIFM 
(1980c) cited 
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Method Results Remarks/Comments Reference 
(washed with 
alkali) 10%.   
Vehicle: DEP.  
from Letizia et al. 
(2005). 
HMT: 
Sample: CA 
(washed with 
alkali) 10%.  
Vehicle: DEP  
1/21 
questionable 
reactions (virgin 
panel)  
No further information 
available from Letizia et 
al. (2005). 
Unpublished 
report from RIFM 
(1980f) cited 
from Letizia et al 
2005 
HMT: 
Sample: 79-10-
CADEP 10%. 
Vehicle: DEP.  
6/26 (23%) were 
positive. 
No further information 
available from Letizia et 
al. (2005). 
Unpublished 
report from RIFM 
(1979a) cited 
from Letizia et al. 
(2005). 
HMT: 
Sample: 79-4-5J 
4%. 
Vehicle: pet.  
1 irritation 
reaction in 24 
Japanese 
Americans 
No further information 
available from Letizia et 
al. (2005). 
Unpublished 
report from RIFM 
(1979b) cited 
from Letizia et al. 
(2005). 
HMT: 
Sample: SKK-10-
OX 10%. 
Vehicle: pet.  
10/33 (30%) 
were positive 
plus 3 
questionable and 
2 irritant 
reactions  
No further information 
available from Letizia et 
al. (2005). 
Unpublished 
report from RIFM 
(1977a) cited 
from Letizia et al. 
(2005). 
HMT: 
Sample: CA-10-
STY (extracted 
from styrax) 10%. 
Vehicle: pet.  
5/25 (20%) were 
positive  
No further information 
available from Letizia et 
al. (2005). 
Unpublished 
report from RIFM 
(1977b) cited 
from Letizia et al. 
(2005). 
HMT: 
Sample: 76-
Bedoukianol-10 
(2nd retest) 10%. 
Vehicle: pet.  
3/25 (12%) were 
positive  
No further information 
available from Letizia et 
al. (2005). 
Unpublished 
report from RIFM 
(1977d) cited 
from Letizia et al. 
(2005). 
HMT: 
Sample: SKK-10-P 
(pure form of SKK-
10-OX) 10%. 
Vehicle: pet.  
1/24 (4%) was 
positive plus 3 
questionable and 
2 irritant 
reactions. 
No further information 
available from Letizia et 
al. (2005). 
Unpublished 
report from RIFM 
(1977e) cited 
from Letizia et al. 
(2005). 
HMT: 
Sample: 35-10-
35R (0) (retest) 
10%. 
Vehicle: 
hydrophilic 
ointment.  
2/25 (8%)were 
positive 
No further information 
available from Letizia et 
al. (2005). 
Unpublished 
report from RIFM 
(1976a) cited 
from Letizia et al. 
(2005). 
HMT: 7/25 (28%) were No further information Unpublished 
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Method Results Remarks/Comments Reference 
Sample: 76-
Bedoukianol-10 
10%. 
Vehicle: pet.  
positive  available from Letizia et 
al. (2005). 
report from RIFM 
(1976b) cited 
from Letizia et al. 
(2005). 
HMT: 
Sample: 76-
Bedoukianol-10 
(retest) 10%. 
Vehicle: pet.  
9/25 (36%) were 
positive  
No further information 
available from Letizia et 
al. (2005). 
Unpublished 
report from RIFM 
(1976c) cited 
from Letizia et al. 
(2005). 
HMT: 
Sample: Cinnamyl 
alcohol 10%.  
Vehicle: 
hydrophilic 
ointment 
2/25 (8%) were 
positive 
No further information 
available from Bickers 
et al. (2005). 
Unpublished 
report from RIFM 
(1976d) cited 
from Bickers et 
al. (2005). 
HMT: 
Sample: CA 10%. 
Vehicle: pet.  
5/25 (20%) were 
positive (virgin 
panel) 
No further information 
available from Letizia et 
al. (2005). 
Unpublished 
report from RIFM 
(1976e) cited 
from Letizia et al. 
(2005). 
HMT: 
Sample: 76-
10FDO-B 10% 
Vehicle: pet.  
1/11 (9%) were 
positive  
No further information 
available from Letizia et 
al. (2005). 
Unpublished 
report from RIFM 
(1976f) cited 
from Letizia et al. 
(2005). 
HMT: 
Sample: 35-10-
35R (0) 10%. 
Vehicle: pet.  
3/25 (12%) were 
positive 
No further information 
available from Letizia et 
al. (2005). 
Unpublished 
report from RIFM 
(1975) cited from 
Letizia et al. 
(2005). 
HMT: 
Sample: NA 4%. 
Vehicle not 
reported.  
0/25 (0%) were 
positive. 
 Greif 1967 cited 
from Letizia et al. 
(2005). 
Modified HMT: 
Sample: NA 4%. 
Vehicle: EtOH and 
pet.  
1 reaction (25-30 
subjects) with 
ethanol as 
vehicle; no 
reactions with 
petrolatum as 
vehicle. 
 Jordan and King 
1977 cited from 
Letizia et al. 
(2005). 
1NA: Not Available 
 
Case studies 
Table 4 summarises case reports with allergic contact dermatitis in different clinics in Europe where 
cinnamyl alcohol has been found as a causative agent.  
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Table 4. Case studies with cinnamyl alcohol. 
Method Results Remarks/Comments Reference 
Patch test: A 33-
year old man with 
itching eczematous 
lesions was patch 
tested with 
cinnamyl alcohol. 
Concentration and 
vehicle not 
reported.  
Positive reaction 
on Day 2 (D2) 
and D4 was 
observed. 
Case study, Italy (year 
not stated). 
Guarneri (2010). 
Patch test: An 18-
year old woman 
with acute eczema 
was patch tested 
with cinnamyl 
alcohol 5% in 
petrolatum (pet.).  
Positive reaction 
on D2 and D3 
was observed. 
Case study, Italy (year 
not stated). 
Lauriola et al. 
(2009). 
Patch test: A 74-
year old woman 
with extensive 
eczematous and 
bullous dermatitis 
was patch tested 
with cinnamyl 
alcohol 1% in pet.  
Positive reaction 
on D2 and D4 
was observed. 
Case study, Spain (year 
not stated). 
Garcia-Abujeta et 
al. (2005). 
Patch test: A 47-
year old man with 
vesicular 
dermatitis was 
patch tested with 
cinnamyl alcohol 
1% in pet.  
Positive reaction 
on D2 and D3 
was observed. 
Case study, Germany 
(year not stated). 
Hartmann and 
Hunzelmann 
(2004).  
 
A total of 34 patch test population studies, 3 HRIPTs, 25 HMTs and 4 case studies with cinnamyl 
alcohol are summarised above (Table 2, 3 and 4).   As shown in Table 1 the positive patch test 
frequencies from all of the reported patch test studies vary between 0.56 and 100% in dermatitis 
patients. For unselected/consecutive dermatitis patients positive reactions range between 0.56 and 
1.8% (4 studies) and for selected dermatitis patients positive reactions range between 1.5 and 100% 
(30 studies). The total number of published cases is > 600. Sensitisation was reported in 2/3 
HRIPT studies at a cinnamyl alcohol concentration of 4%. In the HMT studies 17/24 studies with 
cinnamyl alcohol showed a positive result after 10%. The Research Institute for Fragrance 
materials, Inc. (RIFM) deducted a NOEL8-HRIPT (induction) of 3000 µg/cm2, a NOEL-HMT 
(induction) of 2759 µg/cm2 and a LOEL9 (induction) of 4724 µg/cm2 for cinnamyl alcohol.  In 
addition, based on weight of evidence, a No Expected Sensitization Induction Level (NESIL) of 
3000 µg/cm2 was established for cinnamyl alcohol by the RIFM Expert Panel (IFRA, 2008a). 
 
                                                                    
8NOEL: No Observed Effect Level 
9LOEL: Lowest Observed Effect Level 
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According to SCCS (2012) cinnamyl alcohol is used in volumes less than 175 ton per year in perfume 
formulations. It has been reported that 6.4% of a total of 516 consumer products; 8% of a total of 
300 fragrance products, ca. 4% or 3000 products  and 6.7% of children cosmetics were labelled to 
contain cinnamyl alcohol (Wijnhoven et al., 2008; Buckley, 2007; Schnuch et al., 2009 and Poulsen 
& Schmidt, 2007 cited from SCCS (2012)). In addition, in 2007, 12.5% of 88 tested deodorants were 
labelled to contain cinnamyl alcohol and the fragrance was detected in 48% (range: 2-503 mg/kg) of 
23 deodorants selected for analysis (Rastogi et al., 2007 cited from SCCS (2012)).  
 
The IFRA standard limits for cinnamyl alcohol in different IFRA QRA product categories reported 
by IFRA (2008a and 2015) are shown in table 5. 
 
Table 5. The IFRA standard limits for cinnamyl alcohol in IFRA QRA product categories. 
IFRA QRA product 
category 
Product type that drives the 
category consumer exposure 
level 
IFRA standard limits 
Category 1 Lip products 0.09% 
Category 2 Deodorants/antiperspirants 0.1% 
Category 3 Hydroalcoholics for shaved skin 0.4% 
Category 4 Hydroalcoholics for unshaved skin 0.4% 
Category 5 Hand cream 0.4% 
Category 6 Mouthwash 2.2% 
Category 7 Intimate wipes 0.2% 
Category 8 Hair styling aids 0.4% 
Category 9 Rinse-off hair conditioners 0.4% 
Category 10 Hard surface cleaners 0.4% 
Category 11 Candles Not restricted 
IFRA: International Fragrance Association, QRA: Quantitative Risk Assessment. 
 
Cinnamyl alcohol is registered under the REACH regulation with an annual tonnage band of 100-
1000 tonnes/year. 
 
Summary and discussion of skin sensitization 
Human data 
A total of 34 patch test population studies, 3 HRIPTs, 25 HMTs and 4 case studies, were identified 
with cinnamyl alcohol.   The positive patch test frequencies from all of the reported patch test 
studies vary between 0.56 and 100% in dermatitis patients. In studies with unselected/consecutive 
dermatitis patients positive reactions range between 0.56 and 1.8% (4 studies) and in studies with 
selected dermatitis patients positive reactions range between 1.5 and 100% (30 studies). The total 
number of published cases is > 600. A LOEL (induction) of 4724 µg/cm2 was derived from the 
HRIPT/HMT studies. 
 
Non-human data  
A total of 5 LLNAs (two of which were reported to be conducted in accordance with OECD TG 429), 
2 GPMT, 1 Freund’s complete adjuvant test (FCAT) and 1 Buehler test were identified testing the 
skin sensitisation of cinnamyl alcohol. EC3 values between 17.9 and 30% were reported for 
cinnamyl alcohol in the LLNAs and positive reactions were observed in a GPMT (30% positive) and 
FCAT (15% positive) at intradermal induction doses of 25 and 100%, respectively. No positive 
reactions were observed in the Buehler test. 
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No relevant in vitro studies on cinnamyl alcohol (i.e. OECD TG 442C and OECD 442D) were 
identified in the literature.  
   
Exposure 
According to data from IFRA (2008a) the exposure of cinnamyl alcohol when used as fragrance in 
cosmetics and in other consumer products appears to be low.     
 
Comparison with criteria 
For unselected/consecutive dermatitis patients positive reactions range between 0.56 and 1.8% with 
1/4 studies reporting frequencies higher than 1%. For selected dermatitis patients positive reactions 
range between 1.5 and 100% with 28 out of 30 studies reporting frequencies higher than 2%. In 
addition to this there are more than 600 published cases of positive patch test reactions to cinnamyl 
alcohol. According to the CLP criteria a frequency ≥ 1% for unselected/consecutive dermatitis 
patients and/or ≥ 2% for selected dermatitis patients and/or a total number of published cases ≥ 
100, equals a high frequency of occurrence of skin sensitisation (Table 3.4.2-b) (ECHA, 2015). The 
collected data described above from patch test studies show that cinnamyl alcohol causes a high 
frequency of occurrence of skin sensitisation based on frequencies in selected dermatitis patients 
and total number of cases.  
In regard to the HRIPT/HMT data the positive response reported at > 500 µg/cm2 for HRIPT/HMT 
induction threshold indicate evidence for sub-category 1B according to Annex I: 3.4.2.2.2.2.  
 
In the LLNAs EC3 values between 17.9 and 30% were reported for cinnamyl alcohol. According to 
the CLP Regulation an EC3 value larger than 2% indicates placement of cinnamyl alcohol into sub-
category 1B (Annex I: 3.4.2.2.3.2.).  
 
In the GPMT sensitisation was observed in 30% of the animals after an intradermal induction dose 
of 25% cinnamyl alcohol. According to the CLP criteria a positive response ≥ 30% of the animals 
responding at >1% intradermal induction dose indicates classification of a substance in sub-
category 1B (Annex I: 3.4.2.2.3.2.). 
 
No sensitisation was observed in the Buehler test after an induction dose of 30% cinnamyl alcohol.  
 
Overall, there is clear evidence for classification in sub-category 1A based on the frequency of 
sensitisation in human patch test studies with selected dermatitis patients and the total number of 
cases combined with the estimated low exposure. Data from HRIPT/HMT indicate evidence for 
sub-category 1B. All animal studies indicate a classification in sub-category 1B. A classification as a 
skin sensitiser in sub-category 1A is warranted for cinnamyl alcohol. 
 
Conclusions on classification and labelling 
Based on the high frequency of sensitisation observed in human patch test studies and the high 
number of published cases combined with the estimated low exposure a classification of cinnamyl 
alcohol as a skin sensitiser in sub-category 1A is justified.  
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Appendix 7 Coumarin CAS RN 91-64-5 
Non-human information 
Table 1 summarises relevant animal studies with coumarin i.e. Local Lymph Node Assays (LLNAs), 
Guinea Pig Maximization tests (GPMTs) and Buehler tests.  
 
Table 1. Animal studies with coumarin. 
Method Results Remarks/Comments Reference 
LLNA: 
10, 25 and 50% 
coumarin (purity 
99.9%).  
Vehicle: Dimethyl 
formamide (DMF). 
Coumarin was 
shown to have a 
stimulation index 
(SI) < 3 at all 
concentrations. 
According to SCCS 
(2012) the study did 
not deviate from OECD 
429 except that 
coumarin should have 
been tested in higher 
concentrations.  
Vocanson et al., 
2006 cited from 
SCCS (2012). 
LLNA: 
5, 10 and 25% 
Rhodiascent TM 
Coumarine (purity 
not reported).  
Vehicle: 4:1 
acetone:olive oil 
(AOO). 
Coumarin was 
shown to have a 
stimulation index 
(SI) < 3 at all 
concentrations. 
According to SCCP 
(2006) the study was 
performed in 
compliance with EEC 
96/54/EC Part B, 
Method B.6. EEC 
96/54/EC Part B, 
Method B.6 is, 
however, similar to 
OECD TG 406, which is 
the GPMT/Buehler test. 
CIT 2001 cited 
from SCCP 
(2006). 
LLNA: 
10, 25 and 50% 
Coumarine 
Rhodiascent TM 
(purity not 
reported).  
Vehicle: DMF. 
Three sets of 
experiments were 
performed. 
Coumarin was 
shown to have SI 
< 3 in all 
experiments 
except of 
Experiment 2 at 
50% were the SI 
was 3.1. 
According to SCCP 
(2006) the study was 
performed in 
compliance with OECD 
draft 429 (2000).  
INSERM 2003 
cited from SCCP 
(2006). 
LLNA: 
10, 25 and 50% 
Coumarine – 
Chine 
0013090/01 Ex 
PRC (purity not 
reported).  
Vehicle: DMF. 
Three sets of 
experiments were 
performed. 
Coumarin was 
shown to have SI 
< 3 in all 
experiments 
except of 
Experiment 1 at 
50% were the SI 
was 3. 
According to SCCP 
(2006) the study was 
performed in 
compliance with OECD 
draft 429 (2000).  
INSERM 2003 
cited from SCCP 
(2006). 
LLNA: 
10, 25 and 50% 
Coumarine – 
Coumarin was 
shown to have SI 
< 3 in all 
According to SCCP 
(2006) the study was 
performed in 
INSERM 2003 
cited from SCCP 
(2006). 
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Chine Tianjin 
freeword (purity 
not reported).  
Vehicle: DMF. 
Three sets of 
experiments were 
performed. 
experiments 
except of 
Experiment 2 at 25 
and 50% were the 
SI was 3.7 and 4, 
respectively. 
compliance with OECD 
draft 429 (2000).  
LLNA: 
1, 2.5, 5 and 10% 
6-Chloro-
Coumarine (purity 
not reported).  
Vehicle: DMF. 
Three sets of 
experiments were 
performed. 
Coumarin was 
shown to have SI 
< 3 in all 
experiments 
except of 
Experiment 1 at 5 
and 10% were the 
SI was 3.4 and 
3.3, respectively. 
According to SCCP 
(2006) the study was 
performed in 
compliance with OECD 
draft 429 (2000).  
INSERM 2003 
cited from SCCP 
(2006). 
LLNA: 
10, 25 and 50% 
Coumarine 
Rhodiascent TM 
(purity not 
reported).  
Vehicle: DMF. 
Coumarin was 
shown to have a SI 
< 3 at all 
concentrations. 
According to SCCP 
(2006) the study was 
performed in 
compliance with OECD 
draft 429 (2000).  
INSERM 2004 
cited from SCCP 
(2006). 
LLNA: 
10, 25 and 50% 
Coumarine – 
Chine 
0013090/01 Ex 
PRC (purity not 
reported).  
Vehicle: DMF. 
Coumarin was 
shown to have SI 
< 3 except at 50% 
were the SI was 
3.19. 
According to SCCP 
(2006) the study was 
performed in 
compliance with OECD 
draft 429 (2000).  
INSERM 2004 
cited from SCCP 
(2006). 
LLNA: 
10, 25 and 50% 
Coumarine – 
Chine Tianjin 
freeword (purity 
not reported).  
Vehicle: DMF. 
Two experiments. 
Coumarin was 
shown to have a SI 
< 3 at all 
concentrations. 
According to SCCP 
(2006) the study was 
performed in 
compliance with OECD 
draft 429 (2000).  
INSERM 2004 
cited from SCCP 
(2006). 
LLNA: 
2.5, 5 and 10% 
6-Chloro-
Coumarine (purity 
not reported).  
Vehicle: DMF. 
Coumarin was 
shown to have SI 
< 3 except at 5% 
were the SI was 
4.94. 
According to SCCP 
(2006) the study was 
performed in 
compliance with OECD 
draft 429 (2000).  
INSERM 2004 
cited from SCCP 
(2006). 
LLNA: 
10, 25 and 50% 
Coumarine – SRD 
aromatics LTD – 
Coumarin was 
shown to have a SI 
< 3 at all 
concentrations. 
According to SCCP 
(2006) the study was 
performed in 
compliance with OECD 
INSERM 2004 
cited from SCCP 
(2006). 
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Indian no. 2 
(purity not 
reported).  
Vehicle: DMF. 
draft 429 (2000).  
GPMT: 
Intradermal 
induction 0.5%; 
topical induction 
25%; challenge 
dose 25% 
coumarin. 
Vehicle not 
reported. 
No positive 
reactions were 
observed in the 
tested animals. 
According to REACH-RD 
(2015h) the study was 
performed equivalent 
or similar to OECD TG 
406. 
Study report 
from 1979 cited 
from REACH-RD 
(2015h). 
 
A total of 20 LLNAs and 1 GPMT with coumarin is summarised in table 1. The majority of LLNAs 
reported SI values below 3 at concentrations up to 50% coumarin and the SCCS (2012) established 
an EC3 > 50% for coumarin. Sensitisation was not observed in the GPMT after an intradermal 
induction dose of 0.5% coumarin. 
 
According to SCCS (2012) “Researchers from INSERM and “Rhodia Organique, Lyon , France” 
observed that pure coumarin is not an allergen in the LLNA, however, commercially available 
materials, containing “contaminants” (3,4-dihydrocoumarin, 6-chlorocoumarin and 6,12-epoxy- 
6H,12H-dibenzo[b,f][1,5] dioxocin, were identified as weak and moderate sensitisers, resp.” 
 
No relevant in vitro studies on coumarin (i.e. OECD TG 442C and OECD 442D) were identified in 
the literature.   
 
Human information 
Population studies 
Table 2 summarises patch test studies on coumarin involving several thousand dermatitis patients 
from various countries in Europe. Most of the studies are diagnostic patch test studies.  
 
Table 2. Population studies with coumarin. 
Method Results Remarks/Comments Reference 
Patch test: 
Retrospective 
study of 324 
selected patients 
patch tested with 
coumarin 5% in 
petrolatum (pet.). 
66/324 (4%) 
patients were 
positive.  
A retrospective study 
on patch test data from 
multicentre project 
IVDK (Information 
Network of 
Departments of 
Dermatology) (2007-
2009). 
Schnuch et al. 
(2015). 
Patch test: 
Retrospective 
study of 1951 
selected eczema 
patients patch 
tested with 
coumarin 5% in 
pet. 
8/1951 (0.41%, 
95% CI: 0.1-
0.7%) patients 
were positive. 
A retrospective study 
on patch test data at St 
John’s Institute of 
Dermatology at St 
Thomas’ Hospital, UK 
(2011-2012). 
Mann et al. 
(2014). 
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Patch test: 
Retrospective 
study of 205 
selected patients 
tested with 
coumarin 5% in 
pet. 
9/205 (4.4%) 
patients were 
positive. 
A retrospective study 
on patch test data from 
Department of 
Dermatology, 
University Hospital St 
Rafaël, Belgium (1990-
2011). 
Nardelli et al. 
(2013). 
Patch test: 
Prospective study 
of 100 selected 
patients with 
contact allergy 
patch tested with 
coumarin 5% in 
pet. 
2/100 (2%, 95% 
CI: 0.24-7.04%) 
patients were 
positive. 
Single-centre, double-
blind prospective 
experimental 
longitudinal volunteer 
study at the 
department of 
Dermatology of the VU 
University Medical 
Centre, The 
Netherlands (2005-
2010). 
Nagtegaal et al. 
(2012). 
Patch test: 
Prospective study 
of 565 selected 
patients patch 
tested with 
coumarin 5% in 
vaseline. 
29/565 (5.1%) 
patients were 
positive. In 
addtition 8 
patients had 
contact uriticaria. 
A prospective study on 
patch test data from 
multicentre study, 
Hungary (2009-2010). 
Ponyai et al. 
(2012). 
Patch test: 
Retrospective 
study of 1503 
consecutive 
eczema patients 
patch tested with 
coumarin 5% in 
pet. 
3/1503 (0.7%, 
95% CI: 0.1-
0.5%) patients 
were positive. 
A retrospective study of 
patch test data at 
Department of 
Dermato-Allergology, 
Copenhagen University 
Hospital Gentofte, 
Denmark (2008-2010).   
Heisterberg et al. 
(2011). 
Patch test: 
Retrospective 
study of 86 
selected patients 
patch tested with 
coumarin 5% in 
pet.  
1/86 (1.2%) 
patients were 
positive.  
A retrospective and 
descriptive analysis of a 
patch test study at the 
Cutaneous Allergy Unit 
of a tertiary referral 
hospital, Spain (2004-
2008). 
Cuesta et al. 
(2010). 
Patch test: 
Retrospective 
study of 367 
selected FM II 
positive patients 
patch tested with 
coumarin 5% in 
pet.  
10/367 (2.7%) 
patients were 
positive.  
A retrospective study 
on patch test data from 
multicentre project 
IVDK (2005-2008). 
Krautheim et al. 
(2010). 
Patch test: 1/18 (6%) Prospective study of Pentinga et al. 
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Prospective study 
of 18 selected 
cinnamon-sensitive 
patients patch 
tested with 
coumarin 5% in 
pet. 
patients were 
positive. 
cinnamon-sensitive 
patients at the 
Department of 
Dermatology of the VU 
University Medical 
Centre, The 
Netherlands (year not 
stated). 
(2009). 
Patch test: 
Prospective study 
of 320 selected 
eczema patients 
patch tested with 
coumarin 5% in 
pet. 
2/320 (0.6%) 
patients were 
positive. 
A prospective analysis 
of selected eczema 
patients at the 
University Medical 
Center in Groningen, 
the Netherlands (2005-
2007). 
van Oosten et al. 
(2009). 
Patch test: 
Retrospective 
study of 2020 
consecutive 
patients patch 
tested with 
coumarin 5%. 
Vehicle not 
reported.  
8/2020 (0.4%, 
95% CI: 0.2-
0.8%) patients 
were positive. 
A retrospective study 
on patch test data from 
multicentre project 
IVDK (2003-2004). 
Schnuch et al. 
(2007). 
Patch test: Study 
of 252 selected 
dermatitis patients 
patch tested with 
2% coumarin and 
100 selected 
dermatitis patients 
patch tested with 1 
and 10% 
coumarin. Vehicle 
not reported. 
1/252 (0.4%) 
and 0/100 (0%) 
patients were 
positive, 
respectively. 
According to the 
authors no cases of 
irritancy was observed 
at 10% coumarin. The 
number of reported 
tested subjects is not 
consistent and the one 
positive patch test was 
dismissed by Vocanson 
2006 because the 
patient had “highly 
sensitive skin”. 
Vocanson et al. 
(2006).  
Patch test: Study 
of 101 selected 
patients allergic to 
fragrance mix 
patch tested with 
coumarin 2%. 
Vehicle not 
reported. 
1/101 (1%) 
patients were 
positive. 
 Vocanson et al. 
(2006).  
Patch test: Study 
of 30 selected 
patients with a 
positive patch test 
to their own 
0/30 (0%) 
patients were 
positive. 
 Vocanson et al. 
(2006). 
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perfumed product 
patch tested with 
coumarin 2%. 
Vehicle not 
reported.  
Patch test: 
Prospective study 
of 1701 
consecutive 
patients patch 
tested with 
coumarin 5% in 
pet. 
0/1701 (0%) 
patients were 
positive while 7 
doubtful or 
irritant reactions 
were observed. 
A prospective analysis 
of patients from six 
dermatology 
departments 
(Dortmund, 
Copenhagen, Malmö, 
Odense, London and 
Leuven) (1997-1998). 
Frosch et al. 
(2005). 
Patch test: 
Prospective study 
of 1855 
consecutive 
patients patch 
tested with 
coumarin 5% in 
pet. 
5/1855 (0.3%) 
patients were 
positive. 
A prospective analysis 
of patients from six 
dermatology 
departments 
(Dortmund, 
Copenhagen, Malmö, 
Odense, London and 
Leuven) (1997-1998). 
Frosch et al. 
(2002a). 
Patch test: 
Prospective study 
of 1825 
consecutive 
patients patch 
tested with 
coumarin 5% in 
pet. 
13/1825 (0.7%) 
patients were 
positive. 
Multicenter study of 
patch test data in The 
Netherlands (1998-
1999). 
de Groot et al. 
(2000). 
Patch test: Study 
of 14 000 
consecutive 
eczema patients 
patch tested with 
coumarin 5% or 
8% in pet. (8% for 
a short period 
only). 
58/14 000 
(0.4%) patients 
were positive. 
 Kunkeler et al 
1998 cited from 
SCCNFP (1999). 
Patch test: Study 
of 167 selected 
patients suspected 
of fragrance 
sensitivity patch 
tested with 
coumarin 5%. 
Vehicle not 
reported. 
2/167 (1.2%) 
patients were 
positive. 
 Larsen et al 
1996 cited from 
SCCNFP (1999). 
Patch test: Study 
of 119 selected 
1/119 (0.8%) 
patients were 
 De Groot et al., 
1988 cited from 
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patients with 
contact allergy to 
cosmetic products 
patch tested with 
coumarin 5% in 
pet. 
positive. SCCNFP (1999). 
Patch test: 
Retrospective 
study of 403 
selected patients 
with cutaneous 
reactions to 
cosmetic products 
patch tested with 
coumarin. 
Concentration and 
vehicle not 
reported. 
4/403 (1%) 
patients were 
positive. 
It is unclear from the 
reference exactly how 
many patients were 
tested with coumarin. 
Adams and 
Maibach (1985). 
Patch test: Study 
of 242 randomly 
selected eczema 
patients patch 
tested with 
coumarin 5.8%. 
Vehicle not 
reported. 
9/242 (3.7%) 
patients were 
positive. 
 Van Joost et al., 
1985 cited from 
SCCNFP (1999). 
Patch test: Study 
of 241 consecutive 
patients patch 
tested with 
coumarin 5%. 
Vehicle not 
reported. 
2/241 (0.8%) 
patients were 
positive. 
 Ferguson and 
Shama 1984 
cited from 
SCCNFP (1999). 
Patch test: 
Prospective study 
of 182 selected 
patients suspected 
of contact allergy 
to cosmetics patch 
tested with 
coumarin 8% in 
pet. 
12/182 (6.8%) 
patients were 
positive. 
Coumarin 8% was 
tested in 54 controls 
with no positive 
reactions. 
Malten et al., 
1984 cited from 
SCCNFP (1999). 
Patch test: Study 
of 20 selected per- 
fume allergic 
patients patch 
tested with cou-
marin 5%. Vehicle 
not reported. 
2/20 (10%) 
patients were 
positive. 
 Larsen et al., 
1977 cited from 
SCCNFP (1999). 
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Case studies 
Table 3 summarises case reports with allergic contact dermatitis in different clinics in Europe where 
coumarin has been found as a causative agent.  
 
Table 3. Case studies with coumarin. 
Method Results Remarks/Comments Reference 
Patch test: A 44-
year old woman 
with dermatitis 
after use of 
deodorant and 
eau de toilette 
was tested by 
ROAT1 with 
chemical fractions 
of perfume 
concentrate from 
her eau de 
toilette. 
Coumarin was 
confirmed as the 
allergen by ROAT 
with 1% after 
having caused 
dermatitis by the 
use of a 
deodorant 
containing 
coumarin at 
0.23%. 
Case study, Europe 
(year not stated). 
Mutterer et al. 
(1999). 
Patch test: A 
woman with 
eczema caused by 
a perfumed lotion 
was patch tested 
with coumarin 
0.5% in pet and 
diluent.  
Positive reaction 
was observed. 
Case study, Denmark 
(year not stated). 
Johansen et al., 
1994 cited from 
SCCNFP (1999). 
1ROAT: Repeat Open Application Test 
 
A total of 25 patch test population studies and 2 case studies, one of which included a ROAT, with 
coumarin are summarised above (Table 2 and 3).   As shown in Table 2 the positive patch test 
frequencies from all of the reported patch test studies vary between 0 and 10% in dermatitis 
patients. For unselected/consecutive dermatitis patients positive reactions range between 0 and 
0.8% (7 studies) and for selected dermatitis patients positive reactions range between 0 and 10% 
(19 studies). The total number of published cases is > 200. 
 
According to IFRA (2008b) a NOEL10-HRIPT (induction) of 3543 µg/cm2 and a NOEL-HMT 
(induction) of 5517 µg/cm2 has been established for coumarin. On basis of data from HRIPT or 
HMT (not specified by IFRA (2008b)) a LOEL11 (induction) of 8858 µg/cm2 for coumarin was 
derived.   
 
Coumarin is a ”top 100” substance and is according to SCCS (2012) classified as a skin sensitiser 
with R43 (based on the old classification criteria) (note that the substance does not have a 
harmonised classification as a skin sensitizer). 
 
According to SCCS (2012) coumarin is used in volumes higher than 175 ton per year in perfume 
formulations. It has been reported that in consumer products containing fragrance allergens that 
are required to be labelled 17% of a total of 516 products; 30% of a total of 300 products; ca. 11% of 
                                                                    
10 NOEL: No Observed Effect Level 
11 LOEL: Lowest Observed Effect Level 
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3000 products and 4.8% of children cosmetics were labelled to contain coumarin (Wijnhoven et al., 
2008; Buckley, 2007; Schnuch et al., 2009 and Poulsen & Schmidt, 2007 cited from SCCS (2012)). 
In addition, in 2007, 33% of 88 tested deodorants were labelled to contain coumarin and the 
fragrance was detected in 52% (range: 3.8-1255 mg/kg) of 23 deodorants selected for analysis 
(Rastogi et al., 2007 cited from SCCS (2012)).  
 
The IFRA standard limits for coumarin in different IFRA QRA product categories reported by IFRA 
(2008b and 2015) are shown in table 4. 
 
Table 4. The IFRA standard limits for coumarin in IFRA QRA product categories. 
IFRA QRA product 
category 
Product type that drives the 
category consumer exposure 
level 
IFRA standard limits 
Category 1 Lip products 0.1% 
Category 2 Deodorants/antiperspirants 0.13% 
Category 3 Hydroalcoholics for shaved skin 0.5% 
Category 4 Hydroalcoholics for unshaved skin 1.6% 
Category 5 Hand cream 0.8% 
Category 6 Mouthwash 2.5% 
Category 7 Intimate wipes 0.3% 
Category 8 Hair styling aids 2.0%* 
Category 9 Rinse-off hair conditioners 5.0%* 
Category 10 Hard surface cleaners 2.5%* 
Category 11 Candles Not restricted 
IFRA: International Fragrance Association, QRA: Quantitative Risk Assessment. 
* Maximum pragmatic level. 
 
Coumarin is registered under the REACH regulation with an annual tonnage band of 1000 - 10 000 
tonnes per annum. 
 
Summary and discussion of skin sensitization 
Human data 
A total of 25 patch test population studies and 2 case studies, one of which included a ROAT, were 
identified with coumarin. The positive patch test frequencies from all of the reported patch test 
studies vary between 0 and 10% in dermatitis patients. In studies with unselected/consecutive 
dermatitis patients positive reactions range between 0 and 0.8% (7 studies) and in studies with 
selected dermatitis patients positive reactions range between 0 and 10% (19 studies). The total 
number of published cases is > 200. A LOEL (induction) of 8858 µg/cm2 was derived from the 
HRIPT/HMT studies. 
 
Non-human data  
A total of 20 LLNAs and 1 GPMT were identified testing skin sensitising effects of coumarin. The 
collected evidence from the LLNAs indicates an EC3 for coumarin of ca. 50%. Sensitisation was not 
observed in the GPMT after an intradermal induction dose of 0.5% coumarin. 
 
Contaminants in coumarin may act as weak or moderate sensitizers (SCCS, 2012).  
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No relevant in vitro studies on coumarin (i.e. OECD TG 442C and OECD 442D) were identified in 
the literature.   
   
Exposure 
According to data from IFRA (2008b) the exposure of coumarin when used as fragrance in 
cosmetics and in other consumer products appears to be low.  
 
Comparison with criteria 
For unselected/consecutive dermatitis patients positive reactions range between 0 and 0.8% i.e. all 
7 studies reporting frequencies lower than 1%. For selected dermatitis patients positive reactions 
range between 0 and 10% with 9 out of 19 studies reporting frequencies higher than 2%. In addition 
to this there are more than 200 published cases of positive patch test reactions to coumarin. 
According to the CLP criteria a frequency ≥ 1% for unselected/consecutive dermatitis patients 
and/or ≥ 2% for selected dermatitis patients and/or a total number of published cases ≥ 100, equals 
a high frequency of occurrence of skin sensitisation (Table 3.4.2-b) (ECHA, 2015). The collected 
data described above from patch test studies show that coumarin causes a low/moderate frequency 
of occurrence of skin sensitisation based on unselected/consecutive dermatitis patients and 10/19 
studies with selected dermatitis patients. The remaining studies with selected dermatitis patients 
(9/19) and number of published cases shows that coumarin causes a high frequency of occurrence 
of skin sensitisation in humans.  
In regard to the HRIPT/HMT data the positive response reported at > 500 µg/cm2 for HRIPT/HMT 
induction threshold indicate classification of coumarin in sub-category 1B according to Annex I: 
3.4.2.2.2.2. 
 
The collected evidence from the LLNAs indicates an EC3 for coumarin of ca. 50%. According to the 
CLP Regulation an EC3 value  2% indicates classification of a substance in sub-category 1A 
whereas an EC3 value > 2% indicates classification of a substance in sub-category 1B (Annex I: 
3.4.2.2.3.2.). Thus, all studies indicate classification of coumarin in sub-category 1B. 
 
The single GPMT with an intradermal induction dose of 0.5% gave no positive reactions which does 
not justify sub-categorisation (Table 3.4.3). 
 
Overall, there is evidence for classification in sub-category 1A based on the number of cases 
combined with the estimated low exposure and supported by patch test data from selected 
dermatitis patients. Data from HRIPT/HMT indicate evidence for sub-category 1B. Data from 
LLNAs indicate a classification in sub-category 1B. A classification as a skin sensitiser in sub-
category 1A is warranted for coumarin. 
 
Conclusions on classification and labelling 
Based on the number of cases combined with the estimated low exposure and supported by patch 
test data from selected dermatitis patients, a classification of coumarin as a skin sensitiser in sub-
category 1A is justified.  
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Appendix 8 Eugenol CAS RN 97-53-0 
According to SCCS (2012) eugenol is a fragrance compound known to be a prohapten and to form 
sensitising compounds by metabolic transformation.  
 
Non-human information 
Table 1 summarises relevant animal studies with eugenol i.e. Local Lymph Node Assays (LLNAs), 
Guinea Pig Maximization tests (GPMTs) and Buehler tests.  
 
Table 1. Animal studies with eugenol. 
Method Results Remarks/Comments Reference 
LLNA: 
BrdU-ELISA 
25% eugenol. 
Vehicle: 
acetone:olive oil 
(AOO). 
Eugenol was 
shown to have a 
mean SI of 2.37 
The aim of the study 
was to validate the use 
of BALB/c mice in the 
LLNA:BrdU-ELISA 
(OECD TG 442B). 
Hou et al. 
(2015).  
LLNA: 
Concentrations of 
eugenol not 
specified. 
Vehicle: AOO. 
Eugenol was 
shown to have an 
EC3 value of 
4.2%. 
 Strauss et al. 
(2015).  
LLNA: 
BrdU-ELISA in vivo 
and ex vivo BrdU. 
0, 2, 20 and 40% 
eugenol. 
Vehicle: AOO. 
Eugenol was 
shown to have an 
EC2 value of 
8.5% in the 
BrdU-ELISA in 
vivo and an EC2 
value of 9.5% in 
the ex vivo BrdU. 
Eugenol was classified 
as positive for skin 
sensitisation by 
Williams et al. (2015). 
Williams et al. 
(2015). 
LLNA: 
Ex vivo BrdU. 2.5, 
10, 20 and 50% 
eugenol.  
Vehicle: AOO. 
Eugenol was 
shown to have an 
EC3 value of 
16.6%. 
Eugenol was classified 
as a weak skin 
sensitizer by Ulker et 
al. (2013). 
Ulker et al. 
(2013). 
LLNA (OECD TG 
429): 
2.5, 10 and 25% 
eugenol.  
Vehicle: AOO. 
Eugenol was 
shown to have an 
EC3 value of 
4.6%. 
 Basketter 
(2012).  
LLNA: 
LLNA:BrdU-FCM. 5, 
10 and 25% 
eugenol. Vehicle: 
AOO (proportion 
not specified). 
Eugenol was 
shown to have an 
EC3 value of 
10.1%. 
Eugenol was classified 
as a weak skin 
sensitizer by Jung 
(2012). 
Jung (2012).  
LLNA: 
0, 5, 10 and 25% 
eugenol. 
Eugenol was 
shown to have an 
EC3 value of 
 Fukuyama et al. 
(2010).  
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Method Results Remarks/Comments Reference 
Vehicle: 4:1 AOO. 5.28%. 
LLNA: 1, 3, 10, 30 
and 50% eugenol. 
Vehicle: 3:1 
Ethanol:Diethyl 
phthalate 
(EtOH:DEP). 
Eugenol was 
shown to have an 
EC3 value of 
5.3% (0.32 M). 
According to SCCS 
(2012) there were no 
reported deviations 
from OECD TG 429. 
Unpublished 
summary report 
by RIFM 2009 
(RIFM 2001f) 
cited from SCCS 
(2012). 
LLNA: 1, 3, 10, 30 
and 50% eugenol. 
Vehicle: 1:3 
EtOH:DEP. 
Eugenol was 
shown to have an 
EC3 value of 
10.5% (0.64 M). 
According to SCCS 
(2012) there were no 
reported deviations 
from OECD TG 429. 
Unpublished 
summary report 
by RIFM 2009 
(RIFM 2001g) 
cited from SCCS 
(2012). 
LLNA: 1, 3, 10, 30 
and 50% eugenol. 
Vehicle: EtOH. 
Eugenol was 
shown to have an 
EC3 value of 
10.7% (0.65 M). 
According to SCCS 
(2012) there were no 
reported deviations 
from OECD TG 429. 
Unpublished 
summary report 
by RIFM 2009 
(RIFM 2001h) 
cited from SCCS 
(2012). 
LLNA: 1, 3, 10, 30 
and 50% eugenol. 
Vehicle: DEP. 
Eugenol was 
shown to have an 
EC3 value of 
15.1% (0.92 M). 
According to SCCS 
(2012) there were no 
reported deviations 
from OECD TG 429. 
Unpublished 
summary report 
by RIFM 2009 
(RIFM 2001i) 
cited from SCCS 
(2012). 
LLNA: 0, 2.5, 5, 10 
and 25% eugenol 
tested in five 
different 
laboratories. 
Vehicle: AOO. 
Eugenol was 
shown to have an 
EC3 value of 5.8, 
14.5, 8.9, 13.8 
and 6%, 
respectively. 
 Basketter et al. 
(2007).  
LLNA (OECD TG 
429): 0, 2.5, 5, 
10, 25 and 50% 
eugenol. 
Vehicle: 1:3 
EtOH:DEP. 
Eugenol was 
shown to have an 
EC3 value of 
5.4%. 
 Lalko and Api 
(2006).  
LLNA: BrdU-ELISA 
0, 1, 6, 15 and 
30% eugenol. 
Vehicle: AOO. 
Eugenol was 
shown to have an 
EC3 value of 
25.1%. 
 Takeyoshi et al. 
(2004). 
LLNA: 2.5, 5, 10, 
25 and 50% 
eugenol. Vehicle: 
4:1 AOO. 
Eugenol was 
shown to have an 
EC3 value of 
11.9% (0.72 M). 
According to SCCS 
(2012) there were no 
reported deviations 
from OECD TG 429. 
Basketter et al., 
1999 cited from 
SCCS (2012). 
GPMT: 
Intradermal 
Positive reactions 
in 2/10 (20%) of 
 Takeyoshi et al. 
(2004). 
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Method Results Remarks/Comments Reference 
induction 5%;  
topical induction 
5%; challenge 
dose 5% eugenol.  
Vehicle not 
reported. 
the tested 
animals. 
 
A total of 15 LLNAs are summarised in table 1. One study, validating the use of BALB/c mice in the 
LLNA:BrdU-ELISA (OECD TG 442B), reported a mean stimulation index (SI) of 2.37 (Hou et al., 
2015) and one study reported EC2 values of 8.5 and 9.5% (Williams et al., 2015). The remaining 13 
studies reported EC3 values between 4.2 and 25.1%. In the single GPMT study a 5% eugenol 
induction and challenge concentration resulted in positive reactions in 20% of the tested animals. 
 
No relevant in vitro studies on eugenol (i.e. OECD TG 442C and OECD 442D) were identified in the 
literature. 
 
Human information 
Population studies 
Table 2 summarises patch test studies on eugenol involving several thousand dermatitis patients 
from various countries in Europe and Asia. Most of the studies are diagnostic patch test studies.  
 
Table 2. Population studies with eugenol. 
Method Results Remarks/Comments Reference 
Patch test: Retrospective 
study of 806 selected 
patients patch tested 
with eugenol 1% in 
petrolatum (pet.). 
54/806 (6.7%) patients 
were positive.  
A retrospective study on 
patch test data from 
multicentre project IVDK 
(Information Network of 
Departments of 
Dermatology) (2007-
2009). 
Schnuch et 
al. (2015). 
Patch test: Retrospective 
study of 1951 selected 
eczema patients patch 
tested with 
cinnamaldehyde 2% in 
pet.  
12/1951 (0.62%, 95% CI: 
0.3-1%) patients were 
positive. 
A retrospective study on 
patch test data at St 
John’s Institute of 
Dermatology at St 
Thomas’ Hospital, UK 
(2011-2012). 
Mann et al. 
(2014). 
Patch test: Retrospective 
study of 940 selected 
patients tested with 
eugenol 1% in pet. 
118/940 (12.6%) patients 
were positive. 
A retrospective study on 
patch test data from 
Department of 
Dermatology, University 
Hospital St Rafaël, 
Belgium (1990-2011). 
Nardelli et 
al. (2013). 
Patch test: Prospective 
study of 100 selected 
patients with contact 
allergy patch tested with 
eugenol 1% in pet. 
7/100 (7%, 95% CI: 
2.86-13.89%) patients 
were positive. 
Single-centre, double-
blind prospective 
experimental longitudinal 
volunteer study at the 
department of 
Dermatology of the VU 
University Medical 
Nagtegaal 
et al. 
(2012). 
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Method Results Remarks/Comments Reference 
Centre, The Netherlands 
(2005-2010). 
Patch test: Retrospective 
study of 1502 
consecutive eczema 
patients patch tested 
with eugenol 1% in pet. 
4/1502 (0.3%, 95% CI: 
0.1-0.6%) patients were 
positive. 
A retrospective study of 
patch test data at 
Department of Dermato-
Allergology, Copenhagen 
University Hospital 
Gentofte, Denmark 
(2008-2010).   
Heisterberg 
et al. 
(2011). 
Patch test: Retrospective 
study of 157 selected 
patients (chosen out of 
509 patients positive to 
fragrance allergens) 
patch tested with 
eugenol 5% in pet. 
87/157 (55.4%) patients 
were positive. 
A retrospective study of 
patch test data at the 
Allergy Clinic of the 
Department of 
Dermatology and 
Venereology, Zagreb 
University Hospital 
Center and School of 
Medicine, Zagreb, 
Croatia (2001-2005).   
Turcic et al. 
(2011). 
Patch test: Retrospective 
study of 1214 
consecutive patients and 
4527 selected patients 
patch tested with 
eugenol 1%.  
Vehicle not reported. 
5/1214 (0.44%, 95% CI: 
0.04-0.84%) and 71/4527 
(1.57%, 95% CI: 1.19-
1.95%) patients were 
positive. 
A retrospective study on 
patch test data from 
multicentre project IVDK 
(Information Network of 
Departments of 
Dermatology) (2005-
2008). 
Uter et al. 
(2010). 
Patch test: Retrospective 
study of 86 selected 
patients patch tested 
with eugenol 2% in pet.  
12/86 (13.9%) patients 
were positive.  
A retrospective and 
descriptive analysis of a 
patch test study at the 
Cutaneous Allergy Unit of 
a tertiary referral 
hospital, Spain (2004-
2008). 
Cuesta et 
al. (2010). 
Patch test: Retrospective 
study of 167 selected 
patients patch tested 
with eugenol 2% in pet.  
4/167 (2.4%) patients 
were positive.  
A retrospective study at 
the Division and School 
of Allergy and Clinical 
Immunology, 
Department of Human 
Pathology, University of 
Messina, Italy (year not 
stated). 
Minciullo et 
al. (2010). 
Patch test: Prospective 
study of 18 selected 
cinnamon-sensitive 
patients patch tested 
with eugenol 2% in pet. 
3/18 (17%) patients were 
positive. 
Prospective study of 
cinnamon-sensitive 
patients at the 
Department of 
Dermatology of the VU 
University Medical 
Centre, The Netherlands 
(year not stated). 
Pentinga et 
al. (2009). 
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Patch test: Prospective 
study of 320 selected 
eczema patients patch 
tested with eugenol 2% 
pet. 
4/320 (1.3%) patients 
were positive. 
A prospective analysis of 
selected eczema patients 
at the University Medical 
Center in Groningen, the 
Netherlands (2005-
2007). 
van Oosten 
et al. 
(2009). 
Patch test: Retrospective 
study of 225 selected 
patients with a) current 
allergic dermatitis or b) 
past allergic dermatitis 
patch tested with 
eugenol 1% in pet. 
a) 30/225 (13.3%) and b) 
53/225 (23.4%) patients 
were positive. 
A retrospective study of 
patch test data from 
patients attending the 
Department of 
Cutaneous Allergy at St 
John’s Institute of 
Dermatology, UK (1982-
2007). 
White 
(2009). 
Patch test: Prospective 
study of 15 selected 
patients with eczematous 
reactions from 
ketoprofen-containing 
gels patch tested with 
eugenol 2%.  
Vehicle not reported. 
2/15 (13.3%) patients 
were positive. 
A prospective study on 
patch test data from 
patients from Italy 
(2006-2007). 
Foti et al. 
(2008). 
Patch test: Retrospective 
study of 2065 unselected 
patients patch tested 
with eugenol 1%. Vehicle 
not reported. 
11/2065 (0.5%, 95% CI: 
0.2-0.7%) patients were 
positive. 
A retrospective study on 
patch test data from 
multicentre project IVDK 
(2003-2004). 
Schnuch et 
al. (2007). 
Patch test: Study of 30 
selected patients with a 
positive patch test to 
their own perfumed 
product patch tested 
with eugenol. 
Concentration and 
vehicle not reported. 
6/30 (20%) patients were 
positive. 
 Vocanson 
et al. 
(2006). 
Patch test: prospective 
study of 422 selected 
patients with suspected 
contact allergy patch 
tested with eugenol 2% 
pet. 
8/422 (1.9%) patients 
were positive. 
A prospective analysis of 
patients from nine 
dermatology 
departments of 
university hospitals in 
Korea (2002-2003). 
An et al. 
(2005). 
Patch test: Retrospective 
study of 4900 unselected 
patients patch tested 
with eugenol 1% in pet. 
93/4900 (1.9%) patients 
were positive. 
A retrospective study on 
patch test data from 
multicentre project IVDK 
(1996-1999). 
Schnuch et 
al. (2002). 
Patch test: Retrospective 
study of 1750 selected 
patients with suspected 
21/1750 (1.2%) patients 
were positive. 
A retrospective analysis 
of patients from Italy 
(1998-2000). 
Giusti et al. 
(2001). 
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fragrance allergic contact 
dermatitis patch tested 
with eugenol 1% in pet. 
Patch test: Prospective 
study of 747 selected 
patients with suspected 
fragrance allergy patch 
tested with eugenol 1% 
in pet. 
19/747 (2.5%) patients 
were positive. 
A prospective analysis of 
patients from FAZ-
Floridsdorf Allergy 
Centre, Austria (1997-
2000). 
Wohrl et al. 
(2001). 
Patch test: Study of 226 
selected patients 
sensitive to fragrance 
mix (FM) patch tested 
with eugenol 1% in pet. 
33/226 (14.6%) patients 
were positive. 
Department of 
Dermatology, University 
Hospital, Coimbra, 
Portugal (1989-1999) 
Brites et al. 
(2000). 
Patch test: Retrospective 
study of 50 patients 
sensitive to FM patch 
tested with eugenol ext. 
2% in 1 % sorbitan 
sesquioleate (SSO). 
6/50 (12%) patients were 
positive. 
Retrospective study of 
patch test data. 
University Hospital 
Utrecht, The Netherlands 
(1994-1998). 
Hendriks 
and van 
Ginkel 
(1999). 
Patch test: Retrospective 
study of 40 patients 
sensitive to FM patch 
tested with eugenol in 
pet. Concentration not 
reported. 
2/40 (5%) patients were 
positive. 
 Katsarma 
and 
Gawkrodger 
(1999). 
Patch test: Study of 167 
selected patients 
suspected of fragrance 
sensitivity patch tested 
with eugenol 5%.  
Vehicle not reported. 
13/167 (7.8%) patients 
were positive. 
 Larsen et 
al., 1996 
cited from 
SCCNFP 
(1999). 
Patch test: Prospective 
study of 1072 
consecutive patients 
patch tested with 
eugenol 1%. Vehicle not 
reported. 
13/1072 (1.2%) patients 
were positive. 
Prospective study of 
patients in a multicentre 
study involving 9 
European centres. Year 
not stated. 
Frosch et 
al., 1995 
cited from 
SCCNFP 
(1999). 
Patch test: Retrospective 
study of 367 selected 
patients patch tested 
with eugenol 1-2% in 
pet.   
30/367 (8.2%) patients 
were positive. 
Retrospective study of 
patch test data from 
Department of 
Dermatology, Gentofte 
Hospital, Denmark 
(1979-1983 and 1988-
1992). 
Johansen 
and Menne 
(1995). 
Patch test: Prospective 
study of 50 selected 
patients positive to a FM 
3/50 (6%) patients were 
positive. 
Retrospective study of 
patch test data from 
Department of 
Becker et 
al. (1994). 
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patch tested with 
eugenol. Concentration 
and vehicle not reported. 
Dermatology and 
Venereology, Hungary. 
Year not stated. 
Patch test: Prospective 
study of 61 selected 
patients positive to a FM 
patch tested with 
eugenol 5% in pet. 
12/61 (19.7%) patients 
were positive. 
Control tests in 100 
patients not allergic to 
fragrances showed no 
positive reactions when 
tested with eugenol 5% 
pet. 
Prospective study of 
patch test data from 
University of Amsterdam 
and University of Leiden, 
The Netherlands (1987). 
 
de Groot et 
al. (1993).  
 
Patch test: Prospective 
study of 162 selected 
patients positive to a FM 
patch tested with 
eugenol 1% in pet. 
11/162 (6.8%) patients 
were positive. 
Prospective study of 
patch test data from 
Dermatologische Klinik 
und Poliklinik, Germany 
(1991). 
Enders et 
al. (1989). 
Patch test: Study of 78 
selected patients positive 
to a FM patch tested with 
eugenol 2%.  
Vehicle not reported. 
8/78 (10.3%) patients 
were positive. 
Multicentre study 
involving 6 countries. 
Year not stated. 
Wilkinson 
et al., 1989 
cited from 
SCCNFP 
(1999). 
Patch test: Study of 156 
selected patients with 
pure contact allergy to 
cosmetic products patch 
tested with eugenol. 
Concentration and 
vehicle not reported. 
11/156 (7.1%) patients 
were positive. 
 Broneck et 
al., 1987 
cited from 
SCCNFP 
(1999) 
Patch test: Retrospective 
study of 63 selected 
patients with dermatitis 
tested positive to 
perfume mixture patch 
tested between 1983 and 
1984 with eugenol 5% in 
pet. and 54 selected 
patients with dermatitis 
tested positive to 
perfume mixture patch 
tested between 1984 and 
1985 with eugenol 1% in 
pet. 
Between 1983 and 1984 
8/63 (12.7%) and 
between 1984 and 1985 
9/54 (16.7%) patients 
were positive. 
Retrospective study of 
patch test data from 
Istituto Dermatologico 
Santa Maria e San 
Gallicano, Italy (1983-
1985). 
Santucci et 
al. (1987). 
Patch test: Retrospective 
study of 403 selected 
patients with cutaneous 
reactions to cosmetic 
products patch tested 
with eugenol. 
Concentration and 
4/403 (1%) patients were 
positive. 
It is unclear from the 
reference exactly how 
many patients were 
tested with eugenol. 
Adams and 
Maibach 
(1985).  
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Method Results Remarks/Comments Reference 
vehicle not reported. 
Patch test: Study of 20 
selected perfume allergic 
patients patch tested 
with eugenol 2%.  
Vehicle not reported. 
4/20 (20%) patients were 
positive. 
 Larsen et 
al., 1977 
cited from 
SCCNFP 
(1999).  
Patch test and ROAT1: 5 
patients tested positive 
to FM I and eugenol 
(2%) were tested with a 
dilution series of eugenol 
in patch test (17 
dilutions) and a ROAT 
(0.5, 1 and 2.7% 
eugenol). 
4/5 patients were positive 
to concentrations down to 
1.32% eugenol. 4/5 
patients became positive 
to 2.7% eugenol and 1/5 
became positive to 1% 
eugenol in the ROAT.  
A prospective analysis of 
patients from Sweden 
(year not stated). 
Svedman et 
al. (2012). 
1ROAT: Repeated Open Application Test 
 
Case studies 
Table 3 summarises the case reports with allergic contact dermatitis where eugenol has been found 
as a causative agent.  
 
Table 3. Case studies with eugenol. 
Method Results Remarks/Comments Reference 
Patch test: A 35-
year old dental 
nurse with 
vesicular hand 
eczema and 
rhinitis was patch 
tested with 
eugenol (2% in 
petrolatum) and 
an intermediate 
restorative 
material (IRM® 
liquid) (10% pet.). 
The IRM® liquid 
contained >99% 
eugenol.  
Eugenol (2% 
pet.): weak 
positive reaction. 
IRM® liquid: ++ 
patch test 
reaction. 
Case study, Finland 
(year not stated). 
Kanerva et al. 
(1998). 
 
A total of 36 patch test population studies and 1 case study with eugenol are summarised above 
(Table 2 and 3).   As shown in Table 2 the positive patch test frequencies from all of the reported 
patch test studies vary between 0.3 and 55.4% in dermatitis patients. For unselected/consecutive 
dermatitis patients positive reactions range between 0.3 and 1.9% (5 studies) and for selected 
dermatitis patients positive reactions range between 0.62 and 55.4% (31 studies). The total number 
of published cases is > 700.  
 
In a study by Svedman and co-workers it was shown that 4/5 patients tested positive to eugenol 
concentrations down to 1.32% also tested positive to 2.7% eugenol in a Repeated Open Application 
Test (ROAT) (Svedman et al., 2012).  
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The Research Institute for Fragrance Materials, Inc. (RIFM) reported a NOEL-HRIPT12 (induction) 
of 5906 µg/cm2 for eugenol. In addition, based on weight of evidence, a No Expected Sensitization 
Induction Level (NESIL) of 5900 µg/cm2 was established for eugenol by the RIFM Expert Panel 
(IFRA, 2008c). 
 
According to SCCS (2012) eugenol is used in volumes greater than 175 ton per year in perfume 
formulations. It has been reported that 15.7% of a total of 516 consumer products; 27% of a total of 
300 consumer products, ca. 7.5% of 3000 consumer products and 7.2% of children cosmetics were 
labelled to contain eugenol (Wijnhoven et al., 2008; Buckley, 2007; Schnuch et al., 2009 and 
Poulsen and Schmidt, 2007 cited from SCCS (2012)). In addition, in 2007, 27.3% of 88 tested 
deodorants were labelled to contain eugenol and the fragrance was detected in 30% (range: 1-514 
mg/kg) of 23 deodorants selected for analysis (Rastogi et al., 2007 cited from SCCS (2012)).   
Eugenol is a ”top 100” substance and is according to SCCS classified as a skin sensitiser with R43 
(based on the old classification criteria) (SCCS, 2012) (note that the substance does not have a 
harmonised classification as a skin sensitizer). 
 
The IFRA standard limits for eugenol in different IFRA QRA product categories reported by IFRA 
(2008c and 2015) are shown in table 4. 
 
Table 4. The IFRA standard limits for eugenol in IFRA QRA product categories. 
IFRA QRA product 
category 
Product type that drives the 
category consumer exposure 
level 
IFRA standard limits 
Category 1 Lip products 0.2% 
Category 2 Deodorants/antiperspirants 0.2% 
Category 3 Hydroalcoholics for shaved 
skin 
0.5% 
Category 4 Hydroalcoholics for unshaved 
skin 
0.5% 
Category 5 Hand cream 0.5% 
Category 6 Mouthwash 4.3% 
Category 7 Intimate wipes 0.4% 
Category 8 Hair styling aids 0.5% 
Category 9 Rinse-off hair conditioners 0.5% 
Category 10 Hard surface cleaners 0.5% 
Category 11 Candles Not restricted 
IFRA: International Fragrance Association, QRA: Quantitative Risk Assessment. 
 
Eugenol is registered under the REACH regulation with an annual tonnage band of 100 - 1 000 
tonnes per annum. 
 
Summary and discussion of skin sensitization 
Human data 
A total of 36 patch test population studies, 1 ROAT and 1 case study were identified with eugenol.   
The positive patch test frequencies from all of the reported patch test studies vary between 0.3 and 
                                                                    
12 NOEL-HRIPT: No Observed Effect Level-Human Repeat Insult Patch Test 
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55.4% in dermatitis patients. In studies with unselected/consecutive dermatitis patients positive 
reactions range between 0.3 and 1.9% (5 studies) and in studies with selected dermatitis patients 
positive reactions range between 0.62 and 55.4% (31 studies). The total number of published cases 
is > 700. A NESIL from HRIPT studies of 5900 µg/cm2 was derived based on weight of evidence by 
the RIFM Expert Panel. 
 
Non-human data  
A total of 15 LLNAs and one GPMT were identified testing the skin sensitisation of eugenol. EC3 
values were reported in 13 studies and ranged between 4.2 and 25.1%. Positive reactions (20%) were 
observed in the GPMT at an intradermal induction dose of 5%.  
 
No relevant in vitro studies on eugenol (i.e. OECD TG 442C and OECD 442D) were identified in the 
literature. 
 
Exposure 
According to data from IFRA (2008c) the exposure of eugenol when used as fragrance in cosmetics 
and in other consumer products appears to be low.    
 
Comparison with criteria 
For unselected/consecutive dermatitis patients positive reactions range between 0.3 and 1.9% with 
2 out of 5 studies reporting frequencies higher than 1%.  For selected dermatitis patients positive 
reactions range between 0.62 and 55.4% with 25 out of 31 studies reporting frequencies higher than 
2%. In addition to this there are more than 700 published cases of positive patch test reactions to 
eugenol. According to the CLP criteria a frequency ≥ 1% for unselected/consecutive dermatitis 
patients and/or ≥ 2% for selected dermatitis patients and/or a total number of published cases ≥ 
100, equals a high frequency of occurrence of skin sensitisation (Table 3.4.2-b) (ECHA, 2015). The 
collected data described above from patch test studies show that eugenol causes a high frequency of 
occurrence of skin sensitisation based on the frequency of positive reactions mainly in selected 
dermatitis patients (>2% in 21/27 studies) and the total number of cases.  
In regard to the HRIPT/HMT data the positive response reported at > 500 µg/cm2 for HRIPT/HMT 
induction threshold indicate evidence for sub-category 1B according to Annex I: 3.4.2.2.2.2. 
 
In the LLNA tests, EC3 values between 4.2 and 25.1% (13 studies) were reported for eugenol. 
According to the CLP Regulation an EC3 value larger than 2 indicates placement of eugenol into 
sub-category 1B (Annex I: 3.4.2.2.3.2.).  
 
In the GPMT sensitisation was observed in 20% of the animals after an intradermal induction dose 
of 5% which does not justify sub-categorisation into either sub-category 1A or 1B (Annex I: 
3.4.2.2.3.2.). 
 
Overall, there is clear evidence for classification in sub-category 1A based on the frequency of 
sensitisation in human patch test studies mainly with selected dermatitis patients and the total 
number of cases combined with the estimated low exposure. Data from HRIPT/HMT indicate 
evidence for sub-category 1B. Data from LLNAs indicate a classification in sub-category 1B. A 
classification as a skin sensitiser in sub-category 1A is warranted for eugenol. 
 
Conclusions on classification and labelling 
Based on the high frequency of sensitisation observed in human patch test studies and the high 
number of published cases, combined with the estimated low exposure, a classification of eugenol 
as a skin sensitiser in sub-category 1A is justified.  
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Appendix 9 Farnesol CAS RN 4602-84-0 
Non-human information 
Table 1 summarises relevant animal studies with farnesol i.e. Local Lymph Node Assays (LLNAs), 
Guinea Pig Maximization tests (GPMTs) and Buehler tests.  
 
Table 1. Animal studies with farnesol. 
Method Results Remarks/Comments Reference 
LLNA: 5, 10 and 
25% farnesol. 
Vehicle: 4:1 
Acetone: Olive Oil 
(AOO). 
Farnesol was 
shown to have 
an EC3 value of 
5.5% (0.25 M). 
According to SCCS 
(2012) there were no 
reported deviations 
from OECD TG 429 
except that farnesol 
should also have been 
tested at lower 
concentrations. 
Unpublished 
summary report 
by RIFM 2009 
(RIFM 2004d) 
cited from SCCS 
(2012). 
LLNA: 5, 10 and 
25% farnesol. 
Vehicle: 4:1 AOO. 
Farnesol was 
shown to have 
an EC3 value of 
4.1% (0.18 M). 
According to SCCS 
(2012) there were no 
reported deviations 
from OECD TG 429 
except that farnesol 
should also have been 
tested at lower 
concentrations. 
Unpublished 
summary report 
by RIFM 2009 
(RIFM 2004d) 
cited from SCCS 
(2012). 
GPMT: 
Intradermal 
induction 10% 
farnesol in 
vaseline diluted in 
peanut oil;  
Topical induction 
10%;  
Challenge dose 
25, 50 or 100% 
farnesol in 
vaseline. 
No positive 
reactions 
reported. 
 Unpublished 
report by RIFM 
1983a cited from 
Lapczynski et al. 
(2008a). 
GPMT: 
Intradermal 
induction 5% 
farnesol in peanut 
oil;  
Topical induction 
100%;  
Challenge dose 
25% farnesol in 
peanut oil. 
No positive 
reactions 
reported. 
 Unpublished 
report by RIFM 
1995b cited from 
Lapczynski et al. 
(2008a). 
GPMT: 
Induction 10%;  
Challenge dose 
10% farnesol.  
No positive 
reactions 
reported. 
 Ishihara et al., 
1986 cited from 
Lapczynski et al. 
(2008a). 
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Vehicle not 
reported. 
GPMT: 
Induction 0.16%;  
Challenge dose 
0.16% farnesol in 
acetone. 
No positive 
reactions 
reported. 
 Watanbe et al., 
1985 cited from 
Lapczynski et al. 
(2008a). 
 
A total of two LLNAs and four GPMTs are summarised in table 1. The reported EC3 values in the 
two LNNAs were 5.5 and 4.1%, respectively. In the GPMTs no positive reactions were observed after 
intradermal induction doses of 0.16, 5 and 10% farnesol.  
 
No relevant in vitro studies on farnesol (i.e. OECD TG 442C and OECD 442D) were identified in the 
literature. 
 
Human information 
Population studies 
Table 2 summarises patch test studies on farnesol involving several thousand dermatitis patients 
from various countries in Europe and Asia. Most of the studies are diagnostic patch test studies.  
 
Table 2. Population studies with farnesol. 
Method Results Remarks/Comments Reference 
Patch test: 
Retrospective study 
of 324 selected 
patients patch 
tested with farnesol 
5% in petrolatum 
(pet.). 
39/324 (12%) 
patients were 
positive.  
A retrospective study 
on patch test data from 
multicentre project 
IVDK (Information 
Network of 
Departments of 
Dermatology) (2007-
2009). 
Schnuch et al. 
(2015). 
Patch test: 
Retrospective study 
of 1951 selected 
eczema patients 
patch tested with 
farnesol 5% in pet.  
8/1951 (0.41%, 
95% CI: 0.1-
0.7%) patients 
were positive. 
A retrospective study 
on patch test data at St 
John’s Institute of 
Dermatology at St 
Thomas’ Hospital, UK 
(2011-2012). 
Mann et al. 
(2014). 
Patch test: 
Retrospective study 
of 205 selected 
patients tested with 
farnesol 5% in pet. 
27/205 (13.2%) 
patients were 
positive. 
A retrospective study 
on patch test data from 
Department of 
Dermatology, University 
Hospital St Rafaël, 
Belgium (1990-2011). 
Nardelli et al. 
(2013).  
Patch test: 
Prospective study 
of 100 selected 
patients with 
contact allergy 
patch tested with 
farnesol 5% in pet. 
10/100 (10%, 
95% CI: 4.9-
17.62%) 
patients were 
positive. 
Single-centre, double-
blind prospective 
experimental 
longitudinal volunteer 
study at the 
department of 
Dermatology of the VU 
Nagtegaal et al. 
(2012). 
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Method Results Remarks/Comments Reference 
University Medical 
Centre, The 
Netherlands (2005-
2010). 
Patch test: 
Prospective study 
of 565 selected 
patients patch 
tested with farnesol 
5% in vaseline. 
14/565 (2.5%) 
patients were 
positive. 
A prospective study on 
patch test data from 
multicentre study, 
Hungary (2009-2010). 
Ponyai et al. 
(2012). 
Patch test: 
Retrospective study 
of 1502 
consecutive eczema 
patients patch 
tested with farnesol 
5% in pet. 
6/1502 (0.4%) 
patients were 
positive. 
A retrospective study of 
patch test data at 
Department of 
Dermato-Allergology, 
Copenhagen University 
Hospital Gentofte, 
Denmark (2008-2010).   
Heisterberg et al. 
(2011, 2012). 
Patch test: 
Retrospective study 
of 86 selected 
patients patch 
tested with farnesol 
5% in pet.  
1/86 (1.2%) 
patients were 
positive.  
A retrospective and 
descriptive analysis of a 
patch test study at the 
Cutaneous Allergy Unit 
of a tertiary referral 
hospital, Spain (2004-
2008). 
Cuesta et al. 
(2010). 
Patch test: 
Retrospective study 
of 367 selected 
fragrance mix (FM) 
II positive patients 
patch tested with 
farnesol 5% in pet.  
42/367 (11.4%) 
patients were 
positive.  
A retrospective study 
on patch test data from 
multicentre project 
IVDK (2005-2008). 
Krautheim et al. 
(2010). 
Patch test: 
Prospective study 
of 320 selected 
eczema patients 
patch tested with 
farnesol 5% in pet. 
3/320 (0.9%) 
patients were 
positive. 
A prospective analysis 
of selected eczema 
patients at the 
University Medical 
Center in Groningen, 
the Netherlands (2005-
2007). 
van Oosten et al. 
(2009). 
Patch test: 
Retrospective study 
of 4238 unselected 
patients patch 
tested with farnesol 
5% in pet. 
38/4238 (0.9%, 
95% CI: 0.6-
1.2%) patients 
were positive. 
A retrospective study 
on patch test data from 
multicentre project 
IVDK (2003-2004). 
Schnuch et al. 
(2007). 
Patch test: 
Prospective study 
of 1701 
consecutive 
6/1701 (0.35%, 
95% CI: 0.13-
0.77%) patients 
were positive. 
A prospective analysis 
of patients from six 
dermatology 
departments 
Frosch et al. 
(2005). 
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Method Results Remarks/Comments Reference 
patients patch 
tested with farnesol 
5% in pet. 
(Dortmund, 
Copenhagen, Malmö, 
Odense, London and 
Leuven) (1997-1998). 
Patch test: 
Prospective study 
of 1855 
consecutive 
patients patch 
tested with farnesol 
5% in pet. 
10/1855 (0.5%) 
patients were 
positive. 
A prospective analysis 
of patients from six 
dermatology 
departments 
(Dortmund, 
Copenhagen, Malmö, 
Odense, London and 
Leuven) (1997-1998). 
Frosch et al. 
(2002a). 
Patch test: Study of 
102 selected 
patients patch 
tested with farnesol 
5% in pet. 
4/102 (4%) 
patients were 
positive. 
 Hausen et al., 
2001 cited from 
Lapczynski et al. 
(2008a). 
Patch test: Study of 
1483 selected 
patients with 
suspected cosmetic 
dermatitis patch 
tested with farnesol 
5% in pet. 
16/1483 (1.1%) 
patients were 
positive. 
Nagoya, Japan (year 
not stated). 
Sugiura et al., 
2000 cited from 
SCCS (2012). 
Patch test: 
Retrospective study 
of 8521 selected 
patients patch 
tested with 
farnesol. 
Concentration and 
vehicle not 
reported. 
2/8521 (0.02%) 
patients were 
positive. 
Retrospective study 
performed at the 
Department of 
Dermatology, University 
Hospital, Leuven, 
Belgium (1985-1997). 
Goossens and 
Merckx 1997 
cited from 
SCCNFP (1999). 
Patch test: Study of 
111 selected 
patients patch 
tested with farnesol 
1% in lanolin. 
8/111 (7.2%) 
patients were 
positive. 
 Goossens and 
Merckx 1997 
cited from 
SCCNFP (1999). 
Patch test: Study of 
466 selected 
patients patch 
tested with farnesol 
(2, 5 and 10%).  
Vehicle not 
reported. 
5/466 (1.1%) 
patients were 
positive to 5 or 
10% and 1/466 
(0.2%) were 
positive to 2%. 
Patch test study 
performed by the 
Japanese society of 
contact dermatitis. Year 
not stated. 
Sugai et al., 1994 
cited from 
SCCNFP (1999). 
Patch test: Study of 
573 selected 
patients patch 
7/573 (1.2%) 
patients were 
positive. 
 Hirose et al., 
1987 cited from 
Lapczynski et al. 
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tested with farnesol 
20% in pet. 
(2008a). 
Patch test: Study of 
1367 selected 
patients patch 
tested with farnesol 
2, 5 or 10% in pet. 
11/1367 (0.8%) 
patients were 
positive. 
 Yamamoto et al., 
1985 cited from 
Lapczynski et al. 
(2008a). 
Patch test: 
Prospective study 
of 182 selected 
patients suspected 
of contact allergy 
to cosmetics patch 
tested with farnesol 
4% in pet. 
2/182 (1.1%) 
patients were 
positive. 
Farnesol 4% was tested 
in 20 control eczema 
patients with no 
positive reactions. 
Malten et al., 
1984 cited from 
SCCNFP (1999). 
 
Table 3 summarises Human Repeat Insult Patch Tests (HRIPTs) and Human Maximisation Tests 
(HMTs) with farnesol.  
 
Table 3. HRIPT and HMT studies with farnesol adapted from Lapczynski et al. (2008a). 
Method Results Remarks/Comments Reference 
HRIPT: 
Farnesol 
concentration: 5% 
(2865 µg/cm2) 
Vehicle: 3:1 Diethyl 
phthalate:Ethanol 
(DEP:EtOH).  
 
0/108 (0%) 
tests were 
positive. 
No further information 
available from 
Lapczynski et al. 
(2008a). 
Unpublished 
report from RIFM 
(2004c) cited 
from Lapczynski 
et al. (2008a). 
HRIPT: 
Farnesol 
concentration: 5% 
(1529 µg/cm2) 
Vehicle: petrolatum 
(pet.).  
 
0/103 (0%) 
tests were 
positive. 
No further information 
available from 
Lapczynski et al. 
(2008a). 
Unpublished 
report from RIFM 
(2000b) cited 
from Lapczynski 
et al. (2008a). 
HRIPT: 
Farnesol 
concentration: 5% 
(1529 µg/cm2) 
Vehicle: pet.  
 
0/101 (0%) 
tests were 
positive. 
No further information 
available from 
Lapczynski et al. 
(2008a). 
Unpublished 
report from RIFM 
(2000a) cited 
from Lapczynski 
et al. (2008a). 
HMT: 
Farnesol 
concentration: 12% 
(8280 µg/cm2) 
Vehicle: pet.  
 
0/35 (0%) 
tests were 
positive. 
No further information 
available from 
Lapczynski et al. 
(2008a). 
Unpublished 
report from RIFM 
(1978) cited from 
Lapczynski et al. 
(2008a). 
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HMT: 
Farnesol 
concentration: 10% 
(6900 µg/cm2) 
Vehicle: pet.  
 
4/25 (16%) 
tests were 
positive. 
No further information 
available from 
Lapczynski et al. 
(2008a). 
Unpublished 
report from RIFM 
(1977b) cited 
from Lapczynski 
et al. (2008a). 
HMT: 
Farnesol 
concentration: 12% 
(8280 µg/cm2) 
Vehicle: pet.  
 
0/25 (0%) 
tests were 
positive. 
No further information 
available from 
Lapczynski et al. 
(2008a). 
Unpublished 
report from RIFM 
(1977a) cited 
from Lapczynski 
et al. (2008a). 
HMT: 
Farnesol 
concentration: 12% 
(8280 µg/cm2) 
Vehicle: pet.  
 
0/26 (0%) 
tests were 
positive. 
No further information 
available from 
Lapczynski et al. 
(2008a). 
Unpublished 
report from RIFM 
(1977a) cited 
from Lapczynski 
et al. (2008a). 
HMT: 
Farnesol 
concentration: 10% 
(6900 µg/cm2) 
Vehicle: pet.  
 
6/25 (24%) 
tests were 
positive. 
No further information 
available from 
Lapczynski et al. 
(2008a). 
Unpublished 
report from RIFM 
(1976b) cited 
from Lapczynski 
et al. (2008a). 
HMT: 
Farnesol 
concentration: 10% 
(6900 µg/cm2) 
Vehicle: pet.  
 
0/25 (0%) 
tests were 
positive. 
No further information 
available from 
Lapczynski et al. 
(2008a). 
Unpublished 
report from RIFM 
(1976a) cited 
from Lapczynski 
et al. (2008a). 
HMT: 
Farnesol 
concentration: 12% 
(8280 µg/cm2) 
Vehicle: pet.  
 
0/25 (0%) 
tests were 
positive. 
No further information 
available from 
Lapczynski et al. 
(2008a). 
Unpublished 
report from RIFM 
(1975d) cited 
from Lapczynski 
et al. (2008a). 
HMT: 
Farnesol 
concentration: 12% 
(8280 µg/cm2) 
Vehicle: pet.  
 
2/25 (8%) 
tests were 
positive. 
No further information 
available from 
Lapczynski et al. 
(2008a). 
Unpublished 
report from RIFM 
(1975c) cited 
from Lapczynski 
et al. (2008a). 
HMT: 
Farnesol 
concentration: 12% 
(8280 µg/cm2) 
Vehicle: pet.  
 
0/25 (0%) 
tests were 
positive. 
No further information 
available from 
Lapczynski et al. 
(2008a). 
Unpublished 
report from RIFM 
(1975b) cited 
from Lapczynski 
et al. (2008a). 
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HMT: 
Farnesol 
concentration: 12% 
(8280 µg/cm2) 
Vehicle: pet.  
 
7/25 (28%) 
tests were 
positive. 
No further information 
available from 
Lapczynski et al. 
(2008a). 
Unpublished 
report from RIFM 
(1975a) cited 
from Lapczynski 
et al. (2008a). 
HMT: 
Farnesol 
concentration: 12% 
(8280 µg/cm2) 
Vehicle: pet.  
 
4/25 (16%) 
tests were 
positive. 
No further information 
available from 
Lapczynski et al. 
(2008a). 
Unpublished 
report from RIFM 
(1974a) cited 
from Lapczynski 
et al. (2008a). 
HRIPT: Human Repeat Insult Patch Test, HMT: Human Maximisation Test. 
 
Case studies 
Table 4 summarises case reports with allergic contact dermatitis where farnesol has been found as a 
causative agent.  
 
Table 4. Case studies with farnesol. 
Method Results Remarks/Comments Reference 
Patch test: A 48-
year old 
metalworker with 
recurrent hand 
dermatitis was 
patch tested with 
farnesol and   a 
long list of other 
allergens.  
Farnesol and 
several other 
allergens tested 
positive. 
Case study (Germany, 
2007-2008). 
Tanko et al. 
(2009). 
Patch test: A 
woman with 
axillary dermatitis 
due to a 
deodorant was 
patch tested with 
farnesol.  
Positive result at 
5% farnesol. 
Case study (location 
and year not stated). 
Goossens and 
Merckx 1997 cited 
from SCCNFP 
(1999). 
 
A total of 20 patch test population studies, 3 HRIPTs, 11 HMTs and 2 case studies with farnesol are 
summarised above (Table 2, 3 and 4). As shown in Table 2 the positive patch test frequencies from 
all of the reported patch test population studies vary between 0.02 and 13.2% in dermatitis patients. 
For unselected/consecutive dermatitis patients positive reactions range between 0.35 and 0.9% (4 
studies) and for selected dermatitis patients positive reactions range between 0.02 and 13.2% (16 
studies). The total number of published cases is > 250. No positive results were reported in the 
three HRIPTs at farnesol concentrations of 2865 µg/cm2 or lower. In the HMTs 2/3 studies with 
farnesol showed positive results after 6900 µg/cm2 and 3/8 studies showed positive results after 
8280 µg/cm2. Based on these data the Research Institute for Fragrance Materials, Inc. (RIFM) 
deducted a NOEL13-HRIPT (induction) of 2755 µg/cm2 and a LOEL14 (induction) of 68 974 
                                                                    
13 NOEL: No Observed Effect Level. 
14 LOEL: Lowest Observed Effect Level. 
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µg/cm2. In addition, based on weight of evidence, a No Expected Sensitization Induction Level 
(NESIL) of 2700 µg/cm2 was established for farnesol by the RIFM Expert Panel (IFRA, 2006). 
 
According to SCCS (2012) farnesol is used in volumes less than 175 ton per year in perfume 
formulations. It has been reported that in consumer products containing fragrance allergens that 
are required to be labelled 3.9% of a total of 516 consumer products; 8% of a total of 300 consumer 
products; ca. 4% of 3000 products and 2.9% of children’s cosmetics were labelled to contain 
farnesol (Wijnhoven et al., 2008; Buckley, 2007; Schnuch et al., 2009 and Poulsen & Schmidt, 2007 
cited from SCCS (2012)). In addition, in 2007, 14.8% of 88 tested deodorants were labelled to 
contain farnesol and the fragrance was detected in 39% (range: 9-1791 mg/kg) of 23 deodorants 
selected for analysis (Rastogi et al., 2007 cited from SCCS (2012)).  
  
The IFRA standard limits for farnesol in different IFRA QRA product categories reported by IFRA 
(2006 and 2015) are shown in table 5. 
 
Table 5. The IFRA standard limits for farnesol in IFRA QRA product categories. 
IFRA QRA product 
category 
Product type that drives the 
category consumer exposure 
level 
IFRA standard limits 
Category 1 Lip products 0.08% 
Category 2 Deodorants/antiperspirants 0.11% 
Category 3 Hydroalcoholics for shaved skin 0.4% 
Category 4 Hydroalcoholics for unshaved skin 1.2% 
Category 5 Hand cream 0.6% 
Category 6 Mouthwash 2.0% 
Category 7 Intimate wipes 0.2% 
Category 8 Hair styling aids 2.0%* 
Category 9 Rinse-off hair conditioners 5.0%* 
Category 10 Hard surface cleaners 2.5%* 
Category 11 Candles Not restricted 
IFRA: International Fragrance Association, QRA: Quantitative Risk Assessment. 
*Maximum pragmatic level. 
 
Farnesol is not registered under the REACH regulation. 
 
Summary and discussion of skin sensitization 
Human data 
A total of 20 patch test population studies, 3 HRIPTs, 11 HMTs and 2 case studies were identified 
with farnesol.   The positive patch test frequencies from all of the reported patch test population 
studies vary between 0.02 and 13.2% in dermatitis patients. In studies with unselected/consecutive 
dermatitis patients positive reactions range between 0.35 and 0.9% (4 studies) and in studies with 
selected dermatitis patients positive reactions range between 0.02 and 13.2% (16 studies). The total 
number of published cases is > 250. Positive responses after farnesol were seen at concentrations ≥ 
6900 µg/cm2 in 5/11 HMTs.  
 
Non-human data  
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A total of two LLNAs and four GPMTs were identified testing skin sensitising effects of farnesol. 
EC3 values were 5.5 and 4.1%. In the GPMTs no positive reactions were observed after intradermal 
induction doses of 0.16, 5 and 10% farnesol.  
 
No relevant in vitro studies on farnesol (i.e. OECD TG 442C and OECD 442D) were identified in the 
literature. 
 
Exposure 
According to data from IFRA (2006) the exposure of farnesol when used as fragrance in cosmetics 
and in other consumer products appears to be low.  
 
Comparison with criteria 
For unselected/consecutive dermatitis patients positive reactions range between 0.35 and 0.9% i.e. 
all 4 studies reporting frequencies lower than 1%. For selected dermatitis patients positive reactions 
range between 0.02 and 13.2% with 7 out of 16 studies reporting frequencies higher than 2%. In 
addition to this there are more than 250 published cases of positive patch test reactions to farnesol. 
According to the CLP criteria a frequency ≥ 1% for unselected/consecutive dermatitis patients 
and/or ≥ 2% for selected dermatitis patients and/or a total number of published cases ≥ 100, equals 
a high frequency of occurrence of skin sensitisation (Table 3.4.2-b) (ECHA, 2015). The collected 
data described above from patch test studies show that farnesol causes a low/moderate frequency 
of occurrence of skin sensitisation based on unselected/consecutive dermatitis patients and 9/16 
studies with selected dermatitis patients. The remaining studies with selected dermatitis patients 
(7/16) and number of published cases shows that farnesol causes a high frequency of occurrence of 
skin sensitisation in humans.  
In regard to the HRIPT/HMT data the positive response reported at > 500 µg/cm2 for HRIPT/HMT 
induction threshold indicate classification of farnesol in sub-category 1B according to Annex I: 
3.4.2.2.2.2. 
In the two LLNAs the lowest EC3 value for farnesol was 4.1%. According to the CLP Regulation an 
EC3 value  2% indicates classification of a substance in sub-category 1A whereas an EC3 value > 
2% indicates classification of a substance in sub-category 1B (Annex I: 3.4.2.2.3.2.). Thus, both 
studies indicate classification of farnesol in sub-category 1B. 
 
Sensitisation was not observed in the four GPMTs with intradermal induction doses of 0.16, 5 and 
10% farnesol which do not justify sub-categorisation (Table 3.4.3).  
 
Overall, there is evidence for classification in sub-category 1A based on the number of cases 
combined with the estimated low exposure. Data from HRIPT/HMT indicate evidence for sub-
category 1B. Data from LLNAs indicate a classification in sub-category 1B. A classification as a skin 
sensitiser in sub-category 1A is warranted for farnesol. 
 
Conclusions on classification and labelling 
Based on the number of cases combined with the estimated low exposure, a classification of farnesol 
as a skin sensitiser in sub-category 1A is justified.  
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Appendix 10 Geraniol CAS RN 106-24-1 
Non-human information 
Table 1 summarises relevant animal studies with geraniol i.e. Local Lymph Node Assays (LLNAs), 
Guinea Pig Maximization tests (GPMTs) and Buehler tests.  
 
Table 1. Animal studies with geraniol. 
Method Results Remarks/Comments Reference 
LLNA: 
Ex vivo BrdU. 2.5, 
10, 20 and 50% 
geraniol.  
Vehicle: 4:1 
Acetone:Olive oil 
(AOO). 
Geraniol was 
shown to have an 
EC3 value of 
13.1%. 
 Ulker et al. 
(2014). 
LLNA: 0, 5, 10, 
15, 20 and 30% 
geraniol. 
Vehicle: AOO. 
 
Geraniol was 
shown to have an 
EC3 value of 
22.4% (1.45 M). 
 Hagvall et al. 
(2007). 
LLNA: 0, 1, 3, 6, 
10 and 20% air-
exposed geraniol. 
Vehicle: AOO. 
 
Air-exposed 
geraniol was 
shown to have an 
EC3 value of 
4.4% (0.28 M). 
 Hagvall et al. 
(2007). 
LLNA: 0.5, 1, 3, 6 
and 10% air-
exposed geraniol. 
Vehicle: AOO. 
 
Air-exposed 
geraniol was 
shown to have an 
EC3 value of 
5.8% (0.37 M). 
 Hagvall et al. 
(2007). 
LLNA: 1, 3, 10, 30 
and 50% geraniol. 
Vehicle: Ethanol 
(EtOH). 
 
Geraniol was 
shown to have an 
EC3 value of 
5.6% (0.36 M). 
According to SCCS 
(2012) there were no 
reported deviations 
from OECD TG 429. 
Unpublished 
summary report 
by RIFM 2009 
(RIFM 2001j) 
cited from SCCS 
(2012). 
LLNA: 2.5, 5, 10, 
25 and 50% 
geraniol. 
Vehicle: 3:1 
EtOH:diethyl 
phthalate (DEP). 
 
Geraniol was 
shown to have an 
EC3 value of 
11.4% (0.74 M). 
According to SCCS 
(2012) there were no 
reported deviations 
from OECD TG 429. 
Unpublished 
summary report 
by RIFM 2009 
(RIFM 2003t) 
cited from SCCS 
(2012). 
LLNA: 1, 3, 10, 30 
and 50% geraniol. 
Vehicle: DEP. 
 
Geraniol was 
shown to have an 
EC3 value of 
11.8% (0.76 M). 
According to SCCS 
(2012) there were no 
reported deviations 
from OECD TG 429. 
Unpublished 
summary report 
by RIFM 2009 
(RIFM 2001k) 
cited from SCCS 
(2012). 
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LLNA: 1, 3, 10, 30 
and 50% geraniol. 
Vehicle: 1:3 
EtOH:DEP. 
 
Geraniol was 
shown to have an 
EC3 value of 
20.4% (1.32 M). 
According to SCCS 
(2012) there were no 
reported deviations 
from OECD TG 429. 
Unpublished 
summary report 
by RIFM 2009 
(RIFM 2001l) 
cited from SCCS 
(2012). 
LLNA: 1, 3, 10, 30 
and 50% geraniol. 
Vehicle: 3:1 
EtOH:DEP. 
 
Geraniol was 
shown to have an 
EC3 value of 
25.8% (1.67 M). 
According to SCCS 
(2012) there were no 
reported deviations 
from OECD TG 429. 
Unpublished 
summary report 
by RIFM 2009 
(RIFM 2001m) 
cited from SCCS 
(2012). 
GPMT: 
Intradermal 
induction 0.1% 
geraniol in 
Dobs/saline;  
Topical induction 
50% in 70/30 
acetone/PEG 400;  
Challenge dose 
10% in 70/30 
acetone/PEG 400. 
No positive 
reactions 
reported. 
 Unpublished 
report by RIFM 
1989 cited from 
Lapczynski et al. 
(2008b). 
GPMT: 
Intradermal 
induction 0.1% 
geraniol in 
Dobs/saline;  
Topical induction 
50% in acetone;  
Challenge dose 
10% in acetone. 
Sensitization 
observed. 
No further information 
is available from 
Lapczynski et al. 
(2008b). 
Unpublished 
report by RIFM 
1989 cited from 
Lapczynski et al. 
(2008b). 
GPMT: 
Intradermal 
induction 5% 
geraniol in 
petrolatum (pet.);  
Topical induction 
30% in pet;  
Challenge dose 
10% in pet. 
Sensitization 
observed. 
No further information 
is available from 
Lapczynski et al. 
(2008b). 
Unpublished 
report by RIFM 
1977 cited from 
Lapczynski et al. 
(2008b). 
GPMT: 
Intradermal 
induction 5% 
geraniol in pet.;  
Topical induction 
25% in pet;  
Challenge dose 
sub-irritant. 
Sensitization 
observed. 
No further information 
is available from 
Lapczynski et al. 
(2008b). 
Klecak et al., 
1977 cited from 
Lapczynski et al. 
(2008b). 
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GPMT: 
Intradermal 
induction 10% 
geraniol;  
Topical induction 
10%;  
Challenge dose 
10%. Vehicle not 
reported. 
Sensitization 
observed. 
No further information 
is available from 
Lapczynski et al. 
(2008b). 
Ishihara et al., 
1986 cited from 
Lapczynski et al. 
(2008b). 
Buehler: 
Induction 
concentration 
15% geraniol in 
DEP ;  
Challenge dose 
2.5, 7.5 or 25% in 
DEP. 
No sensitization 
observed. 
No further information 
is available from 
Lapczynski et al. 
(2008b). 
Unpublished 
report by RIFM 
1992 cited from 
Lapczynski et al. 
(2008b). 
 
A total of 9 LLNAs, 5 GPMTs and 1 Buehler test are summarised in table 1. The reported EC3 values 
for geraniol range between 5.6% (vehicle: ethanol) and 25.8% (vehicle: ethanol:diethyl phthalate 
1:3). Air-exposed geraniol was tested in two LLNAs with resulting EC3 values of 4.4 and 5.8%.  In 
the GPMTs sensitisation was observed but not quantified (i.e. number of animals affected) in 4/5 
studies with intradermal induction doses of 0.1, 5 and 10% geraniol. No sensitisation was observed 
in the Buehler test with an induction concentration of 15% geraniol. 
 
No relevant in vitro studies on geraniol (i.e. OECD TG 442C and OECD TG 442D) were identified in 
the literature. 
 
Human information 
Population studies 
Table 2 summarises patch test studies on geraniol involving several thousand dermatitis patients 
from various countries in Europe and Asia. Most of the studies are diagnostic patch test studies.  
 
Table 2. Population studies with geraniol. 
Method Results Remarks/Comments Reference 
Patch test: 
Retrospective 
study of 806 
selected patients 
patch tested with 
geraniol 1 % in 
petrolatum (pet.). 
31/806 (3.8%) 
patients were 
positive.  
A retrospective study on 
patch test data from 
multicentre project IVDK 
(Information Network of 
Departments of 
Dermatology) (2007-
2009). 
Schnuch et al. 
(2015). 
Patch test: 
Retrospective 
study of 1951 
selected eczema 
patients patch 
tested with 
geraniol 2% in 
pet.  
9/1951 (0.46%, 
95% CI: 0.2-
0.8%) patients 
were positive. 
A retrospective study on 
patch test data at St 
John’s Institute of 
Dermatology at St 
Thomas’ Hospital, UK 
(2011-2012). 
Mann et al. 
(2014). 
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Patch test:  
Prospective study 
of 655 consecutive 
patients patch 
tested with 
geraniol 4 and 
11% in pet. 
1/655 (0.15%) 
and 7/655 
(1.1%) patients 
were positive 
after 4 and 11% 
geraniol, 
respectively. 
A prospective study on 
patch test data from 
Department of 
Dermatology, 
Sahlgrenska University 
Hospital, Gothenburg, 
Sweden (2010-2011). 
Hagvall et al. 
(2013). 
Patch test:  
Prospective study 
of 649 consecutive 
patients patch 
tested with 
geraniol 6% in 
pet. 
3/649 (0.46%) 
patients were 
positive. 
A prospective study on 
patch test data from 
Department of 
Dermatology, 
Sahlgrenska University 
Hospital, Gothenburg, 
Sweden (2010-2011). 
Hagvall et al. 
(2013). 
Patch test:  
Prospective study 
of 655 consecutive 
patients patch 
tested with 
oxidised geraniol 
4 and 6% in pet. 
6/655 (0.92%) 
and 15/655 
(2.3%) patients 
were positive 
after 4 and 16% 
geraniol, 
respectively. 
A prospective study on 
patch test data from 
Department of 
Dermatology, 
Sahlgrenska University 
Hospital, Gothenburg, 
Sweden (2010-2011). 
Hagvall et al. 
(2013). 
Patch test:  
Prospective study 
of 653 consecutive 
patients patch 
tested with 
oxidised geraniol 
11% in pet. 
30/655 (4.6%) 
patients were 
positive. 
A prospective study on 
patch test data from 
Department of 
Dermatology, 
Sahlgrenska University 
Hospital, Gothenburg, 
Sweden (2010-2011). 
Hagvall et al. 
(2013). 
Patch test:  
Prospective study 
of 2227 
consecutive 
patients patch 
tested with 
geraniol 2% in 
pet. 
3/2227 (0.13%) 
patients were 
positive. 
A prospective study on 
patch test data from 
Department of 
Dermatology, 
Sahlgrenska University 
Hospital, Gothenburg, 
Sweden (2006-2010). 
Hagvall et al. 
(2012). 
Patch test:  
Prospective study 
of 2179 
consecutive 
patients patch 
tested with 
oxidised geraniol 
2% in pet. 
12/2179 (0.55%) 
patients were 
positive. 
A prospective study on 
patch test data from 
Department of 
Dermatology, 
Sahlgrenska University 
Hospital, Gothenburg, 
Sweden (2006-2010). 
Hagvall et al. 
(2012). 
Patch test: 
Retrospective 
study of 940 
selected patients 
tested with 
52/940 (5.5%) 
patients were 
positive. 
A retrospective study on 
patch test data from 
Department of 
Dermatology, University 
Hospital St Rafaël, 
Nardelli et al. 
(2013). 
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geraniol 1% in 
pet. 
Belgium (1990-2011). 
Patch test: 
Prospective study 
of 100 selected 
patients with 
contact allergy 
patch tested with 
geraniol.  
Vehicle and 
concentration not 
reported. 
9/100 (9%, 95% 
CI: 4.2-16.4%) 
patients were 
positive. 
Single-centre, double-
blind prospective 
experimental 
longitudinal volunteer 
study at the department 
of Dermatology of the 
VU University Medical 
Centre, The Netherlands 
(2005-2010). 
Nagtegaal et al. 
(2012). 
Patch test: 
Retrospective 
study of 1502 
consecutive 
eczema patients 
patch tested with 
geraniol 1% in 
pet. 
0/1502 (0 %) 
patients were 
positive. 
A retrospective study of 
patch test data at 
Department of Dermato-
Allergology, Copenhagen 
University Hospital 
Gentofte, Denmark 
(2008-2010).   
Heisterberg et 
al. (2011, 2012). 
Patch test: 
Retrospective 
study of 157 
selected patients 
(chosen out of 509 
patients positive 
to fragrance 
allergens) patch 
tested with 
geraniol 5% in 
pet. 
Ca. 31/157 (ca. 
20%) patients 
were positive. 
A retrospective study of 
patch test data at the 
Allergy Clinic of the 
Department of 
Dermatology and 
Venereology, Zagreb 
University Hospital 
Center and School of 
Medicine, Zagreb, 
Croatia (2001-2005).   
Turcic et al. 
(2011). 
Patch test: 
Retrospective 
study of 86 
selected patients 
patch tested with 
geraniol 2% in 
pet.  
17/86 (19.7%) 
patients were 
positive.  
A retrospective and 
descriptive analysis of a 
patch test study at the 
Cutaneous Allergy Unit 
of a tertiary referral 
hospital, Spain (2004-
2008). 
Cuesta et al. 
(2010). 
Patch test: 
Retrospective 
study of 1214 
consecutive 
patients and 5695 
selected patients 
patch tested with 
geraniol in 1% 
pet. 
5/1214 (0.39%, 
95% CI: 0.10-
0.69%) and 
50/5695 (0.87%, 
95% CI: 0.63-
1.1%) patients 
were positive. 
A retrospective study on 
patch test data from 
multicentre project IVDK 
(Information Network of 
Departments of 
Dermatology) (2005-
2008). 
Uter et al. 
(2010). 
Patch test: 
Prospective study 
2/320 (0.6%) 
patients were 
A prospective analysis of 
selected eczema 
van Oosten et al. 
(2009). 
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of 320 selected 
eczema patients 
patch tested with 
geraniol 2% in 
pet. 
positive. patients at the 
University Medical 
Center in Groningen, the 
Netherlands (2005-
2007). 
Patch test: 
Retrospective 
study of 89 
selected patients 
with a) current 
allergic dermatitis 
or b) past allergic 
dermatitis patch 
tested with 
geraniol 1% in 
pet. 
a) 15/89 
(16.85%) and b) 
22/89 (24.72%) 
patients were 
positive. 
A retrospective study of 
patch test data from 
patients attending the 
Department of 
Cutaneous Allergy at St 
John’s Institute of 
Dermatology, UK (1982-
2007). 
White (2009). 
Patch test: 
Prospective study 
of 15 selected 
patients with 
eczematous 
reactions from 
ketoprofen-
containing gels 
patch tested with 
geraniol 2% in 
pet. 
0/15 (0%) 
patients were 
positive. 
A prospective study on 
patch test data from 
patients from Italy 
(2006-2007). 
Foti et al. 
(2008). 
Patch test: 
Retrospective 
study of 2063 
unselected 
patients patch 
tested with 
geraniol 1% in 
pet. 
10/2063 (0.5%, 
95% CI: 0.1-
0.7%) patients 
were positive. 
A retrospective study on 
patch test data from 
multicentre project IVDK 
(2003-2004). 
Schnuch et al. 
(2007). 
Patch test: 
Retrospective 
study of a) 29 
patients positive 
to their own 
deodorant and b) 
141 negative to 
their own 
deodorant patch 
tested with 
geraniol 1% in 
pet. 
a) 2/29 (7%) and 
b) 0/141 (0%) 
patients were 
positive. 
A retrospective study on 
patch test data from 
multicentre project IVDK 
(1998-2002). 
Uter et al. 
(2007). 
Patch test: Study 
of 30 selected 
6/30 (20%) 
patients were 
 Vocanson et al. 
(2006). 
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patients with a 
positive patch test 
to their own 
perfumed product 
patch tested with 
geraniol. 
Concentration and 
vehicle not 
reported. 
positive. 
Patch test: Study 
of 658 patients 
patch tested with 
geraniol 5% in 
pet. 
6/658 (0.9%) 
patients were 
positive. 
 Heydorn et al., 
2003 cited from 
Lapczynski et al. 
(2008b). 
Patch test: Study 
of 315 patients 
patch tested with 
geraniol 5% in 
pet. 
0/315 (0%) 
patients were 
positive. 
 Heydorn et al., 
2002 cited from 
Lapczynski et al. 
(2008b). 
Patch test: 
Retrospective 
study of 4900 
unselected 
patients patch 
tested with 
geraniol 1% in 
pet. 
59/4900 (1.2%) 
patients were 
positive. 
A retrospective study on 
patch test data from 
multicentre project IVDK 
(1996-1999). 
Schnuch et al. 
(2002). 
Patch test: Study 
of 160 patients 
sensitive to 
fragrance mix 
(FM) patch tested 
with geraniol. 
Concentration and 
vehicle not 
reported. 
12/160 (7.5%) 
patients were 
positive. 
 Temesvari et al., 
2002 cited from 
Hostynek and 
Maibach (2004). 
Patch test: 
Prospective study 
of 747 selected 
patients with 
suspected 
fragrance allergy 
patch tested with 
geraniol 1% in 
pet. 
7/747 (0.9%) 
patients were 
positive. 
A prospective analysis of 
patients from FAZ-
Floridsdorf Allergy 
Centre, Austria (1997-
2000). 
Wohrl et al. 
(2001). 
Patch test: Study 
of 226 patients 
patch tested with 
geraniol 1% in 
19/226 (8.4%) 
patients were 
positive. 
 Brites et al., 
2000 cited from 
Lapczynski et al. 
(2008b). 
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pet. 
Patch test: Study 
of 934 patients 
patch tested with 
geraniol 1% in 
pet. 
67/934 (7.2%) 
patients were 
positive. 
 Buckley et al., 
2000 cited from 
Lapczynski et al. 
(2008b). 
Patch test: Study 
of 223 patients 
patch tested with 
geraniol 2%. 
Vehicle not 
reported. 
1/223 (0.4%) 
patients were 
positive. 
 Kiec-
Swierczynska & 
Krecisz 2000 
cited from 
Lapczynski et al. 
(2008b). 
Patch test: Study 
of 1483 selected 
patients with 
suspected 
cosmetic 
dermatitis patch 
tested with 
geraniol 5% in 
pet. 
5/1483 (0.3%) 
patients were 
positive. 
Nagoya, Japan (year not 
stated). 
Sugiura et al., 
2000 cited from 
SCCS (2012). 
Patch test: Ten-
centre study of 
542 patients 
sensitive to FM 
patch tested with 
geraniol in pet. 
Concentration not 
reported. 
58/542 (10.7%) 
patients were 
positive. 
 Bordalo et al., 
1999 cited from 
Hostynek and 
Maibach (2004). 
Patch test: 
Retrospective 
study of 50 
patients sensitive 
to FM patch tested 
with geraniol 2% 
in 1% sorbitan 
sesquioleate. 
3/50 (6%) 
patients were 
positive. 
Retrospective study of 
patch test data. 
University Hospital 
Utrecht, The 
Netherlands (1994-
1998). 
Hendriks and 
van Ginkel 
(1999). 
Patch test: 
Retrospective 
study of 40 
patients sensitive 
to FM patch tested 
with geraniol in 
pet. Concentration 
not reported. 
0/40 (0%) 
patients were 
positive. 
 Katsarma and 
Gawkrodger 
(1999). 
Patch test: Study 
of 38 patients 
sensitive to FM 
5/38 (13.2%) 
patients were 
positive. 
 Katsarou 1999 
cited from 
Hostynek and 
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patch tested with 
geraniol 1% in 
pet. 
Maibach (2004). 
Patch test: Study 
of 8 patients 
sensitive to FM 
patch tested with 
geraniol 20% in 
pet. 
3/8 (37.5%) 
patients were 
positive. 
 Goossens & 
Merckx 1997 
cited from 
Hostynek and 
Maibach (2004). 
Patch test: Study 
of 41 eczema 
patients patch 
tested with 
geraniol 1% in 
pet. 
1/41 (2.4%) 
patients were 
positive. 
 Schauder & 
Ippen 1997 cited 
from Hostynek 
and Maibach 
(2004). 
Patch test: Study 
of 167 selected 
patients suspected 
of fragrance 
sensitivity patch 
tested with 
geraniol 5%.  
Vehicle not 
specified. 
5/167 (3%) 
patients were 
positive. 
 Larsen et al., 
1996 cited from 
SCCNFP (1999). 
Patch test: 
Prospective study 
of 1072 
consecutive 
patients patch 
tested with 
geraniol 1% in 
pet. 
4/1072 (0.4%) 
patients were 
positive. 
Prospective study of 
patients in a multicentre 
study involving 9 
European centres. Year 
not stated. 
Frosch et al., 
1995a cited from 
SCCNFP (1999). 
Patch test: 
Multicentre study 
of 702 eczema 
patients patch 
tested with 
geraniol 1% in 
pet. 
5/702 (0.7%) 
with SSO and 
3/702 (0.4%) 
without SSO 
patients were 
positive. 
No further information 
available from Hostynek 
and Maibach (2004). 
Frosch et al., 
1995b cited from 
Hostynek and 
Maibach (2004). 
Patch test: 
Retrospective 
study of 367 
selected patients 
patch tested with 
geraniol in 1-2% 
pet.   
15/367 (4%) 
patients were 
positive. 
Retrospective study of 
patch test data from 
Department of 
Dermatology, Gentofte 
Hospital, Denmark 
(1979-1983 and 1988-
1992). 
Johansen and 
Menne (1995). 
Patch test: 
Prospective study 
3/50 (6%) 
patients were 
Retrospective study of 
patch test data from 
Becker et al. 
(1994). 
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of 50 selected 
patients sensitive 
to FM patch tested 
with geraniol. 
Concentration and 
vehicle not 
reported. 
positive. Department of 
Dermatology and 
Venereology, Hungary. 
Year not stated. 
Patch test: 
Prospective study 
of 61 selected 
patients sensitive 
to FM patch tested 
with geraniol 5% 
in pet. 
8/61 (13%) 
patients were 
positive. 
Control tests in 
100 patients not 
allergic to 
fragrances 
showed no 
positive reactions 
when tested with 
geraniol 5% pet. 
Prospective study of 
patch test data from 
University of Amsterdam 
and University of 
Leiden, The Netherlands 
(1987). 
 
de Groot et al. 
(1993). 
 
Patch test: Study 
of 103 patients 
patch tested with 
geraniol 5% in 
pet. 
4/103 (3.9%) 
patients were 
positive. 
 Haba et al., 
1993 cited from 
Lapczynski et al. 
(2008b). 
Patch test: Study 
of 20 volunteers 
(age: 1-18 years) 
patch tested with 
geraniol 1% in 
pet. 
0/20 (0%) 
patients were 
positive. 
The study by Adifadel et 
al 1992 has a reliability 
score of 2 according to 
REACH-RD( 2015i). 
Abifadel et al., 
1992 cited from 
REACH-RD 
(2015i). 
Patch test: Study 
of 111 patients 
patch tested with 
geraniol 5% pet. 
1/111 (0.9%) 
patients were 
positive. 
 Nagareda et al., 
1992 cited from 
Lapczynski et al. 
(2008b). 
Patch test: Study 
of 115 patients 
patch tested with 
geraniol 5% in 
vaseline. 
0/115 (0%) 
patients were 
positive. 
 Remaut 1992 
cited from 
Lapczynski et al. 
(2008b). 
Patch test: Multi-
centre study of 17 
patients sensitive 
to FM patch tested 
with geraniol 1% 
in pet. 
2/17 (12%) 
patients were 
positive. 
 Roesyanto-
Mahadi et al., 
1990 cited from 
Hostynek and 
Maibach (2004). 
Patch test: Study 
of 20 patients 
sensitive to 
fragrance patch 
2/20 (10%) 
patients were 
positive. 
 Safford et al., 
1990 cited from 
Hostynek and 
Maibach (2004). 
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tested with 
geraniol 2% in 
pet. 
Patch test: 
Prospective study 
of 162 selected 
patients sensitive 
to FM patch tested 
with geraniol 1%. 
Vehicle not 
reported. 
4/162 (2.5%) 
patients were 
positive. 
Retrospective study of 
patch test data from 
Dermatologische Klinik 
und Poliklinik, Germany 
(1987). 
Enders et al. 
(1989). 
Patch test: Study 
of 200 patients 
sensitive to FM 
patch tested with 
geraniol 1-3% in 
pet. 
14/200 (7%) 
patients were 
positive. 
 Malanin & Ohela 
1989 cited from 
Hostynek and 
Maibach (2004). 
Patch test: Study 
of 52 eczema 
patients patch 
tested with 
geraniol 2% in 
pet. 
2/52 (3.8%) 
patients were 
positive. 
 Nethercott et al., 
1989 cited from 
Hostynek and 
Maibach (2004). 
Patch test: Study 
of 78 selected 
patients sensitive 
to FM patch tested 
with geraniol 1%. 
Vehicle not 
reported. 
4/78 (5.1%) 
patients were 
positive. 
Multicentre study 
involving 6 countries. 
Year not stated. 
Wilkinson et al., 
1989 cited from 
SCCNFP (1999). 
Patch test: Study 
of 119 patients 
patch tested with 
geraniol 5% in 
pet. 
2/119 (1.7%) 
patients were 
positive. 
 De Groot et al., 
1988 cited from 
Lapczynski et al. 
(2008b). 
Patch test: Study 
of 31 patients 
sensitive to oak 
moss patch tested 
with geraniol. 
Vehicle not 
reported. 
5/31 (16%) 
patients were 
positive. 
 Goncalo et al., 
1988 cited from 
Hostynek and 
Maibach (2004). 
Patch test: Study 
of 156 selected 
patients with pure 
contact allergy to 
cosmetic products 
patch tested with 
2/156 (1.2%) 
patients were 
positive. 
 Broneck et al., 
1987 cited from 
SCCNFP (1999). 
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geraniol. 
Concentration and 
vehicle not 
reported. 
Patch test: Study 
of 574 selected 
patients patch 
tested with 
geraniol 20% in 
pet. 
5/574 (0.9%) 
patients were 
positive. 
 Hirose et al., 
1987 cited from 
Lapczynski et al. 
(2008b). 
Patch test: 
Retrospective 
study of 63 
selected patients 
with dermatitis 
tested positive to 
perfume mixture 
patch tested 
between 1983 and 
1984 with geraniol 
3% in pet. and 54 
selected patients 
with dermatitis 
tested positive to 
perfume mixture 
patch tested 
between 1984 and 
1985 with geraniol 
1% in pet. 
Between 1983 
and 1984 4/63 
(6.3%) and 
between 1984 
and 1985 4/54 
(7.4%) patients 
were positive. 
Retrospective study of 
patch test data from 
Istituto Dermatologico 
Santa Maria e San 
Gallicano, Italy (1983-
1985). 
Santucci et al. 
(1987). 
Patch test: Study 
of 830 patients 
patch tested with 
geraniol 5%. 
Vehicle not 
reported. 
6/830 (0.7%) 
patients were 
positive. 
 Itoh et al., 1986 
cited from 
Lapczynski et al. 
(2008b). 
Patch test: Study 
of 299 patients 
sensitive to FM 
patch tested with 
geraniol 2% in 
pet. 
10/299 (3.3%) 
patients were 
positive. 
 Rudzki & Grzywa 
1986 cited from 
Hostynek and 
Maibach (2004). 
Patch test: 
Retrospective 
study of 403 
selected patients 
with cutaneous 
reactions to 
cosmetic products 
patch tested with 
8/403 (2%) 
patients were 
positive. 
It is unclear from the 
reference exactly how 
many patients were 
tested with geraniol. 
Adams and 
Maibach (1985). 
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geraniol. 
Concentration and 
vehicle not 
reported. 
Patch test: Study 
of 144 patients 
sensitive to FM 
patch tested with 
geraniol 1% in 
pet. 
10/144 (7%) 
patients were 
positive. 
 Angelini et al., 
1985 cited from 
Hostynek and 
Maibach (2004). 
Patch test: Study 
of 1033 patients 
patch tested with 
geraniol 2% pet. 
6/1033 (0.6%) 
patients were 
positive. 
 Cronin 1985 
cited from 
Lapczynski et al. 
(2008b). 
Patch test: Study 
of 179 patients 
patch tested with 
geraniol 10% in 
pet. 
11/179 (6.2%) 
patients were 
positive. 
 De Groot et al., 
1985 cited from 
Lapczynski et al. 
(2008b). 
Patch test: Study 
of 50 cosmetic 
allergic patients 
patch tested with 
geraniol 5% in 
pet. 
20/50 (40%) 
patients were 
positive. 
 Emmons and 
Marks 1985 cited 
from Hostynek 
and Maibach 
(2004). 
Patch test: Study 
of 242 patients 
patch tested with 
geraniol 7%.  
Vehicle not 
reported. 
1/242 (0.4%) 
patients were 
positive. 
 Van Joost et al., 
1985 cited from 
Lapczynski et al. 
(2008b). 
Patch test: Study 
of 241 patients 
patch tested with 
geraniol 2% in 
yellow paraffin. 
10/241 (4.2%) 
patients were 
positive. 
 Ferguson and 
Sharma 1984 
cited from 
SCCNFP (1999). 
Patch test: 
Prospective study 
of 182 selected 
patients suspected 
of contact allergy 
to cosmetics patch 
tested with 
geraniol 1% in 
pet. 
3/182 (1.6%) 
patients were 
positive. 
 Malten et al., 
1984 cited from 
SCCNFP (1999). 
Patch test: Study 
of 522 patients 
patch tested with 
3/522 (0.6%) 
patients were 
positive. 
 Nishimura et al., 
1984 cited from 
Lapczynski et al. 
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geraniol 5%.  
Vehicle not 
reported. 
(2008b). 
Patch test: Study 
of 242 patients 
patch tested with 
geraniol 1%.  
Vehicle not 
reported. 
1/242 (0.4%) 
patients were 
positive. 
 Van Joost et al., 
1984 cited from 
Lapczynski et al. 
(2008b). 
Patch test: Study 
of 181 patients 
patch tested with 
geraniol 20% in 
pet. 
7/181 (3.9%) 
patients were 
positive. 
 Hayakawa et al., 
1983 cited from 
Lapczynski et al. 
(2008b). 
Patch test: Study 
of 467 patients 
patch tested with 
geraniol 2%.  
Vehicle not 
reported. 
1/467 (0.2%) 
patients were 
positive. 
 Ohela and 
Saramies 1983 
cited from 
Lapczynski et al. 
(2008b). 
Patch test: Study 
of 23 fregrance 
sensitive patients 
patch tested with 
geraniol 1% in 
pet. 
3/23 (13%) 
patients were 
positive. 
 Sugai 1983 cited 
from Hostynek 
and Maibach 
(2004). 
Patch test: Study 
of 539 patients 
patch tested with 
geraniol 2% yellow 
paraffin. 
8/539 (1.5%) 
patients were 
positive. 
 Addo et al., 1982 
cited from 
Lapczynski et al. 
(2008b). 
Patch test: 
Prospective 
multicentre study 
of 487 patients 
allergic to 
cosmetics patch 
tested with 
geraniol. 
Concentration and 
vehicle not 
reported. 
5/487 (1%) 
patients were 
positive. 
 Eiermann et al., 
1982 cited from 
Hostynek and 
Maibach (2004). 
Patch test: Study 
of 155 patients 
patch tested with 
geraniol 5% in 
pet. 
1/155 (0.6%) 
patients were 
positive. 
 Itoh 1982 cited 
from Lapczynski 
et al. (2008b). 
Patch test: Study 28/1277 (2.2%)  Sugai 1982 cited 
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of 1277 patients 
patch tested with 
geraniol 2% in 
pet. 
patients were 
positive. 
from Lapczynski 
et al. (2008b). 
Patch test: Study 
of 172 patients 
patch tested with 
geraniol 2% pet. 
7/172 (4%) 
patients were 
positive. 
 Calnan et al., 
1980 cited from 
Lapczynski et al. 
(2008b). 
Patch test: Study 
of 198 patients 
patch tested with 
geraniol 2% 
vaseline. 
0/198 (0%) 
patients were 
positive. 
 Ishihara et al., 
1979 cited from 
Lapczynski et al. 
(2008b). 
Patch test: Study 
of 198 patients 
patch tested with 
geraniol 5% in 
vaseline. 
3/198 (1.5%) 
patients were 
positive. 
 Ishihara et al., 
1979 cited from 
Lapczynski et al. 
(2008b). 
Patch test: Study 
of 20 selected 
perfume allergic 
patients patch 
tested with 
geraniol 5%. 
Vehicle not 
reported. 
6/20 (30%) 
patients were 
positive. 
 Larsen et al., 
1977 cited from 
SCCNFP (1999).  
Patch test: Study 
of 792 eczema 
patients patch 
tested with 
geraniol 10% in 
pet. 
4/792 (0.5%) 
patients were 
positive. 
 Fregert and 
Hjorth 1969 
cited from 
Hostynek and 
Maibach (2004). 
Patch test: Study 
of 15 eczema 
patients allergic to 
Balsam of Peru 
patch tested with 
geraniol 10% in 
pet. 
2/15 (13%) 
patients were 
positive. 
 Hjorth 1961 
cited from 
Hostynek and 
Maibach (2004). 
Patch test: Study 
of 3 eczema 
patients patch 
tested with 
geraniol 1% in 
acetone. 
1/3 (33%) 
patients were 
positive. 
 Keil 1947 cited 
from Hostynek 
and Maibach 
(2004). 
 
Table 3 summarises Human Repeat Insult Patch Tests (HRIPTs) and Human Maximisation Tests 
(HMTs) with geraniol.  
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Table 3. HRIPT and HMT studies with geraniol adapted from Lapczynski et al. (2008b). 
Method Results Remarks/Comments Reference 
HRIPT: 
Geraniol 
concentration: 2% 
(2362 µg/cm2) 
Vehicle: 3:1 Diethyl 
phthalate:Ethanol 
(DEP:EtOH).  
 
0/110 (0%) 
tests were 
positive. 
No further information 
available from 
Lapczynski et al. 
(2008b). 
Unpublished 
report from RIFM 
(2000) cited from 
Lapczynski et al. 
(2008b). 
HRIPT: 
Geraniol 
concentration: 5% 
(5905 µg/cm2) plus 
0.5% tocopherol 
Vehicle: 3:1 
DEP:EtOH.  
 
1/109 (0.9%) 
tests were 
positive. 
No further information 
available from 
Lapczynski et al. 
(2008b). 
Unpublished 
report from RIFM 
(2002) cited from 
Lapczynski et al. 
(2008b). 
HRIPT: 
Geraniol 
concentration: 10% 
(11810 µg/cm2)  
Vehicle: 3:1 
DEP:EtOH.  
 
3/112 (2.7%) 
tests were 
positive. 
No further information 
available from 
Lapczynski et al. 
(2008b). 
Unpublished 
report from RIFM 
(2004) cited from 
Lapczynski et al. 
(2008b). 
HRIPT: 
Geraniol 
concentration: 5% 
(3876 µg/cm2)  
Vehicle: alcohol SDA 
39C.  
 
0/40 (0%) 
tests were 
positive. 
No further information 
available from 
Lapczynski et al. 
(2008b). 
Unpublished 
report from RIFM 
(1964) cited from 
Lapczynski et al. 
(2008b). 
HRIPT: 
Geraniol 
concentration: 
12.5% (9690 
µg/cm2)  
Vehicle: EtOH.  
 
0/41 (0%) 
tests were 
positive. 
No further information 
available from 
Lapczynski et al. 
(2008b). 
Unpublished 
report from RIFM 
(1964a) cited 
from Lapczynski 
et al. (2008b). 
HRIPT (modified): 
Geraniol 
concentration: 10%  
Vehicle: petrolatum 
(pet.).  
 
0/104 (0%) 
tests were 
positive. 
No further information 
available from 
Lapczynski et al. 
(2008b). 
Marzulli and 
Maibach 1980 
cited from 
Lapczynski et al. 
(2008b). 
HRIPT (modified): 
Geraniol 
concentration: 10%  
Vehicle: alcohol.  
2/73 (2.7%) 
tests were 
positive. 
No further information 
available from 
Lapczynski et al. 
(2008b). 
Marzulli and 
Maibach 1980 
cited from 
Lapczynski et al. 
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 (2008b). 
HMT: 
Geraniol 
concentration: 6%  
Vehicle: not 
reported.  
 
0/25 (0%) 
tests were 
positive. 
No further information 
available from REACH- 
RD (2015j). This study 
was administered a 
reliability score of 4 
(not assignable) in 
REACH-RD (2015j). 
Study report from 
1986 cited from 
REACH-RD 
(2015j). 
HMT: 
Geraniol 
concentration: 6% 
(4140 µg/cm2) 
Vehicle: pet.  
 
0/24 (0%) 
tests were 
positive. 
No further information 
available from 
Lapczynski et al. 
(2008b). 
Unpublished 
report from RIFM 
(1979) cited from 
Lapczynski et al. 
(2008b). 
HMT: 
Geraniol 
concentration: 6% 
(4140 µg/cm2) 
Vehicle: pet.  
 
0/25 (0%) 
tests were 
positive. 
No further information 
available from 
Lapczynski et al. 
(2008b). 
Grief (1967) cited 
from Lapczynski 
et al. (2008b). 
HMT: 
Geraniol 
concentration: 6% 
(4140 µg/cm2) 
Vehicle: pet.  
 
1/26 (3.8%) 
tests were 
positive. 
No further information 
available from 
Lapczynski et al. 
(2008b). 
Unpublished 
report from RIFM 
(1979a) cited 
from Lapczynski 
et al. (2008b). 
HRIPT: Human Repeat Insult Patch Test, HMT: Human Maximisation Test. 
 
Case studies 
Table 4 summarises case reports with allergic contact dermatitis where geraniol has been found to 
be among the causative agents.  
 
Table 4. Case studies with geraniol. 
Method Results Remarks/Comments Reference 
Patch test: A 54-
year old female 
bartender with 
chronic hand 
dermatitis was 
patch tested with 
geraniol and a long 
list of other 
allergens present 
in her 
environment.  
Geraniol, lime 
peel, FM I and 
FM II tested 
positive. 
Case study  
(year not reported). 
Swerdlin et al. 
(2010). 
Patch test: A 48-
year old male 
metalworker with 
Geraniol and 
several other 
allergens tested 
Case study  
(Germany, 2007-2008). 
Tanko et al. 
(2009). 
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recurrent hand 
dermatitis was 
patch tested with 
geraniol and a long 
list of other 
allergens.  
positive. 
 
A total of 84 results from patch test population studies, 7 HRIPTs, 4 HMTs and 2 case studies with 
geraniol are summarised above (Table 2, 3 and 4). In addition there were four patch test studies 
with oxidised geraniol. As shown in Table 2 the positive patch test frequencies from all of the 
reported patch test population studies vary between 0 and 40% in dermatitis patients. For 
unselected/consecutive dermatitis patients, positive reactions range between 0 and 1.2% (10 
studies) and for selected dermatitis patients positive reactions range between 0 and 40% (74 
studies). The total number of published cases is > 900.  
Sensitisation (2.7%) was reported in a HRIPT at a geraniol concentration of 11 810 µg/cm2 (10%) 
and in a modified HRIPT at 10% geraniol. Geraniol (5905 µg/cm2) and tocopherol (0.5%) lead to 
sensitisation in 1/109 subjects. In the HMTs 1/4 studies with geraniol showed a positive result after 
4140 µg/cm2. Based on these data the Research Institute for Fragrance Materials, Inc. (RIFM) 
deducted a NOEL-HRIPT15 (induction) of 11 811 µg/cm2. In addition, based on weight of evidence, 
a No Expected Sensitization Induction Level (NESIL) of 11 800 µg/cm2 was established for geraniol 
by the RIFM Expert Panel (IFRA, 2007). 
 
Geraniol is a ”top 100” substance and is according to SCCS (2012) classified as a skin sensitiser with 
R43 (based on the old classification criteria) (note that the substance does not have a harmonised 
classification as a skin sensitizer). 
 
Geraniol is identified as a prehapten (compounds which sensitization potency are markedly 
increased by air exposure due to oxidation) and forms oxidation products with increased sensitizing 
capacity both via spontaneous autoxidation at air exposure and via metabolic oxidation (SCCS, 
2012).  
 
According to SCCS (2012) geraniol is used in volumes greater than 175 ton per year in perfume 
formulations. It has been reported that in consumer products containing fragrance allergens that 
are required to be labelled 22.1% of a total of 516 consumer products; 42% of a total of 300 
consumer products; ca. 20% of 3000 products and 12% of children’s cosmetics were labelled to 
contain geraniol (Wijnhoven et al., 2008; Buckley, 2007; Schnuch et al., 2009 and Poulsen & 
Schmidt, 2007 cited from SCCS (2012)). In addition, in 2007, 48.9% of 88 tested deodorants were 
labelled to contain geraniol and the fragrance was detected in 87% (range: 1-399 mg/kg) of 23 
deodorants selected for analysis (Rastogi et al., 2007 cited from SCCS (2012)).   
 
In a recent study the Acceptable Exposure Level (AEL) was estimated for geraniol based on human 
studies and LLNA data. Comparing the AEL with the estimated aggregate dermal exposure of 
geraniol from personal care products and household cleaning agents it was shown that between 
0.02 and 0.86% of the population may have an aggregated exposure of geraniol which exceeds the 
lowest AEL of 55 µg/cm2 (Nijkamp et al., 2015). 
 
The IFRA standard limits for geraniol in different IFRA QRA product categories reported by IFRA 
(2007 and 2015) are shown in table 5. 
  
                                                                    
15 NOEL-HRIPT: No Observed Effect Level-Human Repeat Insult Patch Test. 
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Table 5. The IFRA standard limits for geraniol in IFRA QRA product categories. 
IFRA QRA product 
category 
Product type that drives the 
category consumer exposure 
level 
IFRA standard limits 
Category 1 Lip products 0.3% 
Category 2 Deodorants/antiperspirants 0.4% 
Category 3 Hydroalcoholics for shaved skin 1.8% 
Category 4 Hydroalcoholics for unshaved skin 5.3% 
Category 5 Hand cream 2.8% 
Category 6 Mouthwash 8.6% 
Category 7 Intimate wipes 0.9% 
Category 8 Hair styling aids 2.0%* 
Category 9 Rinse-off hair conditioners 5.0%* 
Category 10 Hard surface cleaners 2.5%* 
Category 11 Candles Not restricted 
IFRA: International Fragrance Association, QRA: Quantitative Risk Assessment. 
*Maximum pragmatic level. 
 
Geraniol is registered under the REACH regulation with an annual tonnage band of 1000 - 10 000 
tonnes per annum. 
 
Summary and discussion of skin sensitization 
Human data 
A total of 84 results from patch test population studies, 7 HRIPTs, 4 HMTs and 2 case studies were 
identified with geraniol. The positive patch test frequencies from all of the reported patch test 
population studies vary between 0 and 40% in dermatitis patients. In studies with 
unselected/consecutive dermatitis patients positive reactions range between 0 and 1.2% (10 studies) 
and in studies with selected dermatitis patients positive reactions range between 0 and 40% (74 
studies). The total number of published cases is > 900. Sensitisation was reported in 2/4 HRIPT 
studies after exposure to 10% geraniol (11 810 µg/cm2) and in 1/4 HMT studies after exposure to 
4140 µg/cm2.  
 
Non-human data  
A total of 9 LLNAs, 5 GPMTs and 1 Buehler test were identified testing skin sensitising effects of 
geraniol. The reported EC3 values for geraniol ranged between 5.6% and 25.8% in different 
vehicles.  In the GPMTs sensitisation was observed but not quantified (i.e. number of animals 
affected) in 4/5 studies with intradermal induction doses of 0.1, 5 and 10% geraniol. No 
sensitisation was observed in 1/5 GMPTs with an induction concentration of 50% geraniol and in 
the Buehler test with an induction concentration of 15% geraniol. 
No relevant in vitro studies on geraniol (i.e. OECD TG 442C and OECD TG 442D) were identified in 
the literature. 
 
Exposure 
According to data from IFRA (2007) the exposure of geraniol when used as fragrance in cosmetics 
and in other consumer products appears to be relatively low. A recent study has indicated that up to 
0.86% of the population might be exposed to geraniol from personal care products and household 
cleaning agents at levels exceeding the estimated Acceptable Exposure Level of 55 µg/cm2 (Nijkamp 
et al., 2015).  
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Comparison with criteria 
For unselected/consecutive dermatitis patients positive reactions range between 0 and 1.2% with 
2/10 studies reporting frequencies higher than 1%. For selected dermatitis patients positive 
reactions range between 0 and 40% with 44 out of 74 studies reporting frequencies higher than 2%. 
In addition to this there are more than 900 published cases of positive patch test reactions to 
geraniol. According to the CLP criteria a frequency ≥ 1% for unselected/consecutive dermatitis 
patients and/or ≥ 2% for selected dermatitis patients and/or a total number of published cases ≥ 
100, equals a high frequency of occurrence of skin sensitisation (Table 3.4.2-b) (ECHA, 2015). The 
collected data described above from patch test studies show that geraniol causes a high frequency of 
occurrence of skin sensitisation based on patch test data mainly from selected dermatitis patients 
and the number of published cases.  
In regard to the HRIPT/HMT data the positive response reported at > 500 µg/cm2 for HRIPT/HMT 
induction threshold indicate classification of geraniol in sub-category 1B according to Annex I: 
3.4.2.2.2.2. 
 
In the LLNAs EC3 values between 5.6 (vehicle: ethanol) and 25.8% (vehicle: ethanol:diethyl 
phthalate 1:3) were reported for geraniol. According to the CLP Regulation an EC3 value larger than 
2% indicates classification of geraniol in sub-category 1B.  
 
In the GPMTs sensitisation was reported to be observed but not quantified (i.e. number of animals 
affected) in 4/5 studies with intradermal induction doses of 0.1, 5 and 10% geraniol, therefore, these 
GPMTs cannot be compared with the classification criteria.  
 
No sensitisation was observed in the Buehler test with an induction concentration of 15% geraniol. 
 
Overall, there is clear evidence for classification in sub-category 1A based on the frequency of 
sensitisation in human patch test studies mainly with selected dermatitis patients and the total 
number of cases combined with the estimated relatively low exposure. Data from HRIPT/HMT 
indicate evidence for sub-category 1B. LLNAs indicate a classification in sub-category 1B. A 
classification as a skin sensitiser in sub-category 1A is warranted for geraniol. 
 
Conclusions on classification and labelling 
Based on the high frequency of sensitisation observed in human patch test studies and the high 
number of published cases, combined with the estimated relatively low exposure, a classification of 
geraniol as a skin sensitiser in sub-category 1A is justified.  
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Appendix 11 7-Hydroxycitronellal CAS RN 107-75-5 
Non-human information 
Table 1 summarises relevant animal studies with 7-hydroxycitronellal i.e. Local Lymph Node Assays 
(LLNAs), Guinea Pig Maximization tests (GPMTs) and Buehler tests. 
  
Table 1. Animal studies with 7-hydroxycitronellal. 
Method Results Remarks/Comments Reference 
LLNA: 
Ex vivo BrdU. 0.5, 1, 
5 and 10% 7-
hydroxycitronellal.  
Vehicle: 4:1 
Acetone:Olive oil 
(AOO). 
7-
hydroxycitronellal 
was shown to 
have an EC3 value 
of 9.8%. 
 Ulker et al. 
(2014). 
LLNA: 1, 3, 10, 30 
and 50% 7-
hydroxycitronellal. 
Vehicle: 1:3 
ethanol:diethyl 
phthalate 
(EtOH:DEP). 
7-
hydroxycitronellal 
was shown to 
have an EC3 value 
of 19.3% (1.12 
M). 
According to SCCS 
(2012) there were no 
reported deviations 
from OECD TG 429. 
Unpublished 
summary 
report by 
RIFM 2009 
(RIFM 2001n) 
cited from 
SCCS (2012). 
LLNA: 1, 3, 10, 30 
and 50% 7-
hydroxycitronellal. 
Vehicle: DEP. 
7-
hydroxycitronellal 
was shown to 
have an EC3 value 
of 19.7% (1.14 
M). 
According to SCCS 
(2012) there were no 
reported deviations 
from OECD TG 429. 
Unpublished 
summary 
report by 
RIFM 2009 
(RIFM 2001o) 
cited from 
SCCS (2012). 
LLNA: 1, 3, 10, 30 
and 50% 7-
hydroxycitronellal. 
Vehicle: 3:1 
EtOH:DEP. 
7-
hydroxycitronellal 
was shown to 
have an EC3 value 
of 22.2% (1.29 
M). 
According to SCCS 
(2012) there were no 
reported deviations 
from OECD TG 429. 
Unpublished 
summary 
report by 
RIFM 2009 
(RIFM 2001p) 
cited from 
SCCS (2012). 
LLNA: 1, 3, 10, 30 
and 50% 7-
hydroxycitronellal. 
Vehicle: EtOH. 
7-
hydroxycitronellal 
was shown to 
have an EC3 value 
of 26.4% (1.53 
M). 
According to SCCS 
(2012) there were no 
reported deviations 
from OECD TG 429. 
Unpublished 
summary 
report by 
RIFM 2009 
(RIFM 2001q) 
cited from 
SCCS (2012). 
LLNA: 2.5, 5, 10, 25 
and 50% 7-
hydroxycitronellal. 
Vehicle: 4:1 AOO. 
7-
hydroxycitronellal 
was shown to 
have an EC3 value 
of 33% (1.92 M). 
According to SCCS 
(2012) there were no 
reported deviations 
from OECD TG 429. 
Basketter et 
al., 2001 cited 
from SCCS 
(2012). 
LLNA: 10 and 25% 7- 7- 7-hydroxycitronellal Smith and 
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hydroxycitronellal. 
Vehicle: 4:1 AOO. 
hydroxycitronellal 
was shown to 
have an EC3 value 
of 23% (1.34 M). 
was only tested in two 
concentrations. 
Hotchkiss 
2001 cited 
from SCCS 
(2012). 
GPMT: 
Intradermal induction 
0.5% 7-
hydroxycitronellal;  
Topical induction 
100% 7-
hydroxycitronellal;  
Challenge dose 50% 
7-hydroxycitronellal. 
Vehicle: 70:30 
acetone:polyethylene 
glycol 400. 
60% of the 
animals were 
positive (total 
number of animals 
not reported). 
According to REACH- 
RD (2015a) the study 
is reliable with 
restrictions (reliability 
2) and performed 
according to 
Magnusson and 
Kligman (1970). 
Basketter and 
Scholes 1992 
cited from 
REACH-RD 
(2015a). 
Buehler: 
Induction 
concentration 10 and 
30% 7-
hydroxycitronellal;  
Challenge dose 3 and 
10% 7-
hydroxycitronellal. 
Vehicle: EtOH 
(induction), acetone 
(challenge). 
30% induction: 
3/8 (38%) animals 
showed sensitising 
effects. 
10% induction: 
0/8 (0%) animals 
showed sensitising 
effects.  
According to REACH-
RD (2015b) the study 
is reliable with 
restrictions (reliability 
2) and performed 
according to Buehler 
(1965). 
Buehler 1985 
cited from 
REACH-RD 
(2015b). 
 
 
A total of 7 LLNAs including 1 LLNA ex vivo BrdU, 1 GPMT and 1 Buehler test with 7-
hydroxycitronellal are summarised in table 1. The reported EC3 values for 7-hydroxycitronellal 
range between 9.8% and 33% both with acetone:olive oil (4:1) as vehicle. In the GPMT sensitisation 
in 60% of the animals (number of animals not reported) after an intradermal induction dose of 
0.5% 7-hydroxycitronellal. Sensitisation was also observed in 38% of the animals in the Buehler test 
with an induction concentration of 30%7-hydroxycitronellal. No sensitisation was observed after 
10% 7-hydroxycitronellal in the Buehler test. 
 
No relevant in vitro studies on 7-hydroxycitronellal (i.e. OECD TG 442C and OECD TG 442D) were 
identified in the literature. 
 
Human information 
Population studies 
Table 2 summarises patch test studies on 7-hydroxycitronellal involving several thousand 
dermatitis patients from various countries in Europe and Asia. Most of the studies are diagnostic 
patch test studies.  
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Table 2. Population studies with 7-hydroxycitronellal. 
Method Results Remarks/Comments Reference 
Patch test: 
Retrospective study 
of 806 selected 
patients patch 
tested with 7-
hydroxycitronellal 
1% in petrolatum 
(pet.). 
77/806 (9.6%) 
patients were 
positive.  
A retrospective study 
on patch test data 
from multicentre 
project IVDK 
(Information Network 
of Departments of 
Dermatology) (2007-
2009). 
 
Schnuch et al. 
(2015). 
Patch test: 
Retrospective study 
of 1951 selected 
eczema patients 
patch tested with 
7-hydroxycitronellal 
in 2% pet.  
20/1951 (1%, 
95% CI: 0.6-
1.4%) patients 
were positive. 
A retrospective study 
on patch test data at 
St John’s Institute of 
Dermatology at St 
Thomas’ Hospital, UK 
(2011-2012). 
Mann et al. 
(2014). 
Patch test: 
Retrospective study 
of 940 selected 
patients tested with 
7-hydroxycitronellal 
in pet. 
Concentration not 
reported. 
24/940 (2.6%) 
patients were 
positive. 
A retrospective study 
on patch test data 
from Department of 
Dermatology, 
University Hospital St 
Rafaël, Belgium (1990-
2011). 
Nardelli et al. 
(2013). 
Patch test: 
Prospective study 
of 100 selected 
patients with 
contact allergy 
patch tested with 
7-hydroxycitronellal 
in pet. 
Concentration not 
reported. 
8/100 (8%, 95% 
CI: 3.52-15.16%) 
patients were 
positive. 
Single-centre, double-
blind prospective 
experimental 
longitudinal volunteer 
study at the 
department of 
Dermatology of the VU 
University Medical 
Centre, The 
Netherlands (2005-
2010). 
Nagtegaal et al. 
(2012). 
Patch test: 
Retrospective study 
of 1498 
consecutive 
eczema patients 
patch tested with 
7-hydroxycitronellal 
in 1% pet. 
13/1498 (0.9 %) 
patients were 
positive. 
A retrospective study 
of patch test data at 
Department of 
Dermato-Allergology, 
Copenhagen University 
Hospital Gentofte, 
Denmark (2008-2010).   
Heisterberg et 
al. (2011) and 
Heisterberg et 
al. (2012) 
(corrigendum). 
Patch test: 
Retrospective study 
of 157 selected 
patients (chosen 
out of 509 patients 
Ca. 31/157 (ca. 
20%) patients 
were positive. 
A retrospective study 
of patch test data at 
the Allergy Clinic of the 
Department of 
Dermatology and 
Turcic et al. 
(2011). 
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positive to 
fragrance 
allergens) patch 
tested with 7-
hydroxycitronellal 
in 1% pet. 
Venereology, Zagreb 
University Hospital 
Center and School of 
Medicine, Zagreb, 
Croatia (2001-2005).   
Patch test: 
Retrospective study 
of 86 selected 
patients patch 
tested with 7-
hydroxycitronellal 
in 5% pet.  
6/86 (7%) 
patients were 
positive.  
A retrospective and 
descriptive analysis of 
a patch test study at 
the Cutaneous Allergy 
Unit of a tertiary 
referral hospital, Spain 
(2004-2008). 
Cuesta et al. 
(2010). 
Patch test: 
Retrospective study 
of 1214 
consecutive 
patients and 4359 
selected patients 
patch tested with 
7-hydroxycitronellal 
in 1%. 
14/1214 (1.17%, 
95% CI: 0.48-
1.85%) and 
129/4359 (2.95%, 
95% CI: 2.43-
3.47%) patients 
were positive. 
A retrospective study 
on patch test data 
from multicentre 
project IVDK 
(Information Network 
of Departments of 
Dermatology) (2005-
2008). 
Uter et al. 
(2010). 
Patch test: 
Prospective study 
of 320 selected 
eczema patients 
patch tested with 
7-hydroxycitronellal 
in 2% pet. 
7/320 (2.2%) 
patients were 
positive. 
A prospective analysis 
of selected eczema 
patients at the 
University Medical 
Center in Groningen, 
the Netherlands (2005-
2007). 
van Oosten et 
al. (2009). 
Patch test: 
Retrospective study 
of 153 selected 
patients with a) 
current allergic 
dermatitis or b) 
past allergic 
dermatitis patch 
tested with 7-
hydroxycitronellal 
in 1% pet. 
a) 41/153 
(26.8%) and b) 
49/153 (32.03%) 
patients were 
positive. 
A retrospective study 
of patch test data from 
patients attending the 
Department of 
Cutaneous Allergy at 
St John’s Institute of 
Dermatology, UK 
(1982-2007). 
White (2009). 
Patch test: 
Prospective study 
of 15 selected 
patients with 
eczematous 
reactions from 
ketoprofen-
containing gels 
patch tested with 
0/15 (0%) 
patients were 
positive. 
A prospective study on 
patch test data from 
patients from Italy 
(2006-2007). 
Foti et al. 
(2008). 
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7-hydroxycitronellal 
in 2% pet. 
Patch test: 
Retrospective study 
of 2063 
consecutive 
patients patch 
tested with 7-
hydroxycitronellal 
in 1% pet. 
27/2063 (1.3%, 
95% CI: 0.7-
1.8%) patients 
were positive. 
A retrospective study 
on patch test data 
from multicentre 
project IVDK (2003-
2004). 
Schnuch et al. 
(2007). 
Patch test: 
Retrospective study 
of a) 33 patients 
positive to their 
own deodorant and 
b) 204 negative to 
their own 
deodorant patch 
tested with 7-
hydroxycitronellal 
in 1% pet. 
a) 4/33 (12%) 
and b) 9/204 
(4.4%) patients 
were positive. 
A retrospective study 
on patch test data 
from multicentre 
project IVDK (1998-
2002). 
Uter et al. 
(2007). 
Patch test: 
Retrospective study 
of a) 31 patients 
positive to their 
own shaving 
product/eau de 
toilette/perfume 
and b) 210 
negative to their 
own shaving 
product/eau de 
toilette/perfume, 
patch tested with 
7-hydroxycitronellal 
in 1% pet. 
a) 4/31 (13%) 
and b) 4/210 
(2%) patients 
were positive. 
A retrospective study 
on patch test data 
from multicentre 
project IVDK (1998-
2002). 
Uter et al. 
(2007). 
Patch test: study of 
30 selected 
patients with a 
positive patch test 
to their own 
perfumed product 
patch tested with 
hydroxycitronellal. 
Concentration and 
vehicle not 
reported. 
11/30 (35%) 
patients were 
positive. 
 Vocanson et al. 
(2006). 
Patch test: 
Retrospective study 
127/4900 (2.6%) 
patients were 
A retrospective study 
on patch test data 
Schnuch et al. 
(2002). 
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of 4900 unselected 
patients patch 
tested with 7-
hydroxycitronellal 
in 1% pet. 
positive. In 
addition, 566 
patients had a + 
reaction to FM and 
46 (8%) of them 
were positive to 
hydroxycitronellal 
1 % pet. 425 
patients had 
++/+++ reaction 
to FM and 77 
(18%) were 
positive to 
hydroxycitronellal 
1 % pet.   
from multicentre 
project IVDK (1996-
1999). 
Patch test: 
Retrospective study 
of 160 selected 
patients sensitive 
to FM patch tested 
with 7-
hydroxycitronellal. 
Concentration and 
vehicle not 
reported. 
4/160 (2.5%) 
patients were 
positive. 
A retrospective study 
on patch test data 
from the seven 
members of the 
Hungarian Contact 
Dermatitis Research 
Group (1998-1999). 
Temesvari et al. 
(2002).  
Patch test: 
prospective study 
of 747 selected 
patients with 
suspected 
fragrance allergy 
patch tested with 
7-hydroxycitronellal 
1% in pet. 
11/747 (1.5%) 
patients were 
positive. 
A prospective analysis 
of patients from FAZ-
Floridsdorf Allergy 
Centre, Austria (1997-
2000). 
Wohrl et al. 
(2001). 
Patch test: Study 
of 226 selected 
patients sensitive 
to FM patch tested 
with 7-
hydroxycitronellal 
1% in pet. 
15/226 (6.6%) 
patients were 
positive. 
Department of 
Dermatology, 
University Hospital, 
Coimbra, Portugal 
(1989-1999). 
Brites et al. 
(2000).  
Patch test: Study 
of 1483 selected 
patients with 
suspected cosmetic 
dermatitis patch 
tested with 7-
hydroxycitronellal 
in 5% pet. 
15/1483 (1%) 
patients were 
positive. 
Nagoya, Japan (year 
not stated). 
Sugiura et al., 
2000 cited from 
SCCS (2012). 
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Patch test: 
Retrospective study 
of 50 patients 
sensitive to FM 
patch tested with 
7-hydroxycitronellal 
2% in 1% sorbitan 
sesquioleate. 
10/50 (20%) 
patients were 
positive. 
Retrospective study of 
patch test data. 
University Hospital 
Utrecht, The 
Netherlands (1994-
1998). 
Hendriks and 
van Ginkel 
(1999).  
Patch test: 
Retrospective study 
of 40 patients 
sensitive to FM 
patch tested with 
7-hydroxycitronellal 
in pet. 
Concentration not 
reported. 
1/40 (2.5%) 
patients were 
positive. 
 Katsarma and 
Gawkrodger 
(1999). 
Patch test: Study 
of 11 patients with 
perfume allergy 
patch tested with 
7-
hydroxycitronellal. 
Concentration and 
vehicle not 
reported. 
6/11 (55%) 
patients were 
positive. 
The patients’ cosmetic 
products were 
subjected to chemical 
analysis. The content 
of 7-hydroxycitronellal 
was at average 5 times 
higher in cosmetics 
from 7-
hydroxycitronellal 
sensitive patients 
compared with 7-
hydroxycitronellal 
negative patients. 
Johansen et al., 
1996 cited from 
SCCNFP (1999). 
Patch test: study of 
167 selected 
patients suspected 
of fragrance 
sensitivity patch 
tested with 7-
hydroxycitronellal 
4%. Vehicle not 
reported. 
23/167 (13.8%) 
patients were 
positive. 
 Larsen et al., 
1996 cited from 
SCCNFP (1999). 
Patch test: Study 
of 1072 patients 
patch tested with 
7-hydroxycitronellal 
1% in pet. 
8/1072 (0.75%) 
patients were 
positive. 
European multicentre 
study with 9 different 
centres. 
Frosch et al., 
1995 cited from 
SCCNFP (1999). 
Patch test: 
Retrospective study 
of 367 selected 
patients patch 
tested with 7-
27/367 (7.4%) 
patients were 
positive. 
Retrospective study of 
patch test data from 
Department of 
Dermatology, Gentofte 
Hospital, Denmark 
Johansen and 
Menne (1995). 
  
 
Evaluation of selected sensitizing fragrance substances  191 
Method Results Remarks/Comments Reference 
hydroxycitronellal 
in 1-2% pet.   
(1979-1983 and 1988-
1992). 
Patch test: 
Prospective study 
of 50 selected 
patients positive to 
a fragrance mix 
patch tested with 
7-
hydroxycitronellal. 
Concentration and 
vehicle not 
reported. 
5/50 (10%) 
patients were 
positive. 
Retrospective study of 
patch test data from 
Department of 
Dermatology and 
Venereology, Hungary. 
Year not stated. 
Becker et al. 
(1994). 
Patch test: 
Prospective study 
of 61 selected 
patients positive to 
a fragrance mix 
patch tested with 
7-hydroxycitronellal 
5% in pet. 
12/61 (20%) 
patients were 
positive. 
Control tests in 
100 patients not 
allergic to 
fragrances showed 
no positive 
reactions when 
tested with 7-
hydroxycitronellal 
5% pet. 
Prospective study of 
patch test data from 
University of 
Amsterdam and 
University of Leiden, 
The Netherlands 
(1987). 
 
de Groot et al. 
(1993). 
 
Patch test: 
Prospective study 
of 162 selected 
patients positive to 
a fragrance mix 
patch tested with 
7-hydroxycitronellal 
1% in pet. 
10/162 (6.2%) 
patients were 
positive. 
Prospective study of 
patch test data from 
Dermatologische Klinik 
und Poliklinik, 
Germany (1991). 
Enders et al. 
(1989).  
Patch test: Study 
of 78 selected 
patients sensitive 
to FM patch tested 
with 7-
hydroxycitronellal 
5%. Vehicle not 
reported. 
7/78 (9%) 
patients were 
positive. 
Multicentre study 
involving 6 countries. 
Year not stated. 
Wilkinson et al., 
1989 cited from 
SCCNFP (1999). 
Patch test: Study 
of 156 selected 
patients with pure 
contact allergy to 
cosmetic products 
patch tested with 
7-
hydroxycitronellal. 
6/156 (3.8%) 
patients were 
positive. 
 Broneck et al., 
1987 cited from 
SCCNFP (1999). 
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Concentration and 
vehicle not 
reported. 
Patch test: 
Retrospective study 
of 63 selected 
patients with 
dermatitis tested 
positive to perfume 
mixture patch 
tested between 
1983 and 1984 
with 7-
hydroxycitronellal 
in 5% pet. and 54 
selected patients 
with dermatitis 
tested positive to 
perfume mixture 
patch tested 
between 1984 and 
1985 with 7-
hydroxycitronellal 
in 1% pet. 
Between 1983 and 
1984 13/63 (21%) 
and between 1984 
and 1985 9/54 
(16%) patients 
were positive. 
Retrospective study of 
patch test data from 
Istituto Dermatologico 
Santa Maria e San 
Gallicano, Italy (1983-
1985). 
Santucci et al. 
(1987). 
Patch test: 
Retrospective study 
of 403 selected 
patients with 
cutaneous 
reactions to 
cosmetic products 
patch tested with 
7-
hydroxycitronellal. 
Concentration and 
vehicle not 
reported. 
7/403 (1.7%) 
patients were 
positive. 
The number of patients 
is not clearly stated in 
the article by Adams & 
Maibach 1985. 
Adams and 
Maibach (1985). 
Patch test: 
Prospective study 
of 182 selected 
patients suspected 
of contact allergy 
to cosmetics patch 
tested with 7-
hydroxycitronellal 
10%. Vehicle not 
reported. 
19/182 (10.5%) 
patients were 
positive. 
 Malten et al.,,, 
1984 cited from 
SCCNFP (1999). 
Patch test: study of 
20 selected 
perfume allergic 
9/20 (45%) 
patients were 
positive. 
 Larsen et al., 
1977 cited from 
SCCNFP (1999). 
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patients patch 
tested with 7-
hydroxycitronellal 
in 4%. 
Patch test and 
ROAT1: 13 7-
hydroxycitronellal-
sensitive patients 
were tested with 10 
and 250 mg/kg of 
7-hydroxycitronellal 
in 10% ethanol in a 
patch test and a 
ROAT.   
10 mg/kg: 1/13 
(8%) positive and 
250 mg/kg: 5/13 
(38%) positive. 
Vehicle control: 
4/13 (31%) 
positive. 
 Heydorn et al., 
2003 cited from 
SCCS (2012). 
Patch test and 
ROAT1: 7 7-
hydroxycitronellal-
sensitive patients 
and 7 controls were 
tested with a 
dilution series from 
4 to 0.00006% (17 
steps) of 7-
hydroxycitronellal 
in a patch test and 
a ROAT.   
Step 1: 57% 
positive, Step 2: 
71% positive and 
Step 3: 100% 
positive reactions 
were observed. No 
positive reactions 
observed in patch 
test <0.00012% 
(0.036 µg/cm2). 
 Svedman et al., 
2003 cited from 
SCCNFP (1999). 
1ROAT: Repeated Open Application Test 
 
Table 3 summarises Human Repeat Insult Patch Tests (HRIPTs) and Human Maximisation Tests 
(HMTs) with 7-hydroxycitronellal.  
 
Table 3. HRIPT and HMT studies with 7-hydroxycitronellal. 
Method Results Remarks/Comments Reference 
Modified HRIPT: 
7-hydroxycitronellal 
concentration: 2.5% 
Vehicle: 3:1 
ethanol:diethyl 
phthalate 
(EtOH:DEP). 
0/65 (0%) 
tests were 
positive. 
 Ford et al. 
(1988). 
Modified HRIPT: 
7-hydroxycitronellal 
concentration: 5% 
Vehicle: 3:1 
EtOH:DEP. 
1/66 (2%) 
tests were 
positive. 
 Ford et al. 
(1988). 
Modified HRIPT: 
7-hydroxycitronellal 
concentration: 7.5% 
Vehicle: 3:1 
1/66 (2%) 
tests were 
positive. 
 Ford et al. 
(1988). 
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EtOH:DEP.  
Modified HRIPT: 
7-hydroxycitronellal 
concentration: 2.5 
or 5%  
Vehicle: 3:1 
EtOH:DEP. 
33/100 (33%) 
tests were 
positive. 
The test was performed 
in 100 of the subjects 
that had completed the 
three HRIPTs described 
directly above. 
Ford et al. 
(1988). 
HMT: 
7-hydroxycitronellal 
concentration: 5%  
Vehicle: petrolatum 
(pet.).  
0/26 (0%) 
tests were 
positive. 
 Unpublished data 
(Epstein 1976) 
cited from Ford et 
al. (1988). 
HMT: 
7-hydroxycitronellal 
concentration: 5%  
Vehicle: pet.  
0/25 (0%) 
tests were 
positive. 
Males only Unpublished data 
(Kligman 1973) 
cited from Ford et 
al. (1988). 
HMT: 
7-hydroxycitronellal 
concentration: 10%  
Vehicle: pet.  
2/25 (8%) 
tests were 
positive. 
 Unpublished data 
(Kligman 1976) 
cited from Ford et 
al. (1988). 
HMT: 
7-hydroxycitronellal 
concentration: 10%  
Vehicle: pet.  
0/25 (0%) 
tests were 
positive. 
 Unpublished data 
(Kligman 1976) 
cited from Ford et 
al. (1988). 
HMT: 
7-hydroxycitronellal 
concentration: 12%  
Vehicle: pet.  
 
4/27 (15%) 
tests were 
positive. 
 Unpublished data 
(Epstein 1978) 
cited from Ford et 
al. (1988). 
HMT: 
7-hydroxycitronellal 
concentration: 12%  
Vehicle: pet.  
0/25 (0%) 
tests were 
positive. 
 Unpublished data 
(Kligman 1978) 
cited from Ford et 
al. (1988). 
HMT: 
7-hydroxycitronellal 
concentration: 12%  
Vehicle: pet.  
7/26 (27%) 
tests were 
positive. 
 Unpublished data 
(Epstein 1979) 
cited from Ford et 
al. (1988). 
HMT: 
7-hydroxycitronellal 
concentration: 12%  
Vehicle: pet.  
6/26 (23%) 
tests were 
positive. 
 Unpublished data 
(Epstein 1979) 
cited from Ford et 
al. (1988). 
HMT: 
7-hydroxycitronellal 
concentration: 12%  
Vehicle: pet.  
0/25 (0%) 
tests were 
positive. 
7-hydroxycitronellal 
purified from α-pinene 
Unpublished data 
(Kligman 1979) 
cited from Ford et 
al. (1988). 
HMT: 3/25 (12%) 7-hydroxycitronellal Unpublished data 
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7-hydroxycitronellal 
concentration: 12%  
Vehicle: pet.  
tests were 
positive. 
purified from d-
stereoisomer 
(Kligman 1979) 
cited from Ford et 
al. (1988). 
HMT: 
7-hydroxycitronellal 
concentration: 12%  
Vehicle: pet.  
0/25 (0%) 
tests were 
positive. 
7-hydroxycitronellal 
purified from l-
stereoisomer 
Unpublished data 
(Kligman 1979) 
cited from Ford et 
al. (1988). 
HMT: 
Pseudo 7-
hydroxycitronellal 
concentration: 12%  
Vehicle: pet.  
1/25 (4%) 
tests were 
positive. 
 Unpublished data 
(Kligman 1979) 
cited from Ford et 
al. (1988). 
HMT: 
7-hydroxycitronellal 
concentration: 12%  
Vehicle: DEP.  
 
2/22 (9%) 
tests were 
positive. 
Lower boiling point 
fraction 
Unpublished data 
(Epstein 1980) 
cited from Ford et 
al. (1988). 
HMT: 
7-hydroxycitronellal 
concentration: 12%  
Vehicle: DEP.  
1/26 (4%) 
tests were 
positive. 
Higher boiling point 
fraction 
Unpublished data 
(Epstein 1980) 
cited from Ford et 
al. (1988). 
HMT: 
7-hydroxycitronellal 
concentration: 12%  
Vehicle: DEP.  
 
2/21 (10%) 
tests were 
positive. 
According to Ford et al 
1988 7-
hydroxycitronellal was 
“Tested on same panel 
with washed cinnamic 
alcohol.”. 
Unpublished data 
(Epstein 1980) 
cited from Ford et 
al. (1988). 
HRIPT: Human Repeat Insult Patch Test, HMT: Human Maximisation Test. 
 
Case studies 
Table 4 summarises case reports with ACD where 7-hydroxycitronellal has been found to be among 
the causative agents.  
 
Table 4. Case studies with 7-hydroxycitronellal. 
Method Results Remarks/Comments Reference 
Patch test: A 48-
year old male 
metalworker with 
recurrent hand 
dermatitis was 
patch tested with 7-
hydroxycitronellal 
and a long list of 
other allergens.  
7-hydroxycitronellal 
and several other 
allergens tested 
positive. 
Case study  
(Germany, 2007-
2008). 
Tanko et al. 
(2009).  
Patch test: A 52-
year old man with 
contact allergy to 
his after-shave was 
Positive reaction 
was observed.  
 
Case study, (year and 
country not stated). 
De Groot and 
Liem 1983 
cited from 
SCCNFP 
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Method Results Remarks/Comments Reference 
patch tested with 7-
hydroxycitronellal. 
Concentration and 
vehicle not 
reported. 
(1999). 
Patch test: A 32-
year old barber 
with hand eczema 
was patch tested 
with 10% 7-
hydroxycitronellal 
in petrolatum. 
Positive reactions to 
7-
hydroxycitronellal, 
methyl 2-octynoate 
and cinnamyl 
alcohol were 
observed. 
Case study, (year and 
country not stated). 
Van Ketel 
1978 cited 
from SCCNFP 
(1999). 
 
A total of 39 results from patch test population studies, 4 modified HRIPTs, 15 HMTs and 3 case 
studies with 7-hydroxycitronellal are summarised above (Table 2, 3 and 4). As shown in Table 2 the 
positive patch test frequencies from all of the reported patch test population studies vary between 0 
and 55% in dermatitis patients. For unselected/consecutive dermatitis patients, positive reactions 
range between 0.9 and 2.6% (4 studies) and for selected dermatitis patients positive reactions range 
between 0 and 55% (35 studies). The total number of published cases is > 800. Sensitisation was 
reported in 3/4 modified HRIPT studies at 7-hydroxycitronellal concentrations from 2.5 to 7.5% but 
without dose-response.  In the HMT studies, sensitisation was reported in 0/2 tests with 5% 7-
hydroxycitronellal, 1/2 tests with 10% 7-hydroxycitronellal and in 8/11 tests with 12% 7-
hydroxycitronellal. Based on these data the Research Institute for Fragrance Materials, Inc. (RIFM) 
deducted a NOEL-HRIPT16 (induction) of 5000 µg/cm2 and a LOEL-HRIPT/HMT17 (induction) of 
5906 µg/cm2. In addition, based on weight of evidence, a No Expected Sensitization Induction Level 
(NESIL) of 5000 µg/cm2 was established for 7-hydroxycitronellal by the RIFM Expert Panel (IFRA, 
2013c). 
 
According to SCCS (2012) 7-hydroxycitronellal is used in volumes less than 175 ton per year in 
perfume formulations. It has been reported that in consumer products containing fragrance 
allergens that are required to be labelled 10.8% of a total of 516 consumer products; 17% of a total of 
300 consumer products; ca. 8% of 3000 products and 6.3% of children’s cosmetics were labelled to 
contain 7-hydroxycitronellal (Wijnhoven et al., 2008; Buckley, 2007; Schnuch et al., 2009 and 
Poulsen & Schmidt, 2007 cited from SCCS (2012)). In addition, in 2007, 27.3% of 88 tested 
deodorants were labelled to contain 7-hydroxycitronellal and the fragrance was detected in 70% 
(range: 1-1746 mg/kg) of 23 deodorants selected for analysis (Rastogi et al., 2007 cited from SCCS 
(2012)).   
 
The IFRA standard limits for 7-hydroxycitronellal in different IFRA QRA product categories 
reported by IFRA (2013c and 2015) are shown in table 5. 
  
                                                                    
16 NOEL-HRIPT: No Observed Effect Level-Human Repeat Insult Patch Test. 
17 LOEL-HRIPT/HMT: Lowest Observed Effect Level-Human Repeat Insult Patch Test/Human Maximisation test. 
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Table 5. The IFRA standard limits for 7-hydroxycitronellal in IFRA QRA product categories. 
IFRA QRA product 
category 
Product type that drives the 
category consumer exposure 
level 
IFRA standard limits 
Category 1 Lip products 0.1% 
Category 2 Deodorants/antiperspirants 0.2% 
Category 3 Hydroalcoholics for shaved skin 0.8% 
Category 4 Hydroalcoholics for unshaved skin 1.0% 
Category 5 Hand cream 1.0% 
Category 6 Mouthwash 3.6% 
Category 7 Intimate wipes 0.4% 
Category 8 Hair styling aids 1.0% 
Category 9 Rinse-off hair conditioners 1.0% 
Category 10 Hard surface cleaners 1.0% 
Category 11 Candles Not restricted 
IFRA: International Fragrance Association, QRA: Quantitative Risk Assessment. 
 
7-Hydroxycitronellal is registered under the REACH regulation with an annual tonnage band of 100 
- 1000 tonnes per annum. 
 
Summary and discussion of skin sensitization 
Human data 
A total of 39 results from patch test population studies, 4 modified HRIPTs, 15 HMTs and 3 case 
studies were identified with 7-hydroxycitronellal. The positive patch test frequencies from all of the 
reported patch test population studies vary between 0 and 55% in dermatitis patients. In studies 
with unselected/consecutive dermatitis patients positive reactions range between 0.9 and 2.6% (4 
studies) and in studies with selected dermatitis patients positive reactions range between 0 and 55% 
(35 studies). The total number of published cases is > 800. A LOEL-HRIPT/HMT (induction) of 
5906 µg/cm2 was established for 7-hydroxycitronellal by the RIFM Expert Panel.  
 
Non-human data  
A total of 7 LLNAs including 1 LLNA ex vivo BrdU, 1 GPMT and 1 Buehler test were identified 
testing skin sensitising effects of 7-hydroxycitronellal. The reported EC3 values for 7-
hydroxycitronellal range between 9.8 and 33%. In the GPMTs sensitisation was observed but not 
quantified (i.e. number of animals affected) in 3/6 studies with intradermal induction doses of 0.4, 
5 and 10% citral. In the GPMT sensitisation in 60% of the animals (number of animals not 
reported) after an intradermal induction dose of 0.5% 7-hydroxycitronellal. Sensitisation was also 
observed in 38% of the animals in the Buehler test with an induction concentration of 30% 7-
hydroxycitronellal. 
 
No relevant in vitro studies on 7-hydroxycitronellal (i.e. OECD TG 442C and OECD TG 442D) were 
identified in the literature. 
 
Exposure 
According to data from IFRA (2013c) the exposure of 7-hydroxycitronellal when used as fragrance 
in cosmetics and in other consumer products appears to be low.    
 
Comparison with criteria 
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For unselected/consecutive dermatitis patients positive reactions range between 0.9 and 2.6% with 
1/4 studies reporting frequencies higher than 1%. For selected dermatitis patients positive reactions 
range between 0 and 55% with 29 out of 33 studies reporting frequencies equal to or higher than 
2%. In addition to this there are more than 800 published cases of positive patch test reactions to 7-
hydroxycitronellal. According to the CLP criteria a frequency ≥ 1% for unselected/consecutive 
dermatitis patients and/or ≥ 2% for selected dermatitis patients and/or a total number of published 
cases ≥ 100, equals a high frequency of occurrence of skin sensitisation (Table 3.4.2-b). The 
collected data described above from patch test studies show that 7-hydroxycitronellal causes a high 
frequency of occurrence of skin sensitisation based on these three types of information.  
In regard to the HRIPT/HMT data the positive response reported at > 500 µg/cm2 for HRIPT/HMT 
induction threshold indicate evidence for sub-category 1B according to Annex I: 3.4.2.2.2.2.  
 
In the seven LLNAs EC3 values between 9.8 and 33% were reported for 7-hydroxycitronellal. 
According to the CLP Regulation an EC3 value  2% indicates classification of a substance in sub-
category 1A whereas an EC3 value > 2% indicates classification of a substance in sub-category 1B 
(Annex I: 3.4.2.2.3.2.). Thus, all seven studies indicate classification of 7-hydroxycitronellal in sub-
category 1B.  
 
In the GPMT sensitisation was observed in 60% of the animals after an intradermal induction dose 
of 0.5% 7-hydroxycitronellal. According to the CLP criteria a positive response ≥ 60% of the animals 
responding at >0.1% to ≤ 1% intradermal induction dose indicates classification of a substance in 
sub-category 1A (Annex I: 3.4.2.2.3.2.) and thus, this study indicates classification of 7-
hydroxycitronellal into sub-category 1A.  
 
Sensitisation was also observed in 38% of the animals in a Buehler test with an induction 
concentration of 30% 7-hydroxycitronellal. According to the CLP criteria a positive response ≥ 15% 
of the animals responding at >20% topical induction dose indicates classification of a substance in 
sub-category 1B (Annex I: 3.4.2.2.3.3.) and thus, this study indicates classification of 7-
hydroxycitronellal into sub-category 1B. 
 
Overall, there is clear evidence for classification in sub-category 1A based on the human patch test 
studies showing a high frequency of occurrence of skin sensitisation and the total number of cases 
combined with the estimated low exposure. Except from the GMTP study, which supports a sub-
category 1A classification, the remaining animal studies (LLNA and Buehler) indicate a 
classification in sub-category 1B. A classification as a skin sensitiser in sub-category 1A is thus 
warranted for 7-hydroxycitronellal. 
 
Conclusions on classification and labelling 
Based on the high frequency of sensitisation observed in human patch test studies and the high 
number of published cases combined with the estimated low exposure a classification of 7-
hydroxycitronellal as a skin sensitiser in sub-category 1A is justified.  
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Appendix 12 Methyl oct-2-ynate CAS RN 111-12-6 
Non-human information 
Table 1 summarises relevant animal studies with methyl oct-2-ynate i.e. Local Lymph Node Assays 
(LLNAs), Guinea Pig Maximization Tests (GPMTs) and Buehler tests.  
 
Table 1. Animal studies with methyl oct-2-ynate. 
Method Results Remarks/Comments Reference 
LLNA, according 
to OECD test 
guideline 429.  
Methyl oct-2-
ynate was shown 
to have an EC3 
value of 0.45%. 
The reaction 
mechanistic domain 
was reported to be the 
Michael receptor. 
Unpublished 
report by RIFM 
2006 cited from 
Kern et al. 
(2010). 
LLNA, according 
to OECD test 
guideline 429. 
0.5, 1, 2, 5 and 
10% methyl oct-
2-ynate. 
Vehicle not 
reported. 
Methyl oct-2-
ynate was shown 
to have an EC3 
value of <0.5% 
(<0.032 M). 
Methyl oct-2-ynate 
should also have been 
tested at lower 
concentrations. 
Unpublished 
report by RIFM 
2005k cited from 
SCCS (2012). 
GPMT, 
intradermal 
induction 0.625, 
5 and 10%; 
topical induction 
1, 3 and 30%; 
challenge 0.3, 
0.9 and 3% 
methyl oct-2-
ynate. 
Vehicle not 
reported. 
18/20 (90%) at 
the least severe 
and middle 
regimens and 
20/20 (100%) at 
the most severe. 
No further information 
was available from 
Hostynek and Maibach 
(2006). 
Unpublished 
report by Buehler 
et al., 1985 cited 
from Hostynek 
and Maibach 
(2006). 
Buehler test, 
induction dose 
2.5% with 
challenge doses 
of 0.5, 1.5 and 
5% methyl oct-2-
ynate. 
Vehicle not 
reported. 
Positive reactions 
in 9/20 (45%), 
12/20 (60%) and 
14/20 (70%) at 
challenge doses of 
0.5, 1.5 and 5% 
methyl oct-2-
ynate, 
respectively. 
No further information 
was available from 
Hostynek and Maibach 
(2006). 
Unpublished 
report by Buehler 
et al., 1986 cited 
from Hostynek 
and Maibach 
(2006). 
 
A total of 2 LLNAs (OECD TG 429), 1 GPMT and 1 Buehler test with methyl oct-2-ynate are 
summarised in table 1. In both LLNA studies an EC3 value of <0.5% was reported. In the GPMT 
sensitisation was observed in 90 % of the animals after an intradermal induction dose of 0.625% 
methyl oct-2-ynate. Sensitisation was also observed in the Buehler test with positive reactions in 45-
70% of the animals after an induction dose of 2.5%  
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According to the review by Hostynek and Maibach (2006) several other (mostly unpublished) 
animal tests including open and closed epicutaneous tests, Draize tests, a Maguire test, a Freund’s 
Complete Adjuvant Test and an additional GPMT testing the sensitising potential of methyl oct-2-
ynate exist. However, these tests were either not relevant for the purpose of sub-categorisation or 
considered by Hostynek and Maibach (2006) to be of poor quality and are not reported here. 
 
No relevant in vitro studies on methyl oct-2-ynate (i.e. OECD TG 442C and OECD 442D) were 
identified in the literature.  
 
Human Studies 
Population studies 
Table 2 summarises patch test studies on methyl oct-2-ynate involving several thousand dermatitis 
patients from various countries in Europe and the US. Most of the studies are diagnostic patch test 
studies.  
 
Table 2. Population studies with methyl oct-2-ynate. 
Method Results Remarks/Comments Reference 
Patch test: 
Retrospective 
study of 1870 
patients patch 
tested with methyl 
oct-2-ynate. 
Concentration and 
vehicle not 
reported. 
3/1870 (0.16%) 
patients were 
positive.  
A retrospective study 
on patch test data from 
multicentre project 
IVDK (Information 
Network of 
Departments of 
Dermatology) (2007-
2009). 
Schnuch et al. 
(2015). 
Patch test: 
Retrospective and 
descriptive study 
of 1951 eczema 
patients patch 
tested with methyl 
oct-2-ynate 1% in 
petrolatum (pet.). 
3/1951 (0.15%, 
95% CI: 0.0-
0.3%) patients 
were positive. 
A retrospective study 
on patch test data at 
St John’s Institute of 
Dermatology at St 
Thomas’ Hospital, UK 
(2011-2012). 
Mann et al. 
(2014). 
Patch test: 
Retrospective and 
descriptive study 
on 211 eczema 
patients tested 
with methyl oct-2-
ynate 1% in pet. 
1/211 (0.5%) 
patients were 
positive.  
Active 
sensitisation was 
observed in two 
patients and the 
testing was 
stopped.   
Retrospective 
descriptive analysis of 
a patch test study at 
Gentofte Hospital, 
Denmark (2008-2010).   
Heisterberg et al. 
(2011). 
Patch test: Study 
of 230 consecutive 
eczema patients 
patch tested with 
methyl oct-2-
ynate 1% in pet. 
0/230 (0%) 
patients were 
positive. 
Retrospective 
descriptive analysis of 
a patch test study at 
Gentofte Hospital, 
Denmark (2007-2008).  
Heisterberg 
(2010). 
Patch test: Study 
of 120 consecutive 
2/120 (1.67%) 
patients were 
Retrospective 
descriptive analysis of 
Heisterberg 
(2010). 
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Method Results Remarks/Comments Reference 
eczema patients 
patch tested with 
methyl oct-2-
ynate 2% in pet. 
positive. a patch test study at 
the department of 
Dermatologie at CHU 
Saint Jacques, France. 
Patch test: Study 
of 988 selected 
patients tested 
with methyl oct-2-
ynate 1% in pet.  
1/988 (0.1%, 
95% CI: 0-0.2%) 
patients were 
positive. 
A retrospective study 
on patch test data from 
multicentre project 
IVDK (Information 
Network of 
Departments of 
Dermatology) (2005-
2008). 
Uter et al. 
(2010). 
Patch test: Study 
of 320 selected 
eczema patients 
patch tested with 
methyl oct-2-
ynate 0.5% in pet. 
1/320 (0.3%) 
patients were 
positive. 
Retrospective analysis 
of a patch test study at 
the University Medical 
Center in Groningen, 
the Netherlands (2005-
2007). 
van Oosten et al. 
(2009). 
Patch test: Study 
of 2401 
unselected 
patients patch 
tested with methyl 
oct-2-ynate 1% in 
pet. 
6/2401 (0.2%, 
95% CI: 0.0-
0.4%) patients 
were positive. 
A retrospective study 
on patch test data from 
multicentre project 
IVDK (Information 
Network of 
Departments of 
Dermatology) (2003-
2004). 
Schnuch et al. 
(2007). 
Patch test: Study 
of 182 patients 
suspected of 
contact allergy to 
cosmetics patch 
tested with 0.5% 
methyl oct-2-
ynate.  
Vehicle not 
reported. 
2/182 (1.1%) 
patients were 
positive. 
 Unpublished 
report by Malten 
et al., 1984 cited 
from SCCNFP 
(1999). 
Patch test: Study 
of 34 patients with 
allergic contact 
dermatitis to 
cosmetics patch 
tested with 0.5% 
methyl oct-2-
ynate. Vehicle not 
reported. 
1/34 (2.9%) 
patients were 
positive. 
Pilot study performed 
prior to the study 
described directly 
above. 
Unpublished 
report by Malten 
et al., 1984 cited 
from SCCNFP 
(1999). 
Patch test: Study 
of 278 patients 
patch tested with 
1% methyl oct-2-
1/278 (0.4%) 
patients were 
positive. 
A study performed by 
the North American 
Contact Dermatitis 
Research Group. 
Unpublished 
report by Mitchell 
et al., 1982 cited 
from SCCNFP 
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Method Results Remarks/Comments Reference 
ynate. Vehicle not 
reported. 
(1999). 
 
Case studies 
Table 3 summarises case reports with allergic contact dermatitis in different clinics in Europe where 
methyl oct-2-ynate has been found as a causative agent.  
 
Table 3. Case studies with methyl oct-2-ynate. 
Method Results Remarks/Comments Reference 
Patch test: A 42-
year old woman 
under 
investigation for 
postsurgical 
1ACD and with a 
previous reaction 
towards 
deodorants was 
patch tested with 
2% methyl oct-
2-ynate in 
petrolatum 
(pet.). 
Delayed positive 
reaction on D16 was 
observed. 
Case study, France 
(year not stated). 
Heisterberg 
(2010). 
Patch test: A 28-
year old woman 
with facial 
eczema was 
tested and 
repeat tested 
with 1% methyl 
oct-2-ynate in 
pet.  
Delayed positive 
reaction on D20 and 
on D2 (1+) in the 
repeat test was 
observed. 
Case study, Denmark 
(year not stated). 
Heisterberg 
(2010). 
Patch test: A 21-
year old woman 
suspected of 
occupational 
hand eczema 
was patch tested  
and repeat 
tested with 1% 
methyl oct-2-
ynate in pet. 
Delayed positive 
reaction 4 weeks 
after first test and 
positive reaction on 
D2 (2+) in the 
repeat test was 
observed. 
Case study, Denmark 
(year not stated). 
Heisterberg 
(2010). 
Patch test: A 19-
year old woman 
with work-
related 1ACD was 
patch tested with 
1% methyl oct-
2-ynate in 
Positive reaction on 
D2 was observed. 
Case study, UK (1985). English and 
Rycroft (1988). 
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Method Results Remarks/Comments Reference 
methyl ethyl 
ketone. 
Patch test: A 32-
year old man 
with hand 
eczema was 
patch tested with 
0.5% methyl oct-
2-ynate in pet. 
Positive reactions to 
methyl oct-2-ynate, 
7-hydroxycitronellal 
and cinnamyl 
alcohol were 
observed. 
Case study, (year and 
country not stated). 
Van Ketel 
(1978) cited 
from SCCNFP 
(1999). 
1ACD: Allergic Contact Dermatitis. 
 
A total of 11 results from patch test population studies and 5 cases with methyl oct-2-ynate are 
summarised above (Table 2 and 3). As shown in Table 2 the positive patch test frequencies from all 
of the reported patch test population studies vary between 0 and 2.9% in dermatitis patients. For 
unselected/consecutive dermatitis patients, positive reactions range between 0 and 1.67% (3 
studies) and for selected dermatitis patients positive reactions range between 0.1 and 2.9% (8 
studies). The total number of published cases is > 25. The Research Institute for Fragrance 
Materials, Inc. (RIFM) deducted a NOEL-HRIPT18 (induction) of 118 µg/cm2 and a LOEL-
HRIPT/HMT19 (induction) of 194 µg/cm2. In addition, based on weight of evidence, a No Expected 
Sensitization Induction Level (NESIL) of 110 µg/cm2 was established for methyl oct-2-ynate by the 
RIFM Expert Panel (IFRA, 2008d). 
 
One of the case studies reports three individual cases (table 3) (Heisterberg, 2010). In these cases 
late patch test reactions (after 2-4 weeks) were observed. Positive repeat tests in two of these cases 
were reported indicating active sensitization (i.e. the subjects were sensibilized by the patch test). 
The third case was not repeat patch tested. 
 
SCCS (2012) describes methyl oct-2-ynate as an extreme but rare allergen. 
 
According to SCCS (2012) methyl oct-2-ynate is used in volumes less than 175 ton per year in 
perfume formulations. It has been reported that in consumer products containing fragrance 
allergens that are required to be labelled 1.1% of 88 tested deodorants (in 2007), 1% of a total of 516 
consumer products; 0% of a total of 300 consumer products; ca. 0.5% of 3000 products and 0% of 
children’s cosmetics were labelled to contain citral (Wijnhoven et al., 2008; Buckley, 2007; Schnuch 
et al., 2009 and Poulsen & Schmidt, 2007 cited from SCCS (2012)). Based on these data SCCS 
(2012) concluded that methyl oct-2-ynate was among the least used fragrance ingredients in 
cosmetics and other consumer products.     
 
The IFRA standard limits for methyl oct-2-ynate in different IFRA QRA product categories reported 
by IFRA (2008d and 2015) are shown in table 4. 
  
                                                                    
18 NOEL-HRIPT: No Observed Effect Level-Human Repeat Insult Patch Test. 
19 LOEL-HRIPT/HMT: Lowest Observed Effect Level-Human Repeat Insult Patch Test/Human Maximisation test. 
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Table 4. The IFRA standard limits for methyl oct-2-ynate in IFRA QRA product categories. 
IFRA QRA product 
category 
Product type that drives the 
category consumer exposure 
level 
IFRA standard limits 
Category 1 Lip products 0.003% 
Category 2 Deodorants/antiperspirants 0.004% 
Category 3 Hydroalcoholics for shaved skin 0.01% 
Category 4 Hydroalcoholics for unshaved 
skin 
0.01% 
Category 5 Hand cream 0.01% 
Category 6 Mouthwash 0.08% 
Category 7 Intimate wipes 0.008% 
Category 8 Hair styling aids 0.01% 
Category 9 Rinse-off hair conditioners 0.01% 
Category 10 Hard surface cleaners 0.01% 
Category 11 Candles Not restricted 
IFRA: International Fragrance Association, QRA: Quantitative Risk Assessment. 
 
Methyl oct-2-ynate is not registered under the REACH regulation. 
 
Summary and discussion of skin sensitization 
Human data 
A total of 11 results from patch test population studies and 5 case studies were identified with 
methyl oct-2-ynate. The positive patch test frequencies from all of the reported patch test 
population studies vary between 0 and 2.9% in dermatitis patients. In studies with 
unselected/consecutive dermatitis patients positive reactions range between 0 and 1.67% (3 studies) 
and in studies with selected dermatitis patients positive reactions range between 0.1 and 2.9% (8 
studies). The total number of published cases is > 25. A LOEL-HRIPT/HMT (induction) of 194 
µg/cm2 was established for methyl oct-2-ynate by the RIFM Expert Panel based on unpublished 
reports.  
 
Non-human data 
A total of 2 LLNAs (OECD TG 429), 1 GPMT and 1 Buehler test were identified testing skin 
sensitising effects of methyl oct-2-ynate. In both LLNA studies an EC3 value of <0.5% was reported. 
In the GPMT sensitisation was observed in 90 % of the animals after an intradermal induction dose 
of 0.625% methyl oct-2-ynate. Sensitisation was also observed in the Buehler test with positive 
reactions in 45-70% of the animals after an induction dose of 2.5%. 
 
No relevant in vitro studies on methyl oct-2-ynate (i.e. OECD TG 442C and OECD 442D) were 
identified in the literature.  
 
Exposure 
 
According to data from IFRA (2008d) the exposure of methyl oct-2-ynate when used as fragrance in 
cosmetics and in other consumer products appears to be low.    
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Comparison with criteria 
For unselected/consecutive dermatitis patients positive reactions range between 0 and 1.67% with 
1/3 studies reporting frequencies higher than 1%. For selected dermatitis patients positive reactions 
range between 0.1 and 2.9% with 1 out of 8 studies reporting frequencies higher than 2%. In 
addition to this there are more than 25 published cases of positive patch test reactions to methyl 
oct-2-ynate. According to the CLP criteria a frequency ≥ 1% for unselected/consecutive dermatitis 
patients and/or ≥ 2% for selected dermatitis patients and/or a total number of published cases ≥ 
100, equals a high frequency of occurrence of skin sensitisation (Table 3.4.2-b) (ECHA, 2015). The 
collected data described above from patch test studies show that methyl oct-2-ynate causes a 
low/moderate frequency of occurrence of skin sensitisation based on these three types of 
information.  
In regard to HRIPT studies positive responses were observed at exposure to 194 µg/cm2 methyl 2-
ocytnoate. A positive response at ≤ 500 µg/cm2 in a HRIPT or HMT suggests categorisation into 
sub-category 1A according to Annex I: 3.4.2.2.2.1 and 3.4.2.2.2.2.  
 
In the 2 LLNAs EC3 values were <0.5%. According to the CLP Regulation an EC3 value  2% 
indicates classification of a substance in sub-category 1A (Annex I: 3.4.2.2.3.2.).  
 
In the GPMT sensitisation was observed in 90% of the animals after an intradermal induction dose 
of 0.625%. According to the CLP criteria a positive response ≥ 60% of the animals responding at > 
0.1% to ≤ 1% intradermal induction dose indicates classification of a substance in sub-category 1A 
(Annex I: 3.4.2.2.3.2.). 
 
In the Buehler test sensitisation was observed in 45-70% of the animals after an induction does of 
2.5%. According to the CLP criteria a positive response ≥ 60% of the animals responding at > 0.2% 
to ≤ 20% topical induction dose indicates classification of a substance in sub-category 1A (Annex I: 
3.4.2.2.3.2.).  
 
Overall, there is clear evidence for classification in sub-category 1A based on the very low EC3 
values from the LLNAs. The results from GPMT and the Buehler test also supports sub-category 1A. 
Data from human patch test studies and the number of published cases justify classification of 
methyl oct-2-ynate in sub-category 1B while data from HRIPT studies justify classification of methyl 
oct-2-ynate in sub-category 1A. A classification as a skin sensitiser in sub-category 1A is thus 
warranted for methyl oct-2-ynate. 
 
Conclusions on classification and labelling 
Based on HRIPT data, the very low EC3 value from LLNAs and results from GPMT and Buehler 
tests a classification of methyl oct-2-ynate as a skin sensitser in sub-category 1A is justified.  
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Appendix 13 Cinnamomum cassia leaf oil and Cinnamomum zeylanicum, 
ext. CAS RN 84961-46-6/8007-80-5 and 84649-98-9 
Cinnamomum cassia leaf oil and Cinnamomum zeylanicum ext. are not specifically defined 
chemical substances but oils and extracts of leaves, twigs, wood, bark or the whole plant of Chinese 
Cinnamom Cinnamomum cassia (L.), Lauraceae and Ceylon Cinnamon, Cinnamomum 
zeylanicum, Lauraceae, respectively. 
 
Searching for the CAS RN for Cinnamomum cassia leaf oil (84961-46-6 / 8007-80-5) in the 
European Cosmetic ingredient database CosIng yields a total of seven INCI names (Table 1). 
 
Table 1. Cinnamomum cassia leaf oil.  
CAS RN EC No INCI Name Description 
84961-46-6 
/ 8007-80-5 
284-635-0 
/ -  
Cinnamomum 
cassia leaf oil 
"Cassia Oil"; "Cassia leaf Oil"; 
"Cinnamon Oil Chinense". 
Cinnamomum Cassia Leaf Oil is the 
volatile oil obtained by steam 
distillation from the leaves and 
twigs of the Chinese Cinnamom, 
Cinnamomum cassia (L.), 
Lauraceae. 
Cinnamomum 
cassia bark 
Cinnamomum Cassia Bark is a plant 
material derived from the dried 
bark of the Chinese Cinnamon, 
Cinnamomum cassia (L.), 
Lauraceae. 
Cinnamomum 
cassia bark extract 
Cinnamomum Cassia Bark Extract is 
an extract obtained from the dried 
bark of the Chinese Cinnamon, 
Cinnamomum cassia (L.), 
Lauraceae. 
Cinnamomum 
cassia extract 
Cinnamomum Cassia Extract is the 
extract of the whole plant, 
Cinnamomum cassia, Lauraceae. 
Cinnamomum 
cassia leaf extract* 
Cinnamomum Cassia Leaf Extract is 
an extract obtained from the leaves 
of the Chinese Cinnamon, 
Cinnamomum cassia (L.), 
Lauraceae. 
Cinnamomum 
cassia oil 
Cinnamomum Cassia Oil is the 
volatile oil obtained from the whole 
plant of the Chinese Cinnamon, 
Cinnamomum cassia (L.), 
Lauraceae. 
Cinnamomum 
cassia wood 
extract* 
Cinnamomum Cassia Wood Extract 
is an extract obtained from the 
wood of the Chinese Cinnamon, 
Cinnamomum cassia (L.), 
Lauraceae. 
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*According to the Cosmetic Directive not an INCI name but Perfuming Name 
(http://ec.europa.eu/growth/tools-
databases/cosing/index.cfm?fuseaction=search.results). 
 
The constituents of Cassia bark extract and Cassia oil and their concentrations are reported 
reported in Annex I to the IFRA Standards (48th Amendment) (http://www.ifraorg.org/en-
us/search/s/84649-98-9#.Vjsc1rcveUk) and summarized in Table 2. 
 
Table 2. Constituents of Cinnamomum cassia leaf oil. 
Cinnamomum cassia leaf oil  Constituents 
CAS 
RN 
EC 
No 
Principle 
Name 
Botanical 
name 
CAS 
RN 
Principle name Level 
(%) 
84961-
46-6 / 
8007-
80-5 
284-
635-
0 / -
  
Cassia 
bark 
extract 
Cinnamomum 
cassia Blume 
1504-
74-1 
o-
Methoxycinnamaldehyde 
2 
100-
52-7 
Benzaldehyde 2 
120-
51-4 
Benzyl benzoate 0.07 
104-
55-2 
Cinnamaldehyde 44 
104-
54-1 
Cinnamyl alcohol 0.5 
91-
64-5 
Coumarin 0.15 
97-
53-0 
Eugenol 0.03 
84961-
46-6 / 
8007-
80-5 
284-
635-
0 / -
  
Cassia 
oil 
Cinnamomum 
cassia Blume 
1504-
74-1 
o-
Methoxycinnamaldehyde 
4 
100-
52-7 
Benzaldehyde 4 
120-
51-4 
Benzyl benzoate 0.14 
104-
55-2 
Cinnamaldehyde 87 
104-
54-1 
Cinnamyl alcohol 1 
91-
64-5 
Coumarin 0.3 
97-
53-0 
Eugenol 0.06 
 
Searching for the CAS RN for Cinnamomum zeylanicum bark oil (84649-98-9) in the European 
Cosmetic ingredient database CosIng yields five INCI names (Table 3).  
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Table 3. Cinnamomum zeylanicum bark. 
CAS RN EC No INCI Name Description 
84649-
98-9 
283-479-0 Cinnamomum zeylanicum 
bark oil 
("Cummamon Bark Oil 
Ceylon"; "Cinnamon Oil 
Ceylon". Cinnamomum 
Zeylanicum Bark Oil is the 
volatile oil expressed from 
the bark of the Ceylon 
Cinnamon, Cinnamomum 
zeylanicum, Lauraceae. It 
contains cinnamaldehyde 
(50-60%), eugenol (4-8%), 
phellandrene 
Cinnamomum zeylanicum 
bark extract 
Cinnamomum zeylanicum 
Bark Extract is an extract 
obtained from the dried 
bark of the Ceylon 
Cinnamon, Cinnamomum 
zeylanicum, Lauraceae. 
Cinnamomum zeylanicum 
bark powder 
Cinnamomum zeylanicum 
Bark Powder is the powder 
obtained from the dried, 
ground bark of the Ceylon 
Cinnamon, Cinnamomum 
zeylanicum, Lauraceae. 
Cinnamomum zeylanicum 
leaf extract 
Cinnamomum zeylanicum 
Leaf Extract is an extract 
obtained from the leaves 
of the Ceylon Cinnamon, 
Cinnamomum zeylanicum, 
Lauraceae. 
Cinnamomum zeylanicum 
leaf oil 
("Cinnamon Leaf Oil 
Ceylon". Cinnamomum 
Zeylanicum Leaf Oil is the 
volatile oil obtained from 
the leaves of the Ceylon 
Cinnamon, Cinnamomum 
zeylanicum, Lauraceae. 
 
The constituents of Cinnamon bark extract, Cinnamon bark oil and cinnamon leaf oil and their 
concentrations are reported in Annex I to the IFRA Standards (48th Amendment) 
(http://www.ifraorg.org/en-us/search/s/84649-98-9#.Vjsc1rcveUk) and summarized in 
Table 4. 
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Table 4. Constituents of Cinnamomum zeylanicum ext. 
Cinnamomum zeylanicum ext.  Constituents 
CAS RN EC 
No 
Principle 
Name 
Botanical 
name 
CAS 
RN 
Principle name Level 
(%) 
84649-
98-9  
283-
479-
0 
Cinnamon 
bark extract 
Cinnamomum 
spp. 
100-
52-7 
Benzaldehyde 0.1 
120-
51-4 
Benzyl benzoate 0.3 
104-
55-2 
Cinnamaldehyde 38 
104-
54-1 
Cinnamyl alcohol 0.1 
91-64-
5 
Coumarin 0.3 
97-53-
0 
Eugenol 1 
97-54-
1 
Isoeugenol 0.01 
84649-
98-9  
283-
479-
0 
Cinnamon 
bark oil 
Cinnamomum 
spp. 
100-
52-7 
Benzaldehyde 0.26 
120-
51-4 
Benzyl benzoate 0.66 
104-
55-2 
Cinnamaldehyde 75 
104-
54-1 
Cinnamyl alcohol 0.26 
91-64-
5 
Coumarin 0.66 
97-53-
0 
Eugenol 2.2 
97-54-
1 
Isoeugenol 0.02 
84649-
98-9  
283-
479-
0 
Cinnamon 
leaf oil 
Cinnamomum 
zeylanicum 
Blume 
100-
52-7 
Benzaldehyde 0.16 
120-
51-4 
Benzyl benzoate 3.5 
104-
55-2 
Cinnamaldehyde 2 
91-64-
5 
Coumarin 0.3 
97-53-
0 
Eugenol 70 
4602-
84-0 
Farnesol 0.12 
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Cinnamomum zeylanicum ext.  Constituents 
97-54-
1 
Isoeugenol 0.13 
93-15-
2 
Methyl eugenol 0.01 
 
In conclusion the actual composition and concentration of compounds varies between 
Cinnamomum cassia leaf oil and Cinnamomum zeylanicum ext. and especially according to the 
source of the oil or extract (e.g. leaves, bark etc.). This complicates the evaluation unless the source 
is specified e.g. for patch test studies or LLNA. This is reflected in the few relevant studies identified 
and summarised below. 
 
Non-human information 
No animal studies (LLNA, GPMT or Buehler) with Cinnamomum cassia leaf oil/Cinnamomum 
zeylanicum, ext. have been identified. 
 
No relevant in vitro studies (OECD TG 442C and OECD 442D) with Cinnamomum cassia leaf 
oil/Cinnamomum zeylanicum, ext. have been identified. 
 
Human information  
Population studies 
Table 5 summarises the few patch test studies on Cinnamomum cassia leaf oil/Cinnamomum 
zeylanicum, ext. involving less than 300 dermatitis patients.  
 
Table 5. Population studies with Cinnamomum cassia leaf oil/Cinnamomum zeylanicum, ext. 
Method Results Remarks/Comments Reference 
Patch test: Study 
of 86 selected 
fragrance mix I 
positive patients 
patch tested with 
“cassia” essential 
oil 2% in 
petrolatum (pet.). 
24/86 (27.9%) 
patients were 
positive.  
 Rudzki & Grzywa 
1986 cited from 
SCCS (2012). 
Patch test: Study 
of 200 patients 
patch tested with 
“cassia” essential 
oil 2% in pet. 
2/200 (1%) 
patients were 
positive.  
 Rudzki et al 1976 
cited from SCCS 
(2012). 
 
Case studies 
Table 6 shows one case report with allergic contact dermatitis in Spain where Cinnamomum cassia 
leaf oil/Cinnamomum zeylanicum, ext. has been found as causative agents.  
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Table 6. Case studies with Cinnamomum cassia leaf oil/Cinnamomum zeylanicum, ext. 
Method Results Remarks/Comments Reference 
Patch test: A 32-
year old man with 
dermatitis was 
patch tested with 
“cinnamon oil” 
0.5% in 
petrolatum.  
Positive reaction 
was observed. 
Case study, Spain (year 
not stated). 
Sanchez-Perez & 
Garcia-Diez 1999 
cited from SCCS 
(2012). 
 
As reflected in table 5 and 6 very few human studies with Cinnamomum cassia leaf 
oil/Cinnamomum zeylanicum, ext. have been identified. All three studies are cited from SCCS 
(2012). A total of 27 positive cases and frequencies between 1 and 27.8% in selected dermatitis 
patients tested with “cassia” essential oil or “cinnamon oil” were observed. 
 
SCCS (2012) considered the “essential oil” as an ‘Established contact allergen in humans’ 
considering the content of well-known allergenic compounds. 
 
Cinnamomum zeylanicum, ext. is registered under the REACH regulation with an annual tonnage 
band of 1000 - 10 000 tonnes per annum. 
 
Summary and discussion of skin sensitization 
Human data 
A total of 27 positive cases and frequencies between 1 and 27.8% in selected dermatitis patients 
tested with “cassia” essential oil or “cinnamon oil” were observed.  
 
Non-human data  
No animal studies with Cinnamomum cassia leaf oil/Cinnamomum zeylanicum, ext. have been 
identified. 
 
Exposure 
It has not been possible to identify any data on exposure to Cinnamomum cassia leaf oil or 
Cinnamomum zeylanicum, ext. 
 
Comparison with criteria 
One out of two studies with “cassia” essential oil gave a frequency of positive patch tests in selected 
patients of 27.8% i.e. ≥ 2%, which indicate categorisation into sub-category 1A.  
 
No animal studies with Cinnamomum cassia leaf oil/Cinnamomum zeylanicum, ext. have been 
identified. 
 
Conclusions on classification and labelling 
Data on Cinnamomum cassia leaf oil/Cinnamomum zeylanicum, ext. alone is insufficient for sub-
categorisation of Cinnamomum cassia leaf oil/Cinnamomum zeylanicum, ext. according to CLP 
criteria. It may be possible to sub-categorise Cinnamomum cassia leaf oil/Cinnamomum 
zeylanicum, ext. based on their constituents by read across to the major compounds such as 
cinnamaldehyde (for Cassia bark extract, Cassia oil, Cinnamon bark extract and Cinnamon bark oil) 
and eugenol (for Cinnamon leaf oil). 
 
References 
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Appendix 14 Evernia prunastri ext. CAS RN 90028-68-5 
The main sensitizers of Evernia prunastri ext. has been identified as atranol (CAS RN 526-37-4) 
and chloroatranol (CAS RN 57074-21-2) which are degradation products of atranorin and 
chloratranorin, respectively, and very potent allergens according to the SCCS (2012).  
 
Non-human information 
Table 1 summarises relevant animal studies with Evernia prunastri ext. i.e. Local Lymph Node 
Assays (LLNAs), Guinea Pig Maximization tests (GPMTs) and Buehler tests.  
 
Table 1. Animal studies with Evernia prunastri ext. 
Method Results Remarks/Comments Reference 
LLNA: 
Ex vivo BrdU. 0.5, 
1, 5 and 10% 
Evernia prunastri 
ext.  
Vehicle: 4:1 
Acetone:Olive oil. 
Evernia prunastri 
ext. was shown 
to have an EC3 
value of 3.4%. 
 Ulker et al. 
(2014). 
LLNA: 2.5, 5, 10, 
25 and 50% 
Evernia prunastri 
ext. 
Vehicle: 1:3 
ethanol:diethyl 
phthalate. 
Evernia prunastri 
ext. was shown 
to have an EC3 
value of 3.9%. 
According to SCCS 
(2012) there were no 
reported deviations 
from OECD TG 429. 
Unpublished 
summary report 
by RIFM 2009 
(RIFM 2004j) 
cited from SCCS 
(2012). 
GPMT: 
Intradermal 
induction 20%;  
Topical induction 
5% and  
Challenge dose 
0.1, 0.3 and 1% 
Evernia prunastri 
ext. Vehicle: not 
reported. 
0/8 (0%), 2/8 
(25%) and 5/8 
(63%) animals 
were sensitised 
at challenge 
doses of 0.1, 0.3 
and 1% Evernia 
prunastri ext., 
respectively. 
 Ehret et al., 1992 
cited from 
SCCNFP (2000). 
 
A total of 1 LLNA, 1 LLNA ex vivo BrdU and 1 GPMT with Evernia prunastri ext. are summarised in 
table 1. The reported EC3 value for Evernia prunastri ext. was 3.9% in the LLNA and 3.4% in the 
LLNA ex vivo BrdU. In the GPMT sensitisation was observed in 5/8 (63%) animals after an 
intradermal induction dose of 20% Evernia prunastri ext. 
 
No relevant in vitro studies on Evernia prunastri ext. (i.e. OECD TG 442C and OECD TG 442D) 
were identified in the literature. 
 
Human information 
Population studies 
Table 2 summarises patch test studies on Evernia prunastri ext. involving several thousand 
dermatitis patients from various countries mainly in Europe. Most of the studies are diagnostic 
patch test studies.  
 
216 Evaluation of selected sensitizing fragrance substances 
 
Table 2. Population studies with Evernia prunastri ext. 
Method Results Remarks/Comments Reference 
Patch test: 
Retrospective study 
of 806 selected 
patients patch 
tested with Evernia 
prunastri ext.  1% 
in petrolatum (pet.). 
221/806 (27.4%) 
patients were 
positive.  
A retrospective study 
on patch test data from 
multicentre project 
IVDK (Information 
Network of 
Departments of 
Dermatology) (2007-
2009). 
Schnuch et al. 
(2015). 
Patch test: 
Retrospective study 
of 1951 selected 
eczema patients 
patch tested with 
Evernia prunastri 
ext. 2% in pet.  
34/1951 (1.7%, 
95% CI: 1.1-
2.3%) patients 
were positive. 
A retrospective study 
on patch test data at St 
John’s Institute of 
Dermatology at St 
Thomas’ Hospital, UK 
(2011-2012). 
Mann et al. 
(2014). 
Patch test: Study of 
228 selected 
patients with 
occupational 
dermatitis tested 
with Evernia 
prunastri ext. 
Vehicle and 
concentration not 
reported. 
2/228 (0.9%) 
patients were 
positive. 
Study on patch test 
data from Department 
of Dermato-Allergology, 
Copenhagen University 
Hospital Gentofte, 
Denmark (2010-2011). 
Friis et al. 
(2013). 
Patch test: 
Retrospective study 
of 940 selected 
patients tested with 
Evernia prunastri 
ext. in petrolatum. 
Concentration not 
reported. 
230/940 (24.6%) 
patients were 
positive. 
A retrospective study 
on patch test data from 
Department of 
Dermatology, 
University Hospital St 
Rafaël, Belgium (1990-
2011). 
Nardelli et al. 
(2013). 
Patch test: 
Prospective study of 
100 selected 
patients with 
contact allergy 
patch tested with 
Evernia prunastri 
ext. in petrolatum. 
Concentration not 
reported. 
25/100 (25%, 
95% CI: 16.88-
34.66%) patients 
were positive. 
Single-centre, double-
blind prospective 
experimental 
longitudinal volunteer 
study at the 
department of 
Dermatology of the VU 
University Medical 
Centre, The 
Netherlands (2005-
2010). 
Nagtegaal et al. 
(2012). 
Patch test: 
Retrospective study 
of 1503 consecutive 
eczema patients 
37/1503 (2.5 %) 
patients were 
positive. 
A retrospective study of 
patch test data at 
Department of 
Dermato-Allergology, 
Heisterberg et 
al. (2011, 
2012). 
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Method Results Remarks/Comments Reference 
patch tested with 
Evernia prunastri 
ext. 1% in pet. 
Copenhagen University 
Hospital Gentofte, 
Denmark (2008-2010).   
Patch test: 
Retrospective study 
of 157 selected 
patients (chosen out 
of 509 patients 
positive to fragrance 
allergens) patch 
tested with Evernia 
prunastri ext. 2% in 
pet 
Ca. 39/157 (ca. 
25%) patients 
were positive. 
A retrospective study of 
patch test data at the 
Allergy Clinic of the 
Department of 
Dermatology and 
Venereology, Zagreb 
University Hospital 
Center and School of 
Medicine, Zagreb, 
Croatia (2001-2005).   
Turcic et al. 
(2011). 
Patch test: 
Retrospective study 
of 86 selected 
patients patch 
tested with Evernia 
prunastri ext. 2% in 
pet.  
2/86 (2.3%) 
patients were 
positive.  
A retrospective and 
descriptive analysis of a 
patch test study at the 
Cutaneous Allergy Unit 
of a tertiary referral 
hospital, Spain (2004-
2008). 
Cuesta et al. 
(2010). 
Patch test: 
Retrospective study 
of 1213 consecutive 
patients and 4482 
selected patients 
patch tested with 
Evernia prunastri 
ext. 1% in pet. 
22/1213 (1.81%, 
95% CI: 1.07-
2.56%) and 
251/4482 
(5.59%, 95% CI: 
4.9-6.27%) 
patients were 
positive. 
A retrospective study 
on patch test data from 
multicentre project 
IVDK (Information 
Network of 
Departments of 
Dermatology) (2005-
2008). 
Uter et al. 
(2010). 
Patch test: 
Prospective study of 
320 selected 
eczema patients 
patch tested with 
Evernia prunastri 
ext. 2% in pet. 
6/320 (1.9%) 
patients were 
positive. 
A prospective analysis 
of selected eczema 
patients at the 
University Medical 
Center in Groningen, 
the Netherlands (2005-
2007). 
van Oosten et 
al. (2009). 
Patch test: 
Retrospective study 
of 597 selected 
patients with a) 
current allergic 
dermatitis or b) past 
allergic dermatitis 
patch tested with 
Evernia prunastri 
ext. 1% in pet. 
a) 120/597 
(20.1%) and b) 
165/597 (27.6%) 
patients were 
positive. 
A retrospective study of 
patch test data from 
patients attending the 
Department of 
Cutaneous Allergy at St 
John’s Institute of 
Dermatology, UK 
(1982-2007). 
White (2009). 
Patch test: 
Prospective study of 
15 selected patients 
with eczematous 
0/15 (0%) 
patients were 
positive. 
A prospective study on 
patch test data from 
patients from Italy 
(2006-2007). 
Foti et al. 
(2008). 
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Method Results Remarks/Comments Reference 
reactions from 
ketoprofen-
containing gels 
patch tested with 
Evernia prunastri 
ext. 2% in pet. 
Patch test: 
Retrospective study 
of 2063 consecutive 
patients patch 
tested with Evernia 
prunastri ext. 1% in 
pet. 
46/2063 (2.2%, 
95% CI: 1.4-
2.6%) patients 
were positive. 
A retrospective study 
on patch test data from 
multicentre project 
IVDK (2003-2004). 
Schnuch et al. 
(2007). 
Patch test: 
Retrospective study 
of a) 28 patients 
positive to their own 
shaving product/eau 
de toilette/perfume 
and b) 153 negative 
to their own shaving 
product/eau de 
toilette/perfume, 
patch tested with 
Evernia prunastri 
ext.  1% in pet. 
a) 8/28 (29%) 
and b) 14/153 
(9%) patients 
were positive. 
A retrospective study 
on patch test data from 
multicentre project 
IVDK (1998-2002). 
Uter et al. 
(2007). 
Patch test: Study of 
30 selected patients 
with a positive patch 
test to their own 
perfumed product 
patch tested with 
Evernia prunastri 
ext. Concentration 
and vehicle not 
specified. 
9/30 (30%) 
patients were 
positive. 
 Vocanson et al. 
(2006). 
Patch test: 
Prospective study of 
422 selected 
patients with 
suspected contact 
allergy patch tested 
with Evernia 
prunastri ext. 2% in 
pet. 
6/422 (1.4%) 
patients were 
positive. 
A prospective analysis 
of patients from nine 
dermatology 
departments of 
university hospitals in 
Korea (2002-2003). 
An et al. (2005). 
Patch test: Study of 
885 consecutive 
eczema patients 
patch tested with 
28/885 (3.2%) 
patients were 
positive or had a 
follicular patch 
Two types of Evernia 
prunastri ext. (oak 
moss absolute) were 
tested, one 
Johansen et al., 
2002 cited from 
SCCS (2012). 
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Method Results Remarks/Comments Reference 
Evernia prunastri 
ext. Concentration 
and vehicle not 
reported. 
test response. contaminated by resin 
acids and one without 
any detectable resin 
acids. There was no 
difference in reactivity 
between the two types. 
Patch test: 
Retrospective study 
of 4900 unselected 
patients patch 
tested with Evernia 
prunastri ext. 1% in 
pet. 
333/4900 (6.8%) 
patients were 
positive. 
A retrospective study 
on patch test data from 
multicentre project 
IVDK (1996-1999). 
Schnuch et al. 
(2002). 
Patch test: 
Prospective study of 
747 selected 
patients with 
suspected fragrance 
allergy patch tested 
with Evernia 
prunastri ext. 1% in 
pet. with 1% 
sorbitan 
sesquioleate (SSO). 
37/747 (5%) 
patients were 
positive. 
A prospective analysis 
of patients from FAZ-
Floridsdorf Allergy 
Centre, Austria (1997-
2000). 
Wohrl et al. 
(2001). 
Patch test: Study of 
226 selected 
patients sensitive to 
FM patch tested 
with Evernia 
prunastri ext. 1% in 
pet. 
50/226 (22%) 
patients were 
positive. 
Department of 
Dermatology, 
University Hospital, 
Coimbra, Portugal 
(1989-1999). 
Brites et al. 
(2000). 
Patch test: 
Retrospective study 
of 50 patients 
sensitive to FM 
patch tested with 
Evernia prunastri 
ext. 2% in 1% SSO. 
22/50 (44%) 
patients were 
positive. 
Retrospective study of 
patch test data. 
University Hospital 
Utrecht, The 
Netherlands (1994-
1998). 
Hendriks and 
van Ginkel 
(1999). 
Patch test: 
Retrospective study 
of 40 patients 
sensitive to FM 
patch tested with 
Evernia prunastri 
ext. in pet. 
Concentration not 
reported. 
12/40 (30%) 
patients were 
positive. 
 Katsarma and 
Gawkrodger 
(1999). 
Patch test: Study of 
167 selected 
22/167 (13.2%) 
patients were 
Multicentre study of 
patch test data from 
Larsen et al. 
(1996). 
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Method Results Remarks/Comments Reference 
patients suspected 
of fragrance 
sensitivity patch 
tested with Evernia 
prunastri ext. 5% in 
pet.  
positive. Japan, Northern 
Ireland, USA, UK, 
Switzerland and 
Sweden.  
Patch test: Study of 
702 unselected 
consecutive patients 
patch tested with 
Evernia prunastri 
ext. 1% in pet. with 
1% SSO. 
18/702 (2.6%) 
patients were 
positive. 
European multicentre 
study with 7 different 
centres. 
Frosch et al. 
(1995a). 
Patch test: Study of 
702 unselected 
consecutive patients 
patch tested with 
Evernia prunastri 
ext. 1% in pet.  
13/702 (1.9%) 
patients were 
positive. 
European multicentre 
study with 7 different 
centres. 
Frosch et al. 
(1995a). 
Patch test: Study of 
1072 patients patch 
tested with Evernia 
prunastri ext. 1% in 
pet with 1% SSO. 
24/1072 (2.24%) 
patients were 
positive. 
European multicentre 
study with 9 different 
centres. 
Frosch et al. 
(1995b). 
Patch test: 
Retrospective study 
of 367 selected 
patients patch 
tested with Evernia 
prunastri ext. 1 or 
2% in pet. with 5% 
SSO. 
86/367 (23%) 
patients were 
positive. 
Retrospective study of 
patch test data from 
Department of 
Dermatology, Gentofte 
Hospital, Denmark 
(1979-1983 and 1988-
1992). 
Johansen and 
Menne (1995). 
Patch test: 
Prospective study of 
61 selected patients 
positive to a 
fragrance mix patch 
tested with Evernia 
prunastri ext. 5% in 
pet. 
21/61 (34%) 
patients were 
positive. 
Control tests in 
100 patients not 
allergic to 
fragrances 
showed no 
positive reactions 
when tested with 
Evernia prunastri 
ext. 5% pet. 
Prospective study of 
patch test data from 
University of 
Amsterdam and 
University of Leiden, 
The Netherlands 
(1987). 
 
de Groot et al. 
(1993). 
 
Patch test: 
Prospective study of 
162 selected 
patients positive to 
a fragrance mix 
14/162 (8.6%) 
patients were 
positive. 
Prospective study of 
patch test data from 
Dermatologische Klinik 
und Poliklinik, Germany 
(1991). 
Enders et al. 
(1989). 
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Method Results Remarks/Comments Reference 
patch tested with 
Evernia prunastri 
ext. 1% in pet. 
Patch test: Study of 
55 selected patients 
sensitive to 
perfumes or after-
shave lotions patch 
with Evernia 
prunastri ext. 2%. 
Vehicle not 
reported. 
35/55 (64%) 
patients were 
positive. 
According to SCCNFP 
2000 16 of the 55 
patients had a definite 
history of contact 
allergy to plants 
following direct contact. 
Thune and 
Sandberg 1987 
cited from 
SCCNFP (2000). 
Patch test: 
Prospective study of 
179 selected 
patients patch 
tested Evernia 
prunastri ext. 10% 
in pet.  
21/179 (11.7%) 
patients were 
positive. 
 de Groot et al. 
(1985). 
Patch test: Study of 
20 selected perfume 
allergic patients 
patch tested with 
Evernia prunastri 
ext. 5% in pet. 
3/20 (15%) 
patients were 
positive. 
 Larsen (1977). 
Patch test and 
ROAT1: 30 Evernia 
prunastri ext. 
sensitive patients 
were tested with 
0.1% of Evernia 
prunastri ext. in a 
ROAT and with a 
serial dilution of 
Evernia prunastri 
ext. 0.00003-2% in 
a patch test. 
Vehicle: diethyl 
phthalate:ethanol 
2:98   
22/30 patients 
were positive in 
the ROAT. 
Positive reactions 
were observed in 
6/30 (20%) 
patients at a 
concentration of 
0.0027%. 
 Andersen et al. 
(2015). 
1ROAT: Repeated Open Application Test 
 
Table 3 summarises Human Repeat Insult Patch Tests (HRIPTs) with Evernia prunastri ext. 
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Table 3. HRIPT studies with Evernia prunastri ext. 
Method Results Remarks/Comments Reference 
Modified HRIPT 
(Draize): 
Evernia prunastri 
ext. Induction 
concentration: 5% 
Vehicle: 1:1 
Acetone:Ethanol. 
 
7/53 (13%) tests 
were positive. 
 Ehret et al., 
1992 cited from 
SCCNFP (2000). 
HRIPT: 
Evernia prunastri 
ext. Induction 
concentration: 5% 
Vehicle: 3:1 
Ethanol:diethyl 
phthalate 
(EtOH:DEP).  
 
Sensitisation was 
observed. 
 Ford and Api 
1990 cited from 
SCCNFP (2000). 
HRIPT: 
Evernia prunastri 
ext. Induction 
concentration: 
0.6% Vehicle: 3:1 
EtOH:DEP. 
 
0/103 tests were 
positive. 
 Ford and Api 
1990 cited from 
SCCNFP (2000). 
HRIPT: 
Evernia prunastri 
ext. Induction 
concentration: 
1.2% Vehicle: not 
reported. 
 
0/47 tests were 
positive. 
 IFRA 1988 
amended in 
1992 and 1998 
cited from 
SCCNFP (2000). 
HRIPT: 
Evernia prunastri 
ext. Induction 
concentration: 
1.2% Vehicle: not 
reported. 
 
1/48 (2%) tests 
were positive. 
 IFRA 1988 
amended in 
1992 and 1998 
cited from 
SCCNFP (2000). 
HRIPT: Human Repeat Insult Patch Test. 
 
Case studies 
Table 4 summarises case reports with allergic contact dermatitis where Evernia prunastri ext. has 
been found to be among the causative agents.  
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Table 4. Case studies with Evernia prunastri ext. 
Method Results Remarks/Comments Reference 
Patch test: A 41-
year old female 
hairdresser with 
occupational hand 
dermatitis and 
scalp dermatitis 
was patch tested 
with Evernia 
prunastri ext.  
Positive reaction 
to Evernia 
prunastri ext. 
contained in a 
perming solution. 
 Kanerva et al., 
1999 cited from 
SCCS (2012). 
Patch test: A 
woman with ACD1 
was patch tested 
with her 
husband’s 
aftershave lotion 
and Evernia 
prunastri ext. 5% 
in petrolatum.  
Positive reaction 
to Evernia 
prunastri ext. 
and her 
husband’s 
aftershave lotion 
containing 3% 
Evernia prunastri 
ext. 
 Held et al., 1988 
cited from 
SCCNFP (2000). 
1ACD: Allergic Contact Dermatitis. 
 
A total of 35 results from patch test population studies, 5 HRIPTs and 2 case studies with Evernia 
prunastri ext. are summarised above (Table 2, 3 and 4). As shown in Table 2 the positive patch test 
frequencies from all of the reported patch test population studies vary between 0 and 64% in 
dermatitis patients. For unselected/consecutive dermatitis patients, positive reactions range 
between 1.8 and 6.8% (7 studies) and for selected dermatitis patients positive reactions range 
between 0 and 64% with 21/28 studies reporting frequencies equal to or higher than 5%. The total 
number of published cases is > 1900. Sensitisation was reported in 3/5 HRIPT studies with no 
reactions at 0.6%, 0-2% at 1.2% and 13% at 5% induction concentrations of Evernia prunastri ext. 
The Research Institute for Fragrance Materials, Inc. (RIFM) has on the basis of these and other 
unpublished studies deducted a NOEL20-HRIPT (induction) of 700 µg/cm2, a NOEL-HMT of 1724 
µg/cm2 and a LOEL-HRIPT/HMT21 (induction) of 1417 µg/cm2. In addition, based on weight of 
evidence, a No Expected Sensitization Induction Level (NESIL) of 700 µg/cm2 was established for 
Evernia prunastri ext. by the RIFM Expert Panel (IFRA, 2008e). 
 
According to SCCS (2012) Evernia prunastri ext. is used in volumes less than 175 ton per year in 
perfume formulations. It has been reported that in consumer products containing fragrance 
allergens that are required to be labelled 4.6% of 88 tested deodorants (in 2007), 0.8% of a total of 
516 consumer products; 4% of a total of 300 consumer products; ca. 1% of 3000 products and 0% of 
children’s cosmetics were labelled to contain Evernia prunastri ext. (Wijnhoven et al., 2008; 
Buckley, 2007; Schnuch et al., 2009 and Poulsen & Schmidt, 2007 cited from SCCS (2012)). Based 
on these data SCCS (2012) concluded that Evernia prunastri ext. was among the least used 
fragrance ingredients in cosmetics and other consumer products.   
 
The IFRA standard limits for Evernia prunastri ext. in different IFRA QRA product categories 
reported by IFRA (2008e and 2015) are shown in table 5. 
  
                                                                    
20 NOEL: No Observed Effect Level. 
21 LOEL-HRIPT/HMT: Lowest Observed Effect Level-Human Repeat Insult Patch Test/Human Maximisation test. 
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Table 5.The IFRA standard limits for Evernia prunastri ext. in IFRA QRA product categories. 
IFRA QRA product 
category 
Product type that drives the 
category consumer exposure 
level 
IFRA standard limits 
Category 1 Lip products 0.02% 
Category 2 Deodorants/antiperspirants 0.03% 
Category 3 Hydroalcoholics for shaved skin 0.1% 
Category 4 Hydroalcoholics for unshaved 
skin 
0.1% 
Category 5 Hand cream 0.1% 
Category 6 Mouthwash 0.5% 
Category 7 Intimate wipes 0.1% 
Category 8 Hair styling aids 0.1% 
Category 9 Rinse-off hair conditioners 0.1% 
Category 10 Hard surface cleaners 0.1% 
Category 11 Candles Not restricted 
IFRA: International Fragrance Association, QRA: Quantitative Risk Assessment. 
 
Evernia prunastri ext. is not registered under the REACH regulation.  
 
Summary and discussion of skin sensitization 
Human data 
A total of 35 results from patch test population studies, 5 HRIPTs and 2 case studies were identified 
with Evernia prunastri ext. The positive patch test frequencies from all of the reported patch test 
population studies vary between 0 and 64% in dermatitis patients. In studies with 
unselected/consecutive dermatitis patients positive reactions range between 1.8 and 6.8% (7 
studies) and in studies with selected dermatitis patients positive reactions range between 0 and 
64% (28 studies). The total number of published cases is > 1900. A LOEL-HRIPT/HMT (induction) 
of 1417 µg/cm2 was established for Evernia prunastri ext. by the RIFM Expert Panel based on 
unpublished reports.  
 
Non-human data  
A total of 1 LLNA, 1 LLNA ex vivo BrdU and 1 GPMT were identified testing skin sensitising effects 
of Evernia prunastri ext. The reported EC3 value for Evernia prunastri ext. was 3.9% in the LLNA 
and 3.4% in the LLNA ex vivo BrdU. In the GPMT sensitisation was observed in 63% of the animals 
after an intradermal induction dose of 20% Evernia prunastri ext. 
 
No relevant in vitro studies on Evernia prunastri ext. (i.e. OECD TG 442C and OECD TG 442D) 
were identified in the literature. 
 
Exposure 
According to data from IFRA (2008e) the exposure of Evernia prunastri ext. when used as 
fragrance in cosmetics and in other consumer products appears to be low.  
 
Comparison with criteria 
For unselected/consecutive dermatitis patients positive reactions range between 1.81 and 6.8% i.e. 
all studies are reporting frequencies higher than 1%. For selected dermatitis patients positive 
reactions range between 0 and 64% with 23 out of 28 studies reporting frequencies higher than 2%. 
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In addition to this there are more than 1900 published cases of positive patch test reactions to 
Evernia prunastri ext. According to the CLP criteria a frequency ≥ 1% for unselected/consecutive 
dermatitis patients and/or ≥ 2% for selected dermatitis patients and/or a total number of published 
cases ≥ 100, equals a high frequency of occurrence of skin sensitisation (Table 3.4.2-b) (ECHA, 
2015). The collected data described above from patch test studies show that Evernia prunastri ext. 
causes a high frequency of occurrence of skin sensitisation based on these three types of 
information.  
In regard to the HRIPT/HMT data the positive response reported at > 500 µg/cm2 for HRIPT/HMT 
induction threshold indicate evidence for sub-category 1B according to Annex I: 3.4.2.2.2.2. 
 
In the 2 LLNAs EC3 values were 3.4 and 3.9%. According to the CLP Regulation an EC3 value  2% 
indicates classification of a substance in sub-category 1A whereas an EC3 value > 2% indicates 
classification of a substance in sub-category 1B (Annex I: 3.4.2.2.3.2.). Thus, both studies indicate 
classification of Evernia prunastri ext. in sub-category 1B.  
 
In the GPMT sensitisation was observed in 63% of the animals after an intradermal induction dose 
of 20%. According to the CLP criteria a positive response ≥ 30% of the animals responding at > 1% 
intradermal induction dose indicates classification of a substance in sub-category 1B (Annex I: 
3.4.2.2.3.2.) and thus, this study indicates classification of Evernia prunastri ext. into sub-category 
1B. 
 
Overall, there is clear evidence for classification in sub-category 1A based on the human patch test 
studies showing a high frequency of occurrence of skin sensitisation and the total number of cases 
combined with the estimated low exposure. The results from the animal studies indicate 
classification in sub-category 1B.  A classification as a skin sensitiser in sub-category 1A is thus 
warranted for Evernia prunastri ext. 
 
Conclusions on classification and labelling 
Based on the high frequency of sensitisation observed in human patch test studies and the high 
number of published cases combined with the estimated low exposure, a classification of Evernia 
prunastri ext. as a skin sensitiser in sub-category 1A is justified.  
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Evaluation of selected sensitising fragrance substances 
Fragrances are widely used in many different types of consumer products and consumers may thus be exposed 
to fragrances from many different sources. The exposure can be substantial despite the fact that fragrances are 
typically used in relatively low concentrations in individual products. Skin sensitisation (contact allergy) is a 
critical effect for human health for many fragrances. The purpose of this project was to retrieve and review the 
available data for 42 selected sensitising fragrance substances in order to assess whether these substances are 
potent enough fulfil the criteria for classification as strong sensitisers in sub-category 1A according to the CLP 
Regulation on classification, labelling and packaging. A classification as a strong sensitizer in category 1A will 
impact the level of information that has to be supplied on the label on e.g. washing and cleaning products 
containing such substances. The more stringent labelling requirements for products containing potent 
sensitisers will provide better protection of users (both consumers and workers) as it will allow sensitised 
individuals to take precautionary measures to prevent direct skin contact with such products. 
 
Parfume er vidt udbredt i mange forskellige typer forbrugerprodukter, og forbrugere bliver eksponeret for 
parfume fra mange forskellige kilder. Eksponeringen kan være betragtelig på trods af, at parfumestoffer generelt 
anvendes i relativt lave koncentrationer i de enkelte produkter. Hudsensibilisering (kontakt allergi) er en af de 
kritiske effekter for sundheden for mange parfumestoffer. Formålet med dette projekt var at søge og vurdere de 
tilgængelige data for 42 udvalgte sensibiliserende parfumestoffer for at vurdere, om disse stoffer er potente nok 
til at opfylde kriterierne for klassificering som stærkt sensibiliserende stoffer i kategori 1A i henhold til CLP 
forordningen om klassificering, mærkning og emballering. En klassificering som stærkt sensibiliserende i 
kategori 1A vil have betydning for mærkningen af f.eks. vaske- og rengøringsmidler indeholdende sådanne 
stoffer. De strengere mærkningskrav for produkter indeholdende potente allergener vil give en bedre beskyttelse 
af brugerne (både forbrugere og arbejdstagere), da det vil give sensibiliserede personer den nødvendige 
information i forhold til at forebygge direkte hudkontakt med sådanne produkter. 
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